Token1	Label1	Offset1	Token2	Label2	Offset2	Relation	Sentence
phosphatase	Enzyme	(127, 138)	SHP-2	Gene	(121, 126)	ThemeOf	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
SHP-2	Gene	(1581, 1586)	interactions	Interaction	(1558, 1570)	ThemeOf	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
mutant	Var	(1574, 1580)	SHP-2	Gene	(1581, 1586)	ThemeOf	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
increased	PosReg	(1548, 1557)	hyperactivation	PosReg	(1624, 1639)	CauseOf	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways	Pathway	(1643, 1709)	hyperactivation	PosReg	(1624, 1639)	ThemeOf	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
catalytic activity	MPA	(1764, 1782)	increase	PosReg	(1748, 1756)	ThemeOf	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
dephosphorylation of STAT5	MPA	(1784, 1810)	dampened	NegReg	(1829, 1837)	ThemeOf	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
E76K	Var	(1820, 1824)	SHP-2	Gene	(1814, 1819)	ThemeOf	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
SHP-2	Gene	(1814, 1819)	dephosphorylation of STAT5	MPA	(1784, 1810)	ThemeOf	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
E76K	Var	(1881, 1885)	increase	PosReg	(1947, 1955)	CauseOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
interaction	Interaction	(1960, 1971)	increase	PosReg	(1947, 1955)	ThemeOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
SHP-2	Gene	(121, 126)	Mutations	Var	(108, 117)	ThemeOf	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
Gab2	Protein	(1977, 1981)	interaction	Interaction	(1960, 1971)	ThemeOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
E76K	Var	(1881, 1885)	enhance	PosReg	(1989, 1996)	CauseOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
PI3K pathway	Pathway	(2019, 2031)	enhance	PosReg	(1989, 1996)	ThemeOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
leukemias	Disease	(222, 231)	hyperactivation	PosReg	(150, 165)	ThemeOf	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
juvenile myelomonocytic leukemia	Disease	(246, 278)	hyperactivation	PosReg	(150, 165)	ThemeOf	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
SHP-2	Gene	(1875, 1880)	E76K	Var	(1881, 1885)	ThemeOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
C459S	Var	(1905, 1910)	increase	PosReg	(1947, 1955)	CauseOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
SHP-2	Gene	(1875, 1880)	C459S	Var	(1905, 1910)	ThemeOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
C459S	Var	(1905, 1910)	enhance	PosReg	(1989, 1996)	CauseOf	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
Mutations	Var	(108, 117)	hyperactivation	PosReg	(150, 165)	CauseOf	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
catalytic activity	MPA	(173, 191)	hyperactivation	PosReg	(150, 165)	ThemeOf	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
SHP-2	Gene	(1314, 1319)	E76K mutation	Var	(1320, 1333)	ThemeOf	Our results showed that SHP-2 E76K mutation caused myeloproliferative disease in mice, while overexpression of WT SHP-2 decreased hematopoietic potential of the transduced cells in recipient animals.
E76K mutation	Var	(1320, 1333)	myeloproliferative disease	Disease	(1341, 1367)	CauseOf	Our results showed that SHP-2 E76K mutation caused myeloproliferative disease in mice, while overexpression of WT SHP-2 decreased hematopoietic potential of the transduced cells in recipient animals.
E76K	Var	(1494, 1498)	increased	PosReg	(1548, 1557)	CauseOf	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
interactions	Interaction	(1558, 1570)	increased	PosReg	(1548, 1557)	ThemeOf	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
Grb2	Protein	(1592, 1596)	interactions	Interaction	(1558, 1570)	ThemeOf	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
SHP-2	Gene	(13, 18)	hyperactivation	PosReg	(42, 57)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
phosphatase	Enzyme	(19, 30)	Mutations	Var	(0, 9)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
phosphatase	Enzyme	(19, 30)	hyperactivation	PosReg	(42, 57)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
Mutations	Var	(0, 9)	leukemias	Disease	(114, 123)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
catalytic activity	MPA	(65, 83)	juvenile myelomonocytic leukemia	Disease	(138, 170)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
leukemias	Disease	(114, 123)	juvenile myelomonocytic leukemia	Disease	(138, 170)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
Mutations	Var	(0, 9)	juvenile myelomonocytic leukemia	Disease	(138, 170)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
leukemias	Disease	(114, 123)	catalytic activity	MPA	(65, 83)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
phosphatase	Enzyme	(19, 30)	catalytic activity	MPA	(65, 83)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
catalytic activity	MPA	(65, 83)	SHP-2	Gene	(13, 18)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
catalytic activity	MPA	(65, 83)	Mutations	Var	(0, 9)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
E76K	Var	(4, 8)	mutant	Var	(84, 90)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
interactions	Interaction	(68, 80)	hyperactivation	PosReg	(134, 149)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
Grb2	Protein	(102, 106)	hyperactivation	PosReg	(134, 149)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
Grb2	Protein	(102, 106)	increased	PosReg	(58, 67)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
Grb2	Protein	(102, 106)	mutant	Var	(84, 90)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
increased	PosReg	(58, 67)	mutant	Var	(84, 90)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
E76K	Var	(4, 8)	interactions	Interaction	(68, 80)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
SHP-2	Gene	(91, 96)	hyperactivation	PosReg	(134, 149)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
E76K	Var	(4, 8)	hyperactivation	PosReg	(134, 149)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
E76K	Var	(4, 8)	Grb2	Protein	(102, 106)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
Grb2	Protein	(102, 106)	SHP-2	Gene	(91, 96)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
SHP-2	Gene	(91, 96)	increased	PosReg	(58, 67)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
SHP-2	Gene	(91, 96)	IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways	Pathway	(153, 219)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
mutant	Var	(84, 90)	interactions	Interaction	(68, 80)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
E76K	Var	(4, 8)	SHP-2	Gene	(91, 96)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways	Pathway	(153, 219)	increased	PosReg	(58, 67)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
hyperactivation	PosReg	(134, 149)	mutant	Var	(84, 90)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
catalytic activity	MPA	(53, 71)	dampened	NegReg	(118, 126)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
E76K	Var	(109, 113)	catalytic activity	MPA	(53, 71)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
SHP-2	Gene	(103, 108)	increase	PosReg	(37, 45)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
E76K	Var	(109, 113)	increase	PosReg	(37, 45)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
dephosphorylation of STAT5	MPA	(73, 99)	increase	PosReg	(37, 45)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
SHP-2	Gene	(103, 108)	dampened	NegReg	(118, 126)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
E76K	Var	(109, 113)	dephosphorylation of STAT5	MPA	(73, 99)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
SHP-2	Gene	(103, 108)	catalytic activity	MPA	(53, 71)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
increase	PosReg	(37, 45)	dampened	NegReg	(118, 126)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
catalytic activity	MPA	(53, 71)	dephosphorylation of STAT5	MPA	(73, 99)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
E76K	Var	(109, 113)	dampened	NegReg	(118, 126)	NoRelation	In addition, despite the substantial increase in the catalytic activity, dephosphorylation of STAT5 by SHP-2 E76K was dampened.
E76K	Var	(42, 46)	C459S	Var	(66, 71)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
Gab2	Protein	(138, 142)	enhance	PosReg	(150, 157)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
Gab2	Protein	(138, 142)	increase	PosReg	(108, 116)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
interaction	Interaction	(121, 132)	enhance	PosReg	(150, 157)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
SHP-2	Gene	(36, 41)	Gab2	Protein	(138, 142)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
SHP-2	Gene	(36, 41)	increase	PosReg	(108, 116)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
SHP-2	Gene	(36, 41)	interaction	Interaction	(121, 132)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
E76K	Var	(42, 46)	interaction	Interaction	(121, 132)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
PI3K pathway	Pathway	(180, 192)	increase	PosReg	(108, 116)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
enhance	PosReg	(150, 157)	increase	PosReg	(108, 116)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
Gab2	Protein	(138, 142)	C459S	Var	(66, 71)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
SHP-2	Gene	(36, 41)	PI3K pathway	Pathway	(180, 192)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
Gab2	Protein	(138, 142)	E76K	Var	(42, 46)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
C459S	Var	(66, 71)	interaction	Interaction	(121, 132)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
bchs	Gene	(389, 393)	mutations	Var	(343, 352)	ThemeOf	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
ubiquitinated protein profiles	MPA	(1270, 1300)	changes	Reg	(1259, 1266)	ThemeOf	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
mutations	Var	(343, 352)	reduced	NegReg	(403, 410)	CauseOf	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life span	CPA	(411, 426)	reduced	NegReg	(403, 410)	ThemeOf	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
mutations	Var	(343, 352)	increased	PosReg	(428, 437)	CauseOf	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
neuronal death	CPA	(438, 452)	increased	PosReg	(428, 437)	ThemeOf	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
mutations	Var	(343, 352)	degeneration	NegReg	(473, 485)	CauseOf	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
widespread CNS	CPA	(458, 472)	degeneration	NegReg	(473, 485)	ThemeOf	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
lysosomal trafficking genes	Gene	(1151, 1178)	Mutations	Var	(1130, 1139)	ThemeOf	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
Mutations	Var	(1130, 1139)	decreased	NegReg	(1205, 1214)	CauseOf	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
adult life spans	CPA	(1215, 1231)	decreased	NegReg	(1205, 1214)	ThemeOf	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
Mutations	Var	(1130, 1139)	changes	Reg	(1259, 1266)	CauseOf	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
mutations	Var	(53, 62)	neuronal death	CPA	(148, 162)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life span	CPA	(121, 136)	mutations	Var	(53, 62)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
reduced	NegReg	(113, 120)	increased	PosReg	(138, 147)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
bchs	Gene	(99, 103)	degeneration	NegReg	(183, 195)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life span	CPA	(121, 136)	neuronal death	CPA	(148, 162)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life span	CPA	(121, 136)	degeneration	NegReg	(183, 195)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
widespread CNS	CPA	(168, 182)	increased	PosReg	(138, 147)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
reduced	NegReg	(113, 120)	widespread CNS	CPA	(168, 182)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
reduced	NegReg	(113, 120)	degeneration	NegReg	(183, 195)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life span	CPA	(121, 136)	widespread CNS	CPA	(168, 182)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
bchs	Gene	(99, 103)	reduced	NegReg	(113, 120)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
reduced	NegReg	(113, 120)	neuronal death	CPA	(148, 162)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
widespread CNS	CPA	(168, 182)	neuronal death	CPA	(148, 162)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
mutations	Var	(53, 62)	widespread CNS	CPA	(168, 182)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life span	CPA	(121, 136)	increased	PosReg	(138, 147)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
degeneration	NegReg	(183, 195)	neuronal death	CPA	(148, 162)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
degeneration	NegReg	(183, 195)	increased	PosReg	(138, 147)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
Mutations	Var	(0, 9)	adult life spans	CPA	(85, 101)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
ubiquitinated protein profiles	MPA	(140, 170)	Mutations	Var	(0, 9)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
adult life spans	CPA	(85, 101)	changes	Reg	(129, 136)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
lysosomal trafficking genes	Gene	(21, 48)	decreased	NegReg	(75, 84)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
ubiquitinated protein profiles	MPA	(140, 170)	decreased	NegReg	(75, 84)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
lysosomal trafficking genes	Gene	(21, 48)	changes	Reg	(129, 136)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
lysosomal trafficking genes	Gene	(21, 48)	ubiquitinated protein profiles	MPA	(140, 170)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
changes	Reg	(129, 136)	decreased	NegReg	(75, 84)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
adult life spans	CPA	(85, 101)	ubiquitinated protein profiles	MPA	(140, 170)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
heterotrimeric G proteins	Protein	(242, 267)	stimulation	PosReg	(195, 206)	CauseOf	Regulator of G protein signaling (RGS) proteins play a crucial role in the adaptation of cells to stimulation by G protein-coupled receptors via heterotrimeric G proteins.
RGS4	Var	(1223, 1227)	increased	PosReg	(1256, 1265)	CauseOf	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
protein levels	MPA	(1279, 1293)	increased	PosReg	(1256, 1265)	ThemeOf	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
GAP activity	MPA	(1343, 1355)	enhanced	PosReg	(1334, 1342)	ThemeOf	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
RGS4 mutant	Var	(662, 673)	gain-of-function	PosReg	(701, 717)	CauseOf	Here we describe the isolation and characterization of a novel human RGS4 mutant which displays enhanced or gain-of-function (GOF) activity.
RGS	Protein	(284, 287)	Alterations	Var	(269, 280)	ThemeOf	Alterations in RGS function have been implicated in a wide range of disease states, leading to many researchers focusing on controlling the action of these regulatory proteins.
RGS4	Var	(1223, 1227)	enhanced	PosReg	(1334, 1342)	CauseOf	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
G protein-coupled receptors	Protein	(210, 237)	stimulation	PosReg	(195, 206)	ThemeOf	Regulator of G protein signaling (RGS) proteins play a crucial role in the adaptation of cells to stimulation by G protein-coupled receptors via heterotrimeric G proteins.
S30C	Var	(1228, 1232)	RGS4	Var	(1223, 1227)	ThemeOf	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30F	Var	(1233, 1237)	RGS4	Var	(1223, 1227)	ThemeOf	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30K	Var	(1238, 1242)	RGS4	Var	(1223, 1227)	ThemeOf	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
Alterations	Var	(269, 280)	implicated	Reg	(307, 317)	CauseOf	Alterations in RGS function have been implicated in a wide range of disease states, leading to many researchers focusing on controlling the action of these regulatory proteins.
disease	Disease	(337, 344)	implicated	Reg	(307, 317)	ThemeOf	Alterations in RGS function have been implicated in a wide range of disease states, leading to many researchers focusing on controlling the action of these regulatory proteins.
RGS4 mutant	Var	(662, 673)	enhanced	PosReg	(689, 697)	CauseOf	Here we describe the isolation and characterization of a novel human RGS4 mutant which displays enhanced or gain-of-function (GOF) activity.
Alterations	Var	(0, 11)	disease	Disease	(68, 75)	NoRelation	Alterations in RGS function have been implicated in a wide range of disease states, leading to many researchers focusing on controlling the action of these regulatory proteins.
disease	Disease	(68, 75)	RGS	Protein	(15, 18)	NoRelation	Alterations in RGS function have been implicated in a wide range of disease states, leading to many researchers focusing on controlling the action of these regulatory proteins.
RGS	Protein	(15, 18)	implicated	Reg	(38, 48)	NoRelation	Alterations in RGS function have been implicated in a wide range of disease states, leading to many researchers focusing on controlling the action of these regulatory proteins.
gain-of-function	PosReg	(108, 124)	enhanced	PosReg	(96, 104)	NoRelation	Here we describe the isolation and characterization of a novel human RGS4 mutant which displays enhanced or gain-of-function (GOF) activity.
S30F	Var	(53, 57)	GAP activity	MPA	(163, 175)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
protein levels	MPA	(99, 113)	GAP activity	MPA	(163, 175)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30F	Var	(53, 57)	increased	PosReg	(76, 85)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
enhanced	PosReg	(154, 162)	increased	PosReg	(76, 85)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30K	Var	(58, 62)	increased	PosReg	(76, 85)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30C	Var	(48, 52)	S30K	Var	(58, 62)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30C	Var	(48, 52)	increased	PosReg	(76, 85)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30K	Var	(58, 62)	enhanced	PosReg	(154, 162)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30C	Var	(48, 52)	GAP activity	MPA	(163, 175)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30C	Var	(48, 52)	enhanced	PosReg	(154, 162)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
GAP activity	MPA	(163, 175)	RGS4	Var	(43, 47)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30F	Var	(53, 57)	S30K	Var	(58, 62)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
GAP activity	MPA	(163, 175)	increased	PosReg	(76, 85)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30F	Var	(53, 57)	protein levels	MPA	(99, 113)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
protein levels	MPA	(99, 113)	RGS4	Var	(43, 47)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
protein levels	MPA	(99, 113)	enhanced	PosReg	(154, 162)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30K	Var	(58, 62)	protein levels	MPA	(99, 113)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30C	Var	(48, 52)	S30F	Var	(53, 57)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30C	Var	(48, 52)	protein levels	MPA	(99, 113)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30F	Var	(53, 57)	enhanced	PosReg	(154, 162)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
S30K	Var	(58, 62)	GAP activity	MPA	(163, 175)	NoRelation	As with previously identified GOF mutants, RGS4(S30C/S30F/S30K) demonstrate increased steady state protein levels, however these mutants also demonstrate enhanced GAP activity through an additional mechanism distinct from the increased protein content.
p53	Gene	(112, 115)	proteins	Protein	(116, 124)	ThemeOf	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
conditional RNA interference	MPA	(706, 734)	inhibiting	NegReg	(738, 748)	CauseOf	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
activity	MPA	(766, 774)	inhibiting	NegReg	(738, 748)	ThemeOf	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
p53	Gene	(785, 788)	proteins	Protein	(789, 797)	ThemeOf	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
proteins	Protein	(789, 797)	mutant	Var	(778, 784)	ThemeOf	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
mutant	Var	(778, 784)	activity	MPA	(766, 774)	ThemeOf	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
depletion	MPA	(1061, 1070)	impacts	Reg	(1093, 1100)	CauseOf	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
tumor malignancy	CPA	(1104, 1120)	impacts	Reg	(1093, 1100)	ThemeOf	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
mutant	Var	(1074, 1080)	depletion	MPA	(1061, 1070)	ThemeOf	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
p53	Gene	(1081, 1084)	protein	Protein	(1085, 1092)	ThemeOf	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
protein	Protein	(1085, 1092)	mutant	Var	(1074, 1080)	ThemeOf	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
proteins	Protein	(116, 124)	Mutant	Var	(105, 111)	ThemeOf	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
Mutant	Var	(105, 111)	gain of function	PosReg	(157, 173)	CauseOf	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
tumor aggressiveness	CPA	(217, 237)	gain of function	PosReg	(157, 173)	ThemeOf	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
RNA interference	MPA	(312, 328)	downregulation	NegReg	(280, 294)	CauseOf	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
downregulation	NegReg	(280, 294)	reduces	NegReg	(329, 336)	CauseOf	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
p53	Gene	(305, 308)	mutant	Var	(298, 304)	ThemeOf	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
mutant	Var	(298, 304)	downregulation	NegReg	(280, 294)	ThemeOf	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
tumorigenicity of cancer cells in an animal model	CPA	(341, 390)	reduces	NegReg	(329, 336)	ThemeOf	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
Mutant	Var	(0, 6)	p53	Gene	(7, 10)	NoRelation	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
proteins	Protein	(11, 19)	gain of function	PosReg	(52, 68)	NoRelation	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
proteins	Protein	(11, 19)	tumor aggressiveness	CPA	(112, 132)	NoRelation	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
Mutant	Var	(0, 6)	tumor aggressiveness	CPA	(112, 132)	NoRelation	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
reduces	NegReg	(90, 97)	RNA interference	MPA	(73, 89)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
downregulation	NegReg	(41, 55)	tumorigenicity of cancer cells in an animal model	CPA	(102, 151)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
tumorigenicity of cancer cells in an animal model	CPA	(102, 151)	RNA interference	MPA	(73, 89)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
reduces	NegReg	(90, 97)	mutant	Var	(59, 65)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
RNA interference	MPA	(73, 89)	mutant	Var	(59, 65)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
mutant	Var	(59, 65)	tumorigenicity of cancer cells in an animal model	CPA	(102, 151)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
p53	Gene	(66, 69)	RNA interference	MPA	(73, 89)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
p53	Gene	(66, 69)	reduces	NegReg	(90, 97)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
p53	Gene	(66, 69)	downregulation	NegReg	(41, 55)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
proteins	Protein	(124, 132)	conditional RNA interference	MPA	(41, 69)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
p53	Gene	(120, 123)	conditional RNA interference	MPA	(41, 69)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
proteins	Protein	(124, 132)	inhibiting	NegReg	(73, 83)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
p53	Gene	(120, 123)	activity	MPA	(101, 109)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
mutant	Var	(113, 119)	p53	Gene	(120, 123)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
inhibiting	NegReg	(73, 83)	mutant	Var	(113, 119)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
proteins	Protein	(124, 132)	activity	MPA	(101, 109)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
p53	Gene	(120, 123)	inhibiting	NegReg	(73, 83)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
conditional RNA interference	MPA	(41, 69)	activity	MPA	(101, 109)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
conditional RNA interference	MPA	(41, 69)	mutant	Var	(113, 119)	NoRelation	In vivo studies assessed the efficacy of conditional RNA interference in inhibiting gain of function activity of mutant p53 proteins by reducing tumor growth ability.
protein	Protein	(54, 61)	impacts	Reg	(62, 69)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
mutant	Var	(43, 49)	tumor malignancy	CPA	(73, 89)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
depletion	MPA	(30, 39)	protein	Protein	(54, 61)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
p53	Gene	(50, 53)	impacts	Reg	(62, 69)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
tumor malignancy	CPA	(73, 89)	depletion	MPA	(30, 39)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
mutant	Var	(43, 49)	impacts	Reg	(62, 69)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
protein	Protein	(54, 61)	tumor malignancy	CPA	(73, 89)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
mutant	Var	(43, 49)	p53	Gene	(50, 53)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
p53	Gene	(50, 53)	depletion	MPA	(30, 39)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
polymorphism	MPA	(1203, 1215)	silent	NegReg	(1196, 1202)	ThemeOf	p.Asn281Ser corresponds to a functionally silent polymorphism.
p.Val38Met	Var	(1622, 1632)	reduced	NegReg	(1671, 1678)	CauseOf	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
cell surface expression	CPA	(1679, 1702)	reduced	NegReg	(1671, 1678)	ThemeOf	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
coupling	MPA	(1327, 1335)	decreases	NegReg	(1314, 1323)	ThemeOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
functional coupling	MPA	(1414, 1433)	absence	NegReg	(1403, 1410)	ThemeOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
cAMP pathway	Pathway	(1343, 1355)	decreases	NegReg	(1314, 1323)	ThemeOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val38Met	Var	(1357, 1367)	decreases	NegReg	(1314, 1323)	CauseOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(1372, 1382)	decreases	NegReg	(1314, 1323)	CauseOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Ser41Phe	Var	(1435, 1445)	absence	NegReg	(1403, 1410)	CauseOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(1447, 1458)	absence	NegReg	(1403, 1410)	CauseOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Cys289Arg	Var	(1464, 1475)	absence	NegReg	(1403, 1410)	CauseOf	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Cys289Arg	Var	(1502, 1513)	unable	NegReg	(1566, 1572)	CauseOf	The LOF p.Met128Thr and p.Cys289Arg mutants are trafficked to the cell surface, but are unable to bind agonists efficiently.
p.Met128Thr	Var	(1486, 1497)	unable	NegReg	(1566, 1572)	CauseOf	The LOF p.Met128Thr and p.Cys289Arg mutants are trafficked to the cell surface, but are unable to bind agonists efficiently.
bind	Interaction	(1576, 1580)	unable	NegReg	(1566, 1572)	ThemeOf	The LOF p.Met128Thr and p.Cys289Arg mutants are trafficked to the cell surface, but are unable to bind agonists efficiently.
p.Ser41Phe,	Var	(1634, 1645)	reduced	NegReg	(1671, 1678)	CauseOf	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p.Val51Ala	Var	(1650, 1660)	reduced	NegReg	(1671, 1678)	CauseOf	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p.Asn281Ser	Var	(1154, 1165)	silent	NegReg	(1196, 1202)	CauseOf	p.Asn281Ser corresponds to a functionally silent polymorphism.
p.Asn281Ser	Var	(0, 11)	polymorphism	MPA	(49, 61)	NoRelation	p.Asn281Ser corresponds to a functionally silent polymorphism.
p.Ser41Phe	Var	(218, 228)	p.Cys289Arg	Var	(247, 258)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(230, 241)	p.Val38Met	Var	(140, 150)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	p.Met128Thr	Var	(230, 241)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	absence	NegReg	(186, 193)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val38Met	Var	(140, 150)	absence	NegReg	(186, 193)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(230, 241)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(230, 241)	p.Cys289Arg	Var	(247, 258)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val38Met	Var	(140, 150)	p.Cys289Arg	Var	(247, 258)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
cAMP pathway	Pathway	(126, 138)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val38Met	Var	(140, 150)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(230, 241)	decreases	NegReg	(97, 106)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val38Met	Var	(140, 150)	functional coupling	MPA	(197, 216)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Ser41Phe	Var	(218, 228)	p.Met128Thr	Var	(230, 241)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Cys289Arg	Var	(247, 258)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Ser41Phe	Var	(218, 228)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
absence	NegReg	(186, 193)	decreases	NegReg	(97, 106)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Ser41Phe	Var	(218, 228)	p.Val38Met	Var	(140, 150)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
functional coupling	MPA	(197, 216)	decreases	NegReg	(97, 106)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
cAMP pathway	Pathway	(126, 138)	absence	NegReg	(186, 193)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
functional coupling	MPA	(197, 216)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
absence	NegReg	(186, 193)	coupling	MPA	(110, 118)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Cys289Arg	Var	(247, 258)	decreases	NegReg	(97, 106)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Ser41Phe	Var	(218, 228)	decreases	NegReg	(97, 106)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
cAMP pathway	Pathway	(126, 138)	functional coupling	MPA	(197, 216)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(8, 19)	bind	Interaction	(98, 102)	NoRelation	The LOF p.Met128Thr and p.Cys289Arg mutants are trafficked to the cell surface, but are unable to bind agonists efficiently.
p.Cys289Arg	Var	(24, 35)	bind	Interaction	(98, 102)	NoRelation	The LOF p.Met128Thr and p.Cys289Arg mutants are trafficked to the cell surface, but are unable to bind agonists efficiently.
p.Val38Met	Var	(19, 29)	cell surface expression	CPA	(76, 99)	NoRelation	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p.Ser41Phe,	Var	(31, 42)	cell surface expression	CPA	(76, 99)	NoRelation	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p.Val51Ala	Var	(47, 57)	cell surface expression	CPA	(76, 99)	NoRelation	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p53-R175H expression vector	Protein	(997, 1024)	inducing	Reg	(988, 996)	ThemeOf	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53-R175H expression vector	Protein	(997, 1024)	tested	Reg	(898, 904)	CauseOf	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
up-regulation	PosReg	(925, 938)	tested	Reg	(898, 904)	ThemeOf	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
down-regulation	NegReg	(943, 958)	tested	Reg	(898, 904)	ThemeOf	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53 gene	Gene	(1044, 1052)	suppressing	NegReg	(1028, 1039)	ThemeOf	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53 gene	Gene	(1044, 1052)	tested	Reg	(898, 904)	CauseOf	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(1218, 1306)	activation	PosReg	(1200, 1210)	ThemeOf	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
short hairpin RNA	Gene	(1350, 1367)	suppression	NegReg	(1320, 1331)	CauseOf	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
p53-R175H	Protein	(1335, 1344)	suppression	NegReg	(1320, 1331)	ThemeOf	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
p53-R175H	Protein	(1335, 1344)	inhibited	NegReg	(1382, 1391)	CauseOf	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
cell migration and invasion	CPA	(1392, 1419)	inhibited	NegReg	(1382, 1391)	ThemeOf	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
p53-R175H	Protein	(1335, 1344)	attenuation	NegReg	(1437, 1448)	CauseOf	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
EGFR/PI3K/AKT pathway.	Pathway	(1452, 1474)	attenuation	NegReg	(1437, 1448)	ThemeOf	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
expression	MPA	(1540, 1550)	elevated	PosReg	(1531, 1539)	ThemeOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
function activity	MPA	(1589, 1606)	gain	PosReg	(1581, 1585)	ThemeOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
EGFR/PI3K/AKT pathway	Pathway	(1623, 1644)	activate	PosReg	(1610, 1618)	ThemeOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
endometrial cancer	Disease	(1698, 1716)	contribute	Reg	(1658, 1668)	ThemeOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
p53	Gene	(1554, 1557)	R175H	Var	(1558, 1563)	ThemeOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
R175H	Var	(1558, 1563)	elevated	PosReg	(1531, 1539)	CauseOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
p53	Gene	(554, 557)	mutation	Var	(558, 566)	ThemeOf	In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer.
mutation	Var	(558, 566)	associated	Reg	(581, 591)	CauseOf	In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer.
aggressive nonendometrioid cancer	Disease	(597, 630)	associated	Reg	(581, 591)	ThemeOf	In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer.
R175H	Var	(1558, 1563)	gain	PosReg	(1581, 1585)	CauseOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
gain	PosReg	(1581, 1585)	activate	PosReg	(1610, 1618)	CauseOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
activate	PosReg	(1610, 1618)	contribute	Reg	(1658, 1668)	CauseOf	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
R175H	Var	(53, 58)	gain-of-function	PosReg	(27, 43)	CauseOf	Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
p53	Gene	(23, 26)	R175H	Var	(53, 58)	ThemeOf	Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
EGFR/PI3K/AKT pathway	Pathway	(145, 166)	gain-of-function	PosReg	(27, 43)	ThemeOf	Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
p53	Gene	(1126, 1129)	R175H	Var	(1130, 1135)	ThemeOf	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
R175H	Var	(1130, 1135)	over-expression	PosReg	(1107, 1122)	CauseOf	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
R175H	Var	(1130, 1135)	promoted	PosReg	(1150, 1158)	CauseOf	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
cell migration	CPA	(1159, 1173)	promoted	PosReg	(1150, 1158)	ThemeOf	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
invasion	CPA	(1178, 1186)	promoted	PosReg	(1150, 1158)	ThemeOf	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
p53	Gene	(23, 26)	EGFR/PI3K/AKT pathway	Pathway	(145, 166)	NoRelation	Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
p53	Gene	(29, 32)	associated	Reg	(56, 66)	NoRelation	In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer.
mutation	Var	(33, 41)	aggressive nonendometrioid cancer	Disease	(72, 105)	NoRelation	In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer.
p53-R175H expression vector	Protein	(252, 279)	up-regulation	PosReg	(180, 193)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53-R175H expression vector	Protein	(252, 279)	suppressing	NegReg	(283, 294)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53 gene	Gene	(299, 307)	down-regulation	NegReg	(198, 213)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
suppressing	NegReg	(283, 294)	down-regulation	NegReg	(198, 213)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
suppressing	NegReg	(283, 294)	inducing	Reg	(243, 251)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
up-regulation	PosReg	(180, 193)	inducing	Reg	(243, 251)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53 gene	Gene	(299, 307)	p53-R175H expression vector	Protein	(252, 279)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53-R175H expression vector	Protein	(252, 279)	down-regulation	NegReg	(198, 213)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
tested	Reg	(153, 159)	suppressing	NegReg	(283, 294)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
suppressing	NegReg	(283, 294)	up-regulation	PosReg	(180, 193)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
down-regulation	NegReg	(198, 213)	inducing	Reg	(243, 251)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
up-regulation	PosReg	(180, 193)	down-regulation	NegReg	(198, 213)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	activation	PosReg	(123, 133)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
activation	PosReg	(123, 133)	promoted	PosReg	(73, 81)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
R175H	Var	(53, 58)	activation	PosReg	(123, 133)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
invasion	CPA	(101, 109)	activation	PosReg	(123, 133)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
cell migration	CPA	(82, 96)	over-expression	PosReg	(30, 45)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
p53	Gene	(49, 52)	epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
cell migration	CPA	(82, 96)	invasion	CPA	(101, 109)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
R175H	Var	(53, 58)	invasion	CPA	(101, 109)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
activation	PosReg	(123, 133)	over-expression	PosReg	(30, 45)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	promoted	PosReg	(73, 81)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	over-expression	PosReg	(30, 45)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
cell migration	CPA	(82, 96)	activation	PosReg	(123, 133)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
invasion	CPA	(101, 109)	over-expression	PosReg	(30, 45)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	promoted	PosReg	(73, 81)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	over-expression	PosReg	(30, 45)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
over-expression	PosReg	(30, 45)	promoted	PosReg	(73, 81)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
short hairpin RNA	Gene	(42, 59)	p53-R175H	Protein	(27, 36)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
p53-R175H	Protein	(27, 36)	cell migration and invasion	CPA	(84, 111)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
short hairpin RNA	Gene	(42, 59)	attenuation	NegReg	(129, 140)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
short hairpin RNA	Gene	(42, 59)	inhibited	NegReg	(74, 83)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
EGFR/PI3K/AKT pathway.	Pathway	(144, 166)	suppression	NegReg	(12, 23)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
inhibited	NegReg	(74, 83)	attenuation	NegReg	(129, 140)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
cell migration and invasion	CPA	(84, 111)	attenuation	NegReg	(129, 140)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
suppression	NegReg	(12, 23)	attenuation	NegReg	(129, 140)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
cell migration and invasion	CPA	(84, 111)	suppression	NegReg	(12, 23)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
EGFR/PI3K/AKT pathway.	Pathway	(144, 166)	inhibited	NegReg	(74, 83)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
inhibited	NegReg	(74, 83)	suppression	NegReg	(12, 23)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
endometrial cancer	Disease	(223, 241)	elevated	PosReg	(56, 64)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
gain	PosReg	(106, 110)	contribute	Reg	(183, 193)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
gain	PosReg	(106, 110)	endometrial cancer	Disease	(223, 241)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
function activity	MPA	(114, 131)	EGFR/PI3K/AKT pathway	Pathway	(148, 169)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
contribute	Reg	(183, 193)	elevated	PosReg	(56, 64)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
expression	MPA	(65, 75)	gain	PosReg	(106, 110)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
activate	PosReg	(135, 143)	elevated	PosReg	(56, 64)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
R175H	Var	(83, 88)	contribute	Reg	(183, 193)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
R175H	Var	(83, 88)	endometrial cancer	Disease	(223, 241)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
gain	PosReg	(106, 110)	elevated	PosReg	(56, 64)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
endometrial cancer	Disease	(223, 241)	activate	PosReg	(135, 143)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
endometrial cancer	Disease	(223, 241)	function activity	MPA	(114, 131)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
endometrial cancer	Disease	(223, 241)	EGFR/PI3K/AKT pathway	Pathway	(148, 169)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
function activity	MPA	(114, 131)	elevated	PosReg	(56, 64)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
EGFR/PI3K/AKT pathway	Pathway	(148, 169)	elevated	PosReg	(56, 64)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
function activity	MPA	(114, 131)	contribute	Reg	(183, 193)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
EGFR/PI3K/AKT pathway	Pathway	(148, 169)	contribute	Reg	(183, 193)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
EGFR/PI3K/AKT pathway	Pathway	(148, 169)	gain	PosReg	(106, 110)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
expression	MPA	(65, 75)	function activity	MPA	(114, 131)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
EGFR/PI3K/AKT pathway	Pathway	(148, 169)	expression	MPA	(65, 75)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
R175H	Var	(83, 88)	activate	PosReg	(135, 143)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
expression	MPA	(65, 75)	contribute	Reg	(183, 193)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
p53	Gene	(79, 82)	expression	MPA	(65, 75)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
expression	MPA	(65, 75)	activate	PosReg	(135, 143)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
endometrial cancer	Disease	(223, 241)	expression	MPA	(65, 75)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
function activity	MPA	(114, 131)	activate	PosReg	(135, 143)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
p53	Gene	(79, 82)	function activity	MPA	(114, 131)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
mutations	Var	(807, 816)	gain-of-function	PosReg	(784, 800)	CauseOf	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
Shp2	Gene	(820, 824)	mutations	Var	(807, 816)	ThemeOf	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(849, 858)	loss-of-function	NegReg	(826, 842)	CauseOf	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
Shp2	Gene	(589, 593)	mutations	Var	(594, 603)	ThemeOf	Somatic Shp2 mutations are also associated with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).
mutations	Var	(594, 603)	associated	Reg	(613, 623)	CauseOf	Somatic Shp2 mutations are also associated with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).
juvenile myelomonocytic leukemia	Disease	(709, 741)	associated	Reg	(613, 623)	ThemeOf	Somatic Shp2 mutations are also associated with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).
NS	Disease	(758, 760)	gain-of-function	PosReg	(784, 800)	ThemeOf	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
JMML	Disease	(765, 769)	gain-of-function	PosReg	(784, 800)	ThemeOf	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
LEOPARD syndrome	Disease	(893, 909)	loss-of-function	NegReg	(826, 842)	ThemeOf	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
Shp2	Gene	(820, 824)	mutations	Var	(849, 858)	ThemeOf	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(13, 22)	juvenile myelomonocytic leukemia	Disease	(128, 160)	NoRelation	Somatic Shp2 mutations are also associated with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).
NS	Disease	(8, 10)	JMML	Disease	(15, 19)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(99, 108)	LEOPARD syndrome	Disease	(143, 159)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
loss-of-function	NegReg	(76, 92)	gain-of-function	PosReg	(34, 50)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
NS	Disease	(8, 10)	loss-of-function	NegReg	(76, 92)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(99, 108)	gain-of-function	PosReg	(34, 50)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(57, 66)	JMML	Disease	(15, 19)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(99, 108)	NS	Disease	(8, 10)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(57, 66)	loss-of-function	NegReg	(76, 92)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
NS	Disease	(8, 10)	LEOPARD syndrome	Disease	(143, 159)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
JMML	Disease	(15, 19)	LEOPARD syndrome	Disease	(143, 159)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
LEOPARD syndrome	Disease	(143, 159)	gain-of-function	PosReg	(34, 50)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(57, 66)	NS	Disease	(8, 10)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
JMML	Disease	(15, 19)	loss-of-function	NegReg	(76, 92)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(99, 108)	JMML	Disease	(15, 19)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(57, 66)	LEOPARD syndrome	Disease	(143, 159)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
Shp2	Gene	(70, 74)	loss-of-function	NegReg	(76, 92)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
p53	Gene	(7, 10)	Mutant	Var	(0, 6)	ThemeOf	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
activities	MPA	(286, 296)	gain	PosReg	(275, 279)	ThemeOf	As p53 is usually mutated in human tumors and many mutated forms of p53 gain novel activities, we studied the influence of mutant p53 (mut-p53) on somatic cell reprogramming.
p53	Gene	(271, 274)	mutated	Var	(254, 261)	ThemeOf	As p53 is usually mutated in human tumors and many mutated forms of p53 gain novel activities, we studied the influence of mutant p53 (mut-p53) on somatic cell reprogramming.
mut-p53	Var	(440, 447)	gain	PosReg	(404, 408)	CauseOf	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
function	MPA	(412, 420)	gain	PosReg	(404, 408)	ThemeOf	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
mut-p53	Var	(440, 447)	enhanced	PosReg	(464, 472)	CauseOf	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
reprogramming process	CPA	(495, 516)	enhanced	PosReg	(464, 472)	ThemeOf	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
activity	MPA	(571, 579)	mut	Var	(583, 586)	ThemeOf	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
mut	Var	(583, 586)	alterations	Reg	(599, 610)	CauseOf	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
characteristics of the reprogrammed cells	CPA	(618, 659)	alterations	Reg	(599, 610)	ThemeOf	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
mutant	Var	(808, 814)	lost	NegReg	(819, 823)	CauseOf	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
Mutant	Var	(0, 6)	facilitates	PosReg	(11, 22)	CauseOf	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
pluripotent capacity	MPA	(748, 768)	lost	NegReg	(819, 823)	ThemeOf	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
p53	Gene	(815, 818)	mutant	Var	(808, 814)	ThemeOf	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
mutant	Var	(808, 814)	gave rise	Reg	(844, 853)	CauseOf	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
malignant tumors	CPA	(857, 873)	gave rise	Reg	(844, 853)	ThemeOf	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
overexpression	PosReg	(1089, 1103)	mut	Var	(1124, 1127)	ThemeOf	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
mut	Var	(1124, 1127)	induced	PosReg	(1138, 1145)	CauseOf	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
aggressive tumors	CPA	(1146, 1163)	induced	PosReg	(1138, 1145)	ThemeOf	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
oncogenic activity	MPA	(1054, 1072)	mut	Var	(1124, 1127)	ThemeOf	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
p53	Gene	(1380, 1383)	mutated	Var	(1387, 1394)	ThemeOf	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
mutated	Var	(1387, 1394)	reprogramming	CPA	(1396, 1409)	CauseOf	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
somatic cell reprogramming	CPA	(23, 49)	facilitates	PosReg	(11, 22)	ThemeOf	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
reprogramming	CPA	(1396, 1409)	result in	Reg	(1414, 1423)	CauseOf	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
cells with malignant tumor-forming potential	CPA	(1442, 1486)	result in	Reg	(1414, 1423)	ThemeOf	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
p53	Gene	(587, 590)	mut	Var	(583, 586)	ThemeOf	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
p53	Gene	(1128, 1131)	mut	Var	(1124, 1127)	ThemeOf	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
Mutant	Var	(0, 6)	augments	NegReg	(54, 62)	CauseOf	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
malignant potential of reprogrammed cells	CPA	(67, 108)	augments	NegReg	(54, 62)	ThemeOf	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
p53	Gene	(110, 113)	deficiency	Var	(114, 124)	ThemeOf	p53 deficiency enhances the efficiency of somatic cell reprogramming to a pluripotent state.
deficiency	Var	(114, 124)	enhances	PosReg	(125, 133)	CauseOf	p53 deficiency enhances the efficiency of somatic cell reprogramming to a pluripotent state.
somatic cell reprogramming	CPA	(152, 178)	enhances	PosReg	(125, 133)	ThemeOf	p53 deficiency enhances the efficiency of somatic cell reprogramming to a pluripotent state.
mutated	Var	(254, 261)	gain	PosReg	(275, 279)	CauseOf	As p53 is usually mutated in human tumors and many mutated forms of p53 gain novel activities, we studied the influence of mutant p53 (mut-p53) on somatic cell reprogramming.
malignant potential of reprogrammed cells	CPA	(67, 108)	somatic cell reprogramming	CPA	(23, 49)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
augments	NegReg	(54, 62)	somatic cell reprogramming	CPA	(23, 49)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
augments	NegReg	(54, 62)	facilitates	PosReg	(11, 22)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
p53	Gene	(7, 10)	augments	NegReg	(54, 62)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
malignant potential of reprogrammed cells	CPA	(67, 108)	facilitates	PosReg	(11, 22)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
p53	Gene	(68, 71)	activities	MPA	(83, 93)	NoRelation	As p53 is usually mutated in human tumors and many mutated forms of p53 gain novel activities, we studied the influence of mutant p53 (mut-p53) on somatic cell reprogramming.
enhanced	PosReg	(86, 94)	gain	PosReg	(26, 30)	NoRelation	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
function	MPA	(34, 42)	enhanced	PosReg	(86, 94)	NoRelation	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
reprogramming process	CPA	(117, 138)	gain	PosReg	(26, 30)	NoRelation	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
activity	MPA	(24, 32)	alterations	Reg	(52, 63)	NoRelation	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
p53	Gene	(40, 43)	activity	MPA	(24, 32)	NoRelation	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
pluripotent capacity	MPA	(87, 107)	gave rise	Reg	(183, 192)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
malignant tumors	CPA	(196, 212)	lost	NegReg	(158, 162)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
p53	Gene	(154, 157)	lost	NegReg	(158, 162)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
p53	Gene	(154, 157)	pluripotent capacity	MPA	(87, 107)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
lost	NegReg	(158, 162)	gave rise	Reg	(183, 192)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
induced	PosReg	(115, 122)	overexpression	PosReg	(66, 80)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
oncogenic activity	MPA	(31, 49)	induced	PosReg	(115, 122)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
p53	Gene	(105, 108)	oncogenic activity	MPA	(31, 49)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
aggressive tumors	CPA	(123, 140)	overexpression	PosReg	(66, 80)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
oncogenic activity	MPA	(31, 49)	overexpression	PosReg	(66, 80)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
cells with malignant tumor-forming potential	CPA	(277, 321)	reprogramming	CPA	(231, 244)	NoRelation	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
mutated	Var	(222, 229)	result in	Reg	(249, 258)	NoRelation	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
 CYP2B	Var	(814, 820)	 bioactivation of cyclophosphamid	MPA	(828, 861)	CauseOf	RESULTS: In livers of known CYP2C19 and CYP2B6 genotype and protein expression we observed that there was a combined role for both CYP2C19 and CYP2B6 in the bioactivation of cyclophosphamide in vitro.
 CYP2B	Var	(1549, 1555)	 decrease	NegReg	(1589, 1598)	CauseOf	CONCLUSIONS: The presence of 1 LoF allele(s) at either CYP2B6 or CYP2C19 appeared to result in decreased bioactivation of cyclophosphamide both in vitro and in patients.
 CYP2C1	Var	(1559, 1566)	 decrease	NegReg	(1589, 1598)	CauseOf	CONCLUSIONS: The presence of 1 LoF allele(s) at either CYP2B6 or CYP2C19 appeared to result in decreased bioactivation of cyclophosphamide both in vitro and in patients.
 bioactivation of cyclophosphamid	MPA	(1599, 1632)	 decrease	NegReg	(1589, 1598)	ThemeOf	CONCLUSIONS: The presence of 1 LoF allele(s) at either CYP2B6 or CYP2C19 appeared to result in decreased bioactivation of cyclophosphamide both in vitro and in patients.
 CYP2C1	Var	(802, 809)	 bioactivation of cyclophosphamid	MPA	(828, 861)	CauseOf	RESULTS: In livers of known CYP2C19 and CYP2B6 genotype and protein expression we observed that there was a combined role for both CYP2C19 and CYP2B6 in the bioactivation of cyclophosphamide in vitro.
 combine	Interaction	(779, 787)	 bioactivation of cyclophosphamid	MPA	(828, 861)	ThemeOf	RESULTS: In livers of known CYP2C19 and CYP2B6 genotype and protein expression we observed that there was a combined role for both CYP2C19 and CYP2B6 in the bioactivation of cyclophosphamide in vitro.
 CYP2C1	Var	(941, 948)	 decreas	NegReg	(985, 993)	CauseOf	The presence of at least one loss of function (LoF) allele at either CYP2C19 or CYP2B6 resulted in a significant decrease in both V(max) (P= 0.028) and CL(int) (P= 0.0017) compared with livers with no LoF alleles.
 CYP2B	Var	(952, 958)	 decreas	NegReg	(985, 993)	CauseOf	The presence of at least one loss of function (LoF) allele at either CYP2C19 or CYP2B6 resulted in a significant decrease in both V(max) (P= 0.028) and CL(int) (P= 0.0017) compared with livers with no LoF alleles.
 V(max) (P= 0.028) and CL(int) (P= 0.0017	MPA	(1002, 1043)	 decreas	NegReg	(985, 993)	ThemeOf	The presence of at least one loss of function (LoF) allele at either CYP2C19 or CYP2B6 resulted in a significant decrease in both V(max) (P= 0.028) and CL(int) (P= 0.0017) compared with livers with no LoF alleles.
 CYP2C1	Var	(1215, 1222)	 lowe	NegReg	(1275, 1280)	CauseOf	This dual genotype relationship was also observed in a preliminary clinical study, with patients who had 1 LoF allele at either CYP2C19 or CYP2B6 also displaying significantly (P= 0.0316) lower bioactivation of cyclophosphamide.
 CYP2B	Var	(1226, 1232)	 lowe	NegReg	(1275, 1280)	CauseOf	This dual genotype relationship was also observed in a preliminary clinical study, with patients who had 1 LoF allele at either CYP2C19 or CYP2B6 also displaying significantly (P= 0.0316) lower bioactivation of cyclophosphamide.
 bioactivation of cyclophosphamid	MPA	(1281, 1314)	 lowe	NegReg	(1275, 1280)	ThemeOf	This dual genotype relationship was also observed in a preliminary clinical study, with patients who had 1 LoF allele at either CYP2C19 or CYP2B6 also displaying significantly (P= 0.0316) lower bioactivation of cyclophosphamide.
TP53	Gene	(173, 177)	mutations	Var	(156, 165)	ThemeOf	More than half of all human cancers are associated with mutations of the TP53 gene.
mutations	Var	(156, 165)	associated	Reg	(140, 150)	CauseOf	More than half of all human cancers are associated with mutations of the TP53 gene.
human cancers	Disease	(122, 135)	associated	Reg	(140, 150)	ThemeOf	More than half of all human cancers are associated with mutations of the TP53 gene.
DN activity	MPA	(395, 406)	over the remaining WT allele	PosReg	(407, 435)	ThemeOf	The latter mutant protein has a DN activity over the remaining WT allele.
p53	Gene	(710, 713)	DN	Var	(707, 709)	ThemeOf	We previously showed that the DN p53 mutant was useful as a predictor of poor outcome or a risk factor for metastatic recurrence in patients with some types of cancers, regardless of the presence or absence of loss of heterozygosity (LOH) of WT p53, suggesting that the DN p53 had 'gain-of-function (GOF)' activity besides the transdominance function.
DN	Var	(707, 709)	'gain-of-function (GOF)' activity	PosReg	(718, 751)	CauseOf	We previously showed that the DN p53 mutant was useful as a predictor of poor outcome or a risk factor for metastatic recurrence in patients with some types of cancers, regardless of the presence or absence of loss of heterozygosity (LOH) of WT p53, suggesting that the DN p53 had 'gain-of-function (GOF)' activity besides the transdominance function.
R248Q-transfectants	Var	(1218, 1237)	higher	PosReg	(1257, 1263)	CauseOf	Meanwhile, in vitro invasions of Matrigel and type I collagen gel by R248Q-transfectants were significantly higher than those by R248W-transfectants or the control cells.
vitro invasions of Matrigel and type I collagen gel	CPA	(1163, 1214)	higher	PosReg	(1257, 1263)	ThemeOf	Meanwhile, in vitro invasions of Matrigel and type I collagen gel by R248Q-transfectants were significantly higher than those by R248W-transfectants or the control cells.
mutations	Var	(56, 65)	human cancers	Disease	(22, 35)	NoRelation	More than half of all human cancers are associated with mutations of the TP53 gene.
mutant	Var	(17, 23)	upregulates	PosReg	(28, 39)	CauseOf	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
p53 -R175H, -R273H and -D281G	Var	(390, 419)	enhanced	PosReg	(427, 435)	CauseOf	Cells expressing GOF p53 -R175H, -R273H and -D281G showed enhanced migration, which was reversed by RNA interference (RNAi) or transactivation-deficient mutants.
migration	CPA	(436, 445)	enhanced	PosReg	(427, 435)	ThemeOf	Cells expressing GOF p53 -R175H, -R273H and -D281G showed enhanced migration, which was reversed by RNA interference (RNAi) or transactivation-deficient mutants.
GOF p53	Var	(691, 698)	upregulate	PosReg	(708, 718)	CauseOf	We found that GOF p53 proteins upregulate CXC-chemokine expression, the inflammatory mediators that contribute to multiple aspects of tumorigenesis.
CXC-chemokine expression	MPA	(719, 743)	upregulate	PosReg	(708, 718)	ThemeOf	We found that GOF p53 proteins upregulate CXC-chemokine expression, the inflammatory mediators that contribute to multiple aspects of tumorigenesis.
oncogenic p53	Var	(903, 916)	Elevated	PosReg	(826, 834)	CauseOf	Elevated expression of CXCL5, CXCL8 and CXCL12 was found in cells expressing oncogenic p53.
expression	MPA	(835, 845)	Elevated	PosReg	(826, 834)	ThemeOf	Elevated expression of CXCL5, CXCL8 and CXCL12 was found in cells expressing oncogenic p53.
GOF p53	Var	(1013, 1020)	higher	PosReg	(986, 992)	CauseOf	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
CXCL5 and CXCL8 promoter activity	MPA	(948, 981)	higher	PosReg	(986, 992)	ThemeOf	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
CXCL5 and CXCL8 promoter activity	MPA	(948, 981)	elevated	PosReg	(936, 944)	CauseOf	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
CXC chemokines	MPA	(40, 54)	upregulates	PosReg	(28, 39)	ThemeOf	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Transcription	MPA	(918, 931)	elevated	PosReg	(936, 944)	ThemeOf	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
endogenous mutant	Var	(1383, 1400)	reduced	NegReg	(1438, 1445)	CauseOf	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
CXCL5 expression	MPA	(1446, 1462)	reduced	NegReg	(1438, 1445)	ThemeOf	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
cell migration	CPA	(1467, 1481)	reduced	NegReg	(1438, 1445)	ThemeOf	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
p53	Gene	(1401, 1404)	endogenous mutant	Var	(1383, 1400)	ThemeOf	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
mutant	Var	(1527, 1533)	reduced	NegReg	(1558, 1565)	CauseOf	Furthermore, short hairpin RNA knockdown of mutant p53 in MDA-MB-231 cells reduced expression of a number of key targets, including several chemokines and other inflammatory mediators.
expression of a number of key targets	MPA	(1566, 1603)	reduced	NegReg	(1558, 1565)	ThemeOf	Furthermore, short hairpin RNA knockdown of mutant p53 in MDA-MB-231 cells reduced expression of a number of key targets, including several chemokines and other inflammatory mediators.
p53	Gene	(1534, 1537)	mutant	Var	(1527, 1533)	ThemeOf	Furthermore, short hairpin RNA knockdown of mutant p53 in MDA-MB-231 cells reduced expression of a number of key targets, including several chemokines and other inflammatory mediators.
p53	Gene	(24, 27)	mutant	Var	(17, 23)	ThemeOf	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
GOF p53	Var	(1745, 1752)	elevated	PosReg	(1703, 1711)	CauseOf	Finally, CXCL5 expression was also elevated in lung tumor samples containing GOF p53, indicating relevance to human cancer.
CXCL5 expression	MPA	(1677, 1693)	elevated	PosReg	(1703, 1711)	ThemeOf	Finally, CXCL5 expression was also elevated in lung tumor samples containing GOF p53, indicating relevance to human cancer.
lung tumor	Disease	(1715, 1725)	elevated	PosReg	(1703, 1711)	ThemeOf	Finally, CXCL5 expression was also elevated in lung tumor samples containing GOF p53, indicating relevance to human cancer.
CXC chemokines	MPA	(40, 54)	enhances	PosReg	(59, 67)	CauseOf	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
cell migration	CPA	(68, 82)	enhances	PosReg	(59, 67)	ThemeOf	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
aberrant	Var	(195, 203)	enhance	PosReg	(221, 228)	CauseOf	Our previous data suggested that aberrant p53 proteins can enhance tumorigenesis and metastasis.
tumorigenesis and metastasis	CPA	(229, 257)	enhance	PosReg	(221, 228)	ThemeOf	Our previous data suggested that aberrant p53 proteins can enhance tumorigenesis and metastasis.
p53 proteins	Protein	(204, 216)	aberrant	Var	(195, 203)	ThemeOf	Our previous data suggested that aberrant p53 proteins can enhance tumorigenesis and metastasis.
mutant	Var	(17, 23)	enhances	PosReg	(59, 67)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
cell migration	CPA	(68, 82)	upregulates	PosReg	(28, 39)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
upregulates	PosReg	(28, 39)	enhances	PosReg	(59, 67)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
p53	Gene	(24, 27)	CXC chemokines	MPA	(40, 54)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
p53 proteins	Protein	(42, 54)	enhance	PosReg	(59, 66)	NoRelation	Our previous data suggested that aberrant p53 proteins can enhance tumorigenesis and metastasis.
p53 proteins	Protein	(42, 54)	tumorigenesis and metastasis	CPA	(67, 95)	NoRelation	Our previous data suggested that aberrant p53 proteins can enhance tumorigenesis and metastasis.
elevated	PosReg	(18, 26)	higher	PosReg	(68, 74)	NoRelation	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
GOF p53	Var	(95, 102)	elevated	PosReg	(18, 26)	NoRelation	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
Transcription	MPA	(0, 13)	higher	PosReg	(68, 74)	NoRelation	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
CXCL5 and CXCL8 promoter activity	MPA	(30, 63)	Transcription	MPA	(0, 13)	NoRelation	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
p53	Gene	(57, 60)	CXCL5 expression	MPA	(102, 118)	NoRelation	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
p53	Gene	(51, 54)	expression of a number of key targets	MPA	(83, 120)	NoRelation	Furthermore, short hairpin RNA knockdown of mutant p53 in MDA-MB-231 cells reduced expression of a number of key targets, including several chemokines and other inflammatory mediators.
lung tumor	Disease	(47, 57)	CXCL5 expression	MPA	(9, 25)	NoRelation	Finally, CXCL5 expression was also elevated in lung tumor samples containing GOF p53, indicating relevance to human cancer.
GOF p53	Var	(77, 84)	lung tumor	Disease	(47, 57)	NoRelation	Finally, CXCL5 expression was also elevated in lung tumor samples containing GOF p53, indicating relevance to human cancer.
p53	Gene	(45, 48)	mutants	Var	(49, 56)	ThemeOf	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
mutants	Var	(394, 401)	loss	NegReg	(413, 417)	CauseOf	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
activity	MPA	(425, 433)	loss	NegReg	(413, 417)	ThemeOf	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
mutants	Var	(394, 401)	lowering	NegReg	(446, 454)	CauseOf	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
cell growth rate	CPA	(458, 474)	lowering	NegReg	(446, 454)	ThemeOf	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
mutants p53-P278S and -R267P	Var	(540, 568)	reduction	NegReg	(575, 584)	CauseOf	Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels.
growth rate	MPA	(588, 599)	reduction	NegReg	(575, 584)	ThemeOf	Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels.
tumorigenicity	MPA	(689, 703)	loss	NegReg	(681, 685)	ThemeOf	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
reduction	NegReg	(646, 655)	p53	Var	(663, 666)	ThemeOf	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
mutants	Var	(49, 56)	gain-of-function	PosReg	(16, 32)	CauseOf	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
p53	Var	(663, 666)	escalates	PosReg	(736, 745)	CauseOf	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
tumorigenicity	MPA	(746, 760)	escalates	PosReg	(736, 745)	ThemeOf	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
p53	Var	(663, 666)	loss	NegReg	(681, 685)	CauseOf	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
lung cancer	Disease	(60, 71)	gain-of-function	PosReg	(16, 32)	ThemeOf	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
activity	MPA	(33, 41)	gain-of-function	PosReg	(16, 32)	ThemeOf	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
mutations	Var	(83, 92)	resulting in	Reg	(130, 142)	CauseOf	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
expression	MPA	(143, 153)	resulting in	Reg	(130, 142)	ThemeOf	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
p53	Gene	(79, 82)	mutations	Var	(83, 92)	ThemeOf	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
mutations	Var	(83, 92)	gain of function	PosReg	(187, 203)	CauseOf	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
activity	MPA	(211, 219)	gain of function	PosReg	(187, 203)	ThemeOf	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
p53	Gene	(390, 393)	mutants	Var	(394, 401)	ThemeOf	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
mutants	Var	(49, 56)	lung cancer	Disease	(60, 71)	NoRelation	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
p53	Gene	(45, 48)	activity	MPA	(33, 41)	NoRelation	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
p53	Gene	(0, 3)	expression	MPA	(64, 74)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
activity	MPA	(132, 140)	resulting in	Reg	(51, 63)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
expression	MPA	(64, 74)	gain of function	PosReg	(108, 124)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
resulting in	Reg	(51, 63)	gain of function	PosReg	(108, 124)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
activity	MPA	(132, 140)	expression	MPA	(64, 74)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
p53	Gene	(0, 3)	activity	MPA	(132, 140)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
loss	NegReg	(106, 110)	lowering	NegReg	(139, 147)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
p53	Gene	(83, 86)	activity	MPA	(118, 126)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
activity	MPA	(118, 126)	lowering	NegReg	(139, 147)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
loss	NegReg	(106, 110)	cell growth rate	CPA	(151, 167)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
escalates	PosReg	(107, 116)	reduction	NegReg	(17, 26)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
tumorigenicity	MPA	(60, 74)	escalates	PosReg	(107, 116)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
tumorigenicity	MPA	(117, 131)	loss	NegReg	(52, 56)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
tumorigenicity	MPA	(60, 74)	tumorigenicity	MPA	(117, 131)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
escalates	PosReg	(107, 116)	loss	NegReg	(52, 56)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
tumorigenicity	MPA	(117, 131)	reduction	NegReg	(17, 26)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
tumorigenicity	MPA	(60, 74)	reduction	NegReg	(17, 26)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
loss	NegReg	(52, 56)	reduction	NegReg	(17, 26)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
p53	Gene	(317, 320)	mutant	Var	(310, 316)	ThemeOf	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
expression of genes	MPA	(352, 371)	affect	Reg	(381, 387)	CauseOf	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
cell growth	CPA	(388, 399)	affect	Reg	(381, 387)	ThemeOf	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
mutants	Var	(552, 559)	up-regulated	PosReg	(532, 544)	CauseOf	In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G.
tyrosine kinase Axl	Enzyme	(502, 521)	up-regulated	PosReg	(532, 544)	ThemeOf	In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G.
p53	Gene	(548, 551)	mutants	Var	(552, 559)	ThemeOf	In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G.
p53	Gene	(1205, 1208)	mutant	Var	(1198, 1204)	ThemeOf	Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53.
mutant	Var	(1198, 1204)	histone	Reg	(1148, 1155)	CauseOf	Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53.
acetylation on the Axl promoter region	MPA	(1156, 1194)	histone	Reg	(1148, 1155)	ThemeOf	Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53.
p53	Gene	(1683, 1686)	mutant	Var	(1676, 1682)	ThemeOf	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
mutant	Var	(1676, 1682)	Axl	Protein	(1732, 1735)	ThemeOf	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
Axl	Protein	(1732, 1735)	mediated	Reg	(1707, 1715)	CauseOf	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
activities	MPA	(1692, 1702)	mediated	Reg	(1707, 1715)	ThemeOf	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
mutations	Var	(195, 204)	aggressively	PosReg	(228, 240)	CauseOf	Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53.
grow	CPA	(218, 222)	aggressively	PosReg	(228, 240)	ThemeOf	Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53.
oncogenesis	CPA	(404, 415)	affect	Reg	(381, 387)	ThemeOf	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
p53	Gene	(191, 194)	mutations	Var	(195, 204)	ThemeOf	Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53.
mutant	Var	(310, 316)	up-regulated	PosReg	(339, 351)	CauseOf	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
expression of genes	MPA	(352, 371)	up-regulated	PosReg	(339, 351)	ThemeOf	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
oncogenesis	CPA	(122, 133)	cell growth	CPA	(106, 117)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
up-regulated	PosReg	(57, 69)	affect	Reg	(99, 105)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
p53	Gene	(35, 38)	expression of genes	MPA	(70, 89)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
cell growth	CPA	(106, 117)	up-regulated	PosReg	(57, 69)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
mutant	Var	(28, 34)	affect	Reg	(99, 105)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
oncogenesis	CPA	(122, 133)	up-regulated	PosReg	(57, 69)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
p53	Gene	(131, 134)	tyrosine kinase Axl	Enzyme	(85, 104)	NoRelation	In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G.
tyrosine kinase Axl	Enzyme	(85, 104)	mutants	Var	(135, 142)	NoRelation	In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G.
mutant	Var	(52, 58)	mediated	Reg	(83, 91)	NoRelation	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
Axl	Protein	(108, 111)	p53	Gene	(59, 62)	NoRelation	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
Axl	Protein	(108, 111)	activities	MPA	(68, 78)	NoRelation	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
virulence	MPA	(489, 498)	enhanced	PosReg	(480, 488)	ThemeOf	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
mutations	Var	(910, 919)	decreased	NegReg	(1026, 1035)	CauseOf	GOF mutations in CgPDR1 did not influence survival and replication within macrophages following phagocytosis but led to decreased adherence to and uptake by macrophages.
adherence to and uptake by macrophages	CPA	(1036, 1074)	decreased	NegReg	(1026, 1035)	ThemeOf	GOF mutations in CgPDR1 did not influence survival and replication within macrophages following phagocytosis but led to decreased adherence to and uptake by macrophages.
mutations	Var	(1234, 1243)	increased	PosReg	(1323, 1332)	CauseOf	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
adherence	CPA	(1333, 1342)	increased	PosReg	(1323, 1332)	ThemeOf	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
epithelial colonization	CPA	(1264, 1287)	favor	PosReg	(1258, 1263)	ThemeOf	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
CgPDR1	Gene	(1247, 1253)	mutations	Var	(1234, 1243)	ThemeOf	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
mutations	Var	(1397, 1406)	modulate	Reg	(1417, 1425)	CauseOf	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
interaction	Interaction	(1430, 1441)	modulate	Reg	(1417, 1425)	ThemeOf	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
CgPDR1	Gene	(1410, 1416)	mutations	Var	(1397, 1406)	ThemeOf	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
mutations	Var	(1397, 1406)	increased	PosReg	(1489, 1498)	CauseOf	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
virulence	MPA	(1499, 1508)	increased	PosReg	(1489, 1498)	ThemeOf	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
regulation	MPA	(530, 540)	implicates	Reg	(505, 515)	ThemeOf	This implicates CgPDR1 in the regulation of the interaction of C. glabrata with the host.
interaction	Interaction	(548, 559)	regulation	MPA	(530, 540)	ThemeOf	This implicates CgPDR1 in the regulation of the interaction of C. glabrata with the host.
CgPDR1	Gene	(923, 929)	mutations	Var	(910, 919)	ThemeOf	GOF mutations in CgPDR1 did not influence survival and replication within macrophages following phagocytosis but led to decreased adherence to and uptake by macrophages.
increased	PosReg	(1323, 1332)	favor	PosReg	(1258, 1263)	CauseOf	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
mutations	Var	(395, 404)	gain-of-function	PosReg	(372, 388)	CauseOf	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
CgPDR1	Gene	(408, 414)	mutations	Var	(395, 404)	ThemeOf	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
mutations	Var	(395, 404)	lead	PosReg	(434, 438)	CauseOf	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
azole resistance	MPA	(451, 467)	lead	PosReg	(434, 438)	ThemeOf	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
mutations	Var	(395, 404)	enhanced	PosReg	(480, 488)	CauseOf	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
virulence	MPA	(128, 137)	lead	PosReg	(73, 77)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
azole resistance	MPA	(90, 106)	enhanced	PosReg	(119, 127)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
azole resistance	MPA	(90, 106)	gain-of-function	PosReg	(11, 27)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
enhanced	PosReg	(119, 127)	lead	PosReg	(73, 77)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
virulence	MPA	(128, 137)	gain-of-function	PosReg	(11, 27)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
lead	PosReg	(73, 77)	gain-of-function	PosReg	(11, 27)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
enhanced	PosReg	(119, 127)	gain-of-function	PosReg	(11, 27)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
CgPDR1	Gene	(16, 22)	interaction	Interaction	(48, 59)	NoRelation	This implicates CgPDR1 in the regulation of the interaction of C. glabrata with the host.
interaction	Interaction	(48, 59)	implicates	Reg	(5, 15)	NoRelation	This implicates CgPDR1 in the regulation of the interaction of C. glabrata with the host.
mutations	Var	(86, 95)	favor	PosReg	(110, 115)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
adherence	CPA	(185, 194)	favor	PosReg	(110, 115)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
epithelial colonization	CPA	(116, 139)	increased	PosReg	(175, 184)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
adherence	CPA	(185, 194)	epithelial colonization	CPA	(116, 139)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
virulence	MPA	(129, 138)	interaction	Interaction	(60, 71)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
increased	PosReg	(119, 128)	modulate	Reg	(47, 55)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
interaction	Interaction	(60, 71)	increased	PosReg	(119, 128)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
CgPDR1	Gene	(40, 46)	interaction	Interaction	(60, 71)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
virulence	MPA	(129, 138)	modulate	Reg	(47, 55)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
mutp53	Var	(735, 741)	accumulation	PosReg	(742, 754)	CauseOf	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
NF-B	Protein	(769, 774)	activation	PosReg	(775, 785)	CauseOf	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
activation	PosReg	(775, 785)	progress	PosReg	(699, 707)	CauseOf	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
invasive carcinoma	Disease	(711, 729)	progress	PosReg	(699, 707)	ThemeOf	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
accumulation	PosReg	(742, 754)	progress	PosReg	(699, 707)	CauseOf	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
mutp53	Var	(735, 741)	activation	PosReg	(775, 785)	CauseOf	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
colitis-associated colorectal cancer	Disease	(851, 887)	progress	PosReg	(699, 707)	ThemeOf	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
NF-B	Protein	(147, 152)	progress	PosReg	(77, 85)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
colitis-associated colorectal cancer	Disease	(229, 265)	activation	PosReg	(153, 163)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
colitis-associated colorectal cancer	Disease	(229, 265)	accumulation	PosReg	(120, 132)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
invasive carcinoma	Disease	(89, 107)	activation	PosReg	(153, 163)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
NF-B	Protein	(147, 152)	accumulation	PosReg	(120, 132)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
colitis-associated colorectal cancer	Disease	(229, 265)	invasive carcinoma	Disease	(89, 107)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
invasive carcinoma	Disease	(89, 107)	accumulation	PosReg	(120, 132)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
activation	PosReg	(153, 163)	accumulation	PosReg	(120, 132)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
mutp53	Var	(113, 119)	progress	PosReg	(77, 85)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
NF-B	Protein	(147, 152)	mutp53	Var	(113, 119)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
mutations	Var	(1119, 1128)	higher	PosReg	(1138, 1144)	CauseOf	Clinically, patients with GOF mutations showed a higher frequency of platinum resistance (22/58, 37.9%) than patients with NE-GOF mutations (12/56, 21.4%) (p=0.054).
platinum resistance	CPA	(1158, 1177)	higher	PosReg	(1138, 1144)	ThemeOf	Clinically, patients with GOF mutations showed a higher frequency of platinum resistance (22/58, 37.9%) than patients with NE-GOF mutations (12/56, 21.4%) (p=0.054).
mutations	Var	(1286, 1295)	develop	PosReg	(1316, 1323)	CauseOf	Furthermore, patients with GOF mutations were more likely to develop distant metastasis (36/55, 65.5%) than local recurrence (19/55, 34.5%), whereas patients with NE-GOF mutations showed a higher frequency of locoregional recurrence (26/47, 55.3%) than distant metastasis (21/47, 44.7%) (p=0.035).
distant metastasis	CPA	(1324, 1342)	develop	PosReg	(1316, 1323)	ThemeOf	Furthermore, patients with GOF mutations were more likely to develop distant metastasis (36/55, 65.5%) than local recurrence (19/55, 34.5%), whereas patients with NE-GOF mutations showed a higher frequency of locoregional recurrence (26/47, 55.3%) than distant metastasis (21/47, 44.7%) (p=0.035).
p53	Gene	(319, 322)	mutations	Var	(306, 315)	ThemeOf	In spite of growing evidence that gain-of-function (GOF) mutations of p53 also have oncogenic activity, little is known about the clinical relevance of these mutations.
mutations	Var	(306, 315)	gain-of-function	PosReg	(283, 299)	CauseOf	In spite of growing evidence that gain-of-function (GOF) mutations of p53 also have oncogenic activity, little is known about the clinical relevance of these mutations.
oncogenic activity	CPA	(333, 351)	gain-of-function	PosReg	(283, 299)	ThemeOf	In spite of growing evidence that gain-of-function (GOF) mutations of p53 also have oncogenic activity, little is known about the clinical relevance of these mutations.
mutp53	Var	(1721, 1727)	GOF	PosReg	(1717, 1720)	CauseOf	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
HGS-OvCa	Disease	(1839, 1847)	GOF	PosReg	(1717, 1720)	ThemeOf	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
p53	Gene	(52, 55)	mutations	Var	(39, 48)	ThemeOf	Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
mutations	Var	(39, 48)	gain-of-function	PosReg	(22, 38)	CauseOf	Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
high-grade serous ovarian carcinoma	Disease	(59, 94)	gain-of-function	PosReg	(22, 38)	ThemeOf	Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
mutp53	Var	(1721, 1727)	greater	PosReg	(1750, 1757)	CauseOf	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
platinum treatment resistance	CPA	(1772, 1801)	greater	PosReg	(1750, 1757)	ThemeOf	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
distant metastatic properties	CPA	(1806, 1835)	greater	PosReg	(1750, 1757)	ThemeOf	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
p53 protein	Protein	(775, 786)	mutation	Var	(807, 815)	ThemeOf	RESULTS: Patients with a mutant p53 protein (mutp53) with a GOF mutation showed higher p53 mRNA and protein expression levels than patients with p53 mutation with no evidence of GOF (NE-GOF).
mutation	Var	(807, 815)	higher	PosReg	(823, 829)	CauseOf	RESULTS: Patients with a mutant p53 protein (mutp53) with a GOF mutation showed higher p53 mRNA and protein expression levels than patients with p53 mutation with no evidence of GOF (NE-GOF).
p53 mRNA and protein expression levels	MPA	(830, 868)	higher	PosReg	(823, 829)	ThemeOf	RESULTS: Patients with a mutant p53 protein (mutp53) with a GOF mutation showed higher p53 mRNA and protein expression levels than patients with p53 mutation with no evidence of GOF (NE-GOF).
p53 protein	Protein	(32, 43)	p53 mRNA and protein expression levels	MPA	(87, 125)	NoRelation	RESULTS: Patients with a mutant p53 protein (mutp53) with a GOF mutation showed higher p53 mRNA and protein expression levels than patients with p53 mutation with no evidence of GOF (NE-GOF).
platinum treatment resistance	CPA	(109, 138)	HGS-OvCa	Disease	(176, 184)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
distant metastatic properties	CPA	(143, 172)	platinum treatment resistance	CPA	(109, 138)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
HGS-OvCa	Disease	(176, 184)	distant metastatic properties	CPA	(143, 172)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
GOF	PosReg	(54, 57)	greater	PosReg	(87, 94)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
platinum treatment resistance	CPA	(109, 138)	GOF	PosReg	(54, 57)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
distant metastatic properties	CPA	(143, 172)	GOF	PosReg	(54, 57)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
HGS-OvCa	Disease	(176, 184)	greater	PosReg	(87, 94)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
mutp53	Var	(1066, 1072)	GOF	PosReg	(1073, 1076)	CauseOf	Thus, overexpression of MDM2 isoforms promotes mutp53 accumulation in tumours, contributing to mutp53 GOF in tumorigenesis.
tumorigenesis	CPA	(1080, 1093)	GOF	PosReg	(1073, 1076)	ThemeOf	Thus, overexpression of MDM2 isoforms promotes mutp53 accumulation in tumours, contributing to mutp53 GOF in tumorigenesis.
mutp53	Var	(335, 341)	GOF	PosReg	(342, 345)	CauseOf	Mutp53 can accumulate to high levels in tumours, which promotes mutp53 GOF in tumorigenesis.
tumorigenesis	CPA	(349, 362)	GOF	PosReg	(342, 345)	ThemeOf	Mutp53 can accumulate to high levels in tumours, which promotes mutp53 GOF in tumorigenesis.
promoting tumorigenesis	CPA	(211, 234)	gain new activities	PosReg	(188, 207)	ThemeOf	Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF).
p53	Protein	(160, 163)	Mutant	Var	(153, 159)	ThemeOf	Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF).
Mutant	Var	(153, 159)	gain new activities	PosReg	(188, 207)	CauseOf	Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF).
p53-R248W/P72R	Var	(1700, 1714)	promoted	PosReg	(1729, 1737)	CauseOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
cancer stem-like features	CPA	(1738, 1763)	promoted	PosReg	(1729, 1737)	ThemeOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
p53-R248W/P72R	Var	(1700, 1714)	increased	PosReg	(1892, 1901)	CauseOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(1906, 1933)	increased	PosReg	(1892, 1901)	ThemeOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
p53	Gene	(7, 10)	Mutant	Var	(0, 6)	ThemeOf	Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Mutant	Var	(0, 6)	gain of function	PosReg	(11, 27)	CauseOf	Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
human osteosarcoma	Disease	(71, 89)	gain of function	PosReg	(11, 27)	ThemeOf	Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
high proliferation rate	CPA	(1768, 1791)	cancer stem-like features	CPA	(1738, 1763)	ThemeOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
sphere formation	CPA	(1793, 1809)	cancer stem-like features	CPA	(1738, 1763)	ThemeOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
clonogenic growth	CPA	(1811, 1828)	cancer stem-like features	CPA	(1738, 1763)	ThemeOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high migration	CPA	(1830, 1844)	cancer stem-like features	CPA	(1738, 1763)	ThemeOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
invasive ability	CPA	(1849, 1865)	cancer stem-like features	CPA	(1738, 1763)	ThemeOf	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
p53-R248W/P72R	Var	(1984, 1998)	involvement	Reg	(1969, 1980)	CauseOf	Overall, the findings suggest the involvement of p53-R248W/P72R at the origin of the aberrant characters of the 3AB-OS cells with the hypothesis that its GOF can be at the root of the dedifferentiation of MG63 cells into CSCs.
origin of the aberrant characters of the 3AB-OS cells	CPA	(2006, 2059)	involvement	Reg	(1969, 1980)	ThemeOf	Overall, the findings suggest the involvement of p53-R248W/P72R at the origin of the aberrant characters of the 3AB-OS cells with the hypothesis that its GOF can be at the root of the dedifferentiation of MG63 cells into CSCs.
high migration	CPA	(180, 194)	invasive ability	CPA	(199, 215)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	high migration	CPA	(180, 194)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	sphere formation	CPA	(143, 159)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	increased	PosReg	(242, 251)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(256, 283)	promoted	PosReg	(79, 87)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
sphere formation	CPA	(143, 159)	high migration	CPA	(180, 194)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
cancer stem-like features	CPA	(88, 113)	increased	PosReg	(242, 251)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high migration	CPA	(180, 194)	increased	PosReg	(242, 251)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
clonogenic growth	CPA	(161, 178)	high migration	CPA	(180, 194)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
invasive ability	CPA	(199, 215)	promoted	PosReg	(79, 87)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	invasive ability	CPA	(199, 215)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	promoted	PosReg	(79, 87)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high migration	CPA	(180, 194)	promoted	PosReg	(79, 87)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
clonogenic growth	CPA	(161, 178)	increased	PosReg	(242, 251)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
invasive ability	CPA	(199, 215)	increased	PosReg	(242, 251)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
sphere formation	CPA	(143, 159)	increased	PosReg	(242, 251)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
sphere formation	CPA	(143, 159)	promoted	PosReg	(79, 87)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
increased	PosReg	(242, 251)	promoted	PosReg	(79, 87)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
clonogenic growth	CPA	(161, 178)	promoted	PosReg	(79, 87)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
mutations	Var	(869, 878)	higher	PosReg	(888, 894)	CauseOf	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
activity	MPA	(895, 903)	higher	PosReg	(888, 894)	ThemeOf	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
p53	Gene	(994, 997)	mutant R282W	Var	(998, 1010)	ThemeOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutant R282W	Var	(998, 1010)	Ectopic expression	MPA	(972, 990)	ThemeOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
Ectopic expression	MPA	(972, 990)	upregulated	PosReg	(1050, 1061)	CauseOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4 mRNA and protein levels	MPA	(1062, 1092)	upregulated	PosReg	(1050, 1061)	ThemeOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
expression	MPA	(1181, 1191)	higher	PosReg	(1167, 1173)	ThemeOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
resistance	CPA	(1196, 1206)	higher	PosReg	(1167, 1173)	ThemeOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(1145, 1148)	mutations	Var	(1149, 1158)	ThemeOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutations	Var	(1149, 1158)	higher	PosReg	(1167, 1173)	CauseOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
drug-metabolizing enzymes	Enzyme	(907, 932)	activity	MPA	(895, 903)	ThemeOf	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
CYP3A4 cytochrome P450	Enzyme	(948, 970)	drug-metabolizing enzymes	Enzyme	(907, 932)	ThemeOf	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
CYP3A4	Enzyme	(1174, 1180)	expression	MPA	(1181, 1191)	ThemeOf	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4 cytochrome P450	Enzyme	(117, 139)	higher	PosReg	(57, 63)	NoRelation	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
CYP3A4 cytochrome P450	Enzyme	(117, 139)	activity	MPA	(64, 72)	NoRelation	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
drug-metabolizing enzymes	Enzyme	(76, 101)	higher	PosReg	(57, 63)	NoRelation	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
drug-metabolizing enzymes	Enzyme	(76, 101)	mutations	Var	(38, 47)	NoRelation	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
CYP3A4 cytochrome P450	Enzyme	(117, 139)	mutations	Var	(38, 47)	NoRelation	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
CYP3A4	Enzyme	(202, 208)	higher	PosReg	(195, 201)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutant R282W	Var	(26, 38)	upregulated	PosReg	(78, 89)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	Ectopic expression	MPA	(0, 18)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
expression	MPA	(209, 219)	upregulated	PosReg	(78, 89)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	p53	Gene	(22, 25)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutations	Var	(177, 186)	upregulated	PosReg	(78, 89)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	mutant R282W	Var	(26, 38)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutant R282W	Var	(26, 38)	higher	PosReg	(195, 201)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	CYP3A4 mRNA and protein levels	MPA	(90, 120)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
upregulated	PosReg	(78, 89)	higher	PosReg	(195, 201)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4 mRNA and protein levels	MPA	(90, 120)	higher	PosReg	(195, 201)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	p53	Gene	(173, 176)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(22, 25)	p53	Gene	(173, 176)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	mutations	Var	(177, 186)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutations	Var	(177, 186)	p53	Gene	(22, 25)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
resistance	CPA	(224, 234)	upregulated	PosReg	(78, 89)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
Ectopic expression	MPA	(0, 18)	higher	PosReg	(195, 201)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
-catenin	Protein	(809, 818)	mutants	Var	(860, 867)	ThemeOf	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
expression levels	MPA	(1206, 1223)	reduced	NegReg	(1198, 1205)	ThemeOf	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
expression	MPA	(1316, 1326)	induced	PosReg	(1414, 1421)	CauseOf	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
-catenin	Protein	(1457, 1466)	mutants	Var	(1471, 1478)	ThemeOf	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
mutants	Var	(1471, 1478)	induced	PosReg	(1414, 1421)	ThemeOf	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Msx2 gene	Gene	(1502, 1511)	expression	MPA	(1484, 1494)	ThemeOf	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
expression	MPA	(1484, 1494)	increased	PosReg	(1587, 1596)	ThemeOf	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
readouts of Bmp signaling	MPA	(1551, 1576)	increased	PosReg	(1587, 1596)	ThemeOf	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
mutants	Var	(1604, 1611)	increased	PosReg	(1587, 1596)	CauseOf	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
mutants	Var	(860, 867)	gain-of-function	PosReg	(829, 845)	CauseOf	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
mutants	Var	(860, 867)	loss	NegReg	(819, 823)	CauseOf	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
clefts in the perineal region	CPA	(887, 916)	loss	NegReg	(819, 823)	ThemeOf	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
hypoplastic elongation of the URS	CPA	(921, 954)	gain-of-function	PosReg	(829, 845)	ThemeOf	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
hypoplastic elongation of the URS	CPA	(921, 954)	loss	NegReg	(819, 823)	CauseOf	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
clefts in the perineal region	CPA	(887, 916)	gain-of-function	PosReg	(829, 845)	CauseOf	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
keratin 1	Protein	(1260, 1269)	expression levels	MPA	(1206, 1223)	ThemeOf	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
filaggrin	Protein	(1274, 1283)	expression levels	MPA	(1206, 1223)	ThemeOf	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
bone morphogenetic protein (Bmp) genes	Gene	(1330, 1368)	expression	MPA	(1316, 1326)	ThemeOf	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Bmp4	Gene	(1378, 1382)	bone morphogenetic protein (Bmp) genes	Gene	(1330, 1368)	ThemeOf	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Bmp7	Gene	(1387, 1391)	bone morphogenetic protein (Bmp) genes	Gene	(1330, 1368)	ThemeOf	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
ARM	Disease	(1882, 1885)	GOF	PosReg	(1914, 1917)	ThemeOf	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
mutants	Var	(1918, 1925)	caused by	Reg	(1931, 1940)	CauseOf	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
Bmp signaling	MPA	(1950, 1963)	caused by	Reg	(1931, 1940)	ThemeOf	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
mutants	Var	(960, 967)	reduced	NegReg	(983, 990)	CauseOf	The mutants also displayed reduced cell proliferation in the URS mesenchyme.
-catenin	Protein	(1904, 1913)	mutants	Var	(1918, 1925)	ThemeOf	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
caused by	Reg	(1931, 1940)	GOF	PosReg	(1914, 1917)	CauseOf	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
cell proliferation in the URS mesenchyme	CPA	(991, 1031)	reduced	NegReg	(983, 990)	ThemeOf	The mutants also displayed reduced cell proliferation in the URS mesenchyme.
-catenin	Protein	(1050, 1059)	mutants	Var	(1064, 1071)	ThemeOf	In addition, the -catenin GOF mutants displayed reduced apoptosis and subsequently increased apoptosis in the URS epithelium.
gain-of-function	PosReg	(25, 41)	loss	NegReg	(15, 19)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
-catenin	Protein	(5, 14)	loss	NegReg	(15, 19)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
filaggrin	Protein	(114, 123)	reduced	NegReg	(38, 45)	NoRelation	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
keratin 1	Protein	(100, 109)	reduced	NegReg	(38, 45)	NoRelation	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
Bmp4	Gene	(66, 70)	-catenin	Protein	(145, 154)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Bmp7	Gene	(75, 79)	-catenin	Protein	(145, 154)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Bmp4	Gene	(66, 70)	Bmp7	Gene	(75, 79)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
bone morphogenetic protein (Bmp) genes	Gene	(18, 56)	-catenin	Protein	(145, 154)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
-catenin	Protein	(145, 154)	expression	MPA	(4, 14)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
-catenin	Protein	(55, 64)	caused by	Reg	(82, 91)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
mutants	Var	(69, 76)	GOF	PosReg	(65, 68)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
Bmp signaling	MPA	(101, 114)	GOF	PosReg	(65, 68)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
ARM	Disease	(33, 36)	caused by	Reg	(82, 91)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
-catenin	Protein	(55, 64)	Bmp signaling	MPA	(101, 114)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
endodermal -catenin	Protein	(1518, 1538)	mutant	Var	(1543, 1549)	ThemeOf	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
mutant	Var	(1543, 1549)	GOF	PosReg	(1539, 1542)	CauseOf	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
GOF	PosReg	(1539, 1542)	reduced	NegReg	(1503, 1510)	CauseOf	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
apoptotic cells	CPA	(1473, 1488)	reduced	NegReg	(1503, 1510)	ThemeOf	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
apoptotic cells	CPA	(13, 28)	GOF	PosReg	(79, 82)	NoRelation	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
endodermal -catenin	Protein	(58, 78)	reduced	NegReg	(43, 50)	NoRelation	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
mutant	Var	(83, 89)	reduced	NegReg	(43, 50)	NoRelation	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
MC1R	Protein	(1114, 1118)	LOF	Var	(1107, 1110)	ThemeOf	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
LOF	Var	(1107, 1110)	compromises	NegReg	(1119, 1130)	CauseOf	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
genomic stability of melanocytes	CPA	(1143, 1175)	compromises	NegReg	(1119, 1130)	ThemeOf	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
DDR	MPA	(1135, 1138)	compromises	NegReg	(1119, 1130)	ThemeOf	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
MC1R	Protein	(141, 145)	DDR	MPA	(162, 165)	NoRelation	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
MC1R	Protein	(141, 145)	compromises	NegReg	(146, 157)	NoRelation	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
mutations	Var	(726, 735)	LOF	NegReg	(722, 725)	CauseOf	Here, we show that two hypocholesterolemia-associated LOF mutations in the PCSK9 gene can be accurately imputed into large-scale GWAS datasets which raises the possibility of assessing LOFs through genomics-linked medical records.
hypocholesterolemia	Disease	(691, 710)	LOF	NegReg	(722, 725)	ThemeOf	Here, we show that two hypocholesterolemia-associated LOF mutations in the PCSK9 gene can be accurately imputed into large-scale GWAS datasets which raises the possibility of assessing LOFs through genomics-linked medical records.
PCSK9	Gene	(743, 748)	mutations	Var	(726, 735)	ThemeOf	Here, we show that two hypocholesterolemia-associated LOF mutations in the PCSK9 gene can be accurately imputed into large-scale GWAS datasets which raises the possibility of assessing LOFs through genomics-linked medical records.
PDGF	Protein	(331, 335)	activity	MPA	(336, 344)	ThemeOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
mutations	Var	(617, 626)	LOF	NegReg	(613, 616)	CauseOf	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
familial idiopathic basal ganglia calcification	Disease	(705, 752)	LOF	NegReg	(613, 616)	ThemeOf	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
PDGF-R	Gene	(693, 700)	mutations	Var	(617, 626)	ThemeOf	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
activity	MPA	(336, 344)	ectopic	Var	(323, 330)	ThemeOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
ectopic	Var	(323, 330)	cause	Reg	(354, 359)	CauseOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
ectopic	Var	(323, 330)	contribute	Reg	(363, 373)	CauseOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
cancer	Disease	(394, 400)	contribute	Reg	(363, 373)	ThemeOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
tissue fibrosis	Disease	(405, 420)	contribute	Reg	(363, 373)	ThemeOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
cancer	Disease	(394, 400)	cause	Reg	(354, 359)	ThemeOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
tissue fibrosis	Disease	(405, 420)	cause	Reg	(354, 359)	ThemeOf	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
PDGF-B	Gene	(649, 655)	mutations	Var	(617, 626)	ThemeOf	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
PDGF	Protein	(21, 25)	ectopic	Var	(13, 20)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
activity	MPA	(26, 34)	cause	Reg	(44, 49)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
PDGF	Protein	(21, 25)	contribute	Reg	(53, 63)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
activity	MPA	(26, 34)	contribute	Reg	(53, 63)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
cancer	Disease	(84, 90)	tissue fibrosis	Disease	(95, 110)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
PDGF	Protein	(21, 25)	cause	Reg	(44, 49)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
PDGF-R	Gene	(135, 142)	PDGF-B	Gene	(91, 97)	NoRelation	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
sIL-1Ra production	MPA	(568, 586)	suppresses	NegReg	(553, 563)	ThemeOf	We show that mutp53 but not wild-type (wt) p53 suppresses the sIL-1Ra production in conditioned media of cancer cells.
p53	Gene	(7, 10)	Mutant	Var	(0, 6)	ThemeOf	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Mutant	Var	(0, 6)	promoting	PosReg	(33, 42)	CauseOf	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
inflammatory signals	MPA	(43, 63)	promoting	PosReg	(33, 42)	ThemeOf	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Mutant	Var	(0, 6)	repression	NegReg	(67, 77)	CauseOf	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Missense mutations	Var	(199, 217)	promote	PosReg	(271, 278)	CauseOf	Missense mutations can add novel functions (gain-of-function, GOF) that promote tumor malignancy.
tumor malignancy	CPA	(279, 295)	promote	PosReg	(271, 278)	ThemeOf	Missense mutations can add novel functions (gain-of-function, GOF) that promote tumor malignancy.
p53	Gene	(330, 333)	mutant	Var	(317, 323)	ThemeOf	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
mutant	Var	(317, 323)	suppressing	NegReg	(363, 374)	CauseOf	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
expression	MPA	(379, 389)	suppressing	NegReg	(363, 374)	ThemeOf	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
suppressing	NegReg	(363, 374)	promotes	PosReg	(334, 342)	CauseOf	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
tumor malignancy	CPA	(343, 359)	promotes	PosReg	(334, 342)	ThemeOf	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
mutp53	Var	(519, 525)	suppresses	NegReg	(553, 563)	CauseOf	We show that mutp53 but not wild-type (wt) p53 suppresses the sIL-1Ra production in conditioned media of cancer cells.
promoting	PosReg	(33, 42)	repression	NegReg	(67, 77)	NoRelation	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
inflammatory signals	MPA	(43, 63)	repression	NegReg	(67, 77)	NoRelation	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
expression	MPA	(82, 92)	promotes	PosReg	(37, 45)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
tumor malignancy	CPA	(46, 62)	suppressing	NegReg	(66, 77)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
mutant	Var	(20, 26)	promotes	PosReg	(37, 45)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
PPARG	Gene	(379, 384)	mutations	Var	(366, 375)	ThemeOf	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
variant	Var	(1521, 1528)	associated	Reg	(1610, 1620)	CauseOf	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
T2D	Disease	(1648, 1651)	associated	Reg	(1610, 1620)	ThemeOf	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
PPARG	Gene	(379, 384)	P12A	Var	(491, 495)	ThemeOf	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
mutations	Var	(366, 375)	loss-of-function	NegReg	(343, 359)	CauseOf	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
lipodystrophy	Disease	(415, 428)	loss-of-function	NegReg	(343, 359)	ThemeOf	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
insulin resistance	Disease	(433, 451)	loss-of-function	NegReg	(343, 359)	ThemeOf	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
P12A	Var	(491, 495)	decreased	NegReg	(525, 534)	CauseOf	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
type 2 diabetes	Disease	(543, 558)	decreased	NegReg	(525, 534)	ThemeOf	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
PPARG	Gene	(1532, 1537)	variant	Var	(1521, 1528)	ThemeOf	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
variant	Var	(1521, 1528)	reduces	NegReg	(1543, 1550)	CauseOf	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
function in a human adipocyte differentiation assay	CPA	(1551, 1602)	reduces	NegReg	(1543, 1550)	ThemeOf	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
type 2 diabetes	Disease	(218, 233)	insulin resistance	Disease	(108, 126)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
lipodystrophy	Disease	(90, 103)	type 2 diabetes	Disease	(218, 233)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
mutations	Var	(41, 50)	decreased	NegReg	(200, 209)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
decreased	NegReg	(200, 209)	insulin resistance	Disease	(108, 126)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
P12A	Var	(166, 170)	loss-of-function	NegReg	(18, 34)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
decreased	NegReg	(200, 209)	loss-of-function	NegReg	(18, 34)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
lipodystrophy	Disease	(90, 103)	decreased	NegReg	(200, 209)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
type 2 diabetes	Disease	(218, 233)	loss-of-function	NegReg	(18, 34)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
lipodystrophy	Disease	(90, 103)	insulin resistance	Disease	(108, 126)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
T2D	Disease	(274, 277)	function in a human adipocyte differentiation assay	CPA	(177, 228)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
reduces	NegReg	(169, 176)	associated	Reg	(236, 246)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
function in a human adipocyte differentiation assay	CPA	(177, 228)	associated	Reg	(236, 246)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
T2D	Disease	(274, 277)	reduces	NegReg	(169, 176)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
SHROOM3	Gene	(823, 830)	DNMs	Var	(790, 794)	ThemeOf	Notably, we identified two protein-truncating DNMs in two independent cases in SHROOM3, previously associated with NTDs only in animal models.
DNMs	Var	(790, 794)	truncating	NegReg	(779, 789)	CauseOf	Notably, we identified two protein-truncating DNMs in two independent cases in SHROOM3, previously associated with NTDs only in animal models.
protein	Protein	(771, 778)	truncating	NegReg	(779, 789)	ThemeOf	Notably, we identified two protein-truncating DNMs in two independent cases in SHROOM3, previously associated with NTDs only in animal models.
DNMs	Var	(1228, 1232)	LoF	NegReg	(1224, 1227)	CauseOf	CONCLUSIONS: Our study demonstrates an important role of LoF DNMs in the development of NTDs and strongly implicates SHROOM3 in its aetiology.
NTDs	Disease	(1255, 1259)	LoF	NegReg	(1224, 1227)	ThemeOf	CONCLUSIONS: Our study demonstrates an important role of LoF DNMs in the development of NTDs and strongly implicates SHROOM3 in its aetiology.
SHROOM3	Gene	(1284, 1291)	DNMs	Var	(1228, 1232)	ThemeOf	CONCLUSIONS: Our study demonstrates an important role of LoF DNMs in the development of NTDs and strongly implicates SHROOM3 in its aetiology.
DNMs	Var	(940, 944)	LoF	NegReg	(936, 939)	CauseOf	We have demonstrated a significant enrichment of LoF DNMs in this gene in NTDs compared with the gene specific DNM rate and to the DNM rate estimated from control cohorts.
NTDs	Disease	(961, 965)	LoF	NegReg	(936, 939)	ThemeOf	We have demonstrated a significant enrichment of LoF DNMs in this gene in NTDs compared with the gene specific DNM rate and to the DNM rate estimated from control cohorts.
protein	Protein	(27, 34)	DNMs	Var	(46, 50)	NoRelation	Notably, we identified two protein-truncating DNMs in two independent cases in SHROOM3, previously associated with NTDs only in animal models.
SHROOM3	Gene	(79, 86)	protein	Protein	(27, 34)	NoRelation	Notably, we identified two protein-truncating DNMs in two independent cases in SHROOM3, previously associated with NTDs only in animal models.
TXNDC5	Gene	(901, 907)	variation	Var	(888, 897)	ThemeOf	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
variation	Var	(888, 897)	LOF	NegReg	(884, 887)	CauseOf	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
LOF	NegReg	(884, 887)	elevated	PosReg	(831, 839)	CauseOf	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
glucose	MPA	(848, 855)	elevated	PosReg	(831, 839)	ThemeOf	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
C1QTNF8	Gene	(1002, 1009)	recessive effects	NegReg	(981, 998)	CauseOf	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
serum magnesium levels	MPA	(1013, 1035)	recessive effects	NegReg	(981, 998)	ThemeOf	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
variation	Var	(99, 108)	elevated	PosReg	(42, 50)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
glucose	MPA	(59, 66)	recessive effects	NegReg	(192, 209)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
serum magnesium levels	MPA	(224, 246)	LOF	NegReg	(95, 98)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
serum magnesium levels	MPA	(224, 246)	elevated	PosReg	(42, 50)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
variation	Var	(99, 108)	recessive effects	NegReg	(192, 209)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
TXNDC5	Gene	(112, 118)	C1QTNF8	Gene	(213, 220)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
recessive effects	NegReg	(192, 209)	LOF	NegReg	(95, 98)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
recessive effects	NegReg	(192, 209)	elevated	PosReg	(42, 50)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
glucose	MPA	(59, 66)	LOF	NegReg	(95, 98)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
p53	Gene	(416, 419)	proteins	Protein	(429, 437)	ThemeOf	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
resistant	CPA	(939, 948)	more	PosReg	(934, 938)	ThemeOf	This coordinated adaptive mechanism renders cancer cells more resistant to proteotoxic stress and provides both, a strong survival advantage to cancer cells and a promising means for therapeutic intervention.
survival advantage	CPA	(999, 1017)	more	PosReg	(934, 938)	ThemeOf	This coordinated adaptive mechanism renders cancer cells more resistant to proteotoxic stress and provides both, a strong survival advantage to cancer cells and a promising means for therapeutic intervention.
proteins	Protein	(429, 437)	mutant	Var	(409, 415)	ThemeOf	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
mutant	Var	(409, 415)	lose	NegReg	(447, 451)	CauseOf	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
tumor suppressor activity	CPA	(468, 493)	lose	NegReg	(447, 451)	ThemeOf	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
mutant	Var	(409, 415)	promote	PosReg	(516, 523)	CauseOf	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
tumor development	CPA	(524, 541)	promote	PosReg	(516, 523)	ThemeOf	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
mutp53	Var	(578, 584)	gain	PosReg	(681, 685)	CauseOf	Two main mechanisms accounting for mutp53 proto-oncogenic activity are inhibition of the wild-type p53 in a dominant-negative fashion and gain of additional oncogenic activities known as gain-of-function (GOF).
oncogenic activities	CPA	(700, 720)	gain	PosReg	(681, 685)	ThemeOf	Two main mechanisms accounting for mutp53 proto-oncogenic activity are inhibition of the wild-type p53 in a dominant-negative fashion and gain of additional oncogenic activities known as gain-of-function (GOF).
tumor suppressor activity	CPA	(72, 97)	promote	PosReg	(120, 127)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
proteins	Protein	(33, 41)	lose	NegReg	(51, 55)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
lose	NegReg	(51, 55)	tumor development	CPA	(128, 145)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
promote	PosReg	(120, 127)	lose	NegReg	(51, 55)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
MC1R	Gene	(737, 741)	p.Tyr298*	Var	(727, 736)	ThemeOf	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
plasma membrane expression	MPA	(1074, 1100)	reduced	NegReg	(1066, 1073)	ThemeOf	Flow cytometry and confocal imaging studies revealed reduced plasma membrane expression of p.Val174del and p.Tyr298*.
p.Val174del	Var	(1104, 1115)	reduced	NegReg	(1066, 1073)	CauseOf	Flow cytometry and confocal imaging studies revealed reduced plasma membrane expression of p.Val174del and p.Tyr298*.
p.Tyr298*	Var	(1120, 1129)	reduced	NegReg	(1066, 1073)	CauseOf	Flow cytometry and confocal imaging studies revealed reduced plasma membrane expression of p.Val174del and p.Tyr298*.
p.Tyr298*	Var	(1142, 1151)	loss-of-function	NegReg	(1164, 1180)	CauseOf	Therefore, p.Tyr298* was a total loss-of-function (LOF) allele, while p.Val174del displayed a partial LOF attribute.
p.Val174del	Var	(1201, 1212)	partial LOF	NegReg	(1225, 1236)	CauseOf	Therefore, p.Tyr298* was a total loss-of-function (LOF) allele, while p.Val174del displayed a partial LOF attribute.
p.Tyr298*	Var	(727, 736)	no	NegReg	(749, 751)	CauseOf	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
p.Tyr298*	Var	(727, 736)	nor	NegReg	(807, 810)	CauseOf	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
agonist binding	Interaction	(822, 837)	nor	NegReg	(807, 810)	ThemeOf	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
no	NegReg	(749, 751)	agonist-induced signaling	MPA	(752, 777)	ThemeOf	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cAMP	Pathway	(785, 789)	agonist-induced signaling	MPA	(752, 777)	ThemeOf	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
ERK pathways	Pathway	(793, 805)	agonist-induced signaling	MPA	(752, 777)	ThemeOf	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
p.Val174del	Var	(880, 891)	impaired	NegReg	(979, 987)	CauseOf	Conversely, signaling was comparable for p.Val174del and wild-type in HEK cells overexpressing the proteins, but binding analysis suggested impaired cell surface expression.
cell surface expression	MPA	(988, 1011)	impaired	NegReg	(979, 987)	ThemeOf	Conversely, signaling was comparable for p.Val174del and wild-type in HEK cells overexpressing the proteins, but binding analysis suggested impaired cell surface expression.
no	NegReg	(22, 24)	nor	NegReg	(80, 83)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
ERK pathways	Pathway	(66, 78)	no	NegReg	(22, 24)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
agonist-induced signaling	MPA	(25, 50)	agonist binding	Interaction	(95, 110)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
agonist binding	Interaction	(95, 110)	no	NegReg	(22, 24)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
MC1R	Gene	(10, 14)	agonist binding	Interaction	(95, 110)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cAMP	Pathway	(58, 62)	no	NegReg	(22, 24)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
agonist-induced signaling	MPA	(25, 50)	nor	NegReg	(80, 83)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
p.Tyr298*	Var	(11, 20)	partial LOF	NegReg	(94, 105)	NoRelation	Therefore, p.Tyr298* was a total loss-of-function (LOF) allele, while p.Val174del displayed a partial LOF attribute.
loss-of-function	NegReg	(33, 49)	partial LOF	NegReg	(94, 105)	NoRelation	Therefore, p.Tyr298* was a total loss-of-function (LOF) allele, while p.Val174del displayed a partial LOF attribute.
p.Val174del	Var	(70, 81)	loss-of-function	NegReg	(33, 49)	NoRelation	Therefore, p.Tyr298* was a total loss-of-function (LOF) allele, while p.Val174del displayed a partial LOF attribute.
p53	Gene	(183, 186)	missense mutations	Var	(187, 205)	ThemeOf	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
MLL2	Enzyme	(454, 458)	chromatin regulatory genes	Gene	(365, 391)	ThemeOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(486, 507)	chromatin regulatory genes	Gene	(365, 391)	ThemeOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
missense mutations	Var	(187, 205)	promotes	PosReg	(291, 299)	CauseOf	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
cancer	Disease	(300, 306)	promotes	PosReg	(291, 299)	ThemeOf	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
upregulate	PosReg	(354, 364)	increases	PosReg	(565, 574)	CauseOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
histone methylation	MPA	(578, 597)	increases	PosReg	(565, 574)	ThemeOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetylation	MPA	(602, 613)	increases	PosReg	(565, 574)	ThemeOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
p53	Gene	(705, 708)	GOF	Var	(709, 712)	ThemeOf	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
GOF	Var	(709, 712)	upregulation	PosReg	(666, 678)	CauseOf	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MLL1	Enzyme	(682, 686)	upregulation	PosReg	(666, 678)	ThemeOf	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
missense mutations	Var	(187, 205)	abrogate	NegReg	(206, 214)	CauseOf	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
MLL2	Enzyme	(688, 692)	upregulation	PosReg	(666, 678)	ThemeOf	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MOZ	Enzyme	(698, 701)	upregulation	PosReg	(666, 678)	ThemeOf	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
tumour suppressive function	CPA	(219, 246)	abrogate	NegReg	(206, 214)	ThemeOf	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
missense mutations	Var	(187, 205)	gain-of-function	PosReg	(262, 278)	CauseOf	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
p53	Gene	(326, 329)	mutants	Var	(334, 341)	ThemeOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
mutants	Var	(334, 341)	GOF	PosReg	(330, 333)	CauseOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
mutants	Var	(334, 341)	upregulate	PosReg	(354, 364)	CauseOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
chromatin regulatory genes	Gene	(365, 391)	upregulate	PosReg	(354, 364)	ThemeOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
methyltransferases MLL1	Enzyme	(407, 430)	chromatin regulatory genes	Gene	(365, 391)	ThemeOf	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
abrogate	NegReg	(33, 41)	cancer	Disease	(127, 133)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
cancer	Disease	(127, 133)	tumour suppressive function	CPA	(46, 73)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
cancer	Disease	(127, 133)	gain-of-function	PosReg	(89, 105)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
tumour suppressive function	CPA	(46, 73)	gain-of-function	PosReg	(89, 105)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
abrogate	NegReg	(33, 41)	promotes	PosReg	(118, 126)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
tumour suppressive function	CPA	(46, 73)	promotes	PosReg	(118, 126)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
gain-of-function	PosReg	(89, 105)	promotes	PosReg	(118, 126)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
gain-of-function	PosReg	(89, 105)	abrogate	NegReg	(33, 41)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
MLL2	Enzyme	(146, 150)	acetylation	MPA	(294, 305)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(146, 150)	methyltransferases MLL1	Enzyme	(99, 122)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
methyltransferases MLL1	Enzyme	(99, 122)	acetylation	MPA	(294, 305)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	acetylation	MPA	(294, 305)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(146, 150)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	histone methylation	MPA	(270, 289)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
upregulate	PosReg	(46, 56)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(146, 150)	histone methylation	MPA	(270, 289)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetylation	MPA	(294, 305)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetylation	MPA	(294, 305)	upregulate	PosReg	(46, 56)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
increases	PosReg	(257, 266)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
methyltransferases MLL1	Enzyme	(99, 122)	histone methylation	MPA	(270, 289)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
histone methylation	MPA	(270, 289)	upregulate	PosReg	(46, 56)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
mutants	Var	(26, 33)	increases	PosReg	(257, 266)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
histone methylation	MPA	(270, 289)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
p53	Gene	(645, 648)	mutant	Var	(638, 644)	ThemeOf	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
expression	MPA	(852, 862)	regulates	Reg	(838, 847)	ThemeOf	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
ABCG2	Gene	(1322, 1327)	expression	MPA	(1328, 1338)	ThemeOf	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
JNK-c-Jun signaling	MPA	(1374, 1393)	induces	PosReg	(1314, 1321)	ThemeOf	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
expression	MPA	(1328, 1338)	induces	PosReg	(1314, 1321)	ThemeOf	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
p53	Gene	(1404, 1407)	mutant	Var	(1397, 1403)	ThemeOf	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
mutant	Var	(1397, 1403)	induces	PosReg	(1314, 1321)	CauseOf	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
mutant	Var	(638, 644)	upregulates	PosReg	(680, 691)	CauseOf	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
EFNB2	Gene	(692, 697)	expression	MPA	(698, 708)	ThemeOf	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
expression	MPA	(698, 708)	upregulates	PosReg	(680, 691)	ThemeOf	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
response to DNA damage	MPA	(712, 734)	upregulates	PosReg	(680, 691)	ThemeOf	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
mutant	Var	(769, 775)	recruited	PosReg	(791, 800)	CauseOf	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
p53	Gene	(776, 779)	protein	Protein	(780, 787)	ThemeOf	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
protein	Protein	(780, 787)	mutant	Var	(769, 775)	ThemeOf	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
mutant	Var	(769, 775)	regulates	Reg	(838, 847)	CauseOf	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
expression	MPA	(116, 126)	recruited	PosReg	(55, 64)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
protein	Protein	(44, 51)	regulates	Reg	(102, 111)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
protein	Protein	(44, 51)	expression	MPA	(116, 126)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
recruited	PosReg	(55, 64)	regulates	Reg	(102, 111)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
PCSK9	Gene	(248, 253)	mutations	Var	(277, 286)	ThemeOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
mutations	Var	(277, 286)	gain-of-function	PosReg	(254, 270)	CauseOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(307, 346)	gain-of-function	PosReg	(254, 270)	ThemeOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(357, 382)	gain-of-function	PosReg	(254, 270)	ThemeOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(384, 389)	mutations	Var	(413, 422)	ThemeOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
mutations	Var	(413, 422)	loss-of-function	NegReg	(390, 406)	CauseOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
familial hypobetalipoproteinemia	Disease	(485, 517)	loss-of-function	NegReg	(390, 406)	ThemeOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
mutations	Var	(413, 422)	have	PosReg	(423, 427)	CauseOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
cardio-protective effect	CPA	(430, 454)	have	PosReg	(423, 427)	ThemeOf	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
gain-of-function	PosReg	(14, 30)	loss-of-function	NegReg	(150, 166)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	loss-of-function	NegReg	(150, 166)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	cardio-protective effect	CPA	(190, 214)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
familial hypobetalipoproteinemia	Disease	(245, 277)	cardio-protective effect	CPA	(190, 214)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
mutations	Var	(173, 182)	gain-of-function	PosReg	(14, 30)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
familial hypobetalipoproteinemia	Disease	(245, 277)	gain-of-function	PosReg	(14, 30)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(67, 106)	loss-of-function	NegReg	(150, 166)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	autosomal dominant hypercholesterolemia	Disease	(67, 106)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
mutations	Var	(37, 46)	loss-of-function	NegReg	(150, 166)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
cardio-protective effect	CPA	(190, 214)	loss-of-function	NegReg	(150, 166)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
loss-of-function	NegReg	(150, 166)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
familial hypobetalipoproteinemia	Disease	(245, 277)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	familial hypobetalipoproteinemia	Disease	(245, 277)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(67, 106)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
mutations	Var	(37, 46)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(67, 106)	familial hypobetalipoproteinemia	Disease	(245, 277)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
cardio-protective effect	CPA	(190, 214)	gain-of-function	PosReg	(14, 30)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
MLK4	Gene	(10, 14)	Mutations	Var	(32, 41)	ThemeOf	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
mutations	Var	(1363, 1372)	LOF	NegReg	(1359, 1362)	CauseOf	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
mutations	Var	(1363, 1372)	diminished	NegReg	(1386, 1396)	CauseOf	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
signaling	MPA	(1397, 1406)	diminished	NegReg	(1386, 1396)	ThemeOf	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
signaling	MPA	(1397, 1406)	JNK pathway	Pathway	(1414, 1425)	ThemeOf	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
mutations	Var	(1363, 1372)	enhanced	PosReg	(1430, 1438)	CauseOf	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
proliferation	CPA	(1439, 1452)	enhanced	PosReg	(1430, 1438)	ThemeOf	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
Mutations	Var	(32, 41)	Loss-of-Function	NegReg	(15, 31)	CauseOf	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Mutations	Var	(32, 41)	Suppress	NegReg	(42, 50)	CauseOf	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
JNK Signaling	Pathway	(51, 64)	Suppress	NegReg	(42, 50)	ThemeOf	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Mutations	Var	(32, 41)	Promote	PosReg	(68, 75)	CauseOf	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Colon Tumorigenesis	Disease	(76, 95)	Promote	PosReg	(68, 75)	ThemeOf	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
MLK4	Gene	(537, 541)	mutations	Var	(542, 551)	ThemeOf	Biochemical data indicated that a majority of MLK4 mutations are loss-of-function (LOF) mutations that can exert dominant-negative effects.
mutations	Var	(542, 551)	loss-of-function	NegReg	(556, 572)	CauseOf	Biochemical data indicated that a majority of MLK4 mutations are loss-of-function (LOF) mutations that can exert dominant-negative effects.
MLK4	Gene	(1299, 1303)	mutations	Var	(1363, 1372)	ThemeOf	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
JNK Signaling	Pathway	(51, 64)	Promote	PosReg	(68, 75)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Suppress	NegReg	(42, 50)	Loss-of-Function	NegReg	(15, 31)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Suppress	NegReg	(42, 50)	Colon Tumorigenesis	Disease	(76, 95)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Promote	PosReg	(68, 75)	Loss-of-Function	NegReg	(15, 31)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Suppress	NegReg	(42, 50)	Promote	PosReg	(68, 75)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Loss-of-Function	NegReg	(15, 31)	Colon Tumorigenesis	Disease	(76, 95)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
diminished	NegReg	(111, 121)	proliferation	CPA	(164, 177)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
signaling	MPA	(122, 131)	LOF	NegReg	(84, 87)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
diminished	NegReg	(111, 121)	LOF	NegReg	(84, 87)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
LOF	NegReg	(84, 87)	enhanced	PosReg	(155, 163)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
JNK pathway	Pathway	(139, 150)	enhanced	PosReg	(155, 163)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
signaling	MPA	(122, 131)	enhanced	PosReg	(155, 163)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
proliferation	CPA	(164, 177)	LOF	NegReg	(84, 87)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
diminished	NegReg	(111, 121)	enhanced	PosReg	(155, 163)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
p53	Gene	(237, 240)	missense mutants	Var	(241, 257)	ThemeOf	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
missense mutants	Var	(241, 257)	gain-of-function	PosReg	(266, 282)	CauseOf	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
chemoresistance	CPA	(351, 366)	enhanced	PosReg	(342, 350)	ThemeOf	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
missense mutants	Var	(241, 257)	enhanced	PosReg	(342, 350)	CauseOf	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
mutant	Var	(1063, 1069)	GOF	PosReg	(1059, 1062)	CauseOf	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
p53	Gene	(1070, 1073)	mutant	Var	(1063, 1069)	ThemeOf	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
mutant	Var	(1063, 1069)	modulate	Reg	(1078, 1086)	CauseOf	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
key cellular pathways	Pathway	(1087, 1108)	modulate	Reg	(1078, 1086)	ThemeOf	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
withstand the cytotoxic effect of the drugs	CPA	(1112, 1155)	modulate	Reg	(1078, 1086)	ThemeOf	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
chemoresistance	CPA	(139, 154)	gain-of-function	PosReg	(54, 70)	NoRelation	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
withstand the cytotoxic effect of the drugs	CPA	(137, 180)	GOF	PosReg	(84, 87)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
TBR1	Gene	(231, 235)	variants	Var	(159, 167)	ThemeOf	Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including TBR1, a master regulator of cortical development.
variants	Var	(159, 167)	loss-of-function	NegReg	(136, 152)	CauseOf	Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including TBR1, a master regulator of cortical development.
autism spectrum disorders	Disease	(188, 213)	loss-of-function	NegReg	(136, 152)	ThemeOf	Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including TBR1, a master regulator of cortical development.
TNFAIP8	Gene	(95, 102)	mutation	Var	(19, 27)	ThemeOf	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
tumor suppressive functions	CPA	(389, 416)	blocking	NegReg	(373, 381)	ThemeOf	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
missense mutations	Var	(471, 489)	gain-of-function	PosReg	(504, 520)	CauseOf	In addition to the loss of canonical functions, some missense mutations in p53 confer gain-of-function (GOF) activities to tumor cells.
activities to tumor cells	CPA	(527, 552)	gain-of-function	PosReg	(504, 520)	ThemeOf	In addition to the loss of canonical functions, some missense mutations in p53 confer gain-of-function (GOF) activities to tumor cells.
p53	Gene	(493, 496)	missense mutations	Var	(471, 489)	ThemeOf	In addition to the loss of canonical functions, some missense mutations in p53 confer gain-of-function (GOF) activities to tumor cells.
mutations at K120	Var	(749, 766)	confer	PosReg	(803, 809)	CauseOf	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
p53	Gene	(810, 813)	mutations at K120	Var	(749, 766)	ThemeOf	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
ability	MPA	(847, 854)	confer	PosReg	(803, 809)	ThemeOf	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
bind	Interaction	(858, 862)	ability	MPA	(847, 854)	ThemeOf	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
mutations at K120	Var	(749, 766)	activate	PosReg	(867, 875)	CauseOf	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
transcription	MPA	(880, 893)	activate	PosReg	(867, 875)	ThemeOf	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
mutation	Var	(19, 27)	confers	PosReg	(38, 45)	CauseOf	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
TNFAIP8	Gene	(914, 921)	transcription	MPA	(880, 893)	ThemeOf	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
mutant	Var	(1274, 1280)	gain-of-function	PosReg	(1244, 1260)	CauseOf	These findings identify induction of pro-survival targets as a mechanism of gain-of-function activity for mutant p53 and will likely broaden our understanding of this phenomenon beyond the limited number of GOF activities currently reported for hotspot mutants.
activity	MPA	(1261, 1269)	gain-of-function	PosReg	(1244, 1260)	ThemeOf	These findings identify induction of pro-survival targets as a mechanism of gain-of-function activity for mutant p53 and will likely broaden our understanding of this phenomenon beyond the limited number of GOF activities currently reported for hotspot mutants.
p53	Gene	(1281, 1284)	activity	MPA	(1261, 1269)	ThemeOf	These findings identify induction of pro-survival targets as a mechanism of gain-of-function activity for mutant p53 and will likely broaden our understanding of this phenomenon beyond the limited number of GOF activities currently reported for hotspot mutants.
binding	Interaction	(351, 358)	result in	Reg	(277, 286)	ThemeOf	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
gain-of-function	PosReg	(50, 66)	confers	PosReg	(38, 45)	ThemeOf	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
p53	Gene	(46, 49)	gain-of-function	PosReg	(50, 66)	ThemeOf	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
tumor cell survival	CPA	(71, 90)	confers	PosReg	(38, 45)	ThemeOf	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
p53	Gene	(230, 233)	Mutations	Var	(194, 203)	ThemeOf	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
Mutations	Var	(194, 203)	result in	Reg	(277, 286)	CauseOf	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
substitutions	Var	(305, 318)	result in	Reg	(277, 286)	ThemeOf	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
blocking	NegReg	(373, 381)	result in	Reg	(277, 286)	ThemeOf	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
mutation	Var	(19, 27)	gain-of-function	PosReg	(50, 66)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
tumor cell survival	CPA	(71, 90)	gain-of-function	PosReg	(50, 66)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
p53	Gene	(36, 39)	binding	Interaction	(157, 164)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
Mutations	Var	(0, 9)	blocking	NegReg	(179, 187)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
substitutions	Var	(111, 124)	blocking	NegReg	(179, 187)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
binding	Interaction	(157, 164)	blocking	NegReg	(179, 187)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
tumor suppressive functions	CPA	(195, 222)	result in	Reg	(83, 92)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
transcription	MPA	(151, 164)	confer	PosReg	(74, 80)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
bind	Interaction	(129, 133)	confer	PosReg	(74, 80)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
bind	Interaction	(129, 133)	activate	PosReg	(138, 146)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
bind	Interaction	(129, 133)	transcription	MPA	(151, 164)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
ability	MPA	(118, 125)	activate	PosReg	(138, 146)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
mutations	Var	(628, 637)	loss-of-function	NegReg	(605, 621)	CauseOf	Here, we report on an ID syndrome caused by de novo heterozygous loss-of-function (LoF) mutations in SON.
Intellectual-Disability Syndrome	Disease	(114, 146)	Causing	Reg	(103, 110)	ThemeOf	De Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development and Metabolism, Causing an Intellectual-Disability Syndrome.
SON	Gene	(21, 24)	Mutations	Var	(8, 17)	ThemeOf	De Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development and Metabolism, Causing an Intellectual-Disability Syndrome.
ID syndrome	Disease	(562, 573)	loss-of-function	NegReg	(605, 621)	ThemeOf	Here, we report on an ID syndrome caused by de novo heterozygous loss-of-function (LoF) mutations in SON.
SON	Gene	(641, 644)	mutations	Var	(628, 637)	ThemeOf	Here, we report on an ID syndrome caused by de novo heterozygous loss-of-function (LoF) mutations in SON.
erroneous SON-mediated RNA splicing	Var	(1239, 1274)	accumulation	PosReg	(1184, 1196)	CauseOf	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
accumulation	PosReg	(1184, 1196)	downregulated	NegReg	(1155, 1168)	CauseOf	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
cortex organization	CPA	(1023, 1042)	downregulated	NegReg	(1155, 1168)	ThemeOf	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
metabolism	CPA	(1092, 1102)	downregulated	NegReg	(1155, 1168)	ThemeOf	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
neuronal migration	CPA	(1000, 1018)	downregulated	NegReg	(1155, 1168)	ThemeOf	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
Mutations	Var	(8, 17)	Causing	Reg	(103, 110)	CauseOf	De Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development and Metabolism, Causing an Intellectual-Disability Syndrome.
neuronal migration	CPA	(88, 106)	accumulation	PosReg	(272, 284)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
cortex organization	CPA	(111, 130)	accumulation	PosReg	(272, 284)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
metabolism	CPA	(180, 190)	accumulation	PosReg	(272, 284)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
erroneous SON-mediated RNA splicing	Var	(327, 362)	downregulated	NegReg	(243, 256)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
PCSK9	Gene	(80, 85)	variants	Var	(103, 111)	ThemeOf	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
variant	Var	(1367, 1374)	absence	NegReg	(1310, 1317)	CauseOf	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
variant	Var	(1367, 1374)	novel role	PosReg	(1396, 1406)	CauseOf	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
interactions	Interaction	(1438, 1450)	novel role	PosReg	(1396, 1406)	ThemeOf	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
PCSK9	Gene	(917, 922)	variant	Var	(927, 934)	ThemeOf	In contrast, PBMC-CM-F or -PP from PCSK9 LOF variant subjects had no effect on adipogenesis.
variant	Var	(927, 934)	LOF	NegReg	(923, 926)	CauseOf	In contrast, PBMC-CM-F or -PP from PCSK9 LOF variant subjects had no effect on adipogenesis.
adipogenesis	MPA	(961, 973)	LOF	NegReg	(923, 926)	ThemeOf	In contrast, PBMC-CM-F or -PP from PCSK9 LOF variant subjects had no effect on adipogenesis.
PCSK9	Gene	(1010, 1015)	variant	Var	(1020, 1027)	ThemeOf	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
variant	Var	(1020, 1027)	LOF	NegReg	(1016, 1019)	CauseOf	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
variant	Var	(1020, 1027)	increases	PosReg	(1056, 1065)	CauseOf	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
mRNA levels of interleukin-1	MPA	(1069, 1098)	increases	PosReg	(1056, 1065)	ThemeOf	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
variants	Var	(103, 111)	loss-of-function	NegReg	(86, 102)	CauseOf	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
tumor necrosis factor-	MPA	(1100, 1123)	increases	PosReg	(1056, 1065)	ThemeOf	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
sterol regulatory element binding protein-1c	MPA	(1125, 1169)	increases	PosReg	(1056, 1065)	ThemeOf	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
CD36	MPA	(1171, 1175)	increases	PosReg	(1056, 1065)	ThemeOf	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
loss-of-function	NegReg	(86, 102)	absent	NegReg	(68, 74)	CauseOf	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
anti-adipogenic effect	MPA	(4, 26)	absent	NegReg	(68, 74)	ThemeOf	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
variant	Var	(257, 264)	loss-of-function	NegReg	(234, 250)	CauseOf	OBJECTIVE: To determine the effect of (1) an oral fat load and (2) pro-protein convertase subtilisin/kexin type (PCSK) 9 loss-of-function (LOF) variant status on the ability of peripheral blood mononuclear cells (PBMC) to inhibit human adipogenesis.
loss-of-function	NegReg	(234, 250)	inhibit	NegReg	(335, 342)	CauseOf	OBJECTIVE: To determine the effect of (1) an oral fat load and (2) pro-protein convertase subtilisin/kexin type (PCSK) 9 loss-of-function (LOF) variant status on the ability of peripheral blood mononuclear cells (PBMC) to inhibit human adipogenesis.
human adipogenesis	MPA	(343, 361)	inhibit	NegReg	(335, 342)	ThemeOf	OBJECTIVE: To determine the effect of (1) an oral fat load and (2) pro-protein convertase subtilisin/kexin type (PCSK) 9 loss-of-function (LOF) variant status on the ability of peripheral blood mononuclear cells (PBMC) to inhibit human adipogenesis.
anti-adipogenic action	MPA	(1321, 1343)	absence	NegReg	(1310, 1317)	ThemeOf	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
PCSK9	Gene	(1357, 1362)	variant	Var	(1367, 1374)	ThemeOf	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
variants	Var	(103, 111)	absent	NegReg	(68, 74)	NoRelation	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
anti-adipogenic effect	MPA	(4, 26)	loss-of-function	NegReg	(86, 102)	NoRelation	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
variant	Var	(144, 151)	inhibit	NegReg	(222, 229)	NoRelation	OBJECTIVE: To determine the effect of (1) an oral fat load and (2) pro-protein convertase subtilisin/kexin type (PCSK) 9 loss-of-function (LOF) variant status on the ability of peripheral blood mononuclear cells (PBMC) to inhibit human adipogenesis.
human adipogenesis	MPA	(230, 248)	loss-of-function	NegReg	(121, 137)	NoRelation	OBJECTIVE: To determine the effect of (1) an oral fat load and (2) pro-protein convertase subtilisin/kexin type (PCSK) 9 loss-of-function (LOF) variant status on the ability of peripheral blood mononuclear cells (PBMC) to inhibit human adipogenesis.
LOF	NegReg	(41, 44)	increases	PosReg	(81, 90)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
sterol regulatory element binding protein-1c	MPA	(150, 194)	LOF	NegReg	(41, 44)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
mRNA levels of interleukin-1	MPA	(94, 123)	LOF	NegReg	(41, 44)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
tumor necrosis factor-	MPA	(125, 148)	LOF	NegReg	(41, 44)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
CD36	MPA	(196, 200)	LOF	NegReg	(41, 44)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
anti-adipogenic action	MPA	(28, 50)	novel role	PosReg	(103, 113)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
interactions	Interaction	(145, 157)	anti-adipogenic action	MPA	(28, 50)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
interactions	Interaction	(145, 157)	absence	NegReg	(17, 24)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
extensive genetic variation	Var	(258, 285)	mutations	Var	(341, 350)	CauseOf	The extensive genetic variation in this gene, especially common loss-of-function (LoF) mutations, has been established as primary risk factors for atopic dermatitis.
mutations	Var	(341, 350)	loss-of-function	NegReg	(318, 334)	CauseOf	The extensive genetic variation in this gene, especially common loss-of-function (LoF) mutations, has been established as primary risk factors for atopic dermatitis.
loss-of-function	NegReg	(318, 334)	atopic dermatitis	Disease	(401, 418)	ThemeOf	The extensive genetic variation in this gene, especially common loss-of-function (LoF) mutations, has been established as primary risk factors for atopic dermatitis.
extensive genetic variation	Var	(4, 31)	loss-of-function	NegReg	(64, 80)	NoRelation	The extensive genetic variation in this gene, especially common loss-of-function (LoF) mutations, has been established as primary risk factors for atopic dermatitis.
variants	Var	(1526, 1534)	dyshomeostasis	Reg	(1543, 1557)	CauseOf	Transcriptome sequencing revealed that identified variants induced dyshomeostasis in expression of collagens-TIMPs/MMPs systems.
expression of collagens-TIMPs/MMPs systems	CPA	(1561, 1603)	dyshomeostasis	Reg	(1543, 1557)	ThemeOf	Transcriptome sequencing revealed that identified variants induced dyshomeostasis in expression of collagens-TIMPs/MMPs systems.
Germline heterozygous mutations	Var	(149, 180)	loss of function	NegReg	(259, 275)	CauseOf	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
coiled-coil domain	MPA	(533, 551)	domains	MPA	(500, 507)	ThemeOf	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
DNA-binding domain	MPA	(562, 580)	domains	MPA	(500, 507)	ThemeOf	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
signal transducer	Gene	(190, 207)	Germline heterozygous mutations	Var	(149, 180)	ThemeOf	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
Germline heterozygous mutations	Var	(149, 180)	gain of function	PosReg	(358, 374)	CauseOf	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
chronic mucocutaneous candidiasis	Disease	(402, 435)	gain of function	PosReg	(358, 374)	ThemeOf	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
mycobacterial diseases	Disease	(331, 353)	loss of function	NegReg	(259, 275)	ThemeOf	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
activator of transcription 1	Gene	(212, 240)	Germline heterozygous mutations	Var	(149, 180)	ThemeOf	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
mutations	Var	(449, 458)	affect	Reg	(484, 490)	CauseOf	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
domains	MPA	(500, 507)	affect	Reg	(484, 490)	ThemeOf	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
STAT1	Gene	(511, 516)	domains	MPA	(500, 507)	ThemeOf	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
mycobacterial diseases	Disease	(194, 216)	gain of function	PosReg	(221, 237)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
mycobacterial diseases	Disease	(194, 216)	chronic mucocutaneous candidiasis	Disease	(265, 298)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
chronic mucocutaneous candidiasis	Disease	(265, 298)	loss of function	NegReg	(122, 138)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
coiled-coil domain	MPA	(96, 114)	affect	Reg	(47, 53)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
DNA-binding domain	MPA	(125, 143)	affect	Reg	(47, 53)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
mutations	Var	(223, 232)	impaired	NegReg	(356, 364)	CauseOf	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH17cell responses	CPA	(1191, 1210)	suppressed	NegReg	(1180, 1190)	ThemeOf	Naive lymphocytes from the affected patient displayed increased TH1 and follicular T helper cell and suppressed TH17cell responses.
mutation	Var	(1216, 1224)	augmented	PosReg	(1225, 1234)	CauseOf	The mutation augmented cytokine-induced STAT1 phosphorylation without affecting dephosphorylation kinetics.
cytokine-induced STAT1 phosphorylation	MPA	(1235, 1273)	augmented	PosReg	(1225, 1234)	ThemeOf	The mutation augmented cytokine-induced STAT1 phosphorylation without affecting dephosphorylation kinetics.
STAT1	Gene	(987, 992)	mutation in the linker domain	Var	(954, 983)	ThemeOf	RESULTS: We report a child with a novel mutation in the linker domain of STAT1 who had life-threatening autoimmune cytopenias and chronic mucocutaneous candidiasis.
mutations	Var	(1671, 1680)	GOF	PosReg	(1667, 1670)	CauseOf	CONCLUSIONS: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses.
T helper cell responses	CPA	(1712, 1735)	GOF	PosReg	(1667, 1670)	ThemeOf	CONCLUSIONS: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses.
STAT1	Gene	(1661, 1666)	mutations	Var	(1671, 1680)	ThemeOf	CONCLUSIONS: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses.
mutations	Var	(223, 232)	Gain-of-function	PosReg	(200, 216)	CauseOf	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
human signal transducer and activator of transcription 1	Gene	(240, 296)	mutations	Var	(223, 232)	ThemeOf	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH17cell differentiation	CPA	(365, 390)	impaired	NegReg	(356, 364)	ThemeOf	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
mutations	Var	(223, 232)	exaggerated	PosReg	(395, 406)	CauseOf	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
responsiveness to type I and II interferons	Interaction	(407, 450)	exaggerated	PosReg	(395, 406)	ThemeOf	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH1 and follicular T helper cell	CPA	(1143, 1175)	increased	PosReg	(1133, 1142)	ThemeOf	Naive lymphocytes from the affected patient displayed increased TH1 and follicular T helper cell and suppressed TH17cell responses.
TH17cell differentiation	CPA	(177, 202)	exaggerated	PosReg	(207, 218)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
responsiveness to type I and II interferons	Interaction	(219, 262)	impaired	NegReg	(168, 176)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
responsiveness to type I and II interferons	Interaction	(219, 262)	Gain-of-function	PosReg	(12, 28)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH17cell differentiation	CPA	(177, 202)	Gain-of-function	PosReg	(12, 28)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH17cell responses	CPA	(112, 131)	increased	PosReg	(54, 63)	NoRelation	Naive lymphocytes from the affected patient displayed increased TH1 and follicular T helper cell and suppressed TH17cell responses.
suppressed	NegReg	(101, 111)	TH1 and follicular T helper cell	CPA	(64, 96)	NoRelation	Naive lymphocytes from the affected patient displayed increased TH1 and follicular T helper cell and suppressed TH17cell responses.
variants	Var	(144, 152)	gain-of-function	PosReg	(226, 242)	CauseOf	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
LDL receptor	Protein	(538, 550)	expression	MPA	(551, 561)	ThemeOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
expression	MPA	(551, 561)	reduce	NegReg	(531, 537)	ThemeOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
variants	Var	(452, 460)	cause	Reg	(602, 607)	CauseOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
familial hypercholesterolemia	Disease	(611, 640)	cause	Reg	(602, 607)	ThemeOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
variants	Var	(860, 868)	LOF	NegReg	(856, 859)	CauseOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
variants	Var	(860, 868)	affect	Reg	(964, 970)	CauseOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
affect	Reg	(964, 970)	increase	PosReg	(1006, 1014)	CauseOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
domains of the protein	Protein	(975, 997)	affect	Reg	(964, 970)	ThemeOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
variants	Var	(860, 868)	lowering	NegReg	(1097, 1105)	CauseOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL cholesterol	MPA	(1081, 1096)	lowering	NegReg	(1097, 1105)	ThemeOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
variants	Var	(144, 152)	loss-of-function	NegReg	(252, 268)	CauseOf	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
CVD	Disease	(1155, 1158)	decreased	NegReg	(1145, 1154)	ThemeOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
variants	Var	(860, 868)	decreased	NegReg	(1145, 1154)	CauseOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(1015, 1027)	expression	MPA	(1028, 1038)	ThemeOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
expression	MPA	(1028, 1038)	increase	PosReg	(1006, 1014)	ThemeOf	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
PCSK9	Gene	(203, 208)	variants	Var	(144, 152)	ThemeOf	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
variants	Var	(144, 152)	effects	Reg	(292, 299)	CauseOf	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
LDL cholesterol	Disease	(303, 318)	effects	Reg	(292, 299)	ThemeOf	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
cardiovascular disease	Disease	(323, 345)	effects	Reg	(292, 299)	ThemeOf	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
variants	Var	(452, 460)	affect	Reg	(489, 495)	CauseOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
domains of the protein	Protein	(500, 522)	affect	Reg	(489, 495)	ThemeOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
variants	Var	(452, 460)	GOF	PosReg	(448, 451)	CauseOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
affect	Reg	(489, 495)	reduce	NegReg	(531, 537)	CauseOf	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
cardiovascular disease	Disease	(230, 252)	LDL cholesterol	Disease	(210, 225)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
loss-of-function	NegReg	(159, 175)	effects	Reg	(199, 206)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
cardiovascular disease	Disease	(230, 252)	loss-of-function	NegReg	(159, 175)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
LDL cholesterol	Disease	(210, 225)	gain-of-function	PosReg	(133, 149)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
LDL cholesterol	Disease	(210, 225)	loss-of-function	NegReg	(159, 175)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
cardiovascular disease	Disease	(230, 252)	gain-of-function	PosReg	(133, 149)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
familial hypercholesterolemia	Disease	(180, 209)	reduce	NegReg	(100, 106)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
reduce	NegReg	(100, 106)	cause	Reg	(171, 176)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
variants	Var	(21, 29)	reduce	NegReg	(100, 106)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
expression	MPA	(120, 130)	cause	Reg	(171, 176)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
familial hypercholesterolemia	Disease	(180, 209)	affect	Reg	(58, 64)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
LDL receptor	Protein	(107, 119)	reduce	NegReg	(100, 106)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
expression	MPA	(120, 130)	GOF	PosReg	(17, 20)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
domains of the protein	Protein	(69, 91)	variants	Var	(21, 29)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
domains of the protein	Protein	(69, 91)	expression	MPA	(120, 130)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
expression	MPA	(120, 130)	affect	Reg	(58, 64)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
domains of the protein	Protein	(69, 91)	reduce	NegReg	(100, 106)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
LDL receptor	Protein	(107, 119)	variants	Var	(21, 29)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
familial hypercholesterolemia	Disease	(180, 209)	GOF	PosReg	(17, 20)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
domains of the protein	Protein	(132, 154)	decreased	NegReg	(302, 311)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	lowering	NegReg	(254, 262)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	variants	Var	(17, 25)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
decreased	NegReg	(302, 311)	affect	Reg	(121, 127)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL cholesterol	MPA	(238, 253)	increase	PosReg	(163, 171)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
expression	MPA	(185, 195)	affect	Reg	(121, 127)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	lowering	NegReg	(254, 262)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
lowering	NegReg	(254, 262)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
domains of the protein	Protein	(132, 154)	expression	MPA	(185, 195)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
variants	Var	(17, 25)	increase	PosReg	(163, 171)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL cholesterol	MPA	(238, 253)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	decreased	NegReg	(302, 311)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
lowering	NegReg	(254, 262)	affect	Reg	(121, 127)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
domains of the protein	Protein	(132, 154)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
decreased	NegReg	(302, 311)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL cholesterol	MPA	(238, 253)	affect	Reg	(121, 127)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
expression	MPA	(185, 195)	lowering	NegReg	(254, 262)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	affect	Reg	(121, 127)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
domains of the protein	Protein	(132, 154)	LDL cholesterol	MPA	(238, 253)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
lowering	NegReg	(254, 262)	decreased	NegReg	(302, 311)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LOF	NegReg	(13, 16)	affect	Reg	(121, 127)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL cholesterol	MPA	(238, 253)	decreased	NegReg	(302, 311)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
expression	MPA	(185, 195)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	LDL cholesterol	MPA	(238, 253)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
expression	MPA	(185, 195)	decreased	NegReg	(302, 311)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
domains of the protein	Protein	(132, 154)	variants	Var	(17, 25)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	increase	PosReg	(163, 171)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
DAT	Gene	(995, 998)	mutant	Var	(1016, 1022)	ThemeOf	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
mutant	Var	(1016, 1022)	elevated	PosReg	(1037, 1045)	CauseOf	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
subcortical extracellular dopamine concentration	MPA	(1046, 1094)	elevated	PosReg	(1037, 1045)	ThemeOf	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
mutant	Var	(1016, 1022)	altered	Reg	(1104, 1111)	CauseOf	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
balance of monoaminergic transmission	MPA	(1116, 1153)	altered	Reg	(1104, 1111)	ThemeOf	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
DAT	Gene	(995, 998)	Loss	NegReg	(987, 991)	CauseOf	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
mutant	Var	(29, 35)	Loss	NegReg	(0, 4)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
subcortical extracellular dopamine concentration	MPA	(59, 107)	altered	Reg	(117, 124)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
balance of monoaminergic transmission	MPA	(129, 166)	elevated	PosReg	(50, 58)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
balance of monoaminergic transmission	MPA	(129, 166)	Loss	NegReg	(0, 4)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
subcortical extracellular dopamine concentration	MPA	(59, 107)	Loss	NegReg	(0, 4)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
mutations	Var	(194, 203)	caused	Reg	(173, 179)	CauseOf	Activated PI3K Delta Syndrome (APDS) is a primary immunodeficiency disease caused by activating mutations in either the leukocyte-restricted p110 catalytic (PIK3CD) subunit or the ubiquitously expressed p85 regulatory (PIK3R1) subunit of class IA phosphoinositide 3-kinases (PI3Ks).
Activated PI3K Delta Syndrome	Disease	(98, 127)	caused	Reg	(173, 179)	ThemeOf	Activated PI3K Delta Syndrome (APDS) is a primary immunodeficiency disease caused by activating mutations in either the leukocyte-restricted p110 catalytic (PIK3CD) subunit or the ubiquitously expressed p85 regulatory (PIK3R1) subunit of class IA phosphoinositide 3-kinases (PI3Ks).
PIK3CD	Gene	(256, 262)	mutations	Var	(194, 203)	ThemeOf	Activated PI3K Delta Syndrome (APDS) is a primary immunodeficiency disease caused by activating mutations in either the leukocyte-restricted p110 catalytic (PIK3CD) subunit or the ubiquitously expressed p85 regulatory (PIK3R1) subunit of class IA phosphoinositide 3-kinases (PI3Ks).
APDS2	Gene	(1094, 1099)	mutation	Var	(1100, 1108)	ThemeOf	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
mutation	Var	(1100, 1108)	activation	PosReg	(1144, 1154)	CauseOf	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
p110 (>300-fold)	MPA	(1158, 1175)	activation	PosReg	(1144, 1154)	ThemeOf	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
mutation	Var	(1100, 1108)	disrupts	NegReg	(1180, 1188)	CauseOf	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
inhibitory interactions	MPA	(1189, 1212)	disrupts	NegReg	(1180, 1188)	ThemeOf	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
inhibitory interactions	MPA	(125, 148)	activation	PosReg	(80, 90)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
p110 (>300-fold)	MPA	(94, 111)	disrupts	NegReg	(116, 124)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
Cdh2	Gene	(454, 458)	deletion	Var	(459, 467)	ThemeOf	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
deletion	Var	(459, 467)	defective	NegReg	(487, 496)	CauseOf	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
growth	MPA	(497, 503)	defective	NegReg	(487, 496)	ThemeOf	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
deletion	Var	(459, 467)	low	NegReg	(505, 508)	CauseOf	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
bone mass	MPA	(509, 518)	low	NegReg	(505, 508)	ThemeOf	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
deletion	Var	(459, 467)	reduced	NegReg	(524, 531)	CauseOf	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
osteoprogenitor number	MPA	(532, 554)	reduced	NegReg	(524, 531)	ThemeOf	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
bone mass	MPA	(90, 99)	reduced	NegReg	(105, 112)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
growth	MPA	(78, 84)	low	NegReg	(86, 89)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
reduced	NegReg	(105, 112)	defective	NegReg	(68, 77)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
osteoprogenitor number	MPA	(113, 135)	defective	NegReg	(68, 77)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
low	NegReg	(86, 89)	defective	NegReg	(68, 77)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
bone mass	MPA	(90, 99)	defective	NegReg	(68, 77)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
reduced	NegReg	(105, 112)	low	NegReg	(86, 89)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
growth	MPA	(78, 84)	reduced	NegReg	(105, 112)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
osteoprogenitor number	MPA	(113, 135)	low	NegReg	(86, 89)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
KIT	Gene	(98, 101)	mutations	Var	(123, 132)	ThemeOf	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
SDH	Gene	(119, 122)	mutations	Var	(123, 132)	ThemeOf	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
NF1	Gene	(111, 114)	mutations	Var	(123, 132)	ThemeOf	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
PDGFRA	Gene	(103, 109)	mutations	Var	(123, 132)	ThemeOf	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
mutations	Var	(123, 132)	fostering	Reg	(166, 175)	CauseOf	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
gastrointestinal stromal tumours	MPA	(191, 223)	fostering	Reg	(166, 175)	ThemeOf	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
ATR	Gene	(0, 3)	Mutations	Var	(4, 13)	ThemeOf	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
mutant	Var	(468, 474)	decreased	NegReg	(597, 606)	CauseOf	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
Tcell recruitment	MPA	(607, 625)	decreased	NegReg	(597, 606)	ThemeOf	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
mutant	Var	(468, 474)	increased	PosReg	(630, 639)	CauseOf	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
recruitment of macrophages	MPA	(640, 666)	increased	PosReg	(630, 639)	ThemeOf	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
Mutations	Var	(4, 13)	Promote	PosReg	(14, 21)	CauseOf	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Growth	MPA	(26, 32)	Promote	PosReg	(14, 21)	ThemeOf	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Melanoma Tumors	Disease	(36, 51)	Growth	MPA	(26, 32)	ThemeOf	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
mutations	Var	(133, 142)	generate	Reg	(166, 174)	CauseOf	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
neoantigens	MPA	(175, 186)	generate	Reg	(166, 174)	ThemeOf	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
mutations	Var	(133, 142)	suppress	NegReg	(200, 208)	CauseOf	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
immune response to facilitate continued growth	MPA	(213, 259)	suppress	NegReg	(200, 208)	ThemeOf	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
ATR	Gene	(464, 467)	mutant	Var	(468, 474)	ThemeOf	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
Melanoma Tumors	Disease	(36, 51)	Promote	PosReg	(14, 21)	NoRelation	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
immune response to facilitate continued growth	MPA	(118, 164)	generate	Reg	(71, 79)	NoRelation	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
neoantigens	MPA	(80, 91)	suppress	NegReg	(105, 113)	NoRelation	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
recruitment of macrophages	MPA	(176, 202)	decreased	NegReg	(133, 142)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
Tcell recruitment	MPA	(143, 161)	increased	PosReg	(166, 175)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
BDNF	Gene	(902, 906)	polymorphism	Var	(913, 925)	ThemeOf	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
polymorphism	Var	(913, 925)	loss-of-function	NegReg	(931, 947)	CauseOf	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
regulation of endometrial cells growth	MPA	(968, 1006)	loss-of-function	NegReg	(931, 947)	ThemeOf	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
polymorphism	Var	(948, 960)	regulation of endometrial cells growth	MPA	(968, 1006)	ThemeOf	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
polymorphism	Var	(70, 82)	loss-of-function	NegReg	(53, 69)	NoRelation	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
mutations	Var	(27, 36)	gain-of-function	PosReg	(10, 26)	CauseOf	Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
LRP5	Gene	(439, 443)	gain-of-function	PosReg	(444, 460)	CauseOf	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
LRP5	Gene	(439, 443)	reduction	NegReg	(612, 621)	CauseOf	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
serum LDL	MPA	(625, 634)	reduction	NegReg	(612, 621)	ThemeOf	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
LRP5	Gene	(3446, 3450)	variants	Var	(3451, 3459)	ThemeOf	However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease.
variants	Var	(3451, 3459)	affect	Reg	(3464, 3470)	CauseOf	However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease.
LDL metabolism	MPA	(3471, 3485)	affect	Reg	(3464, 3470)	ThemeOf	However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease.
LRP5	Gene	(96, 100)	mutations	Var	(27, 36)	ThemeOf	Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
glucose and lipid homeostasis	MPA	(105, 134)	gain-of-function	PosReg	(10, 26)	ThemeOf	Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
LRP5	Gene	(136, 140)	mutations	Var	(158, 167)	ThemeOf	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
mutations	Var	(158, 167)	loss-of-function	NegReg	(141, 157)	CauseOf	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
profound osteoporosis	MPA	(193, 214)	loss-of-function	NegReg	(141, 157)	ThemeOf	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
impaired insulin sensitivity	MPA	(245, 273)	loss-of-function	NegReg	(141, 157)	ThemeOf	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
dysregulated lipid metabolism	MPA	(278, 307)	loss-of-function	NegReg	(141, 157)	ThemeOf	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
LRP5	Gene	(439, 443)	mutations	Var	(461, 470)	ThemeOf	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
serum LDL	MPA	(224, 233)	gain-of-function	PosReg	(43, 59)	NoRelation	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
mutations	Var	(60, 69)	gain-of-function	PosReg	(43, 59)	NoRelation	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
mutations	Var	(60, 69)	reduction	NegReg	(211, 220)	NoRelation	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
knockdown	Var	(539, 548)	decrease	NegReg	(568, 576)	CauseOf	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
root hair length	MPA	(580, 596)	decrease	NegReg	(568, 576)	ThemeOf	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
MAP18	Gene	(552, 557)	knockdown	Var	(539, 548)	ThemeOf	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
root hair length	MPA	(75, 91)	loss of function	NegReg	(5, 21)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
knockdown	Var	(34, 43)	loss of function	NegReg	(5, 21)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
decrease	NegReg	(63, 71)	loss of function	NegReg	(5, 21)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
Deletion	Var	(972, 980)	affects	Reg	(1044, 1051)	CauseOf	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
circadian clock output	MPA	(1056, 1078)	affects	Reg	(1044, 1051)	ThemeOf	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
Deletion	Var	(972, 980)	yielding	Reg	(1080, 1088)	CauseOf	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
asexual conidiation	MPA	(1102, 1121)	yielding	Reg	(1080, 1088)	ThemeOf	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
circadian clock output	MPA	(84, 106)	yielding	Reg	(108, 116)	NoRelation	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
asexual conidiation	MPA	(130, 149)	affects	Reg	(72, 79)	NoRelation	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
mutant	Var	(779, 785)	escaped	NegReg	(791, 798)	CauseOf	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
nonsense-mediated decay	MPA	(799, 822)	escaped	NegReg	(791, 798)	ThemeOf	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
mutant	Var	(779, 785)	lacking	NegReg	(844, 851)	CauseOf	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
two transmembrane domains	MPA	(852, 877)	lacking	NegReg	(844, 851)	ThemeOf	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
PROKR2	Gene	(1143, 1149)	mutants	Var	(1150, 1157)	ThemeOf	The results indicate that certain inactive PROKR2 mutants can cause early puberty by enhancing the functional property of coexisting wild-type proteins.
mutants	Var	(1150, 1157)	enhancing	PosReg	(1185, 1194)	CauseOf	The results indicate that certain inactive PROKR2 mutants can cause early puberty by enhancing the functional property of coexisting wild-type proteins.
functional	MPA	(1199, 1209)	enhancing	PosReg	(1185, 1194)	ThemeOf	The results indicate that certain inactive PROKR2 mutants can cause early puberty by enhancing the functional property of coexisting wild-type proteins.
two transmembrane domains	MPA	(77, 102)	escaped	NegReg	(16, 23)	NoRelation	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
nonsense-mediated decay	MPA	(24, 47)	lacking	NegReg	(69, 76)	NoRelation	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
mutations	Var	(774, 783)	disrupted	NegReg	(835, 844)	CauseOf	We introduced two point mutations into the predicted pore-lining domain of MSL8 that disrupted normal channel function in different ways.
MSL8	Gene	(1050, 1054)	Phe720Leu mutation	Var	(1008, 1026)	ThemeOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
channel	Pathway	(1055, 1062)	disrupted	NegReg	(1036, 1045)	ThemeOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
mutations	Var	(1078, 1087)	impaired	NegReg	(1088, 1096)	CauseOf	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
ability	MPA	(1101, 1108)	impaired	NegReg	(1088, 1096)	ThemeOf	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
mutations	Var	(1078, 1087)	maintain	Reg	(1170, 1178)	CauseOf	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
integrity	MPA	(1183, 1192)	maintain	Reg	(1170, 1178)	ThemeOf	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
normal channel function	MPA	(845, 868)	disrupted	NegReg	(835, 844)	ThemeOf	We introduced two point mutations into the predicted pore-lining domain of MSL8 that disrupted normal channel function in different ways.
MSL8	Gene	(825, 829)	mutations	Var	(774, 783)	ThemeOf	We introduced two point mutations into the predicted pore-lining domain of MSL8 that disrupted normal channel function in different ways.
Ile711Ser	Var	(892, 901)	increased	PosReg	(911, 920)	CauseOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
tension threshold	MPA	(925, 942)	increased	PosReg	(911, 920)	ThemeOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(950, 954)	Ile711Ser	Var	(892, 901)	ThemeOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Ile711Ser	Var	(892, 901)	leaving	Reg	(969, 976)	CauseOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
conductance unchanged	MPA	(977, 998)	leaving	Reg	(969, 976)	ThemeOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Phe720Leu mutation	Var	(1008, 1026)	disrupted	NegReg	(1036, 1045)	CauseOf	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
tension threshold	MPA	(37, 54)	disrupted	NegReg	(148, 157)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Ile711Ser	Var	(4, 13)	disrupted	NegReg	(148, 157)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
conductance unchanged	MPA	(89, 110)	increased	PosReg	(23, 32)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
conductance unchanged	MPA	(89, 110)	disrupted	NegReg	(148, 157)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
tension threshold	MPA	(37, 54)	leaving	Reg	(81, 88)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Phe720Leu mutation	Var	(120, 138)	leaving	Reg	(81, 88)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
channel	Pathway	(167, 174)	leaving	Reg	(81, 88)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Phe720Leu mutation	Var	(120, 138)	increased	PosReg	(23, 32)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
ability	MPA	(37, 44)	maintain	Reg	(106, 114)	NoRelation	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
integrity	MPA	(119, 128)	impaired	NegReg	(24, 32)	NoRelation	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
Rack1	Gene	(634, 639)	knock-down	Var	(640, 650)	ThemeOf	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
knock-down	Var	(640, 650)	reduces	NegReg	(687, 694)	CauseOf	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
invasiveness	MPA	(695, 707)	reduces	NegReg	(687, 694)	ThemeOf	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
knock-down	Var	(640, 650)	induces	Reg	(712, 719)	CauseOf	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
cell differentiation	MPA	(720, 740)	induces	Reg	(712, 719)	ThemeOf	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
invasiveness	MPA	(74, 86)	induces	Reg	(91, 98)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
cell differentiation	MPA	(99, 119)	reduces	NegReg	(66, 73)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
mutations	Var	(244, 253)	loss-of-function	NegReg	(227, 243)	CauseOf	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
mutant	Var	(807, 813)	decreased	NegReg	(894, 903)	CauseOf	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
formation of lipid droplets	MPA	(904, 931)	decreased	NegReg	(894, 903)	ThemeOf	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
p.L105P missense	Var	(1050, 1066)	reduces	NegReg	(1084, 1091)	CauseOf	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
TG synthesis activity	MPA	(1092, 1113)	reduces	NegReg	(1084, 1091)	ThemeOf	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
p.L105P missense	Var	(1050, 1066)	causes	Reg	(1118, 1124)	CauseOf	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
less severe clinical phenotype	MPA	(1127, 1157)	causes	Reg	(1118, 1124)	ThemeOf	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
DGAT1	Gene	(1206, 1211)	deficiency	Var	(1212, 1222)	ThemeOf	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
deficiency	Var	(1212, 1222)	cause	Reg	(1228, 1233)	CauseOf	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
congenital diarrhea	Disease	(1237, 1256)	cause	Reg	(1228, 1233)	ThemeOf	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
congenital diarrhea	Disease	(286, 305)	loss-of-function	NegReg	(227, 243)	ThemeOf	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
protein-losing enteropathy	Disease	(1262, 1288)	cause	Reg	(1228, 1233)	ThemeOf	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
DGAT1	Gene	(1307, 1312)	mutations	Var	(1313, 1322)	ThemeOf	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
mutations	Var	(1313, 1322)	result in	Reg	(1323, 1332)	CauseOf	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
spectrum of diseases	Disease	(1335, 1355)	result in	Reg	(1323, 1332)	ThemeOf	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
DGAT1	Gene	(776, 781)	p.L105P	Var	(768, 775)	ThemeOf	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
protein-losing enteropathy	Disease	(310, 336)	loss-of-function	NegReg	(227, 243)	ThemeOf	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
DGAT1	Gene	(263, 268)	mutations	Var	(244, 253)	ThemeOf	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
mutant	Var	(807, 813)	less	NegReg	(824, 828)	CauseOf	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
p.L105P	Var	(768, 775)	less	NegReg	(824, 828)	ThemeOf	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
mutant	Var	(807, 813)	loss	NegReg	(860, 864)	CauseOf	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
TG synthesis activity	MPA	(868, 889)	loss	NegReg	(860, 864)	ThemeOf	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
congenital diarrhea	Disease	(69, 88)	protein-losing enteropathy	Disease	(93, 119)	NoRelation	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
p.L105P	Var	(22, 29)	decreased	NegReg	(148, 157)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
TG synthesis activity	MPA	(122, 143)	decreased	NegReg	(148, 157)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
formation of lipid droplets	MPA	(158, 185)	less	NegReg	(78, 82)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
formation of lipid droplets	MPA	(158, 185)	loss	NegReg	(114, 118)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
TG synthesis activity	MPA	(122, 143)	less	NegReg	(78, 82)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
p.L105P	Var	(22, 29)	loss	NegReg	(114, 118)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
less severe clinical phenotype	MPA	(148, 178)	reduces	NegReg	(105, 112)	NoRelation	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
TG synthesis activity	MPA	(113, 134)	causes	Reg	(139, 145)	NoRelation	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
congenital diarrhea	Disease	(78, 97)	spectrum of diseases	Disease	(176, 196)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
mutations	Var	(154, 163)	cause	Reg	(69, 74)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
protein-losing enteropathy	Disease	(103, 129)	result in	Reg	(164, 173)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
spectrum of diseases	Disease	(176, 196)	cause	Reg	(69, 74)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
deficiency	Var	(53, 63)	result in	Reg	(164, 173)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
congenital diarrhea	Disease	(78, 97)	result in	Reg	(164, 173)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
mutations	Var	(67, 76)	caused by	Reg	(57, 66)	CauseOf	Hydrocephalus due to multiple ependymal malformations is caused by mutations in the MPDZ gene.
Hydrocephalus	Disease	(0, 13)	caused by	Reg	(57, 66)	ThemeOf	Hydrocephalus due to multiple ependymal malformations is caused by mutations in the MPDZ gene.
MPDZ	Gene	(84, 88)	mutations	Var	(67, 76)	ThemeOf	Hydrocephalus due to multiple ependymal malformations is caused by mutations in the MPDZ gene.
L1CAM	Gene	(467, 472)	mutations	Var	(473, 482)	ThemeOf	In patients with isolated hydrocephalus, L1CAM mutations represent the most common aetiology.
isolated hydrocephalus	Disease	(443, 465)	common	Reg	(502, 508)	ThemeOf	In patients with isolated hydrocephalus, L1CAM mutations represent the most common aetiology.
mutations	Var	(473, 482)	common	Reg	(502, 508)	CauseOf	In patients with isolated hydrocephalus, L1CAM mutations represent the most common aetiology.
mutations	Var	(482, 491)	perturb	Reg	(499, 506)	CauseOf	As mutations in pnt perturb the development of several tissues, we wanted to examine the effect and efficacy of using RNAi to target Pnt.
development of several tissues	CPA	(511, 541)	perturb	Reg	(499, 506)	ThemeOf	As mutations in pnt perturb the development of several tissues, we wanted to examine the effect and efficacy of using RNAi to target Pnt.
pnt	Gene	(495, 498)	mutations	Var	(482, 491)	ThemeOf	As mutations in pnt perturb the development of several tissues, we wanted to examine the effect and efficacy of using RNAi to target Pnt.
mutation	Var	(21, 29)	gain-of-function	PosReg	(4, 20)	CauseOf	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
autism spectrum disorders	Disease	(75, 100)	gain-of-function	PosReg	(4, 20)	ThemeOf	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
epilepsy	Disease	(105, 113)	gain-of-function	PosReg	(4, 20)	ThemeOf	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
CACNA1D	Gene	(36, 43)	mutation	Var	(21, 29)	ThemeOf	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
current densities	MPA	(1016, 1033)	enhanced	PosReg	(1007, 1015)	ThemeOf	Here we report the discovery and characterization of a third de novo missense mutation in CACNA1D (V401L) in a patient with ASD and epilepsy.For the functional characterization we introduced mutation V401L into two major C-terminal long and short Cav1.3 splice variants, expressed wild-type or mutant channel complexes in tsA-201 cells and performed whole-cell patch-clamp recordings.Mutation V401L, localized within the channel's activation gate, significantly enhanced current densities, shifted voltage dependence of activation and inactivation to more negative voltages and reduced channel inactivation in both Cav1.3 splice variants.
Ca2+-influx through the channel	MPA	(1251, 1282)	enhanced	PosReg	(1242, 1250)	ThemeOf	Altogether these gating changes are expected to result in enhanced Ca2+-influx through the channel, thus representing a strong gain-of-function phenotype.
V401L	Var	(938, 943)	enhanced	PosReg	(1007, 1015)	CauseOf	Here we report the discovery and characterization of a third de novo missense mutation in CACNA1D (V401L) in a patient with ASD and epilepsy.For the functional characterization we introduced mutation V401L into two major C-terminal long and short Cav1.3 splice variants, expressed wild-type or mutant channel complexes in tsA-201 cells and performed whole-cell patch-clamp recordings.Mutation V401L, localized within the channel's activation gate, significantly enhanced current densities, shifted voltage dependence of activation and inactivation to more negative voltages and reduced channel inactivation in both Cav1.3 splice variants.
changes	Var	(1208, 1215)	enhanced	PosReg	(1242, 1250)	CauseOf	Altogether these gating changes are expected to result in enhanced Ca2+-influx through the channel, thus representing a strong gain-of-function phenotype.
Null mutations	Var	(196, 210)	predispose	Reg	(273, 283)	CauseOf	Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood.
AE	Disease	(287, 289)	predispose	Reg	(273, 283)	ThemeOf	Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood.
FLG	Gene	(225, 228)	Null mutations	Var	(196, 210)	ThemeOf	Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood.
Molecular pathways	Pathway	(1386, 1404)	overrepresented	PosReg	(1405, 1420)	ThemeOf	Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress.
FLG	Gene	(1427, 1430)	knockdown	Var	(1431, 1440)	ThemeOf	Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress.
knockdown	Var	(1431, 1440)	overrepresented	PosReg	(1405, 1420)	CauseOf	Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress.
loss	Var	(1722, 1726)	alter	Reg	(1782, 1787)	CauseOf	CONCLUSIONS: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE.
expression level of proteins	MPA	(1792, 1820)	alter	Reg	(1782, 1787)	ThemeOf	CONCLUSIONS: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE.
FLG	Gene	(1730, 1733)	loss	Var	(1722, 1726)	ThemeOf	CONCLUSIONS: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE.
TREM2	Gene	(158, 163)	variations	Var	(90, 100)	ThemeOf	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
variants	Var	(396, 404)	affecting	Reg	(535, 544)	CauseOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipid sensing	MPA	(481, 494)	impairing	NegReg	(471, 480)	ThemeOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(507, 514)	preventing	NegReg	(496, 506)	ThemeOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipoproteins	Protein	(518, 530)	binding	Interaction	(507, 514)	ThemeOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
shielding of amyloid plaques	MPA	(545, 573)	affecting	Reg	(535, 544)	ThemeOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
loss	Var	(891, 895)	impairs	NegReg	(905, 912)	CauseOf	Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels.
TREM2	Gene	(899, 904)	loss	Var	(891, 895)	ThemeOf	Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels.
microglial responses to injury and signals	CPA	(925, 967)	impairs	NegReg	(905, 912)	ThemeOf	Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels.
variations	Var	(90, 100)	linked to	Reg	(175, 184)	CauseOf	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
Alzheimer's disease	Disease	(243, 262)	linked to	Reg	(175, 184)	ThemeOf	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
frontotemporal lobar degeneration	Disease	(267, 300)	linked to	Reg	(175, 184)	ThemeOf	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
TREM2	Gene	(390, 395)	variants	Var	(396, 404)	ThemeOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
variants	Var	(396, 404)	reducing	NegReg	(437, 445)	CauseOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
microglial phagocytosis	CPA	(446, 469)	reducing	NegReg	(437, 445)	ThemeOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
variants	Var	(396, 404)	impairing	NegReg	(471, 480)	CauseOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
variants	Var	(396, 404)	preventing	NegReg	(496, 506)	CauseOf	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipid sensing	MPA	(118, 131)	affecting	Reg	(172, 181)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipoproteins	Protein	(155, 167)	lipid sensing	MPA	(118, 131)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
shielding of amyloid plaques	MPA	(182, 210)	impairing	NegReg	(108, 117)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipid sensing	MPA	(118, 131)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
microglial phagocytosis	CPA	(83, 106)	affecting	Reg	(172, 181)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	affecting	Reg	(172, 181)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
microglial phagocytosis	CPA	(83, 106)	impairing	NegReg	(108, 117)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipid sensing	MPA	(118, 131)	preventing	NegReg	(133, 143)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	impairing	NegReg	(108, 117)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	lipid sensing	MPA	(118, 131)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
TREM2	Gene	(27, 32)	lipoproteins	Protein	(155, 167)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipoproteins	Protein	(155, 167)	shielding of amyloid plaques	MPA	(182, 210)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	shielding of amyloid plaques	MPA	(182, 210)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
shielding of amyloid plaques	MPA	(182, 210)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
shielding of amyloid plaques	MPA	(182, 210)	preventing	NegReg	(133, 143)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
microglial phagocytosis	CPA	(83, 106)	preventing	NegReg	(133, 143)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipoproteins	Protein	(155, 167)	variants	Var	(33, 41)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
mutation	Var	(23, 31)	loss of function	NegReg	(6, 22)	CauseOf	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
KRIT1 protein	Protein	(1556, 1569)	loss of function	NegReg	(1532, 1548)	ThemeOf	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
mutation	Var	(1658, 1666)	loss of function	NegReg	(1641, 1657)	CauseOf	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
KRIT1	Gene	(1670, 1675)	mutation	Var	(1658, 1666)	ThemeOf	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
mutation	Var	(1658, 1666)	associated with	Reg	(1686, 1701)	CauseOf	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
CCMs	Disease	(1737, 1741)	associated with	Reg	(1686, 1701)	ThemeOf	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
KRIT1	Gene	(35, 40)	mutation	Var	(23, 31)	ThemeOf	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
mutation	Var	(23, 31)	associated with	Reg	(49, 64)	CauseOf	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
cerebral and spinal cavernous malformations	Disease	(88, 131)	associated with	Reg	(49, 64)	ThemeOf	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
frameshift	Var	(1445, 1455)	leads to	Reg	(1434, 1442)	ThemeOf	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
premature stop codon	MPA	(1463, 1483)	leads to	Reg	(1434, 1442)	ThemeOf	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
KRIT1	Gene	(1355, 1360)	c.1535_1536delTG	Var	(1390, 1406)	ThemeOf	Genetic analysis demonstrated a novel heterozygous KRIT1/CCM1 two base pair deletion (c.1535_1536delTG) in exon 14.
cerebral and spinal cavernous malformations	Disease	(88, 131)	loss of function	NegReg	(6, 22)	NoRelation	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
KRIT1 protein	Protein	(136, 149)	premature stop codon	MPA	(43, 63)	NoRelation	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
frameshift	Var	(25, 35)	loss of function	NegReg	(112, 128)	NoRelation	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
KRIT1 protein	Protein	(136, 149)	frameshift	Var	(25, 35)	NoRelation	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
premature stop codon	MPA	(43, 63)	loss of function	NegReg	(112, 128)	NoRelation	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
CCMs	Disease	(166, 170)	loss of function	NegReg	(70, 86)	NoRelation	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
EGFR	Gene	(62, 66)	Mutation	Var	(67, 75)	ThemeOf	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Mutation	Var	(67, 75)	Positive	Reg	(76, 84)	CauseOf	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Non-Small Cell Lung Cancer	Disease	(94, 120)	Positive	Reg	(76, 84)	ThemeOf	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Loss	Var	(0, 4)	leads	Reg	(48, 53)	CauseOf	Loss of the homologous recombination gene rad51 leads to Fanconi anemia-like symptoms in zebrafish.
Fanconi anemia-like symptoms	Disease	(57, 85)	leads	Reg	(48, 53)	ThemeOf	Loss of the homologous recombination gene rad51 leads to Fanconi anemia-like symptoms in zebrafish.
rad51	Gene	(42, 47)	Loss	Var	(0, 4)	ThemeOf	Loss of the homologous recombination gene rad51 leads to Fanconi anemia-like symptoms in zebrafish.
mutants	Var	(602, 609)	loss-of-function	NegReg	(585, 601)	CauseOf	Zebrafish rad51 loss-of-function mutants developed key features of FA, including hypocellular kidney marrow, sensitivity to cross-linking agents, and decreased size.
FA	Disease	(636, 638)	loss-of-function	NegReg	(585, 601)	ThemeOf	Zebrafish rad51 loss-of-function mutants developed key features of FA, including hypocellular kidney marrow, sensitivity to cross-linking agents, and decreased size.
rad51	Gene	(579, 584)	mutants	Var	(602, 609)	ThemeOf	Zebrafish rad51 loss-of-function mutants developed key features of FA, including hypocellular kidney marrow, sensitivity to cross-linking agents, and decreased size.
CAG repeat expansion	Var	(202, 222)	caused by	Reg	(192, 201)	CauseOf	Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the ATXN2 gene.
ATXN2	Gene	(230, 235)	CAG repeat expansion	Var	(202, 222)	ThemeOf	Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the ATXN2 gene.
Spinocerebellar ataxia type 2	Disease	(104, 133)	caused by	Reg	(192, 201)	ThemeOf	Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the ATXN2 gene.
FLG	Gene	(304, 307)	mutations	Var	(326, 335)	ThemeOf	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
mutations	Var	(326, 335)	loss-of function	NegReg	(309, 325)	CauseOf	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
trans-epidermal penetration	CPA	(362, 389)	facilitate	PosReg	(351, 361)	ThemeOf	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
mutations	Var	(326, 335)	facilitate	PosReg	(351, 361)	CauseOf	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
trans-epidermal penetration	CPA	(114, 141)	loss-of function	NegReg	(61, 77)	NoRelation	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
mutations	Var	(157, 166)	gain of function	PosReg	(140, 156)	CauseOf	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
epileptic encephalopathies	Disease	(271, 297)	gain of function	PosReg	(140, 156)	ThemeOf	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
infantile spasms	Disease	(309, 325)	gain of function	PosReg	(140, 156)	ThemeOf	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
GRIN2B	Gene	(170, 176)	mutations	Var	(157, 166)	ThemeOf	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
variants	Var	(145, 153)	promote	PosReg	(154, 161)	CauseOf	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
airway fibrosis	CPA	(162, 177)	promote	PosReg	(154, 161)	ThemeOf	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
PAI-1	Gene	(122, 127)	variants	Var	(145, 153)	ThemeOf	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
variants	Var	(145, 153)	associated with	Reg	(186, 201)	CauseOf	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
asthma	Disease	(202, 208)	associated with	Reg	(186, 201)	ThemeOf	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
asthma	Disease	(92, 98)	promote	PosReg	(44, 51)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
airway fibrosis	CPA	(52, 67)	associated with	Reg	(76, 91)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
E396V	Var	(103, 108)	loss-of-function	NegReg	(45, 61)	CauseOf	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
mutations	Var	(1314, 1323)	caused	Reg	(1324, 1330)	CauseOf	However, few LPL were detected in the culture medium for the mutants, suggesting that both mutations caused aberrant triglyceride catabolism.
triglyceride catabolism	MPA	(1340, 1363)	caused	Reg	(1324, 1330)	ThemeOf	However, few LPL were detected in the culture medium for the mutants, suggesting that both mutations caused aberrant triglyceride catabolism.
E396V	Var	(1384, 1389)	dampened	NegReg	(1411, 1419)	CauseOf	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
double mutations	Var	(1394, 1410)	dampened	NegReg	(1411, 1419)	CauseOf	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
transport of LPL to the cell surface	MPA	(1424, 1460)	dampened	NegReg	(1411, 1419)	ThemeOf	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
C310R	Var	(1476, 1481)	reducing	NegReg	(1492, 1500)	CauseOf	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
LPL protein level	MPA	(1501, 1518)	reducing	NegReg	(1492, 1500)	ThemeOf	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
C310R	Var	(97, 102)	loss-of-function	NegReg	(45, 61)	CauseOf	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
E396V	Var	(103, 108)	associated with	Reg	(130, 145)	CauseOf	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
C310R	Var	(97, 102)	associated with	Reg	(130, 145)	CauseOf	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
lipoprotein lipase	Enzyme	(62, 80)	C310R	Var	(97, 102)	ThemeOf	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
recurrent acute pancreatitis	Disease	(146, 174)	associated with	Reg	(130, 145)	ThemeOf	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
hypertriglyceridemia	Disease	(7, 27)	loss-of-function	NegReg	(45, 61)	ThemeOf	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
C310R	Var	(967, 972)	reduced	NegReg	(982, 989)	CauseOf	While C310R markedly reduced the overall LPL protein level, COS-1 cells carrying E396V or double mutations contained similar overall LPL protein levels to the wild-type.
LPL protein level	MPA	(1002, 1019)	reduced	NegReg	(982, 989)	ThemeOf	While C310R markedly reduced the overall LPL protein level, COS-1 cells carrying E396V or double mutations contained similar overall LPL protein levels to the wild-type.
lipoprotein lipase	Enzyme	(62, 80)	loss-of-function	NegReg	(45, 61)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
recurrent acute pancreatitis	Disease	(146, 174)	loss-of-function	NegReg	(45, 61)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
hypertriglyceridemia	Disease	(7, 27)	associated with	Reg	(130, 145)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
LPL protein level	MPA	(136, 153)	dampened	NegReg	(46, 54)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
transport of LPL to the cell surface	MPA	(59, 95)	reducing	NegReg	(127, 135)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
C310R	Var	(111, 116)	dampened	NegReg	(46, 54)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
E396V	Var	(19, 24)	reducing	NegReg	(127, 135)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
double mutations	Var	(29, 45)	reducing	NegReg	(127, 135)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
WNT10A	Gene	(0, 6)	mutation	Var	(7, 15)	ThemeOf	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
mutation	Var	(7, 15)	impairing	NegReg	(47, 56)	CauseOf	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
progenitor cell proliferation	CPA	(57, 86)	impairing	NegReg	(47, 56)	ThemeOf	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
KLF4-mediated differentiation	CPA	(91, 120)	impairing	NegReg	(47, 56)	ThemeOf	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
impairing	NegReg	(47, 56)	causes	Reg	(16, 22)	CauseOf	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
ectodermal dysplasia	Disease	(23, 43)	causes	Reg	(16, 22)	ThemeOf	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
mutation	Var	(7, 15)	causes	Reg	(16, 22)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
ectodermal dysplasia	Disease	(23, 43)	impairing	NegReg	(47, 56)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
KLF4-mediated differentiation	CPA	(91, 120)	causes	Reg	(16, 22)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
progenitor cell proliferation	CPA	(57, 86)	causes	Reg	(16, 22)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
ROBO1	Gene	(20, 25)	Loss of function	Var	(0, 16)	ThemeOf	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
Loss of function	Var	(0, 16)	associated	Reg	(29, 39)	CauseOf	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
tetralogy of Fallot	Disease	(45, 64)	associated	Reg	(29, 39)	ThemeOf	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
septal defects	Disease	(69, 83)	associated	Reg	(29, 39)	ThemeOf	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
NFKBIA	Gene	(128, 134)	mutations	Var	(115, 124)	ThemeOf	Germline heterozygous gain-of-function (GOF) mutations of NFKBIA, encoding IB, cause an autosomal dominant (AD) form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID).
mutations	Var	(115, 124)	gain-of-function	PosReg	(92, 108)	CauseOf	Germline heterozygous gain-of-function (GOF) mutations of NFKBIA, encoding IB, cause an autosomal dominant (AD) form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID).
anhidrotic ectodermal dysplasia with immunodeficiency	Disease	(192, 245)	gain-of-function	PosReg	(92, 108)	ThemeOf	Germline heterozygous gain-of-function (GOF) mutations of NFKBIA, encoding IB, cause an autosomal dominant (AD) form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID).
mutations	Var	(359, 368)	preventing	NegReg	(414, 424)	CauseOf	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
preventing	NegReg	(414, 424)	enhanced	PosReg	(369, 377)	CauseOf	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
IB	Protein	(405, 409)	inhibitory activity	MPA	(382, 401)	ThemeOf	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
inhibitory activity	MPA	(382, 401)	enhanced	PosReg	(369, 377)	ThemeOf	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
degradation	MPA	(483, 494)	preventing	NegReg	(414, 424)	ThemeOf	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
phosphorylation on serine 32 or 36	MPA	(429, 463)	preventing	NegReg	(414, 424)	ThemeOf	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
mutations	Var	(4, 13)	enhanced	PosReg	(14, 22)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
phosphorylation on serine 32 or 36	MPA	(74, 108)	enhanced	PosReg	(14, 22)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
inhibitory activity	MPA	(27, 46)	preventing	NegReg	(59, 69)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
IB	Protein	(50, 54)	phosphorylation on serine 32 or 36	MPA	(74, 108)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
IB	Protein	(50, 54)	degradation	MPA	(128, 139)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
degradation	MPA	(128, 139)	enhanced	PosReg	(14, 22)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
IB	Protein	(50, 54)	mutations	Var	(4, 13)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
ARX	Gene	(1784, 1787)	polyalanine expansion mutations	Var	(1788, 1819)	ThemeOf	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
developmental deficit of calbindin-positive cortical GABAergic interneurons	CPA	(102, 177)	lead to	Reg	(36, 43)	ThemeOf	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
polyalanine expansion mutations	Var	(1788, 1819)	negatively	NegReg	(1761, 1771)	CauseOf	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
cortical calbindin interneuron	CPA	(1701, 1731)	development	CPA	(1732, 1743)	ThemeOf	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
cortical calbindin interneuron	CPA	(1701, 1731)	migration	CPA	(1748, 1757)	ThemeOf	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
migration	CPA	(1748, 1757)	negatively	NegReg	(1761, 1771)	ThemeOf	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
development	CPA	(1732, 1743)	negatively	NegReg	(1761, 1771)	ThemeOf	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
ARX	Gene	(0, 3)	polyalanine expansion mutations	Var	(4, 35)	ThemeOf	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
polyalanine expansion mutations	Var	(4, 35)	lead to	Reg	(36, 43)	CauseOf	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
migration impediment in the rostral cortex coupled	CPA	(44, 94)	lead to	Reg	(36, 43)	ThemeOf	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
cortical calbindin interneuron	CPA	(38, 68)	negatively	NegReg	(98, 108)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
FGFR2	Gene	(237, 242)	mutations	Var	(187, 196)	ThemeOf	Apert syndrome is one of the most severe craniosynostoses, resulting from gain-of-function mutations in fibroblast growth factor receptor 2 (FGFR2).
bone marrow stromal cell	CPA	(1096, 1120)	proliferation	CPA	(1137, 1150)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(1152, 1162)	proliferation	CPA	(1163, 1176)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(1152, 1162)	differentiation	CPA	(1181, 1196)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(1211, 1233)	enhanced	PosReg	(1202, 1210)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(1121, 1132)	increase	PosReg	(1084, 1092)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(1137, 1150)	increase	PosReg	(1084, 1092)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(1163, 1176)	increase	PosReg	(1084, 1092)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(1181, 1196)	increase	PosReg	(1084, 1092)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
mutations	Var	(187, 196)	gain-of-function	PosReg	(170, 186)	CauseOf	Apert syndrome is one of the most severe craniosynostoses, resulting from gain-of-function mutations in fibroblast growth factor receptor 2 (FGFR2).
FGFR2	Gene	(1470, 1475)	mutation	Var	(1458, 1466)	ThemeOf	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
mutation	Var	(1458, 1466)	gain-of-function	PosReg	(1441, 1457)	CauseOf	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
gain-of-function	PosReg	(1441, 1457)	promoting	PosReg	(1547, 1556)	CauseOf	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone formation	CPA	(1557, 1571)	promoting	PosReg	(1547, 1556)	ThemeOf	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
gain-of-function	PosReg	(1441, 1457)	inhibiting	NegReg	(1576, 1586)	CauseOf	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone resorption at the adult stage	CPA	(1587, 1621)	inhibiting	NegReg	(1576, 1586)	ThemeOf	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
exerts a Wnt/-catenin-dependent anabolic effect	MPA	(1476, 1524)	gain-of-function	PosReg	(1441, 1457)	ThemeOf	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
Apert syndrome	Disease	(96, 110)	gain-of-function	PosReg	(170, 186)	ThemeOf	Apert syndrome is one of the most severe craniosynostoses, resulting from gain-of-function mutations in fibroblast growth factor receptor 2 (FGFR2).
Fgfr2	Gene	(812, 817)	mutant	Var	(818, 824)	ThemeOf	Mechanical bone marrow ablation (BMX) was performed in both wild-type and Fgfr2 mutant (MT) mice.
trabecular bone formation	CPA	(988, 1013)	increased	PosReg	(978, 987)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone resorption	CPA	(1028, 1043)	decreased	NegReg	(1018, 1027)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(1096, 1120)	recruitment	CPA	(1121, 1132)	ThemeOf	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(206, 216)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(206, 216)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(191, 204)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(175, 186)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(191, 204)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(235, 250)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(206, 216)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(175, 186)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(217, 230)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(235, 250)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(175, 186)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(217, 230)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(217, 230)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	increase	PosReg	(138, 146)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(191, 204)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	increase	PosReg	(138, 146)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(235, 250)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone resorption	CPA	(82, 97)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(206, 216)	increase	PosReg	(138, 146)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone resorption	CPA	(82, 97)	increase	PosReg	(138, 146)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	increase	PosReg	(138, 146)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone resorption	CPA	(82, 97)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
exerts a Wnt/-catenin-dependent anabolic effect	MPA	(61, 109)	promoting	PosReg	(132, 141)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
mutation	Var	(43, 51)	inhibiting	NegReg	(161, 171)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone resorption at the adult stage	CPA	(172, 206)	promoting	PosReg	(132, 141)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone resorption at the adult stage	CPA	(172, 206)	gain-of-function	PosReg	(26, 42)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone formation	CPA	(142, 156)	gain-of-function	PosReg	(26, 42)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone formation	CPA	(142, 156)	inhibiting	NegReg	(161, 171)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
exerts a Wnt/-catenin-dependent anabolic effect	MPA	(61, 109)	inhibiting	NegReg	(161, 171)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
mutation	Var	(43, 51)	promoting	PosReg	(132, 141)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
TNFAIP3	Gene	(82, 89)	mutation	Var	(70, 78)	ThemeOf	Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20).
mutation	Var	(70, 78)	loss-of-function	NegReg	(53, 69)	CauseOf	Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20).
Early-onset autoimmune disease	Disease	(0, 30)	loss-of-function	NegReg	(53, 69)	CauseOf	Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20).
TgRON4	Gene	(617, 623)	null mutation	Var	(600, 613)	ThemeOf	In this study, we used the CRISPR-Cas9 system to generate a derivative of T. gondii strain RH with a null mutation in TgRON4, thought to be an essential MJ component.
TgRON4	Protein	(680, 686)	Deficiency	NegReg	(666, 676)	ThemeOf	Deficiency of TgRON4 moderately decreased invasion ability relative to that of the wild-type parasite.
Deficiency	NegReg	(666, 676)	decreased	NegReg	(698, 707)	CauseOf	Deficiency of TgRON4 moderately decreased invasion ability relative to that of the wild-type parasite.
invasion ability	CPA	(708, 724)	decreased	NegReg	(698, 707)	ThemeOf	Deficiency of TgRON4 moderately decreased invasion ability relative to that of the wild-type parasite.
mutant	Var	(856, 862)	decreased	NegReg	(839, 848)	CauseOf	In addition, expression of the endogenous N-terminal fragment of RON5 decreased in the mutant.
expression of the endogenous N-terminal fragment	MPA	(782, 830)	decreased	NegReg	(839, 848)	ThemeOf	In addition, expression of the endogenous N-terminal fragment of RON5 decreased in the mutant.
RON5	Protein	(834, 838)	expression of the endogenous N-terminal fragment	MPA	(782, 830)	ThemeOf	In addition, expression of the endogenous N-terminal fragment of RON5 decreased in the mutant.
invasion ability	CPA	(42, 58)	Deficiency	NegReg	(0, 10)	NoRelation	Deficiency of TgRON4 moderately decreased invasion ability relative to that of the wild-type parasite.
RON5	Protein	(65, 69)	mutant	Var	(87, 93)	NoRelation	In addition, expression of the endogenous N-terminal fragment of RON5 decreased in the mutant.
SlMBP21	Gene	(50, 57)	mutations	Var	(37, 46)	ThemeOf	Natural and induced loss of function mutations in SlMBP21 MADS-box gene led to jointless-2 phenotype in tomato.
mutations	Var	(37, 46)	loss of function	NegReg	(20, 36)	CauseOf	Natural and induced loss of function mutations in SlMBP21 MADS-box gene led to jointless-2 phenotype in tomato.
jointless-2 phenotype	CPA	(79, 100)	loss of function	NegReg	(20, 36)	ThemeOf	Natural and induced loss of function mutations in SlMBP21 MADS-box gene led to jointless-2 phenotype in tomato.
LAMB2	Gene	(105, 110)	mutations	Var	(111, 120)	ThemeOf	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
mutations	Var	(111, 120)	caused by	Reg	(90, 99)	CauseOf	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
extrarenal features	CPA	(24, 43)	caused by	Reg	(90, 99)	ThemeOf	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
Nephron development	CPA	(0, 19)	caused by	Reg	(90, 99)	ThemeOf	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
SGCD	Gene	(37, 41)	deletions	Var	(42, 51)	ThemeOf	Exome sequencing reveals independent SGCD deletions causing limb girdle muscular dystrophy in Boston terriers.
limb girdle muscular dystrophy	Disease	(60, 90)	causing	Reg	(52, 59)	ThemeOf	Exome sequencing reveals independent SGCD deletions causing limb girdle muscular dystrophy in Boston terriers.
deletions	Var	(42, 51)	causing	Reg	(52, 59)	CauseOf	Exome sequencing reveals independent SGCD deletions causing limb girdle muscular dystrophy in Boston terriers.
mutations	Var	(1073, 1082)	absence	NegReg	(1109, 1116)	CauseOf	Both mutations are predicted to cause an absence of SGCD protein, confirmed by immunohistochemistry.
protein	Protein	(1125, 1132)	absence	NegReg	(1109, 1116)	ThemeOf	Both mutations are predicted to cause an absence of SGCD protein, confirmed by immunohistochemistry.
SGCD	Gene	(1120, 1124)	protein	Protein	(1125, 1132)	ThemeOf	Both mutations are predicted to cause an absence of SGCD protein, confirmed by immunohistochemistry.
protein	Protein	(57, 64)	mutations	Var	(5, 14)	NoRelation	Both mutations are predicted to cause an absence of SGCD protein, confirmed by immunohistochemistry.
aca10	Gene	(636, 641)	mutants	Var	(665, 672)	ThemeOf	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
bon1	Gene	(1187, 1191)	mutants	Var	(1192, 1199)	ThemeOf	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
mutants	Var	(1192, 1199)	compromised	NegReg	(1158, 1169)	CauseOf	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
calcium and pathogen induced stomatal closure	CPA	(1108, 1153)	compromised	NegReg	(1158, 1169)	ThemeOf	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
mutants	Var	(665, 672)	loss of function	NegReg	(642, 658)	CauseOf	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
bon1	Gene	(725, 729)	mutants	Var	(734, 741)	ThemeOf	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
mutants	Var	(734, 741)	LOF	NegReg	(730, 733)	CauseOf	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
bon1	Gene	(935, 939)	mutants	Var	(940, 947)	ThemeOf	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
aca10	Gene	(925, 930)	mutants	Var	(940, 947)	ThemeOf	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
mutants	Var	(940, 947)	increased	PosReg	(907, 916)	CauseOf	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
steady level of calcium concentration	MPA	(866, 903)	increased	PosReg	(907, 916)	ThemeOf	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
aca10	Gene	(1177, 1182)	mutants	Var	(1192, 1199)	ThemeOf	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
mutants	Var	(117, 124)	LOF	NegReg	(182, 185)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
mutants	Var	(186, 193)	loss of function	NegReg	(94, 110)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
mutation	Var	(394, 402)	LoF	NegReg	(390, 393)	CauseOf	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
mutation	Var	(394, 402)	activation	PosReg	(474, 484)	CauseOf	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
Wnt pathway	Pathway	(492, 503)	activation	PosReg	(474, 484)	ThemeOf	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
APC protein	Protein	(544, 555)	abilities	MPA	(604, 613)	ThemeOf	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
binding	Interaction	(596, 603)	abilities	MPA	(604, 613)	ThemeOf	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
abilities	MPA	(604, 613)	retains partial	NegReg	(580, 595)	ThemeOf	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
Adenomatous polyposis coli	Gene	(423, 449)	mutation	Var	(394, 402)	ThemeOf	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
colon cancer tumors	Disease	(14, 33)	binding	Interaction	(91, 98)	NoRelation	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
APC protein	Protein	(39, 50)	binding	Interaction	(91, 98)	NoRelation	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
colon cancer tumors	Disease	(14, 33)	retains partial	NegReg	(75, 90)	NoRelation	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
binding	Interaction	(91, 98)	retains partial	NegReg	(75, 90)	NoRelation	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
PCSK9	Gene	(62, 67)	mutation	Var	(85, 93)	ThemeOf	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
mutation	Var	(85, 93)	loss-of-function	NegReg	(68, 84)	CauseOf	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
hypocholesterolemia	Disease	(10, 29)	loss-of-function	NegReg	(68, 84)	ThemeOf	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
steatosis	Disease	(34, 43)	loss-of-function	NegReg	(68, 84)	ThemeOf	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
low-density lipoprotein receptor degradation	MPA	(427, 471)	loss of function	NegReg	(398, 414)	ThemeOf	Invitro functional studies demonstrated that this mutation leads to a loss of function of PCSK9 on low-density lipoprotein receptor degradation.
Ovarian aromatase	Protein	(0, 17)	mutant	Var	(35, 41)	ThemeOf	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
mutant	Var	(35, 41)	loss-of-function	NegReg	(18, 34)	CauseOf	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
loss-of-function	NegReg	(18, 34)	undergo	Reg	(49, 56)	CauseOf	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
ovary degeneration	CPA	(57, 75)	undergo	Reg	(49, 56)	ThemeOf	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
partial female-to-male sex reversal	CPA	(80, 115)	undergo	Reg	(49, 56)	ThemeOf	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
mutant	Var	(35, 41)	undergo	Reg	(49, 56)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
ovary degeneration	CPA	(57, 75)	loss-of-function	NegReg	(18, 34)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
partial female-to-male sex reversal	CPA	(80, 115)	loss-of-function	NegReg	(18, 34)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
ALMS1	Gene	(1054, 1059)	protein	Protein	(1060, 1067)	ThemeOf	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
protein	Protein	(1060, 1067)	undetectable	NegReg	(1072, 1084)	ThemeOf	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
loss-of-function	NegReg	(1104, 1120)	mutations	Var	(1127, 1136)	ThemeOf	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
mutations	Var	(1127, 1136)	undetectable	NegReg	(1072, 1084)	CauseOf	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
protein	Protein	(57, 64)	mutations	Var	(124, 133)	NoRelation	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
loss-of-function	Var	(569, 585)	activated	PosReg	(600, 609)	CauseOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(745, 760)	down-regulation	NegReg	(720, 735)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(762, 767)	down-regulation	NegReg	(720, 735)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(777, 786)	down-regulation	NegReg	(720, 735)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
down-regulation	NegReg	(720, 735)	reduced	NegReg	(787, 794)	CauseOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
CG17259	Gene	(592, 599)	loss-of-function	Var	(569, 585)	ThemeOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
protective effect	CPA	(799, 816)	reduced	NegReg	(787, 794)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
CG17259	Gene	(824, 831)	LOF	Var	(820, 823)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
LOF	Var	(820, 823)	protective effect	CPA	(799, 816)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp27	Protein	(768, 773)	down-regulation	NegReg	(720, 735)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
loss-of-function	Var	(569, 585)	up-regulation	PosReg	(647, 660)	CauseOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(616, 631)	activated	PosReg	(600, 609)	ThemeOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
eIF2	Protein	(610, 615)	phosphorylation	CPA	(616, 631)	ThemeOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp26	Protein	(675, 680)	chaperons	CPA	(664, 673)	ThemeOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp27	Protein	(685, 690)	chaperons	CPA	(664, 673)	ThemeOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
chaperons	CPA	(664, 673)	up-regulation	PosReg	(647, 660)	ThemeOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
autophagy	CPA	(696, 705)	up-regulation	PosReg	(647, 660)	ThemeOf	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
eIF2	Protein	(739, 744)	phosphorylation	CPA	(745, 760)	ThemeOf	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
eIF2	Protein	(55, 60)	loss-of-function	Var	(14, 30)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
autophagy	CPA	(141, 150)	activated	PosReg	(45, 54)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
CG17259	Gene	(37, 44)	Hsp26	Protein	(120, 125)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp27	Protein	(130, 135)	loss-of-function	Var	(14, 30)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(61, 76)	up-regulation	PosReg	(92, 105)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp26	Protein	(120, 125)	loss-of-function	Var	(14, 30)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
chaperons	CPA	(109, 118)	activated	PosReg	(45, 54)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(38, 53)	reduced	NegReg	(80, 87)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	LOF	Var	(113, 116)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(70, 79)	reduced	NegReg	(80, 87)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
protective effect	CPA	(92, 109)	down-regulation	NegReg	(13, 28)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp27	Protein	(61, 66)	LOF	Var	(113, 116)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
LOF	Var	(113, 116)	down-regulation	NegReg	(13, 28)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
LOF	Var	(113, 116)	reduced	NegReg	(80, 87)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
eIF2	Protein	(32, 37)	LOF	Var	(113, 116)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
PTPN2	Gene	(973, 978)	deletion	Var	(928, 936)	ThemeOf	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
deletion	Var	(928, 936)	enhancing	PosReg	(1038, 1047)	CauseOf	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
interferon--mediated effects on antigen presentation	MPA	(1048, 1101)	enhancing	PosReg	(1038, 1047)	ThemeOf	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
growth suppression	CPA	(1106, 1124)	enhancing	PosReg	(1038, 1047)	ThemeOf	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
enhancing	PosReg	(1038, 1047)	increased	PosReg	(995, 1004)	CauseOf	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
efficacy of immunotherapy	CPA	(1009, 1034)	increased	PosReg	(995, 1004)	ThemeOf	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
growth suppression	CPA	(191, 209)	increased	PosReg	(80, 89)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
efficacy of immunotherapy	CPA	(94, 119)	enhancing	PosReg	(123, 132)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
deletion	Var	(13, 21)	increased	PosReg	(80, 89)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
interferon--mediated effects on antigen presentation	MPA	(133, 186)	increased	PosReg	(80, 89)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
PDGFRB	Gene	(276, 282)	p.N666H	Var	(283, 290)	ThemeOf	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
p.N666H	Var	(283, 290)	inhibition	NegReg	(359, 369)	CauseOf	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
PDGFRB	Gene	(373, 379)	inhibition	NegReg	(359, 369)	ThemeOf	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
inhibition	NegReg	(359, 369)	responded to the tyrosine kinase inhibitor imatinib	MPA	(304, 355)	CauseOf	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
mutations	Var	(149, 158)	cause	Reg	(169, 174)	CauseOf	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
PDGFRB	Gene	(162, 168)	mutations	Var	(149, 158)	ThemeOf	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
Kosaki and Penttinen syndromes	Disease	(175, 205)	cause	Reg	(169, 174)	ThemeOf	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
myofibromatosis	Disease	(210, 225)	cause	Reg	(169, 174)	ThemeOf	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
PIEZO1	Gene	(234, 240)	mutations	Var	(211, 220)	ThemeOf	Loss-of-function mutations in the human PIEZO1 gene cause autosomal recessive congenital lymphatic dysplasia.
hereditary xerocytosis	Disease	(403, 425)	Gain-of-function	PosReg	(304, 320)	ThemeOf	Gain-of-function mutations in the human PIEZO1 gene cause the autosomal dominant hemolytic anemia, hereditary xerocytosis (also known as dehydrated stomatocytosis).
dehydrated stomatocytosis	Disease	(441, 466)	Gain-of-function	PosReg	(304, 320)	ThemeOf	Gain-of-function mutations in the human PIEZO1 gene cause the autosomal dominant hemolytic anemia, hereditary xerocytosis (also known as dehydrated stomatocytosis).
autosomal recessive syndrome of muscular atrophy	Disease	(530, 578)	Loss-of-function	NegReg	(469, 485)	ThemeOf	Loss-of-function mutations in the human PIEZO2 gene cause an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.
arthrogryposis	Disease	(616, 630)	Loss-of-function	NegReg	(469, 485)	ThemeOf	Loss-of-function mutations in the human PIEZO2 gene cause an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.
scoliosis	Disease	(636, 645)	Loss-of-function	NegReg	(469, 485)	ThemeOf	Loss-of-function mutations in the human PIEZO2 gene cause an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.
autosomal dominant distal arthrogryposis	Disease	(729, 769)	Gain-of-function	PosReg	(647, 663)	ThemeOf	Gain-of-function mutations in the human PIEZO2 gene cause three clinical types of autosomal dominant distal arthrogryposis.
autosomal recessive congenital lymphatic dysplasia	Disease	(252, 302)	Loss-of-function	NegReg	(194, 210)	ThemeOf	Loss-of-function mutations in the human PIEZO1 gene cause autosomal recessive congenital lymphatic dysplasia.
autosomal dominant hemolytic anemia	Disease	(366, 401)	Gain-of-function	PosReg	(304, 320)	ThemeOf	Gain-of-function mutations in the human PIEZO1 gene cause the autosomal dominant hemolytic anemia, hereditary xerocytosis (also known as dehydrated stomatocytosis).
mutations	Var	(211, 220)	Loss-of-function	NegReg	(194, 210)	CauseOf	Loss-of-function mutations in the human PIEZO1 gene cause autosomal recessive congenital lymphatic dysplasia.
PIEZO1	Gene	(344, 350)	mutations	Var	(321, 330)	ThemeOf	Gain-of-function mutations in the human PIEZO1 gene cause the autosomal dominant hemolytic anemia, hereditary xerocytosis (also known as dehydrated stomatocytosis).
mutations	Var	(321, 330)	Gain-of-function	PosReg	(304, 320)	CauseOf	Gain-of-function mutations in the human PIEZO1 gene cause the autosomal dominant hemolytic anemia, hereditary xerocytosis (also known as dehydrated stomatocytosis).
PIEZO2	Gene	(509, 515)	mutations	Var	(486, 495)	ThemeOf	Loss-of-function mutations in the human PIEZO2 gene cause an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.
mutations	Var	(486, 495)	Loss-of-function	NegReg	(469, 485)	CauseOf	Loss-of-function mutations in the human PIEZO2 gene cause an autosomal recessive syndrome of muscular atrophy with perinatal respiratory distress, arthrogryposis, and scoliosis.
PIEZO2	Gene	(687, 693)	mutations	Var	(664, 673)	ThemeOf	Gain-of-function mutations in the human PIEZO2 gene cause three clinical types of autosomal dominant distal arthrogryposis.
mutations	Var	(664, 673)	Gain-of-function	PosReg	(647, 663)	CauseOf	Gain-of-function mutations in the human PIEZO2 gene cause three clinical types of autosomal dominant distal arthrogryposis.
SCN5a	Gene	(80, 85)	mutations	Var	(86, 95)	ThemeOf	KEY POINTS: SCN5a mutations may express gain-of-function (Long QT Syndrome-3), loss-of-function (Brugada Syndrome 1) or both (mixed syndromes), depending on the mutation and environmental triggers.
mutations	Var	(86, 95)	gain-of-function	PosReg	(108, 124)	CauseOf	KEY POINTS: SCN5a mutations may express gain-of-function (Long QT Syndrome-3), loss-of-function (Brugada Syndrome 1) or both (mixed syndromes), depending on the mutation and environmental triggers.
mutations	Var	(86, 95)	loss-of-function	NegReg	(147, 163)	CauseOf	KEY POINTS: SCN5a mutations may express gain-of-function (Long QT Syndrome-3), loss-of-function (Brugada Syndrome 1) or both (mixed syndromes), depending on the mutation and environmental triggers.
Long QT Syndrome-3	Disease	(126, 144)	gain-of-function	PosReg	(108, 124)	ThemeOf	KEY POINTS: SCN5a mutations may express gain-of-function (Long QT Syndrome-3), loss-of-function (Brugada Syndrome 1) or both (mixed syndromes), depending on the mutation and environmental triggers.
Brugada Syndrome 1	Disease	(165, 183)	loss-of-function	NegReg	(147, 163)	ThemeOf	KEY POINTS: SCN5a mutations may express gain-of-function (Long QT Syndrome-3), loss-of-function (Brugada Syndrome 1) or both (mixed syndromes), depending on the mutation and environmental triggers.
Long QT Syndrome-3	Disease	(58, 76)	loss-of-function	NegReg	(79, 95)	NoRelation	KEY POINTS: SCN5a mutations may express gain-of-function (Long QT Syndrome-3), loss-of-function (Brugada Syndrome 1) or both (mixed syndromes), depending on the mutation and environmental triggers.
Brugada Syndrome 1	Disease	(97, 115)	gain-of-function	PosReg	(40, 56)	NoRelation	KEY POINTS: SCN5a mutations may express gain-of-function (Long QT Syndrome-3), loss-of-function (Brugada Syndrome 1) or both (mixed syndromes), depending on the mutation and environmental triggers.
activation kinetics	MPA	(832, 851)	D242N KV7.1 channels	MPA	(855, 875)	ThemeOf	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
conserved charge balance of this region	MPA	(622, 661)	disrupting	NegReg	(607, 617)	ThemeOf	The mutation is located in the S4 transmembrane segment, within the voltage sensor of the KV7.1 channel, disrupting the conserved charge balance of this region.
mutations	Var	(281, 290)	cause	Reg	(333, 338)	CauseOf	Its relevance is underscored by the identification of >500 mutations in KV7.1 and, at least, 36 in KCNE1, that cause Long QT Syndrome (LQTS).
Long QT Syndrome	Disease	(339, 355)	cause	Reg	(333, 338)	ThemeOf	Its relevance is underscored by the identification of >500 mutations in KV7.1 and, at least, 36 in KCNE1, that cause Long QT Syndrome (LQTS).
mutations	Var	(281, 290)	KCNE1	Gene	(321, 326)	ThemeOf	Its relevance is underscored by the identification of >500 mutations in KV7.1 and, at least, 36 in KCNE1, that cause Long QT Syndrome (LQTS).
D242N	Var	(1400, 1405)	impaired	NegReg	(1425, 1433)	CauseOf	Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate.
action potential adaptation to exercise	MPA	(1434, 1473)	impaired	NegReg	(1425, 1433)	ThemeOf	Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate.
D242N	Var	(1400, 1405)	increase	PosReg	(1497, 1505)	CauseOf	Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate.
heart rate	MPA	(1509, 1519)	increase	PosReg	(1497, 1505)	ThemeOf	Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate.
mutation	Var	(727, 735)	removed	NegReg	(792, 799)	CauseOf	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
KV7.1	Gene	(294, 299)	mutations	Var	(281, 290)	ThemeOf	Its relevance is underscored by the identification of >500 mutations in KV7.1 and, at least, 36 in KCNE1, that cause Long QT Syndrome (LQTS).
KCNE1	Gene	(321, 326)	mutations	Var	(281, 290)	ThemeOf	Its relevance is underscored by the identification of >500 mutations in KV7.1 and, at least, 36 in KCNE1, that cause Long QT Syndrome (LQTS).
KV7.1	Gene	(461, 466)	D242N	Var	(455, 460)	ThemeOf	The aim of this study was to characterize the biophysical and cellular consequences of the D242N KV7.1 mutation associated with the LQTS.
D242N	Var	(455, 460)	associated	Reg	(476, 486)	CauseOf	The aim of this study was to characterize the biophysical and cellular consequences of the D242N KV7.1 mutation associated with the LQTS.
inactivation	MPA	(804, 816)	removed	NegReg	(792, 799)	ThemeOf	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
mutation	Var	(727, 735)	slowed	NegReg	(821, 827)	CauseOf	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
activation kinetics	MPA	(832, 851)	slowed	NegReg	(821, 827)	ThemeOf	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
LQTS	Disease	(496, 500)	associated	Reg	(476, 486)	ThemeOf	The aim of this study was to characterize the biophysical and cellular consequences of the D242N KV7.1 mutation associated with the LQTS.
mutation	Var	(506, 514)	disrupting	NegReg	(607, 617)	CauseOf	The mutation is located in the S4 transmembrane segment, within the voltage sensor of the KV7.1 channel, disrupting the conserved charge balance of this region.
activation kinetics	MPA	(169, 188)	removed	NegReg	(129, 136)	NoRelation	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
inactivation	MPA	(141, 153)	slowed	NegReg	(158, 164)	NoRelation	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
D242N KV7.1 channels	MPA	(192, 212)	slowed	NegReg	(158, 164)	NoRelation	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
D242N KV7.1 channels	MPA	(192, 212)	removed	NegReg	(129, 136)	NoRelation	Perforated patch-clamp experiments show that, unexpectedly, the mutation did not disrupt the voltage-dependent activation but it removed the inactivation and slowed the activation kinetics of D242N KV7.1 channels.
heart rate	MPA	(222, 232)	impaired	NegReg	(138, 146)	NoRelation	Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate.
action potential adaptation to exercise	MPA	(147, 186)	increase	PosReg	(210, 218)	NoRelation	Both functional and computational analysis suggest that the clinical phenotype of the LQTS patients carrying the D242N mutation is due to impaired action potential adaptation to exercise and, in particular, to increase in heart rate.
variants	Var	(441, 449)	cause	Reg	(456, 461)	CauseOf	Genetic investigations have identified several gene variants which cause RA, including EYA1, LHX1, and WT1 However, whereas compound null mutations of genes encoding  and  retinoic acid receptors (RARs) cause RA in mice, to date there have been no reports of variants in RAR genes causing RA in humans.
kidney agenesis phenotypes	MPA	(1046, 1072)	revealed	Reg	(1037, 1045)	ThemeOf	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
RA	Disease	(462, 464)	cause	Reg	(456, 461)	ThemeOf	Genetic investigations have identified several gene variants which cause RA, including EYA1, LHX1, and WT1 However, whereas compound null mutations of genes encoding  and  retinoic acid receptors (RARs) cause RA in mice, to date there have been no reports of variants in RAR genes causing RA in humans.
mutant	Var	(913, 919)	loss-of-function	NegReg	(896, 912)	CauseOf	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
pronephric kidney just prior to death	MPA	(944, 981)	loss-of-function	NegReg	(896, 912)	ThemeOf	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
mutagenesis	Var	(1002, 1013)	revealed	Reg	(1037, 1045)	CauseOf	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
mutagenesis	Var	(308, 319)	loss-of-function	NegReg	(202, 218)	NoRelation	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
kidney agenesis phenotypes	MPA	(352, 378)	loss-of-function	NegReg	(202, 218)	NoRelation	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
mutant	Var	(219, 225)	revealed	Reg	(343, 351)	NoRelation	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
pronephric kidney just prior to death	MPA	(250, 287)	revealed	Reg	(343, 351)	NoRelation	In this study, we carried out whole exome sequence analysis of two families showing inheritance of an RA phenotype, and in both identified a single candidate gene, GREB1L Analysis of a zebrafish greb1l loss-of-function mutant revealed defects in the pronephric kidney just prior to death, and F0 CRISPR/Cas9 mutagenesis of Greb1l in the mouse revealed kidney agenesis phenotypes, implicating Greb1l in this disorder.
missense variant	Var	(11, 27)	causes	Reg	(73, 79)	CauseOf	Equivalent missense variant in the FOXP2 and FOXP1 transcription factors causes distinct neurodevelopmental disorders.
global developmental delay	Disease	(487, 513)	includes	Reg	(434, 442)	ThemeOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
intellectual disability	Disease	(515, 538)	includes	Reg	(434, 442)	ThemeOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
speech/language impairment	Disease	(544, 570)	includes	Reg	(434, 442)	ThemeOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
neurodevelopmental disorders	Disease	(89, 117)	causes	Reg	(73, 79)	ThemeOf	Equivalent missense variant in the FOXP2 and FOXP1 transcription factors causes distinct neurodevelopmental disorders.
FOXP2	Gene	(35, 40)	missense variant	Var	(11, 27)	ThemeOf	Equivalent missense variant in the FOXP2 and FOXP1 transcription factors causes distinct neurodevelopmental disorders.
FOXP1	Gene	(45, 50)	missense variant	Var	(11, 27)	ThemeOf	Equivalent missense variant in the FOXP2 and FOXP1 transcription factors causes distinct neurodevelopmental disorders.
mutations	Var	(289, 298)	lead to	Reg	(308, 315)	CauseOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
FOXP2	Gene	(302, 307)	mutations	Var	(289, 298)	ThemeOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
childhood apraxia of speech	Disease	(360, 387)	lead to	Reg	(308, 315)	ThemeOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
FOXP1	Gene	(419, 424)	variants	Var	(425, 433)	ThemeOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
variants	Var	(425, 433)	includes	Reg	(434, 442)	CauseOf	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
intellectual disability	Disease	(241, 264)	lead to	Reg	(34, 41)	NoRelation	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
speech/language impairment	Disease	(270, 296)	lead to	Reg	(34, 41)	NoRelation	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
childhood apraxia of speech	Disease	(86, 113)	includes	Reg	(160, 168)	NoRelation	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
global developmental delay	Disease	(213, 239)	lead to	Reg	(34, 41)	NoRelation	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
variants	Var	(151, 159)	lead to	Reg	(34, 41)	NoRelation	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
mutations	Var	(15, 24)	includes	Reg	(160, 168)	NoRelation	However, while mutations in FOXP2 lead to a speech/language disorder characterized by childhood apraxia of speech (CAS), the clinical profile of FOXP1 variants includes a broader neurodevelopmental phenotype with global developmental delay, intellectual disability, and speech/language impairment.
Leu191Phe	Gene	(1083, 1092)	mutation	Var	(1093, 1101)	ThemeOf	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
mutation	Var	(1093, 1101)	affects	Reg	(1102, 1109)	CauseOf	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
architecture	MPA	(1114, 1126)	affects	Reg	(1102, 1109)	ThemeOf	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
architecture	MPA	(1114, 1126)	preventing	NegReg	(1161, 1171)	CauseOf	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
allosteric inhibition	MPA	(1176, 1197)	preventing	NegReg	(1161, 1171)	ThemeOf	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
enzyme	Enzyme	(1205, 1211)	allosteric inhibition	MPA	(1176, 1197)	ThemeOf	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
enzyme	Enzyme	(189, 195)	architecture	MPA	(98, 110)	NoRelation	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
allosteric inhibition	MPA	(160, 181)	affects	Reg	(86, 93)	NoRelation	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
mutation	Var	(77, 85)	preventing	NegReg	(145, 155)	NoRelation	Analysis of the crystal structure of human PRPPS suggests that the Leu191Phe mutation affects the architecture of both allosteric sites, thereby preventing the allosteric inhibition of the enzyme.
Variation	Var	(22, 31)	Contributes	Reg	(43, 54)	CauseOf	Naturally-Segregating Variation at Ugt86Dd Contributes to Nicotine Resistance in Drosophila melanogaster.
Ugt86Dd	Gene	(1408, 1415)	lesions	Var	(1397, 1404)	ThemeOf	CRISPR/Cas9 editing a relatively resistant genotype to generate lesions in Ugt86Dd that recapitulate the naturally-occurring putative loss-of-function allele leads to a large reduction in resistance.
Ugt86Dd	Gene	(35, 42)	Variation	Var	(22, 31)	ThemeOf	Naturally-Segregating Variation at Ugt86Dd Contributes to Nicotine Resistance in Drosophila melanogaster.
Nicotine Resistance in Drosophila melanogaster	MPA	(58, 104)	Contributes	Reg	(43, 54)	ThemeOf	Naturally-Segregating Variation at Ugt86Dd Contributes to Nicotine Resistance in Drosophila melanogaster.
frameshift deletion	Var	(1157, 1176)	eliminates	NegReg	(1241, 1251)	CauseOf	We discovered a segregating 22-bp frameshift deletion in Ugt86Dd, and accounting for the InDel during mapping largely eliminates the QTL, implying the event explains the bulk of the effect of the mapped locus.
QTL	MPA	(1256, 1259)	eliminates	NegReg	(1241, 1251)	ThemeOf	We discovered a segregating 22-bp frameshift deletion in Ugt86Dd, and accounting for the InDel during mapping largely eliminates the QTL, implying the event explains the bulk of the effect of the mapped locus.
Ugt86Dd	Gene	(1180, 1187)	frameshift deletion	Var	(1157, 1176)	ThemeOf	We discovered a segregating 22-bp frameshift deletion in Ugt86Dd, and accounting for the InDel during mapping largely eliminates the QTL, implying the event explains the bulk of the effect of the mapped locus.
lesions	Var	(1397, 1404)	loss-of-function	NegReg	(1467, 1483)	CauseOf	CRISPR/Cas9 editing a relatively resistant genotype to generate lesions in Ugt86Dd that recapitulate the naturally-occurring putative loss-of-function allele leads to a large reduction in resistance.
lesions	Var	(1397, 1404)	reduction	NegReg	(1508, 1517)	CauseOf	CRISPR/Cas9 editing a relatively resistant genotype to generate lesions in Ugt86Dd that recapitulate the naturally-occurring putative loss-of-function allele leads to a large reduction in resistance.
resistance	MPA	(1521, 1531)	reduction	NegReg	(1508, 1517)	ThemeOf	CRISPR/Cas9 editing a relatively resistant genotype to generate lesions in Ugt86Dd that recapitulate the naturally-occurring putative loss-of-function allele leads to a large reduction in resistance.
resistance	MPA	(188, 198)	loss-of-function	NegReg	(134, 150)	NoRelation	CRISPR/Cas9 editing a relatively resistant genotype to generate lesions in Ugt86Dd that recapitulate the naturally-occurring putative loss-of-function allele leads to a large reduction in resistance.
Sequence exchange	Var	(0, 17)	converts	Reg	(34, 42)	CauseOf	Sequence exchange between R genes converts virus resistance into nematode resistance, and vice versa.
mild nematode resistance in the roots	MPA	(1385, 1422)	convert	Reg	(1333, 1340)	ThemeOf	These data demonstrate that exchanging the recognition moiety in the LRR is sufficient to convert extreme virus resistance in the leaves into mild nematode resistance in the roots, and vice versa.
nematode resistance	MPA	(65, 84)	converts	Reg	(34, 42)	ThemeOf	Sequence exchange between R genes converts virus resistance into nematode resistance, and vice versa.
R	Gene	(26, 27)	Sequence exchange	Var	(0, 17)	ThemeOf	Sequence exchange between R genes converts virus resistance into nematode resistance, and vice versa.
changes	Var	(348, 355)	alter	Reg	(392, 397)	CauseOf	This limitation is thought to be counterbalanced by the rapid evolution of NB-LRR proteins, as only few sequence changes have been shown to be sufficient to alter resistance specificities towards novel strains of a pathogen.
resistance specificities towards novel strains of a pathogen	MPA	(398, 458)	alter	Reg	(392, 397)	ThemeOf	This limitation is thought to be counterbalanced by the rapid evolution of NB-LRR proteins, as only few sequence changes have been shown to be sufficient to alter resistance specificities towards novel strains of a pathogen.
exchange	Var	(1115, 1123)	regain	PosReg	(1176, 1182)	CauseOf	The reciprocal construct (Rx1CN/Gpa2L) showed a loss-of-function phenotype, but exchange of the first 3 LRR repeats of Rx1 was sufficient to regain a wild type resistance response to G. pallida in the roots.
wild type resistance response to G. pallida in the roots	MPA	(1185, 1241)	regain	PosReg	(1176, 1182)	ThemeOf	The reciprocal construct (Rx1CN/Gpa2L) showed a loss-of-function phenotype, but exchange of the first 3 LRR repeats of Rx1 was sufficient to regain a wild type resistance response to G. pallida in the roots.
Rx1	Gene	(1154, 1157)	exchange	Var	(1115, 1123)	ThemeOf	The reciprocal construct (Rx1CN/Gpa2L) showed a loss-of-function phenotype, but exchange of the first 3 LRR repeats of Rx1 was sufficient to regain a wild type resistance response to G. pallida in the roots.
exchanging	Var	(1271, 1281)	convert	Reg	(1333, 1340)	CauseOf	These data demonstrate that exchanging the recognition moiety in the LRR is sufficient to convert extreme virus resistance in the leaves into mild nematode resistance in the roots, and vice versa.
mutations	Var	(15, 24)	associated	Reg	(80, 90)	CauseOf	Lethal digenic mutations in the K(+) channels Kir4.1 (KCNJ10) and SLACK (KCNT1) associated with severe-disabling seizures and neurodevelopmental delay.
protein expression	MPA	(1266, 1284)	reduced	NegReg	(1258, 1265)	ThemeOf	Western Blot analysis revealed reduced protein expression by the mutation.
mutation	Var	(1607, 1615)	loss-of-function	NegReg	(1590, 1606)	CauseOf	We thus report a novel loss-of-function mutation in Kir4.1 found in a patient with a co-exiting mutation in SLACK channels that results in a fatal disease.
mutation	Var	(1663, 1671)	mutation	Var	(1607, 1615)	ThemeOf	We thus report a novel loss-of-function mutation in Kir4.1 found in a patient with a co-exiting mutation in SLACK channels that results in a fatal disease.
mutation	Var	(1607, 1615)	results in	Reg	(1695, 1705)	CauseOf	We thus report a novel loss-of-function mutation in Kir4.1 found in a patient with a co-exiting mutation in SLACK channels that results in a fatal disease.
fatal disease	Disease	(1708, 1721)	results in	Reg	(1695, 1705)	ThemeOf	We thus report a novel loss-of-function mutation in Kir4.1 found in a patient with a co-exiting mutation in SLACK channels that results in a fatal disease.
seizures	Disease	(113, 121)	associated	Reg	(80, 90)	ThemeOf	Lethal digenic mutations in the K(+) channels Kir4.1 (KCNJ10) and SLACK (KCNT1) associated with severe-disabling seizures and neurodevelopmental delay.
KCNJ10	Gene	(54, 60)	mutations	Var	(15, 24)	ThemeOf	Lethal digenic mutations in the K(+) channels Kir4.1 (KCNJ10) and SLACK (KCNT1) associated with severe-disabling seizures and neurodevelopmental delay.
KCNT1	Gene	(73, 78)	mutations	Var	(15, 24)	ThemeOf	Lethal digenic mutations in the K(+) channels Kir4.1 (KCNJ10) and SLACK (KCNT1) associated with severe-disabling seizures and neurodevelopmental delay.
neurodevelopmental delay	Disease	(126, 150)	associated	Reg	(80, 90)	ThemeOf	Lethal digenic mutations in the K(+) channels Kir4.1 (KCNJ10) and SLACK (KCNT1) associated with severe-disabling seizures and neurodevelopmental delay.
KCNJ10	Gene	(1008, 1014)	mutation	Var	(1015, 1023)	ThemeOf	The KCNJ10 mutation c.652C>T resulted in a p.L218F substitution at a highly conserved residue site.
mutation	Var	(1015, 1023)	resulted in	Reg	(1033, 1044)	CauseOf	The KCNJ10 mutation c.652C>T resulted in a p.L218F substitution at a highly conserved residue site.
substitution	Var	(1055, 1067)	resulted in	Reg	(1033, 1044)	ThemeOf	The KCNJ10 mutation c.652C>T resulted in a p.L218F substitution at a highly conserved residue site.
mutation	Var	(1292, 1300)	reduced	NegReg	(1258, 1265)	CauseOf	Western Blot analysis revealed reduced protein expression by the mutation.
mutation	Var	(96, 104)	loss-of-function	NegReg	(23, 39)	NoRelation	We thus report a novel loss-of-function mutation in Kir4.1 found in a patient with a co-exiting mutation in SLACK channels that results in a fatal disease.
mutation	Var	(96, 104)	results in	Reg	(128, 138)	NoRelation	We thus report a novel loss-of-function mutation in Kir4.1 found in a patient with a co-exiting mutation in SLACK channels that results in a fatal disease.
fatal disease	Disease	(141, 154)	loss-of-function	NegReg	(23, 39)	NoRelation	We thus report a novel loss-of-function mutation in Kir4.1 found in a patient with a co-exiting mutation in SLACK channels that results in a fatal disease.
LQTS	Disease	(1410, 1414)	pathogenic	Reg	(1399, 1409)	ThemeOf	Our results indicate that the novel KCNH2-C108Y variant can be a pathogenic LQTS mutation, whereas KCNQ1-p.R583H, KCNH2-p.K897T, and KCNE1-p.G38S could be LQTS modifiers.
KCNH2	Gene	(1050, 1055)	p.C108Y	Var	(1056, 1063)	ThemeOf	We found that KCNQ1-p.R583H was not associated with a severe functional impairment, whereas KCNH2-p.C108Y, a novel variant, encoded a non-functional channel that exerts dominant-negative effects on the wild-type.
p.C108Y	Var	(1056, 1063)	encoded	Reg	(1082, 1089)	CauseOf	We found that KCNQ1-p.R583H was not associated with a severe functional impairment, whereas KCNH2-p.C108Y, a novel variant, encoded a non-functional channel that exerts dominant-negative effects on the wild-type.
non-functional channel	Pathway	(1092, 1114)	encoded	Reg	(1082, 1089)	ThemeOf	We found that KCNQ1-p.R583H was not associated with a severe functional impairment, whereas KCNH2-p.C108Y, a novel variant, encoded a non-functional channel that exerts dominant-negative effects on the wild-type.
non-functional channel	Pathway	(1092, 1114)	dominant-negative	NegReg	(1127, 1144)	CauseOf	We found that KCNQ1-p.R583H was not associated with a severe functional impairment, whereas KCNH2-p.C108Y, a novel variant, encoded a non-functional channel that exerts dominant-negative effects on the wild-type.
effects	MPA	(1145, 1152)	dominant-negative	NegReg	(1127, 1144)	ThemeOf	We found that KCNQ1-p.R583H was not associated with a severe functional impairment, whereas KCNH2-p.C108Y, a novel variant, encoded a non-functional channel that exerts dominant-negative effects on the wild-type.
KCNH2	Gene	(1370, 1375)	C108Y	Var	(1376, 1381)	ThemeOf	Our results indicate that the novel KCNH2-C108Y variant can be a pathogenic LQTS mutation, whereas KCNQ1-p.R583H, KCNH2-p.K897T, and KCNE1-p.G38S could be LQTS modifiers.
C108Y	Var	(1376, 1381)	pathogenic	Reg	(1399, 1409)	CauseOf	Our results indicate that the novel KCNH2-C108Y variant can be a pathogenic LQTS mutation, whereas KCNQ1-p.R583H, KCNH2-p.K897T, and KCNE1-p.G38S could be LQTS modifiers.
effects	MPA	(187, 194)	encoded	Reg	(124, 131)	NoRelation	We found that KCNQ1-p.R583H was not associated with a severe functional impairment, whereas KCNH2-p.C108Y, a novel variant, encoded a non-functional channel that exerts dominant-negative effects on the wild-type.
p.C108Y	Var	(98, 105)	dominant-negative	NegReg	(169, 186)	NoRelation	We found that KCNQ1-p.R583H was not associated with a severe functional impairment, whereas KCNH2-p.C108Y, a novel variant, encoded a non-functional channel that exerts dominant-negative effects on the wild-type.
mutation	Var	(272, 280)	loss-of-function	NegReg	(255, 271)	CauseOf	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
pri1-1	Gene	(910, 916)	mutation	Var	(917, 925)	ThemeOf	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
mutation	Var	(917, 925)	introduced	Interaction	(930, 940)	ThemeOf	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
mutants	Var	(953, 960)	introduced	Interaction	(930, 940)	ThemeOf	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
hrz1-2	Gene	(946, 952)	mutants	Var	(953, 960)	ThemeOf	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
hrz1-2	Gene	(946, 952)	introduced	Interaction	(930, 940)	CauseOf	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
mutants	Var	(953, 960)	more	PosReg	(993, 997)	CauseOf	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
sensitive to Fe deficiency	MPA	(998, 1024)	more	PosReg	(993, 997)	ThemeOf	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
OsPRI1	Gene	(284, 290)	mutation	Var	(272, 280)	ThemeOf	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
mutation	Var	(272, 280)	increased	PosReg	(291, 300)	CauseOf	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
sensitivity	MPA	(305, 316)	increased	PosReg	(291, 300)	ThemeOf	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
mutation	Var	(272, 280)	downregulated	NegReg	(358, 371)	CauseOf	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
expression	MPA	(376, 386)	downregulated	NegReg	(358, 371)	ThemeOf	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
hrz1-2	Gene	(756, 762)	mutant	Var	(763, 769)	ThemeOf	Cell-free degradation assays revealed that the stability of OsPRI1 decreased in wild type roots, but increased in the hrz1-2 mutant, suggesting OsHRZ1 is responsible for the instability of OsPRI1.
mutant	Var	(763, 769)	increased	PosReg	(739, 748)	CauseOf	Cell-free degradation assays revealed that the stability of OsPRI1 decreased in wild type roots, but increased in the hrz1-2 mutant, suggesting OsHRZ1 is responsible for the instability of OsPRI1.
stability	MPA	(685, 694)	increased	PosReg	(739, 748)	ThemeOf	Cell-free degradation assays revealed that the stability of OsPRI1 decreased in wild type roots, but increased in the hrz1-2 mutant, suggesting OsHRZ1 is responsible for the instability of OsPRI1.
expression	MPA	(123, 133)	loss-of-function	NegReg	(2, 18)	NoRelation	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
sensitivity	MPA	(52, 63)	loss-of-function	NegReg	(2, 18)	NoRelation	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
sensitivity	MPA	(52, 63)	downregulated	NegReg	(105, 118)	NoRelation	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
expression	MPA	(123, 133)	increased	PosReg	(38, 47)	NoRelation	A loss-of-function mutation to OsPRI1 increased the sensitivity of plants to Fe-deficient conditions and downregulated the expression of Fe-deficiency-responsive genes.
introduced	Interaction	(29, 39)	sensitive to Fe deficiency	MPA	(97, 123)	NoRelation	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
mutation	Var	(16, 24)	more	PosReg	(92, 96)	NoRelation	When the pri1-1 mutation was introduced into hrz1-2 mutants, the pri1hrz1 double mutant was more sensitive to Fe deficiency than the hrz1-2 mutant.
IKZF1	Gene	(54, 59)	deletions	Var	(60, 69)	ThemeOf	Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.
deletions	Var	(60, 69)	Loss-of-function	NegReg	(0, 16)	CauseOf	Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.
acute lymphoblastic leukemia	Disease	(137, 165)	Loss-of-function	NegReg	(0, 16)	ThemeOf	Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.
deletions	Var	(374, 383)	loss-of-function	NegReg	(453, 469)	CauseOf	Different types of intragenic deletions have been observed, resulting in a functionally inactivated allele ("loss-of-function") or in "dominant-negative" isoforms.
functionally inactivated allele	MPA	(419, 450)	loss-of-function	NegReg	(453, 469)	ThemeOf	Different types of intragenic deletions have been observed, resulting in a functionally inactivated allele ("loss-of-function") or in "dominant-negative" isoforms.
deletions	Var	(374, 383)	dominant-negative	NegReg	(479, 496)	CauseOf	Different types of intragenic deletions have been observed, resulting in a functionally inactivated allele ("loss-of-function") or in "dominant-negative" isoforms.
isoforms	MPA	(498, 506)	dominant-negative	NegReg	(479, 496)	ThemeOf	Different types of intragenic deletions have been observed, resulting in a functionally inactivated allele ("loss-of-function") or in "dominant-negative" isoforms.
high deletion load	Var	(1123, 1141)	shorter	NegReg	(1148, 1155)	CauseOf	Patients exhibiting a loss-of-function isoform with high deletion load had a shorter overall survival (OS at 5 years 28% vs. 59%, p<0.0001), also significant in a subgroup analysis of standard risk patients according to GMALL classification (OS at 5 years 37% vs. 68%, p=0.0002).
overall survival	MPA	(1156, 1172)	shorter	NegReg	(1148, 1155)	ThemeOf	Patients exhibiting a loss-of-function isoform with high deletion load had a shorter overall survival (OS at 5 years 28% vs. 59%, p<0.0001), also significant in a subgroup analysis of standard risk patients according to GMALL classification (OS at 5 years 37% vs. 68%, p=0.0002).
functionally inactivated allele	MPA	(75, 106)	dominant-negative	NegReg	(135, 152)	NoRelation	Different types of intragenic deletions have been observed, resulting in a functionally inactivated allele ("loss-of-function") or in "dominant-negative" isoforms.
isoforms	MPA	(154, 162)	loss-of-function	NegReg	(109, 125)	NoRelation	Different types of intragenic deletions have been observed, resulting in a functionally inactivated allele ("loss-of-function") or in "dominant-negative" isoforms.
mutant	Var	(983, 989)	loss of function	NegReg	(966, 982)	CauseOf	Loss of function mutants of atl-1 had no defect in UVC induced SIS but a partial loss of function mutant of cep-1, gk138, had decreased movement quiescence following UVC irradiation.
cep-1	Gene	(993, 998)	mutant	Var	(983, 989)	ThemeOf	Loss of function mutants of atl-1 had no defect in UVC induced SIS but a partial loss of function mutant of cep-1, gk138, had decreased movement quiescence following UVC irradiation.
mutant	Var	(983, 989)	decreased	NegReg	(1011, 1020)	CauseOf	Loss of function mutants of atl-1 had no defect in UVC induced SIS but a partial loss of function mutant of cep-1, gk138, had decreased movement quiescence following UVC irradiation.
movement quiescence	MPA	(1021, 1040)	decreased	NegReg	(1011, 1020)	ThemeOf	Loss of function mutants of atl-1 had no defect in UVC induced SIS but a partial loss of function mutant of cep-1, gk138, had decreased movement quiescence following UVC irradiation.
cep-1	Gene	(1227, 1232)	mutant	Var	(1240, 1246)	ThemeOf	The cep-1(gk138) mutant suppressed body movement quiescence controlled by EGF, indicating that CEP-1 acts downstream or in parallel to ALA activation to promote quiescence in response to ultraviolet light.
mutant	Var	(1240, 1246)	suppressed	NegReg	(1247, 1257)	CauseOf	The cep-1(gk138) mutant suppressed body movement quiescence controlled by EGF, indicating that CEP-1 acts downstream or in parallel to ALA activation to promote quiescence in response to ultraviolet light.
body movement quiescence controlled by EGF	MPA	(1258, 1300)	suppressed	NegReg	(1247, 1257)	ThemeOf	The cep-1(gk138) mutant suppressed body movement quiescence controlled by EGF, indicating that CEP-1 acts downstream or in parallel to ALA activation to promote quiescence in response to ultraviolet light.
movement quiescence	MPA	(136, 155)	loss of function	NegReg	(81, 97)	NoRelation	Loss of function mutants of atl-1 had no defect in UVC induced SIS but a partial loss of function mutant of cep-1, gk138, had decreased movement quiescence following UVC irradiation.
PCSK9	Gene	(0, 5)	deficiency	Var	(6, 16)	ThemeOf	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
deficiency	Var	(6, 16)	increased	PosReg	(28, 37)	CauseOf	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
ectopic fat accumulation	MPA	(38, 62)	increased	PosReg	(28, 37)	ThemeOf	PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans.
R46L	Gene	(979, 983)	variant	Var	(984, 991)	ThemeOf	R46L variant associated with a two-fold increase prevalence of hepatic steatosis and higher epicardial fat thickness.
variant	Var	(984, 991)	increase	PosReg	(1019, 1027)	CauseOf	R46L variant associated with a two-fold increase prevalence of hepatic steatosis and higher epicardial fat thickness.
hepatic steatosis and higher epicardial fat thickness	MPA	(1042, 1095)	increase	PosReg	(1019, 1027)	ThemeOf	R46L variant associated with a two-fold increase prevalence of hepatic steatosis and higher epicardial fat thickness.
PCSK9	Gene	(1369, 1374)	deficiency	Var	(1375, 1385)	ThemeOf	Conclusions These data suggest that genetically determined PCSK9 deficiency might be associated with ectopic fat accumulation.
deficiency	Var	(1375, 1385)	associated	Reg	(1395, 1405)	CauseOf	Conclusions These data suggest that genetically determined PCSK9 deficiency might be associated with ectopic fat accumulation.
ectopic fat accumulation	MPA	(1411, 1435)	associated	Reg	(1395, 1405)	ThemeOf	Conclusions These data suggest that genetically determined PCSK9 deficiency might be associated with ectopic fat accumulation.
Braf	Gene	(2, 6)	mutant	Var	(23, 29)	ThemeOf	A Braf kinase-inactive mutant induces lung adenocarcinoma.
Kras	Gene	(884, 888)	G12V	Var	(889, 893)	ThemeOf	Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
Braf	Gene	(899, 903)	D631A	Var	(904, 909)	ThemeOf	Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
tumour initiation	MPA	(949, 966)	enhances	PosReg	(940, 948)	ThemeOf	Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
G12V	Var	(889, 893)	enhances	PosReg	(940, 948)	CauseOf	Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
D631A	Var	(904, 909)	enhances	PosReg	(940, 948)	CauseOf	Co-expression of Kras(G12V) and Braf(D631A) in mouse lung cells markedly enhances tumour initiation, a phenomenon mediated by Craf kinase activity, and effectively accelerates tumour progression when activated in advanced lung adenocarcinomas.
mutant	Var	(23, 29)	induces	Reg	(30, 37)	CauseOf	A Braf kinase-inactive mutant induces lung adenocarcinoma.
lung adenocarcinoma	Disease	(38, 57)	induces	Reg	(30, 37)	ThemeOf	A Braf kinase-inactive mutant induces lung adenocarcinoma.
Braf	Gene	(1515, 1519)	loss	Var	(1497, 1501)	ThemeOf	However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions.
loss	Var	(1497, 1501)	induces	Reg	(1525, 1532)	CauseOf	However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions.
transdifferentiation	CPA	(1533, 1553)	induces	Reg	(1525, 1532)	ThemeOf	However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions.
transdifferentiation	CPA	(1533, 1553)	leads to	Reg	(1575, 1583)	CauseOf	However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions.
rapid development of lethal intrabronchiolar lesions	MPA	(1588, 1640)	leads to	Reg	(1575, 1583)	ThemeOf	However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions.
rapid development of lethal intrabronchiolar lesions	MPA	(104, 156)	induces	Reg	(41, 48)	NoRelation	However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions.
loss	Var	(13, 17)	leads to	Reg	(91, 99)	NoRelation	However, the loss of wild-type Braf also induces transdifferentiation of club cells, which leads to the rapid development of lethal intrabronchiolar lesions.
Loss-of-function	Var	(466, 482)	exhibited	Reg	(540, 549)	CauseOf	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
arteriosclerosis	Disease	(629, 645)	exhibited	Reg	(540, 549)	ThemeOf	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
osteoporosis	Disease	(650, 662)	exhibited	Reg	(540, 549)	ThemeOf	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
Enpp1	Gene	(483, 488)	Loss-of-function	Var	(466, 482)	ThemeOf	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
serum 1,25(OH)2D3 levels	MPA	(678, 702)	elevated	PosReg	(669, 677)	ThemeOf	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
Loss-of-function	Var	(466, 482)	elevated	PosReg	(669, 677)	CauseOf	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
osteoporosis	Disease	(184, 196)	elevated	PosReg	(203, 211)	NoRelation	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
arteriosclerosis	Disease	(163, 179)	elevated	PosReg	(203, 211)	NoRelation	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
serum 1,25(OH)2D3 levels	MPA	(212, 236)	exhibited	Reg	(74, 83)	NoRelation	Loss-of-function Enpp1 (ttw/ttw) mice under phosphate overload conditions exhibited phenotypes resembling human aging and Klotho mutants, such as short life span, arteriosclerosis and osteoporosis, with elevated serum 1,25(OH)2D3 levels.
BmATG8	Gene	(638, 644)	Deletion	Var	(626, 634)	ThemeOf	Deletion of BmATG8 impaired localization of cytosolic components to the vacuole under nitrogen starvation, suggesting that autophagy was deficient in the null mutants.
Deletion	Var	(626, 634)	impaired	NegReg	(645, 653)	CauseOf	Deletion of BmATG8 impaired localization of cytosolic components to the vacuole under nitrogen starvation, suggesting that autophagy was deficient in the null mutants.
localization	MPA	(654, 666)	impaired	NegReg	(645, 653)	ThemeOf	Deletion of BmATG8 impaired localization of cytosolic components to the vacuole under nitrogen starvation, suggesting that autophagy was deficient in the null mutants.
Deletion	Var	(626, 634)	deficient	NegReg	(763, 772)	CauseOf	Deletion of BmATG8 impaired localization of cytosolic components to the vacuole under nitrogen starvation, suggesting that autophagy was deficient in the null mutants.
autophagy	CPA	(749, 758)	deficient	NegReg	(763, 772)	ThemeOf	Deletion of BmATG8 impaired localization of cytosolic components to the vacuole under nitrogen starvation, suggesting that autophagy was deficient in the null mutants.
	Var	(976, 977)	reduction	NegReg	(1001, 1010)	CauseOf	In vegetative growth, BmATG8 strains showed a reduction in conidiation and aerial mycelial growth.
BmATG8	Gene	(977, 983)		Var	(976, 977)	ThemeOf	In vegetative growth, BmATG8 strains showed a reduction in conidiation and aerial mycelial growth.
conidiation and aerial mycelial growth	CPA	(1014, 1052)	reduction	NegReg	(1001, 1010)	ThemeOf	In vegetative growth, BmATG8 strains showed a reduction in conidiation and aerial mycelial growth.
localization	MPA	(28, 40)	deficient	NegReg	(137, 146)	NoRelation	Deletion of BmATG8 impaired localization of cytosolic components to the vacuole under nitrogen starvation, suggesting that autophagy was deficient in the null mutants.
autophagy	CPA	(123, 132)	impaired	NegReg	(19, 27)	NoRelation	Deletion of BmATG8 impaired localization of cytosolic components to the vacuole under nitrogen starvation, suggesting that autophagy was deficient in the null mutants.
haploinsufficiency	Var	(316, 334)	caused by	Reg	(306, 315)	CauseOf	It is caused by haploinsufficiency of the TCF4 gene.
partial gene deletion	Var	(993, 1014)	with	Reg	(1066, 1070)	CauseOf	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
mild ID	Disease	(1071, 1078)	with	Reg	(1066, 1070)	ThemeOf	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
c.520C>T	Var	(1163, 1173)	with	Reg	(1227, 1231)	CauseOf	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
PTHS	Disease	(1269, 1273)	with	Reg	(1227, 1231)	ThemeOf	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
TCF4	Gene	(342, 346)	haploinsufficiency	Var	(316, 334)	ThemeOf	It is caused by haploinsufficiency of the TCF4 gene.
variants	Var	(879, 887)	disrupting	NegReg	(888, 898)	CauseOf	There is recent evidence that certain loss-of-function variants disrupting TCF4 are associated with mild ID, but not with typical PTHS.
TCF4	Gene	(899, 903)	variants	Var	(879, 887)	ThemeOf	There is recent evidence that certain loss-of-function variants disrupting TCF4 are associated with mild ID, but not with typical PTHS.
mild ID	Disease	(924, 931)	disrupting	NegReg	(888, 898)	ThemeOf	There is recent evidence that certain loss-of-function variants disrupting TCF4 are associated with mild ID, but not with typical PTHS.
frameshift	Var	(974, 984)	causing	Reg	(985, 992)	CauseOf	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
partial gene deletion	Var	(993, 1014)	causing	Reg	(985, 992)	ThemeOf	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
TCF4	Gene	(1041, 1045)	partial gene deletion	Var	(993, 1014)	ThemeOf	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
PTHS	Disease	(309, 313)	causing	Reg	(25, 32)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
frameshift	Var	(14, 24)	with	Reg	(106, 110)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
mild ID	Disease	(111, 118)	with	Reg	(267, 271)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
mild ID	Disease	(111, 118)	causing	Reg	(25, 32)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
frameshift	Var	(14, 24)	with	Reg	(267, 271)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
c.520C>T	Var	(203, 213)	causing	Reg	(25, 32)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
PTHS	Disease	(309, 313)	with	Reg	(106, 110)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
c.520C>T	Var	(203, 213)	with	Reg	(106, 110)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
partial gene deletion	Var	(33, 54)	with	Reg	(267, 271)	NoRelation	We describe a frameshift-causing partial gene deletion encompassing exons 4-6 of TCF4 in an adult patient with mild ID and nonspecific facial dysmorphisms but without the typical features of PTHS, and a c.520C>T nonsense variant within exon 8 in a child presenting with a severe phenotype largely mimicking PTHS, but lacking the typical facial dysmorphism.
variants	Var	(1722, 1730)	LoF	NegReg	(1718, 1721)	CauseOf	Collectively, our data demonstrate that ARHGAP29 is required for embryonic survival and that heterozygosity for LoF variants of Arhgap29 increases the incidence and length of oral adhesions at a critical time point during orofacial development.
Arhgap29	Gene	(1734, 1742)	variants	Var	(1722, 1730)	ThemeOf	Collectively, our data demonstrate that ARHGAP29 is required for embryonic survival and that heterozygosity for LoF variants of Arhgap29 increases the incidence and length of oral adhesions at a critical time point during orofacial development.
variants	Var	(1722, 1730)	increases	PosReg	(1743, 1752)	CauseOf	Collectively, our data demonstrate that ARHGAP29 is required for embryonic survival and that heterozygosity for LoF variants of Arhgap29 increases the incidence and length of oral adhesions at a critical time point during orofacial development.
incidence and length of oral adhesions at a critical time point during orofacial development	CPA	(1757, 1849)	increases	PosReg	(1743, 1752)	ThemeOf	Collectively, our data demonstrate that ARHGAP29 is required for embryonic survival and that heterozygosity for LoF variants of Arhgap29 increases the incidence and length of oral adhesions at a critical time point during orofacial development.
mutations	Var	(196, 205)	associated	Reg	(218, 228)	CauseOf	Previous studies identified mutations in ARHGAP29 associated with an increased risk for NSCL/P.
NSCL/P	Disease	(256, 262)	associated	Reg	(218, 228)	ThemeOf	Previous studies identified mutations in ARHGAP29 associated with an increased risk for NSCL/P.
ARHGAP29	Gene	(209, 217)	mutations	Var	(196, 205)	ThemeOf	Previous studies identified mutations in ARHGAP29 associated with an increased risk for NSCL/P.
single-nucleotide variation	Var	(419, 446)	loss-of-function	NegReg	(533, 549)	CauseOf	This single-nucleotide variation of ARHGAP29 translates to an early nonsense mutation (K326X), presumably resulting in loss-of-function (LoF).
K326X	Var	(501, 506)	single-nucleotide variation	Var	(419, 446)	ThemeOf	This single-nucleotide variation of ARHGAP29 translates to an early nonsense mutation (K326X), presumably resulting in loss-of-function (LoF).
ARHGAP29	Gene	(450, 458)	single-nucleotide variation	Var	(419, 446)	ThemeOf	This single-nucleotide variation of ARHGAP29 translates to an early nonsense mutation (K326X), presumably resulting in loss-of-function (LoF).
K326X mutation	Var	(1906, 1920)	LoF	NegReg	(1882, 1885)	CauseOf	In conclusion, we validate the LoF nature of the human K326X mutation in vivo and reveal a previously unknown effect of Arhgap29 in murine craniofacial development.
craniofacial development	CPA	(1990, 2014)	LoF	NegReg	(1882, 1885)	ThemeOf	In conclusion, we validate the LoF nature of the human K326X mutation in vivo and reveal a previously unknown effect of Arhgap29 in murine craniofacial development.
Arhgap29	Gene	(1971, 1979)	K326X mutation	Var	(1906, 1920)	ThemeOf	In conclusion, we validate the LoF nature of the human K326X mutation in vivo and reveal a previously unknown effect of Arhgap29 in murine craniofacial development.
K326X	Var	(87, 92)	loss-of-function	NegReg	(119, 135)	NoRelation	This single-nucleotide variation of ARHGAP29 translates to an early nonsense mutation (K326X), presumably resulting in loss-of-function (LoF).
incidence and length of oral adhesions at a critical time point during orofacial development	CPA	(151, 243)	LoF	NegReg	(112, 115)	NoRelation	Collectively, our data demonstrate that ARHGAP29 is required for embryonic survival and that heterozygosity for LoF variants of Arhgap29 increases the incidence and length of oral adhesions at a critical time point during orofacial development.
SLC40A1	Gene	(107, 114)	missense mutations	Var	(115, 133)	ThemeOf	Deciphering the molecular basis of ferroportin resistance to hepcidin: Structure/function analysis of rare SLC40A1 missense mutations found in suspected hemochromatosis type 4 patients.
missense mutations	Var	(115, 133)	found	Reg	(134, 139)	CauseOf	Deciphering the molecular basis of ferroportin resistance to hepcidin: Structure/function analysis of rare SLC40A1 missense mutations found in suspected hemochromatosis type 4 patients.
hemochromatosis type 4	Disease	(153, 175)	found	Reg	(134, 139)	ThemeOf	Deciphering the molecular basis of ferroportin resistance to hepcidin: Structure/function analysis of rare SLC40A1 missense mutations found in suspected hemochromatosis type 4 patients.
FLG	Gene	(149, 152)	mutations	Var	(120, 129)	ThemeOf	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
skin malignancies	Disease	(208, 225)	Loss-of-function	NegReg	(103, 119)	ThemeOf	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
mutations	Var	(120, 129)	Loss-of-function	NegReg	(103, 119)	CauseOf	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
mutations	Var	(120, 129)	reduced	NegReg	(233, 240)	CauseOf	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
levels of epidermal filaggrin	MPA	(241, 270)	reduced	NegReg	(233, 240)	ThemeOf	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
mutations	Var	(120, 129)	degradation products	MPA	(279, 299)	CauseOf	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
urocanic acid	MPA	(301, 314)	degradation products	MPA	(279, 299)	ThemeOf	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
degradation products	MPA	(188, 208)	reduced	NegReg	(142, 149)	NoRelation	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
urocanic acid	MPA	(210, 223)	Loss-of-function	NegReg	(12, 28)	NoRelation	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
degradation products	MPA	(188, 208)	Loss-of-function	NegReg	(12, 28)	NoRelation	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
skin malignancies	Disease	(117, 134)	reduced	NegReg	(142, 149)	NoRelation	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
levels of epidermal filaggrin	MPA	(150, 179)	Loss-of-function	NegReg	(12, 28)	NoRelation	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
urocanic acid	MPA	(210, 223)	reduced	NegReg	(142, 149)	NoRelation	BACKGROUND: Loss-of-function mutations in filaggrin gene (FLG) have been suggested to increase the susceptibility of skin malignancies due to reduced levels of epidermal filaggrin and its degradation products, urocanic acid, which may be protective against ultraviolet irradiation.
mutation	Var	(19, 27)	gain-of-function	PosReg	(2, 18)	CauseOf	A gain-of-function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia.
"cytokine-cytokine receptor interaction" signal	MPA	(1095, 1142)	upregulated	PosReg	(1083, 1094)	ThemeOf	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
serum TNF, IL-17, IFN and BAFF levels	MPA	(1154, 1194)	increased	PosReg	(1144, 1153)	ThemeOf	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
binding capacity of APRIL ligand to B cells	Interaction	(1209, 1252)	enhanced	PosReg	(1200, 1208)	ThemeOf	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
human megakaryocyte line (Meg-01) apoptosis	CPA	(1328, 1371)	induce	PosReg	(1321, 1327)	ThemeOf	Additionally, EBV-transformed B cells with the G76S mutation could induce human megakaryocyte line (Meg-01) apoptosis significantly.
G76S	Var	(1301, 1305)	induce	PosReg	(1321, 1327)	CauseOf	Additionally, EBV-transformed B cells with the G76S mutation could induce human megakaryocyte line (Meg-01) apoptosis significantly.
p.G76S	Var	(1399, 1405)	responsible	Reg	(1436, 1447)	CauseOf	CONCLUSION: p.G76S mutation on TNFRSF13B gene is responsible for ITP, and is a genetic predisposing factor for familial or sporadic ITP.
ITP	Disease	(1452, 1455)	responsible	Reg	(1436, 1447)	ThemeOf	CONCLUSION: p.G76S mutation on TNFRSF13B gene is responsible for ITP, and is a genetic predisposing factor for familial or sporadic ITP.
TNFRSF13B	Gene	(1418, 1427)	p.G76S	Var	(1399, 1405)	ThemeOf	CONCLUSION: p.G76S mutation on TNFRSF13B gene is responsible for ITP, and is a genetic predisposing factor for familial or sporadic ITP.
TNFRSF13B	Gene	(31, 40)	mutation	Var	(19, 27)	ThemeOf	A gain-of-function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia.
familial or sporadic immune thrombocytopenia	Disease	(78, 122)	gain-of-function	PosReg	(2, 18)	ThemeOf	A gain-of-function mutation in TNFRSF13B is a candidate for predisposition to familial or sporadic immune thrombocytopenia.
TNFRSF13B	Gene	(995, 1004)	p.G76S	Var	(959, 965)	ThemeOf	RESULTS: Whole-exome sequencing identified a potential pathologic p.G76S heterozygous mutation on the TNFRSF13B gene in familial ITP patients.
familial ITP	Disease	(1013, 1025)	pathologic	Reg	(948, 958)	ThemeOf	RESULTS: Whole-exome sequencing identified a potential pathologic p.G76S heterozygous mutation on the TNFRSF13B gene in familial ITP patients.
p.G76S	Var	(959, 965)	pathologic	Reg	(948, 958)	CauseOf	RESULTS: Whole-exome sequencing identified a potential pathologic p.G76S heterozygous mutation on the TNFRSF13B gene in familial ITP patients.
G76S	Var	(1059, 1063)	upregulated	PosReg	(1083, 1094)	CauseOf	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
G76S	Var	(1059, 1063)	increased	PosReg	(1144, 1153)	CauseOf	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
G76S	Var	(1059, 1063)	enhanced	PosReg	(1200, 1208)	CauseOf	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
"cytokine-cytokine receptor interaction" signal	MPA	(59, 106)	enhanced	PosReg	(164, 172)	NoRelation	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
serum TNF, IL-17, IFN and BAFF levels	MPA	(118, 158)	enhanced	PosReg	(164, 172)	NoRelation	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
"cytokine-cytokine receptor interaction" signal	MPA	(59, 106)	increased	PosReg	(108, 117)	NoRelation	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
serum TNF, IL-17, IFN and BAFF levels	MPA	(118, 158)	upregulated	PosReg	(47, 58)	NoRelation	ITP patients harboring G76S mutation displayed upregulated "cytokine-cytokine receptor interaction" signal, increased serum TNF, IL-17, IFN and BAFF levels, and enhanced binding capacity of APRIL ligand to B cells.
S148C	Var	(1262, 1267)	increased	PosReg	(1334, 1343)	CauseOf	Finally, we introduced the S148C mutation into a polyketide synthase module (PikAIII-TE) to impart increased substrate flexibility, enabling the production of diastereomeric macrolactones.
substrate flexibility	MPA	(1344, 1365)	increased	PosReg	(1334, 1343)	ThemeOf	Finally, we introduced the S148C mutation into a polyketide synthase module (PikAIII-TE) to impart increased substrate flexibility, enabling the production of diastereomeric macrolactones.
production of diastereomeric macrolactones	MPA	(1380, 1422)	enabling	PosReg	(1367, 1375)	ThemeOf	Finally, we introduced the S148C mutation into a polyketide synthase module (PikAIII-TE) to impart increased substrate flexibility, enabling the production of diastereomeric macrolactones.
S148C	Var	(1262, 1267)	enabling	PosReg	(1367, 1375)	CauseOf	Finally, we introduced the S148C mutation into a polyketide synthase module (PikAIII-TE) to impart increased substrate flexibility, enabling the production of diastereomeric macrolactones.
production of diastereomeric macrolactones	MPA	(145, 187)	increased	PosReg	(99, 108)	NoRelation	Finally, we introduced the S148C mutation into a polyketide synthase module (PikAIII-TE) to impart increased substrate flexibility, enabling the production of diastereomeric macrolactones.
substrate flexibility	MPA	(109, 130)	enabling	PosReg	(132, 140)	NoRelation	Finally, we introduced the S148C mutation into a polyketide synthase module (PikAIII-TE) to impart increased substrate flexibility, enabling the production of diastereomeric macrolactones.
rs151291296	Var	(786, 797)	loss-of-function	NegReg	(904, 920)	CauseOf	Five nsSNPs including L40Ter (rs151291296), G142E (rs121912777), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) were found to be loss-of-function variants for metabolizing the CES1 substrates clopidogrel, enalapril, and sacubitril.
rs151291296	Var	(1223, 1234)	reduced	NegReg	(1317, 1324)	CauseOf	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
rs146456965	Var	(1244, 1255)	reduced	NegReg	(1317, 1324)	CauseOf	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
rs148947808	Var	(1265, 1276)	reduced	NegReg	(1317, 1324)	CauseOf	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
rs201065375	Var	(1290, 1301)	reduced	NegReg	(1317, 1324)	CauseOf	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
metabolizing	MPA	(934, 946)	loss-of-function	NegReg	(904, 920)	ThemeOf	Five nsSNPs including L40Ter (rs151291296), G142E (rs121912777), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) were found to be loss-of-function variants for metabolizing the CES1 substrates clopidogrel, enalapril, and sacubitril.
CES1	Enzyme	(951, 955)	metabolizing	MPA	(934, 946)	ThemeOf	Five nsSNPs including L40Ter (rs151291296), G142E (rs121912777), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) were found to be loss-of-function variants for metabolizing the CES1 substrates clopidogrel, enalapril, and sacubitril.
CES1	Enzyme	(1120, 1124)	activity	MPA	(1125, 1133)	ThemeOf	Additionally, the A158V (rs202121317), R199H (rs2307243), E220G (rs200707504), and T290M (rs202001817) decreased CES1 activity to a lesser extent in a substrate-dependent manner.
activity	MPA	(1125, 1133)	decreased	NegReg	(1110, 1119)	ThemeOf	Additionally, the A158V (rs202121317), R199H (rs2307243), E220G (rs200707504), and T290M (rs202001817) decreased CES1 activity to a lesser extent in a substrate-dependent manner.
CES1 protein	Protein	(1325, 1337)	reduced	NegReg	(1317, 1324)	ThemeOf	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
mRNA expressions	MPA	(1345, 1361)	reduced	NegReg	(1317, 1324)	ThemeOf	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
rs121912777	Var	(807, 818)	loss-of-function	NegReg	(904, 920)	CauseOf	Five nsSNPs including L40Ter (rs151291296), G142E (rs121912777), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) were found to be loss-of-function variants for metabolizing the CES1 substrates clopidogrel, enalapril, and sacubitril.
rs146456965	Var	(828, 839)	loss-of-function	NegReg	(904, 920)	CauseOf	Five nsSNPs including L40Ter (rs151291296), G142E (rs121912777), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) were found to be loss-of-function variants for metabolizing the CES1 substrates clopidogrel, enalapril, and sacubitril.
rs148947808	Var	(849, 860)	loss-of-function	NegReg	(904, 920)	CauseOf	Five nsSNPs including L40Ter (rs151291296), G142E (rs121912777), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) were found to be loss-of-function variants for metabolizing the CES1 substrates clopidogrel, enalapril, and sacubitril.
rs201065375	Var	(874, 885)	loss-of-function	NegReg	(904, 920)	CauseOf	Five nsSNPs including L40Ter (rs151291296), G142E (rs121912777), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) were found to be loss-of-function variants for metabolizing the CES1 substrates clopidogrel, enalapril, and sacubitril.
rs202121317	Var	(1032, 1043)	decreased	NegReg	(1110, 1119)	CauseOf	Additionally, the A158V (rs202121317), R199H (rs2307243), E220G (rs200707504), and T290M (rs202001817) decreased CES1 activity to a lesser extent in a substrate-dependent manner.
rs2307243	Var	(1053, 1062)	decreased	NegReg	(1110, 1119)	CauseOf	Additionally, the A158V (rs202121317), R199H (rs2307243), E220G (rs200707504), and T290M (rs202001817) decreased CES1 activity to a lesser extent in a substrate-dependent manner.
rs200707504	Var	(1072, 1083)	decreased	NegReg	(1110, 1119)	CauseOf	Additionally, the A158V (rs202121317), R199H (rs2307243), E220G (rs200707504), and T290M (rs202001817) decreased CES1 activity to a lesser extent in a substrate-dependent manner.
rs202001817	Var	(1097, 1108)	decreased	NegReg	(1110, 1119)	CauseOf	Additionally, the A158V (rs202121317), R199H (rs2307243), E220G (rs200707504), and T290M (rs202001817) decreased CES1 activity to a lesser extent in a substrate-dependent manner.
CES1 protein	Protein	(139, 151)	rs146456965	Var	(58, 69)	NoRelation	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
CES1 protein	Protein	(139, 151)	rs151291296	Var	(37, 48)	NoRelation	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
CES1 protein	Protein	(139, 151)	mRNA expressions	MPA	(159, 175)	NoRelation	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
CES1 protein	Protein	(139, 151)	rs201065375	Var	(104, 115)	NoRelation	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
CES1 protein	Protein	(139, 151)	rs148947808	Var	(79, 90)	NoRelation	Several nsSNPs including the L40Ter (rs151291296), G147C (rs146456965), Y170D (rs148947808), and R171C (rs201065375) significantly reduced CES1 protein and/or mRNA expressions in the transfected cells.
Progranulin	Protein	(0, 11)	haploinsufficiency	Var	(12, 30)	ThemeOf	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice.
Grn	Protein	(499, 502)	mutations	Var	(503, 512)	ThemeOf	Moreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease.
Alzheimer's disease	Disease	(597, 616)	associated	Reg	(517, 527)	ThemeOf	Moreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease.
mutations	Var	(503, 512)	associated	Reg	(517, 527)	CauseOf	Moreover, recent findings indicate that Grn mutations are associated with other neurodegenerative disorders with tau pathology, including Alzheimer's disease.
PGRN	Protein	(1358, 1362)	haploinsufficiency	Var	(1363, 1381)	ThemeOf	Our data suggest that PGRN haploinsufficiency may decrease accumulation of A.
accumulation of A	MPA	(1395, 1413)	decrease	NegReg	(1386, 1394)	ThemeOf	Our data suggest that PGRN haploinsufficiency may decrease accumulation of A.
haploinsufficiency	Var	(1363, 1381)	decrease	NegReg	(1386, 1394)	CauseOf	Our data suggest that PGRN haploinsufficiency may decrease accumulation of A.
amyloid beta deposition	MPA	(39, 62)	reduces	NegReg	(31, 38)	ThemeOf	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice.
Alzheimer's disease	Disease	(66, 85)	reduces	NegReg	(31, 38)	ThemeOf	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice.
haploinsufficiency	Var	(12, 30)	reduces	NegReg	(31, 38)	CauseOf	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice.
Grn	Protein	(259, 262)	haploinsufficiency	Var	(274, 292)	ThemeOf	Grn transcript haploinsufficiency is proposed as a disease mechanism that leads to the loss of functional progranulin (PGRN) protein.
PGRN	Protein	(378, 382)	loss of functional	NegReg	(346, 364)	ThemeOf	Grn transcript haploinsufficiency is proposed as a disease mechanism that leads to the loss of functional progranulin (PGRN) protein.
FTLD	Disease	(440, 444)	involved	Reg	(428, 436)	ThemeOf	Thus, these mutations are strongly involved in FTLD pathogenesis.
haploinsufficiency	Var	(274, 292)	loss of functional	NegReg	(346, 364)	CauseOf	Grn transcript haploinsufficiency is proposed as a disease mechanism that leads to the loss of functional progranulin (PGRN) protein.
mutations	Var	(405, 414)	involved	Reg	(428, 436)	CauseOf	Thus, these mutations are strongly involved in FTLD pathogenesis.
Progranulin	Protein	(0, 11)	amyloid beta deposition	MPA	(39, 62)	NoRelation	Progranulin haploinsufficiency reduces amyloid beta deposition in Alzheimer's disease model mice.
PGRN	Protein	(119, 123)	haploinsufficiency	Var	(15, 33)	NoRelation	Grn transcript haploinsufficiency is proposed as a disease mechanism that leads to the loss of functional progranulin (PGRN) protein.
PGRN	Protein	(22, 26)	accumulation of A	MPA	(59, 77)	NoRelation	Our data suggest that PGRN haploinsufficiency may decrease accumulation of A.
CUL3	Gene	(1548, 1552)	deleted	Var	(1570, 1577)	ThemeOf	CUL3 was homozygously deleted specifically in OSCC and other squamous cell cancers (SCCs).
deleted	Var	(1570, 1577)	in	Reg	(1591, 1593)	CauseOf	CUL3 was homozygously deleted specifically in OSCC and other squamous cell cancers (SCCs).
OSCC	Disease	(1594, 1598)	in	Reg	(1591, 1593)	ThemeOf	CUL3 was homozygously deleted specifically in OSCC and other squamous cell cancers (SCCs).
squamous cell cancers	Disease	(1609, 1630)	in	Reg	(1591, 1593)	ThemeOf	CUL3 was homozygously deleted specifically in OSCC and other squamous cell cancers (SCCs).
PIK3CA	Gene	(567, 573)	c.3140 A>G	Var	(575, 587)	ThemeOf	A mosaic gain-of-function mutation in the catalytic domain of PIK3CA (c.3140 A>G; p.His1047Arg) was detected in the adipose tissue and in skin cultured fibroblasts from the macrodactyly but not in blood.
PIK3CA	Gene	(567, 573)	p.His1047Arg	Var	(589, 601)	ThemeOf	A mosaic gain-of-function mutation in the catalytic domain of PIK3CA (c.3140 A>G; p.His1047Arg) was detected in the adipose tissue and in skin cultured fibroblasts from the macrodactyly but not in blood.
c.3140 A>G	Var	(575, 587)	gain-of-function	PosReg	(514, 530)	CauseOf	A mosaic gain-of-function mutation in the catalytic domain of PIK3CA (c.3140 A>G; p.His1047Arg) was detected in the adipose tissue and in skin cultured fibroblasts from the macrodactyly but not in blood.
p.His1047Arg	Var	(589, 601)	gain-of-function	PosReg	(514, 530)	CauseOf	A mosaic gain-of-function mutation in the catalytic domain of PIK3CA (c.3140 A>G; p.His1047Arg) was detected in the adipose tissue and in skin cultured fibroblasts from the macrodactyly but not in blood.
mutation	Var	(1514, 1522)	damaged	NegReg	(1523, 1530)	CauseOf	Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site.
sumoylation site	MPA	(1543, 1559)	damaged	NegReg	(1523, 1530)	ThemeOf	Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site.
mutation	Var	(1514, 1522)	disrupted	NegReg	(1573, 1582)	CauseOf	Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site.
CK1 phosphorylation	MPA	(1595, 1614)	disrupted	NegReg	(1573, 1582)	ThemeOf	Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site.
GRHL3	Gene	(1858, 1863)	mutations	Var	(1845, 1854)	ThemeOf	This study provides evidence that, as in Caucasian populations, mutations in GRHL3 contribute to the risk of nonsyndromic CPO in the African population.
mutations	Var	(1845, 1854)	risk	Reg	(1882, 1886)	CauseOf	This study provides evidence that, as in Caucasian populations, mutations in GRHL3 contribute to the risk of nonsyndromic CPO in the African population.
CPO	Disease	(1903, 1906)	risk	Reg	(1882, 1886)	ThemeOf	This study provides evidence that, as in Caucasian populations, mutations in GRHL3 contribute to the risk of nonsyndromic CPO in the African population.
CK1 phosphorylation	MPA	(98, 117)	damaged	NegReg	(26, 33)	NoRelation	Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site.
sumoylation site	MPA	(46, 62)	disrupted	NegReg	(76, 85)	NoRelation	Interestingly, 1 mutation damaged a predicted sumoylation site, and another disrupted a predicted CK1 phosphorylation site.
apolipoprotein C-III	Protein	(4, 24)	Gln38Lys	Var	(26, 34)	ThemeOf	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.
C3QK	Var	(1172, 1176)	enhanced	PosReg	(1261, 1269)	ThemeOf	These results suggest that C3QK variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL.
Gln38Lys	Var	(26, 34)	gain-of-function	PosReg	(92, 108)	ThemeOf	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.
human hypertriglyceridemia	Disease	(60, 86)	gain-of-function	PosReg	(92, 108)	ThemeOf	The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation.
DNL	MPA	(1071, 1074)	increase	PosReg	(1059, 1067)	ThemeOf	Liver of C3QK mice also displayed an increase in DNL and expression of lipogenic genes as compared with that in C3WT mice.
lipogenic genes	Gene	(1093, 1108)	expression	MPA	(1079, 1089)	ThemeOf	Liver of C3QK mice also displayed an increase in DNL and expression of lipogenic genes as compared with that in C3WT mice.
expression	MPA	(1079, 1089)	increase	PosReg	(1059, 1067)	ThemeOf	Liver of C3QK mice also displayed an increase in DNL and expression of lipogenic genes as compared with that in C3WT mice.
VLDL1 production	MPA	(1235, 1251)	stimulate	PosReg	(1225, 1234)	ThemeOf	These results suggest that C3QK variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL.
DNL	MPA	(1270, 1273)	enhanced	PosReg	(1261, 1269)	ThemeOf	These results suggest that C3QK variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL.
C3QK	Var	(1031, 1035)	increase	PosReg	(1059, 1067)	CauseOf	Liver of C3QK mice also displayed an increase in DNL and expression of lipogenic genes as compared with that in C3WT mice.
C3QK	Var	(1172, 1176)	stimulate	PosReg	(1225, 1234)	ThemeOf	These results suggest that C3QK variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL.
VLDL1 production	MPA	(90, 106)	enhanced	PosReg	(116, 124)	NoRelation	These results suggest that C3QK variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL.
DNL	MPA	(125, 128)	stimulate	PosReg	(80, 89)	NoRelation	These results suggest that C3QK variant is a gain-of-function mutation that can stimulate VLDL1 production, through enhanced DNL.
KCNK3	Gene	(200, 205)	mutations	Var	(183, 192)	ThemeOf	BACKGROUND: Heterozygous loss of function mutations in the KCNK3 gene cause hereditary pulmonary arterial hypertension (PAH).
pulmonary arterial hypertension	Disease	(228, 259)	cause	Reg	(211, 216)	ThemeOf	BACKGROUND: Heterozygous loss of function mutations in the KCNK3 gene cause hereditary pulmonary arterial hypertension (PAH).
channel function	MPA	(1379, 1395)	loss	NegReg	(1371, 1375)	ThemeOf	CONCLUSIONS: Heterozygous KCNK3 mutations in PAH lead to variable loss of channel function via distinct mechanisms.
KCNK3	Gene	(1331, 1336)	mutations	Var	(1337, 1346)	ThemeOf	CONCLUSIONS: Heterozygous KCNK3 mutations in PAH lead to variable loss of channel function via distinct mechanisms.
mutations	Var	(183, 192)	cause	Reg	(211, 216)	CauseOf	BACKGROUND: Heterozygous loss of function mutations in the KCNK3 gene cause hereditary pulmonary arterial hypertension (PAH).
mutations	Var	(1337, 1346)	loss	NegReg	(1371, 1375)	CauseOf	CONCLUSIONS: Heterozygous KCNK3 mutations in PAH lead to variable loss of channel function via distinct mechanisms.
mutations	Var	(99, 108)	loss-of-function	NegReg	(76, 92)	CauseOf	Heterozygous loss-of-function (LOF) mutations in the human progranulin gene (GRN) cause frontotemporal lobar degeneration (FTLD) by a mechanism of haploinsufficiency.
GRN	Gene	(140, 143)	mutations	Var	(99, 108)	ThemeOf	Heterozygous loss-of-function (LOF) mutations in the human progranulin gene (GRN) cause frontotemporal lobar degeneration (FTLD) by a mechanism of haploinsufficiency.
frontotemporal lobar degeneration	Disease	(151, 184)	loss-of-function	NegReg	(76, 92)	ThemeOf	Heterozygous loss-of-function (LOF) mutations in the human progranulin gene (GRN) cause frontotemporal lobar degeneration (FTLD) by a mechanism of haploinsufficiency.
SETD5	Gene	(8, 13)	variant	Var	(31, 38)	ThemeOf	De novo SETD5 loss-of-function variant as a cause for intellectual disability in a 10-year old boy with an aberrant blind ending bronchus.
intellectual disability	Disease	(54, 77)	loss-of-function	NegReg	(14, 30)	ThemeOf	De novo SETD5 loss-of-function variant as a cause for intellectual disability in a 10-year old boy with an aberrant blind ending bronchus.
ID	Disease	(672, 674)	Loss-of-Function	NegReg	(594, 610)	ThemeOf	Loss-of-Function (LoF) variants in SETD5 are now considered a likely cause of ID.
SETD5	Gene	(629, 634)	variants	Var	(617, 625)	ThemeOf	Loss-of-Function (LoF) variants in SETD5 are now considered a likely cause of ID.
variant	Var	(31, 38)	loss-of-function	NegReg	(14, 30)	CauseOf	De novo SETD5 loss-of-function variant as a cause for intellectual disability in a 10-year old boy with an aberrant blind ending bronchus.
variants	Var	(617, 625)	Loss-of-Function	NegReg	(594, 610)	CauseOf	Loss-of-Function (LoF) variants in SETD5 are now considered a likely cause of ID.
STAT	Gene	(276, 280)	mutations	Var	(213, 222)	ThemeOf	PURPOSE OF REVIEW: To describe primary immunodeficiencies caused by gain-of-function (GOF) mutations of signal transducer and activator of transcription (STAT) genes, a group of genetically determined disorders characterized by susceptibility to infections and, in many cases, autoimmune manifestations.
primary immunodeficiencies	Disease	(153, 179)	gain-of-function	PosReg	(190, 206)	ThemeOf	PURPOSE OF REVIEW: To describe primary immunodeficiencies caused by gain-of-function (GOF) mutations of signal transducer and activator of transcription (STAT) genes, a group of genetically determined disorders characterized by susceptibility to infections and, in many cases, autoimmune manifestations.
STAT1	Gene	(467, 472)	mutations	Var	(447, 456)	ThemeOf	RECENT FINDINGS: GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons.
STAT tyrosine phosphorylation	MPA	(493, 522)	increased	PosReg	(483, 492)	ThemeOf	RECENT FINDINGS: GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons.
response to STAT1-signaling cytokines	MPA	(549, 586)	increased	PosReg	(539, 548)	ThemeOf	RECENT FINDINGS: GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons.
mutations	Var	(213, 222)	gain-of-function	PosReg	(190, 206)	CauseOf	PURPOSE OF REVIEW: To describe primary immunodeficiencies caused by gain-of-function (GOF) mutations of signal transducer and activator of transcription (STAT) genes, a group of genetically determined disorders characterized by susceptibility to infections and, in many cases, autoimmune manifestations.
mutations	Var	(447, 456)	increased	PosReg	(483, 492)	CauseOf	RECENT FINDINGS: GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons.
mutations	Var	(447, 456)	increased	PosReg	(539, 548)	CauseOf	RECENT FINDINGS: GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons.
response to STAT1-signaling cytokines	MPA	(123, 160)	increased	PosReg	(57, 66)	NoRelation	RECENT FINDINGS: GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons.
STAT tyrosine phosphorylation	MPA	(67, 96)	increased	PosReg	(113, 122)	NoRelation	RECENT FINDINGS: GOF mutations affecting STAT1 result in increased STAT tyrosine phosphorylation and secondarily increased response to STAT1-signaling cytokines, such as interferons.
GNPTAB	Gene	(543, 549)	p.D76G	Var	(627, 633)	ThemeOf	By sequencing of genomic GNPTAB of the MLII and MLIII alpha/beta patients we identified six novel mutations: p.D76G, p.S385L, p.Q278Kfs*3, p.H588Qfs*27, p.N642Lfs*10 and p.Y1111*.
activity	MPA	(1045, 1053)	loss	NegReg	(1009, 1013)	ThemeOf	Both mutations lead to complete loss of GlcNAc-1-phosphotransferase activity, consistent with the severe clinical MLII phenotype of the patients.
GNPTAB	Gene	(543, 549)	p.S385L	Var	(635, 642)	ThemeOf	By sequencing of genomic GNPTAB of the MLII and MLIII alpha/beta patients we identified six novel mutations: p.D76G, p.S385L, p.Q278Kfs*3, p.H588Qfs*27, p.N642Lfs*10 and p.Y1111*.
GNPTAB	Gene	(543, 549)	p.Q278Kfs*3	Var	(644, 655)	ThemeOf	By sequencing of genomic GNPTAB of the MLII and MLIII alpha/beta patients we identified six novel mutations: p.D76G, p.S385L, p.Q278Kfs*3, p.H588Qfs*27, p.N642Lfs*10 and p.Y1111*.
GNPTAB	Gene	(543, 549)	p.H588Qfs*27	Var	(657, 669)	ThemeOf	By sequencing of genomic GNPTAB of the MLII and MLIII alpha/beta patients we identified six novel mutations: p.D76G, p.S385L, p.Q278Kfs*3, p.H588Qfs*27, p.N642Lfs*10 and p.Y1111*.
GNPTAB	Gene	(543, 549)	p.N642Lfs*10	Var	(671, 683)	ThemeOf	By sequencing of genomic GNPTAB of the MLII and MLIII alpha/beta patients we identified six novel mutations: p.D76G, p.S385L, p.Q278Kfs*3, p.H588Qfs*27, p.N642Lfs*10 and p.Y1111*.
GNPTAB	Gene	(543, 549)	p.Y1111*	Var	(688, 696)	ThemeOf	By sequencing of genomic GNPTAB of the MLII and MLIII alpha/beta patients we identified six novel mutations: p.D76G, p.S385L, p.Q278Kfs*3, p.H588Qfs*27, p.N642Lfs*10 and p.Y1111*.
GlcNAc-1-phosphotransferase	Enzyme	(1017, 1044)	activity	MPA	(1045, 1053)	ThemeOf	Both mutations lead to complete loss of GlcNAc-1-phosphotransferase activity, consistent with the severe clinical MLII phenotype of the patients.
CACNA1C	Gene	(431, 438)	mutation	Var	(419, 427)	ThemeOf	Additionally, a gain-of-function mutation in CACNA1C is responsible for the neurodevelopmental disorder Timothy syndrome that presents with prominent behavioral features on the autism spectrum.
mutation	Var	(419, 427)	gain-of-function	PosReg	(402, 418)	CauseOf	Additionally, a gain-of-function mutation in CACNA1C is responsible for the neurodevelopmental disorder Timothy syndrome that presents with prominent behavioral features on the autism spectrum.
Timothy syndrome	Disease	(490, 506)	gain-of-function	PosReg	(402, 418)	ThemeOf	Additionally, a gain-of-function mutation in CACNA1C is responsible for the neurodevelopmental disorder Timothy syndrome that presents with prominent behavioral features on the autism spectrum.
Cdc7	Gene	(1173, 1177)	point mutation	Var	(1178, 1192)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
55-amino acid C-terminal truncation	MPA	(1256, 1291)	Cdc7	Gene	(1295, 1299)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
Cdc7	Gene	(1295, 1299)	bind	Interaction	(1311, 1315)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
point mutation	Var	(1178, 1192)	increases	PosReg	(1193, 1202)	CauseOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
point mutation	Var	(1178, 1192)	unable	NegReg	(1301, 1307)	CauseOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
bind	Interaction	(1311, 1315)	unable	NegReg	(1301, 1307)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
Dbf4	Gene	(1316, 1320)	bind	Interaction	(1311, 1315)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
unable	NegReg	(1301, 1307)	reduces	NegReg	(1322, 1329)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
Cdc7	Gene	(1330, 1334)	binding	Interaction	(1335, 1342)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
binding	Interaction	(1335, 1342)	reduces	NegReg	(1322, 1329)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
Ty5 retrotransposon integration efficiency	MPA	(1207, 1249)	increases	PosReg	(1193, 1202)	ThemeOf	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
Ty5 retrotransposon integration efficiency	MPA	(48, 90)	unable	NegReg	(142, 148)	NoRelation	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
Ty5 retrotransposon integration efficiency	MPA	(48, 90)	reduces	NegReg	(163, 170)	NoRelation	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
55-amino acid C-terminal truncation	MPA	(97, 132)	reduces	NegReg	(163, 170)	NoRelation	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
55-amino acid C-terminal truncation	MPA	(97, 132)	unable	NegReg	(142, 148)	NoRelation	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
55-amino acid C-terminal truncation	MPA	(97, 132)	increases	PosReg	(34, 43)	NoRelation	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
point mutation	Var	(19, 33)	reduces	NegReg	(163, 170)	NoRelation	A kinase dead Cdc7 point mutation increases the Ty5 retrotransposon integration efficiency and a 55-amino acid C-terminal truncation of Cdc7, unable to bind Dbf4, reduces Cdc7 binding suggesting a requirement for Dbf4 to stabilize Cdc7 on chromatin during S phase.
PTPN11	Gene	(29, 35)	mutation	Var	(17, 25)	ThemeOf	Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
mutation	Var	(17, 25)	Gain-of-function	PosReg	(0, 16)	CauseOf	Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
histiocytic sarcomas	Disease	(39, 59)	Gain-of-function	PosReg	(0, 16)	ThemeOf	Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs.
PTPN11	Gene	(588, 594)	E76K	Var	(534, 538)	ThemeOf	Recently, E76K gain-of-function mutation in SHP2 encoded by the PTPN11 gene has been described in human histiocytic malignancies.
E76K	Var	(534, 538)	gain-of-function	PosReg	(539, 555)	CauseOf	Recently, E76K gain-of-function mutation in SHP2 encoded by the PTPN11 gene has been described in human histiocytic malignancies.
histiocytic malignancies	Disease	(628, 652)	gain-of-function	PosReg	(539, 555)	ThemeOf	Recently, E76K gain-of-function mutation in SHP2 encoded by the PTPN11 gene has been described in human histiocytic malignancies.
KIDINS220	Gene	(11, 20)	variants	Var	(38, 46)	ThemeOf	Homozygous KIDINS220 loss-of-function variants in fetuses with cerebral ventriculomegaly and limb contractures.
obesity	Disease	(242, 249)	cause	Reg	(174, 179)	ThemeOf	Heterozygous mutations in KIDINS220 were recently suggested a cause of spastic paraplegia, intellectual disability, nystagmus and obesity.
variants	Var	(38, 46)	loss-of-function	NegReg	(21, 37)	CauseOf	Homozygous KIDINS220 loss-of-function variants in fetuses with cerebral ventriculomegaly and limb contractures.
loss-of-function	NegReg	(21, 37)	cerebral ventriculomegaly	CPA	(63, 88)	CauseOf	Homozygous KIDINS220 loss-of-function variants in fetuses with cerebral ventriculomegaly and limb contractures.
loss-of-function	NegReg	(21, 37)	limb contractures	CPA	(93, 110)	CauseOf	Homozygous KIDINS220 loss-of-function variants in fetuses with cerebral ventriculomegaly and limb contractures.
KIDINS220	Gene	(138, 147)	Heterozygous mutations	Var	(112, 134)	ThemeOf	Heterozygous mutations in KIDINS220 were recently suggested a cause of spastic paraplegia, intellectual disability, nystagmus and obesity.
Heterozygous mutations	Var	(112, 134)	cause	Reg	(174, 179)	CauseOf	Heterozygous mutations in KIDINS220 were recently suggested a cause of spastic paraplegia, intellectual disability, nystagmus and obesity.
spastic paraplegia	Disease	(183, 201)	cause	Reg	(174, 179)	ThemeOf	Heterozygous mutations in KIDINS220 were recently suggested a cause of spastic paraplegia, intellectual disability, nystagmus and obesity.
intellectual disability	Disease	(203, 226)	cause	Reg	(174, 179)	ThemeOf	Heterozygous mutations in KIDINS220 were recently suggested a cause of spastic paraplegia, intellectual disability, nystagmus and obesity.
nystagmus	Disease	(228, 237)	cause	Reg	(174, 179)	ThemeOf	Heterozygous mutations in KIDINS220 were recently suggested a cause of spastic paraplegia, intellectual disability, nystagmus and obesity.
GNAS	Gene	(1102, 1106)	missense mutation	Var	(1062, 1079)	ThemeOf	One variant that has been identified recurrently in CHIP is a gain-of-function missense mutation in the imprinted gene GNAS (Guanine Nucleotide Binding Protein, Alpha Stimulating).
missense mutation	Var	(1062, 1079)	gain-of-function	PosReg	(1045, 1061)	CauseOf	One variant that has been identified recurrently in CHIP is a gain-of-function missense mutation in the imprinted gene GNAS (Guanine Nucleotide Binding Protein, Alpha Stimulating).
GNAS	Gene	(1266, 1270)	R201C	Var	(1270, 1275)	ThemeOf	Ectopic expression of GNASR201C supported transplantable HSC activity and improved lymphoid output in secondary recipients.
CHIP	CPA	(1035, 1039)	gain-of-function	PosReg	(1045, 1061)	ThemeOf	One variant that has been identified recurrently in CHIP is a gain-of-function missense mutation in the imprinted gene GNAS (Guanine Nucleotide Binding Protein, Alpha Stimulating).
R201C	Var	(1270, 1275)	supported	PosReg	(1276, 1285)	CauseOf	Ectopic expression of GNASR201C supported transplantable HSC activity and improved lymphoid output in secondary recipients.
transplantable HSC activity	CPA	(1286, 1313)	supported	PosReg	(1276, 1285)	ThemeOf	Ectopic expression of GNASR201C supported transplantable HSC activity and improved lymphoid output in secondary recipients.
lymphoid output	CPA	(1327, 1342)	improved	PosReg	(1318, 1326)	ThemeOf	Ectopic expression of GNASR201C supported transplantable HSC activity and improved lymphoid output in secondary recipients.
R201C	Var	(1270, 1275)	improved	PosReg	(1318, 1326)	CauseOf	Ectopic expression of GNASR201C supported transplantable HSC activity and improved lymphoid output in secondary recipients.
lymphoid output	CPA	(83, 98)	supported	PosReg	(32, 41)	NoRelation	Ectopic expression of GNASR201C supported transplantable HSC activity and improved lymphoid output in secondary recipients.
transplantable HSC activity	CPA	(42, 69)	improved	PosReg	(74, 82)	NoRelation	Ectopic expression of GNASR201C supported transplantable HSC activity and improved lymphoid output in secondary recipients.
SCN4A	Gene	(188, 193)	missense mutations	Var	(162, 180)	ThemeOf	KEY POINTS: Paramyotonia congenita is a hereditary channelopathy caused by missense mutations in the SCN4A gene, which encodes the  subunit of the human skeletal muscle voltage-gated sodium channel NaV1.4.
N1366S	Var	(1938, 1944)	accelerated	PosReg	(2137, 2148)	CauseOf	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
fast inactivation	MPA	(2115, 2132)	rate	MPA	(2107, 2111)	ThemeOf	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
rate	MPA	(2107, 2111)	reduced	NegReg	(2099, 2106)	ThemeOf	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
fast inactivation	MPA	(2163, 2180)	recovery	MPA	(2149, 2157)	ThemeOf	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
recovery	MPA	(2149, 2157)	accelerated	PosReg	(2137, 2148)	ThemeOf	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
missense mutations	Var	(162, 180)	caused	Reg	(152, 158)	CauseOf	KEY POINTS: Paramyotonia congenita is a hereditary channelopathy caused by missense mutations in the SCN4A gene, which encodes the  subunit of the human skeletal muscle voltage-gated sodium channel NaV1.4.
Paramyotonia congenita	Disease	(99, 121)	caused	Reg	(152, 158)	ThemeOf	KEY POINTS: Paramyotonia congenita is a hereditary channelopathy caused by missense mutations in the SCN4A gene, which encodes the  subunit of the human skeletal muscle voltage-gated sodium channel NaV1.4.
SCN4A	Gene	(1242, 1247)	missense mutations	Var	(1220, 1238)	ThemeOf	ABSTRACT: Paramyotonia congenita is an autosomal dominant skeletal muscle channelopathy caused by missense mutations in SCN4A, the gene encoding the  subunit of the human skeletal muscle voltage-gated sodium channel NaV1.4.
missense mutations	Var	(1220, 1238)	caused	Reg	(1210, 1216)	CauseOf	ABSTRACT: Paramyotonia congenita is an autosomal dominant skeletal muscle channelopathy caused by missense mutations in SCN4A, the gene encoding the  subunit of the human skeletal muscle voltage-gated sodium channel NaV1.4.
Paramyotonia congenita	Disease	(1132, 1154)	caused	Reg	(1210, 1216)	ThemeOf	ABSTRACT: Paramyotonia congenita is an autosomal dominant skeletal muscle channelopathy caused by missense mutations in SCN4A, the gene encoding the  subunit of the human skeletal muscle voltage-gated sodium channel NaV1.4.
N1366S	Var	(2433, 2439)	gain-of-function	PosReg	(2445, 2461)	CauseOf	Together, our results suggest that N1366S is a gain-of-function mutation of NaV1.4 at low temperature and the mutation may be responsible for the clinical symptoms of paramyotonia congenita in the affected family and constitute a basis for studies into its pathogenesis.
paramyotonia congenita	Disease	(2565, 2587)	gain-of-function	PosReg	(2445, 2461)	ThemeOf	Together, our results suggest that N1366S is a gain-of-function mutation of NaV1.4 at low temperature and the mutation may be responsible for the clinical symptoms of paramyotonia congenita in the affected family and constitute a basis for studies into its pathogenesis.
N1366S	Var	(1938, 1944)	reduced	NegReg	(2099, 2106)	CauseOf	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
fast inactivation	MPA	(181, 198)	accelerated	PosReg	(203, 214)	NoRelation	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
fast inactivation	MPA	(229, 246)	reduced	NegReg	(165, 172)	NoRelation	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
rate	MPA	(173, 177)	accelerated	PosReg	(203, 214)	NoRelation	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
fast inactivation	MPA	(181, 198)	reduced	NegReg	(165, 172)	NoRelation	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
fast inactivation	MPA	(229, 246)	accelerated	PosReg	(203, 214)	NoRelation	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
recovery	MPA	(215, 223)	reduced	NegReg	(165, 172)	NoRelation	The N1366S mutant displayed a cold-induced hyperpolarizing shift in the voltage dependence of activation and a depolarizing shift in fast inactivation, as well as a reduced rate of fast inactivation and accelerated recovery from fast inactivation.
NFIA	Gene	(29, 33)	variants	Var	(17, 25)	ThemeOf	Loss-of-function variants in NFIA provide further support that NFIA is a critical gene in 1p32-p31 deletion syndrome: A four patient series.
1p32-p31 deletion syndrome	Disease	(90, 116)	Loss-of-function	NegReg	(0, 16)	ThemeOf	Loss-of-function variants in NFIA provide further support that NFIA is a critical gene in 1p32-p31 deletion syndrome: A four patient series.
variants	Var	(17, 25)	Loss-of-function	NegReg	(0, 16)	CauseOf	Loss-of-function variants in NFIA provide further support that NFIA is a critical gene in 1p32-p31 deletion syndrome: A four patient series.
CLCN7	Gene	(94, 99)	mutations	Var	(81, 90)	ThemeOf	Dominant negative mutations in CLCN7, which encodes a homodimeric chloride channel needed for matrix acidification by osteoclasts, cause Albers-Schnberg disease (also known as autosomal dominant osteopetrosis type 2).
p.F318L	Var	(882, 889)	non	NegReg	(908, 911)	CauseOf	Clcn7F318L/F318L and Clcn7F318L/G213R mice die by 1month of age and resemble Clcn7 knockout mice, which indicate that p.F318L mutant protein is non-functional and p.F318L and p.G213R mutant proteins do not complement one another.
functional	MPA	(912, 922)	non	NegReg	(908, 911)	ThemeOf	Clcn7F318L/F318L and Clcn7F318L/G213R mice die by 1month of age and resemble Clcn7 knockout mice, which indicate that p.F318L mutant protein is non-functional and p.F318L and p.G213R mutant proteins do not complement one another.
protein	Protein	(897, 904)	p.F318L	Var	(882, 889)	ThemeOf	Clcn7F318L/F318L and Clcn7F318L/G213R mice die by 1month of age and resemble Clcn7 knockout mice, which indicate that p.F318L mutant protein is non-functional and p.F318L and p.G213R mutant proteins do not complement one another.
mutations	Var	(81, 90)	negative	NegReg	(72, 80)	CauseOf	Dominant negative mutations in CLCN7, which encodes a homodimeric chloride channel needed for matrix acidification by osteoclasts, cause Albers-Schnberg disease (also known as autosomal dominant osteopetrosis type 2).
Albers-Schnberg disease	Disease	(200, 224)	negative	NegReg	(72, 80)	ThemeOf	Dominant negative mutations in CLCN7, which encodes a homodimeric chloride channel needed for matrix acidification by osteoclasts, cause Albers-Schnberg disease (also known as autosomal dominant osteopetrosis type 2).
Clcn7	Gene	(713, 718)	F318L	Var	(718, 723)	ThemeOf	Compared to Clcn7+/+ mice, 12-week-old Clcn7F318L/+ mice have significantly increased trabecular bone volume, consistent with Clcn7F318L acting as a dominant negative mutation.
F318L	Var	(718, 723)	negative	NegReg	(745, 753)	CauseOf	Compared to Clcn7+/+ mice, 12-week-old Clcn7F318L/+ mice have significantly increased trabecular bone volume, consistent with Clcn7F318L acting as a dominant negative mutation.
negative	NegReg	(745, 753)	increased	PosReg	(663, 672)	CauseOf	Compared to Clcn7+/+ mice, 12-week-old Clcn7F318L/+ mice have significantly increased trabecular bone volume, consistent with Clcn7F318L acting as a dominant negative mutation.
trabecular bone volume	CPA	(673, 695)	increased	PosReg	(663, 672)	ThemeOf	Compared to Clcn7+/+ mice, 12-week-old Clcn7F318L/+ mice have significantly increased trabecular bone volume, consistent with Clcn7F318L acting as a dominant negative mutation.
F318L	Var	(131, 136)	increased	PosReg	(76, 85)	NoRelation	Compared to Clcn7+/+ mice, 12-week-old Clcn7F318L/+ mice have significantly increased trabecular bone volume, consistent with Clcn7F318L acting as a dominant negative mutation.
trabecular bone volume	CPA	(86, 108)	negative	NegReg	(158, 166)	NoRelation	Compared to Clcn7+/+ mice, 12-week-old Clcn7F318L/+ mice have significantly increased trabecular bone volume, consistent with Clcn7F318L acting as a dominant negative mutation.
protein	Protein	(133, 140)	functional	MPA	(148, 158)	NoRelation	Clcn7F318L/F318L and Clcn7F318L/G213R mice die by 1month of age and resemble Clcn7 knockout mice, which indicate that p.F318L mutant protein is non-functional and p.F318L and p.G213R mutant proteins do not complement one another.
IL-36Ra	Gene	(587, 594)	mutation	Var	(552, 560)	ThemeOf	This was first highlighted by the discovery that a loss-of-function mutation of the IL-36R antagonist (IL-36Ra) causes pustular psoriasis.
pustular psoriasis	Disease	(603, 621)	loss-of-function	NegReg	(535, 551)	ThemeOf	This was first highlighted by the discovery that a loss-of-function mutation of the IL-36R antagonist (IL-36Ra) causes pustular psoriasis.
mutation	Var	(552, 560)	loss-of-function	NegReg	(535, 551)	CauseOf	This was first highlighted by the discovery that a loss-of-function mutation of the IL-36R antagonist (IL-36Ra) causes pustular psoriasis.
TNF	Protein	(1593, 1597)	expression	MPA	(1579, 1589)	ThemeOf	Further, heterozygous subjects exhibited significantly decreased expression of TNF in periodontal tissues, pointing to a functional effect of the mutation in periodontal tissues during the progression of the disease.
expression	MPA	(1579, 1589)	decreased	NegReg	(1569, 1578)	ThemeOf	Further, heterozygous subjects exhibited significantly decreased expression of TNF in periodontal tissues, pointing to a functional effect of the mutation in periodontal tissues during the progression of the disease.
host response	CPA	(655, 668)	modulate	Reg	(642, 650)	ThemeOf	CCR532 (rs333) is a loss-of-function mutation in the CCR5 gene, which can potentially modulate the host response and, consequently periodontitis outcome.
loss-of-function	NegReg	(576, 592)	modulate	Reg	(642, 650)	CauseOf	CCR532 (rs333) is a loss-of-function mutation in the CCR5 gene, which can potentially modulate the host response and, consequently periodontitis outcome.
CCR5	Gene	(609, 613)	rs333	Var	(564, 569)	ThemeOf	CCR532 (rs333) is a loss-of-function mutation in the CCR5 gene, which can potentially modulate the host response and, consequently periodontitis outcome.
rs333	Var	(564, 569)	loss-of-function	NegReg	(576, 592)	CauseOf	CCR532 (rs333) is a loss-of-function mutation in the CCR5 gene, which can potentially modulate the host response and, consequently periodontitis outcome.
mutation	Var	(1661, 1669)	decreased	NegReg	(1569, 1578)	CauseOf	Further, heterozygous subjects exhibited significantly decreased expression of TNF in periodontal tissues, pointing to a functional effect of the mutation in periodontal tissues during the progression of the disease.
rs333	Var	(9, 14)	modulate	Reg	(87, 95)	NoRelation	CCR532 (rs333) is a loss-of-function mutation in the CCR5 gene, which can potentially modulate the host response and, consequently periodontitis outcome.
host response	CPA	(100, 113)	loss-of-function	NegReg	(21, 37)	NoRelation	CCR532 (rs333) is a loss-of-function mutation in the CCR5 gene, which can potentially modulate the host response and, consequently periodontitis outcome.
TNF	Protein	(79, 83)	mutation	Var	(147, 155)	NoRelation	Further, heterozygous subjects exhibited significantly decreased expression of TNF in periodontal tissues, pointing to a functional effect of the mutation in periodontal tissues during the progression of the disease.
(BMP9)-ALK1-Smad1/5/8 signaling	MPA	(438, 469)	mutations	Var	(396, 405)	ThemeOf	Because HHT is caused by loss-of-function mutations in bone morphogenetic protein 9 (BMP9)-ALK1-Smad1/5/8 signaling, interventions aimed at activating this pathway are of therapeutic value.
mutations	Var	(396, 405)	loss-of-function	NegReg	(379, 395)	CauseOf	Because HHT is caused by loss-of-function mutations in bone morphogenetic protein 9 (BMP9)-ALK1-Smad1/5/8 signaling, interventions aimed at activating this pathway are of therapeutic value.
HHT	Disease	(362, 365)	loss-of-function	NegReg	(379, 395)	ThemeOf	Because HHT is caused by loss-of-function mutations in bone morphogenetic protein 9 (BMP9)-ALK1-Smad1/5/8 signaling, interventions aimed at activating this pathway are of therapeutic value.
(BMP9)-ALK1-Smad1/5/8 signaling	MPA	(84, 115)	loss-of-function	NegReg	(25, 41)	NoRelation	Because HHT is caused by loss-of-function mutations in bone morphogenetic protein 9 (BMP9)-ALK1-Smad1/5/8 signaling, interventions aimed at activating this pathway are of therapeutic value.
ORC1	Gene	(233, 237)	mutations	Var	(220, 229)	ThemeOf	Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
cell cycle arrest at the S phase	CPA	(700, 732)	Loss-of-function	NegReg	(576, 592)	ThemeOf	Loss-of-function mutations of cdc6, as manifested by cdc6tsu4305 and cdc6tsu7cd mutants, lead to embryonic lethality due to cell cycle arrest at the S phase and extensive apoptosis.
apoptosis	CPA	(747, 756)	Loss-of-function	NegReg	(576, 592)	ThemeOf	Loss-of-function mutations of cdc6, as manifested by cdc6tsu4305 and cdc6tsu7cd mutants, lead to embryonic lethality due to cell cycle arrest at the S phase and extensive apoptosis.
Loss-of-function	NegReg	(576, 592)	embryonic lethality	CPA	(673, 692)	CauseOf	Loss-of-function mutations of cdc6, as manifested by cdc6tsu4305 and cdc6tsu7cd mutants, lead to embryonic lethality due to cell cycle arrest at the S phase and extensive apoptosis.
body weight and length	CPA	(976, 998)	reduced	NegReg	(1024, 1031)	ThemeOf	Later on, compared with their wild-type (WT) siblings, cdc6tsu21cd mutant fish show growth retardation, and their body weight and length in adulthood are greatly reduced, which resemble human MGS.
cdc6tsu21cd mutant	Var	(917, 935)	reduced	NegReg	(1024, 1031)	CauseOf	Later on, compared with their wild-type (WT) siblings, cdc6tsu21cd mutant fish show growth retardation, and their body weight and length in adulthood are greatly reduced, which resemble human MGS.
cdc6tsu21cd mutant	Var	(1073, 1091)	defective	NegReg	(1173, 1182)	CauseOf	Surprisingly, cdc6tsu21cd mutant fish become males with a short life and fail to mate with WT females, suggesting defective reproduction.
reproduction	CPA	(1183, 1195)	defective	NegReg	(1173, 1182)	ThemeOf	Surprisingly, cdc6tsu21cd mutant fish become males with a short life and fail to mate with WT females, suggesting defective reproduction.
CDC6	Gene	(1252, 1256)	mutation	Var	(1264, 1272)	ThemeOf	Overexpression of Cdc6 mutant forms, which mimic human CDC6(T323R) mutation found in a MGS patient, in zebrafish cdc6tsu4305 mutant embryos partially represses cell death phenotype, suggesting that the human CDC6(T323R) mutation is a hypomorph.
mutation	Var	(1264, 1272)	represses	NegReg	(1347, 1356)	CauseOf	Overexpression of Cdc6 mutant forms, which mimic human CDC6(T323R) mutation found in a MGS patient, in zebrafish cdc6tsu4305 mutant embryos partially represses cell death phenotype, suggesting that the human CDC6(T323R) mutation is a hypomorph.
cell death phenotype	CPA	(1357, 1377)	represses	NegReg	(1347, 1356)	ThemeOf	Overexpression of Cdc6 mutant forms, which mimic human CDC6(T323R) mutation found in a MGS patient, in zebrafish cdc6tsu4305 mutant embryos partially represses cell death phenotype, suggesting that the human CDC6(T323R) mutation is a hypomorph.
ORC4	Gene	(239, 243)	mutations	Var	(220, 229)	ThemeOf	Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
ORC6	Gene	(245, 249)	mutations	Var	(220, 229)	ThemeOf	Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
CDT1	Gene	(251, 255)	mutations	Var	(220, 229)	ThemeOf	Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
CDC6	Gene	(259, 263)	mutations	Var	(220, 229)	ThemeOf	Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
mutations	Var	(220, 229)	cause	Reg	(286, 291)	CauseOf	Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
Meier-Gorlin syndrome	Disease	(292, 313)	cause	Reg	(286, 291)	ThemeOf	Recessive mutations in ORC1, ORC4, ORC6, CDT1 or CDC6 of the preRC in human cause Meier-Gorlin syndrome (MGS) that is characterized by impaired post-natal growth, short stature and microcephaly.
cdc6	Gene	(606, 610)	mutations	Var	(593, 602)	ThemeOf	Loss-of-function mutations of cdc6, as manifested by cdc6tsu4305 and cdc6tsu7cd mutants, lead to embryonic lethality due to cell cycle arrest at the S phase and extensive apoptosis.
mutations	Var	(593, 602)	Loss-of-function	NegReg	(576, 592)	CauseOf	Loss-of-function mutations of cdc6, as manifested by cdc6tsu4305 and cdc6tsu7cd mutants, lead to embryonic lethality due to cell cycle arrest at the S phase and extensive apoptosis.
KCNT1	Gene	(136, 141)	mutations	Var	(142, 151)	ThemeOf	KCNT1 mutations are gain-of-function mutations in potassium channels resulting in severe infantile epilepsy.
mutations	Var	(142, 151)	gain-of-function	PosReg	(156, 172)	CauseOf	KCNT1 mutations are gain-of-function mutations in potassium channels resulting in severe infantile epilepsy.
infantile epilepsy	Disease	(225, 243)	gain-of-function	PosReg	(156, 172)	ThemeOf	KCNT1 mutations are gain-of-function mutations in potassium channels resulting in severe infantile epilepsy.
CDH11	Gene	(1679, 1684)	mutations	Var	(1666, 1675)	ThemeOf	We consider that this study reveals loss-of-function mutations in CDH11 as a probable cause of this phenotype.
Elsahy-Waters syndrome	Disease	(60, 82)	cause	Reg	(51, 56)	ThemeOf	Homozygous indel mutation in CDH11 as the probable cause of Elsahy-Waters syndrome.
cell proliferation rate	CPA	(1526, 1549)	slow	NegReg	(1554, 1558)	ThemeOf	In addition, cell proliferation rate was slow and osteogenic differentiation potential was delayed.
osteogenic differentiation potential	CPA	(1563, 1599)	delayed	NegReg	(1604, 1611)	ThemeOf	In addition, cell proliferation rate was slow and osteogenic differentiation potential was delayed.
CDH11	Gene	(29, 34)	Homozygous indel mutation	Var	(0, 25)	ThemeOf	Homozygous indel mutation in CDH11 as the probable cause of Elsahy-Waters syndrome.
Homozygous indel mutation	Var	(0, 25)	cause	Reg	(51, 56)	CauseOf	Homozygous indel mutation in CDH11 as the probable cause of Elsahy-Waters syndrome.
osteogenic differentiation potential	CPA	(50, 86)	slow	NegReg	(41, 45)	NoRelation	In addition, cell proliferation rate was slow and osteogenic differentiation potential was delayed.
cell proliferation rate	CPA	(13, 36)	delayed	NegReg	(91, 98)	NoRelation	In addition, cell proliferation rate was slow and osteogenic differentiation potential was delayed.
Mutant	Var	(10, 16)	Effect	Reg	(0, 6)	CauseOf	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
proteins	Protein	(357, 365)	mutant	Var	(350, 356)	ThemeOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
activities	MPA	(443, 453)	gain-of-function	PosReg	(420, 436)	ThemeOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
accumulate	PosReg	(371, 381)	gain-of-function	PosReg	(420, 436)	CauseOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
gain-of-function	PosReg	(420, 436)	promote	PosReg	(457, 464)	CauseOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
tumorigenic events	CPA	(465, 483)	promote	PosReg	(457, 464)	ThemeOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
tumor development	CPA	(586, 603)	promote	PosReg	(578, 585)	ThemeOf	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
GOF	PosReg	(571, 574)	promote	PosReg	(578, 585)	CauseOf	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
mutant	Var	(495, 501)	GOF	PosReg	(571, 574)	CauseOf	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
metabolic changes	CPA	(542, 559)	GOF	PosReg	(571, 574)	ThemeOf	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
proteins	Protein	(506, 514)	mutant	Var	(495, 501)	ThemeOf	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
Glycolysis	MPA	(33, 43)	Effect	Reg	(0, 6)	ThemeOf	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
p53	Gene	(502, 505)	proteins	Protein	(506, 514)	ThemeOf	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
p53	Gene	(17, 20)	Proteins	Protein	(21, 29)	ThemeOf	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Mitochondrial Metabolism	MPA	(48, 72)	Effect	Reg	(0, 6)	ThemeOf	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Proteins	Protein	(21, 29)	Mutant	Var	(10, 16)	ThemeOf	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
TP53	Gene	(253, 257)	mutations	Var	(258, 267)	ThemeOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
mutations	Var	(258, 267)	accumulate	PosReg	(371, 381)	CauseOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
missense substitutions	Var	(282, 304)	mutations	Var	(258, 267)	CauseOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
proteins	Protein	(357, 365)	expression	MPA	(324, 334)	ThemeOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
expression	MPA	(324, 334)	accumulate	PosReg	(371, 381)	ThemeOf	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
Proteins	Protein	(21, 29)	Glycolysis	MPA	(33, 43)	NoRelation	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Proteins	Protein	(21, 29)	Mitochondrial Metabolism	MPA	(48, 72)	NoRelation	Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
tumorigenic events	CPA	(326, 344)	accumulate	PosReg	(232, 242)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
activities	MPA	(304, 314)	promote	PosReg	(318, 325)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
missense substitutions	Var	(143, 165)	gain-of-function	PosReg	(281, 297)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
mutant	Var	(211, 217)	promote	PosReg	(318, 325)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
mutant	Var	(211, 217)	accumulate	PosReg	(232, 242)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
mutations	Var	(119, 128)	gain-of-function	PosReg	(281, 297)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
proteins	Protein	(218, 226)	activities	MPA	(304, 314)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
expression	MPA	(185, 195)	promote	PosReg	(318, 325)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
activities	MPA	(304, 314)	accumulate	PosReg	(232, 242)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
mutations	Var	(119, 128)	promote	PosReg	(318, 325)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
tumorigenic events	CPA	(326, 344)	gain-of-function	PosReg	(281, 297)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
missense substitutions	Var	(143, 165)	accumulate	PosReg	(232, 242)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
expression	MPA	(185, 195)	gain-of-function	PosReg	(281, 297)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
mutant	Var	(211, 217)	gain-of-function	PosReg	(281, 297)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
missense substitutions	Var	(143, 165)	promote	PosReg	(318, 325)	NoRelation	Unlike other tumor suppressors that are frequently deleted or acquire loss-of-function mutations, the majority of TP53 mutations in tumors are missense substitutions, which lead to the expression of full-length mutant proteins that accumulate in cancer cells and may confer unique gain-of-function (GOF) activities to promote tumorigenic events.
mutant	Var	(10, 16)	promote	PosReg	(93, 100)	NoRelation	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
tumor development	CPA	(101, 118)	GOF	PosReg	(86, 89)	NoRelation	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
metabolic changes	CPA	(57, 74)	promote	PosReg	(93, 100)	NoRelation	Recently, mutant p53 proteins have been shown to mediate metabolic changes as a novel GOF to promote tumor development.
Mparf1	Gene	(773, 779)	mutants	Var	(780, 787)	ThemeOf	Mparf1 mutants showed reduced auxin-inducible gene expression and various developmental defects, including thallus twisting and gemma malformation.
mutants	Var	(780, 787)	reduced	NegReg	(795, 802)	CauseOf	Mparf1 mutants showed reduced auxin-inducible gene expression and various developmental defects, including thallus twisting and gemma malformation.
auxin-inducible gene	Gene	(803, 823)	expression	MPA	(824, 834)	ThemeOf	Mparf1 mutants showed reduced auxin-inducible gene expression and various developmental defects, including thallus twisting and gemma malformation.
expression	MPA	(824, 834)	reduced	NegReg	(795, 802)	ThemeOf	Mparf1 mutants showed reduced auxin-inducible gene expression and various developmental defects, including thallus twisting and gemma malformation.
developmental defects	CPA	(847, 868)	reduced	NegReg	(795, 802)	ThemeOf	Mparf1 mutants showed reduced auxin-inducible gene expression and various developmental defects, including thallus twisting and gemma malformation.
Tas1R3	Gene	(765, 771)	mutant	Var	(772, 778)	ThemeOf	Here, we independently corroborate the increased thickness of cortical bone in femurs of 20-week-old male Tas1R3 mutant mice and confirm that Tas1R3 is expressed in the bone environment.
cortical bone mass	CPA	(559, 577)	increased	PosReg	(549, 558)	ThemeOf	It was recently reported that deletion of TAS1R3 expression in Tas1R3 mutant mice leads to increased cortical bone mass but the underlying cellular mechanism leading to this phenotype remains unclear.
mutant	Var	(1574, 1580)	reduced	NegReg	(1627, 1634)	CauseOf	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
osteoclast function	CPA	(1635, 1654)	reduced	NegReg	(1627, 1634)	ThemeOf	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
reduced	NegReg	(1627, 1634)	high	PosReg	(1549, 1553)	CauseOf	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
bone mass	CPA	(1554, 1563)	high	PosReg	(1549, 1553)	ThemeOf	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
mutant	Var	(772, 778)	increased	PosReg	(698, 707)	CauseOf	Here, we independently corroborate the increased thickness of cortical bone in femurs of 20-week-old male Tas1R3 mutant mice and confirm that Tas1R3 is expressed in the bone environment.
thickness of cortical bone	CPA	(708, 734)	increased	PosReg	(698, 707)	ThemeOf	Here, we independently corroborate the increased thickness of cortical bone in femurs of 20-week-old male Tas1R3 mutant mice and confirm that Tas1R3 is expressed in the bone environment.
Tas1R3	Gene	(1301, 1307)	mutant	Var	(1308, 1314)	ThemeOf	In contrast, levels of the bone resorption marker collagen type I C-telopeptide are reduced greater than 60% in Tas1R3 mutant mice.
mutant	Var	(1308, 1314)	reduced	NegReg	(1273, 1280)	CauseOf	In contrast, levels of the bone resorption marker collagen type I C-telopeptide are reduced greater than 60% in Tas1R3 mutant mice.
levels of the bone resorption marker collagen type I C-telopeptide	MPA	(1202, 1268)	reduced	NegReg	(1273, 1280)	ThemeOf	In contrast, levels of the bone resorption marker collagen type I C-telopeptide are reduced greater than 60% in Tas1R3 mutant mice.
Tas1R3	Gene	(1567, 1573)	mutant	Var	(1574, 1580)	ThemeOf	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
TAS1R3	Gene	(500, 506)	deletion	Var	(488, 496)	ThemeOf	It was recently reported that deletion of TAS1R3 expression in Tas1R3 mutant mice leads to increased cortical bone mass but the underlying cellular mechanism leading to this phenotype remains unclear.
deletion	Var	(488, 496)	increased	PosReg	(549, 558)	CauseOf	It was recently reported that deletion of TAS1R3 expression in Tas1R3 mutant mice leads to increased cortical bone mass but the underlying cellular mechanism leading to this phenotype remains unclear.
mutant	Var	(67, 73)	high	PosReg	(42, 46)	NoRelation	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
bone mass	CPA	(47, 56)	reduced	NegReg	(120, 127)	NoRelation	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
osteoclast function	CPA	(128, 147)	high	PosReg	(42, 46)	NoRelation	Collectively, these findings suggest that high bone mass in Tas1R3 mutant mice is due to uncoupled bone remodeling with reduced osteoclast function and provide rationale for future experiments examining the cell-type-dependent role for TAS1R family members in nutrient sensing in postnatal bone remodeling.
heparin binding site	MPA	(1313, 1333)	lost	NegReg	(1339, 1343)	ThemeOf	In both cases, critical functional domains of FGF5, including one heparin binding site, are lost.
critical functional domains	MPA	(1262, 1289)	lost	NegReg	(1339, 1343)	ThemeOf	In both cases, critical functional domains of FGF5, including one heparin binding site, are lost.
FLNA	Gene	(183, 187)	mutations	Var	(152, 161)	ThemeOf	Loss-of-function mutations in the X-linked gene FLNA can lead to abnormal neuronal migration, vascular and cardiac defects, and congenital intestinal pseudo-obstruction (CIPO), the latter characterized by anomalous intestinal smooth muscle layering.
mutations	Var	(152, 161)	Loss-of-function	NegReg	(135, 151)	CauseOf	Loss-of-function mutations in the X-linked gene FLNA can lead to abnormal neuronal migration, vascular and cardiac defects, and congenital intestinal pseudo-obstruction (CIPO), the latter characterized by anomalous intestinal smooth muscle layering.
abnormal neuronal migration	CPA	(200, 227)	Loss-of-function	NegReg	(135, 151)	ThemeOf	Loss-of-function mutations in the X-linked gene FLNA can lead to abnormal neuronal migration, vascular and cardiac defects, and congenital intestinal pseudo-obstruction (CIPO), the latter characterized by anomalous intestinal smooth muscle layering.
vascular and cardiac defects	CPA	(229, 257)	Loss-of-function	NegReg	(135, 151)	ThemeOf	Loss-of-function mutations in the X-linked gene FLNA can lead to abnormal neuronal migration, vascular and cardiac defects, and congenital intestinal pseudo-obstruction (CIPO), the latter characterized by anomalous intestinal smooth muscle layering.
congenital intestinal pseudo-obstruction	Disease	(263, 303)	Loss-of-function	NegReg	(135, 151)	ThemeOf	Loss-of-function mutations in the X-linked gene FLNA can lead to abnormal neuronal migration, vascular and cardiac defects, and congenital intestinal pseudo-obstruction (CIPO), the latter characterized by anomalous intestinal smooth muscle layering.
mutations	Var	(541, 550)	confer	Reg	(556, 562)	CauseOf	In apricot, Prunus armeniaca (Rosaceae), we previously mapped two pollen-part mutations that confer self-compatibility in cultivars Canino and Katy at the distal end of chromosome 3 (M-locus) unlinked to the S-locus.
self-compatibility	MPA	(563, 581)	confer	Reg	(556, 562)	ThemeOf	In apricot, Prunus armeniaca (Rosaceae), we previously mapped two pollen-part mutations that confer self-compatibility in cultivars Canino and Katy at the distal end of chromosome 3 (M-locus) unlinked to the S-locus.
MITE	Gene	(1304, 1308)	insertion	Var	(1309, 1318)	ThemeOf	The MITE insertion truncates the ParMDO ORF and produces a loss of SI function, suggesting that pollen rejection in Prunus is dependent on redox regulation.
insertion	Var	(1309, 1318)	truncates	NegReg	(1319, 1328)	CauseOf	The MITE insertion truncates the ParMDO ORF and produces a loss of SI function, suggesting that pollen rejection in Prunus is dependent on redox regulation.
ParMDO ORF	MPA	(1333, 1343)	truncates	NegReg	(1319, 1328)	ThemeOf	The MITE insertion truncates the ParMDO ORF and produces a loss of SI function, suggesting that pollen rejection in Prunus is dependent on redox regulation.
insertion	Var	(1309, 1318)	loss	NegReg	(1359, 1363)	CauseOf	The MITE insertion truncates the ParMDO ORF and produces a loss of SI function, suggesting that pollen rejection in Prunus is dependent on redox regulation.
SI function	MPA	(1367, 1378)	loss	NegReg	(1359, 1363)	ThemeOf	The MITE insertion truncates the ParMDO ORF and produces a loss of SI function, suggesting that pollen rejection in Prunus is dependent on redox regulation.
ParMDO ORF	MPA	(33, 43)	loss	NegReg	(59, 63)	NoRelation	The MITE insertion truncates the ParMDO ORF and produces a loss of SI function, suggesting that pollen rejection in Prunus is dependent on redox regulation.
SI function	MPA	(67, 78)	truncates	NegReg	(19, 28)	NoRelation	The MITE insertion truncates the ParMDO ORF and produces a loss of SI function, suggesting that pollen rejection in Prunus is dependent on redox regulation.
Variant	Var	(39, 46)	Gain-of-Function	PosReg	(4, 20)	CauseOf	The Gain-of-Function Integrin 3 Pro33 Variant Alters the Serotonin System in the Mouse Brain.
Itgb3	Gene	(878, 883)	variant	Var	(884, 891)	ThemeOf	Here, we used knock-in (KI) mice expressing an Itgb3 variant that phenocopies the human Pro33 variant to elucidate the consequences of constitutively enhanced v3 signaling to the 5-HT system in the brain.
variant	Var	(884, 891)	enhanced	PosReg	(981, 989)	CauseOf	Here, we used knock-in (KI) mice expressing an Itgb3 variant that phenocopies the human Pro33 variant to elucidate the consequences of constitutively enhanced v3 signaling to the 5-HT system in the brain.
v3 signaling to the 5-HT system	MPA	(990, 1023)	enhanced	PosReg	(981, 989)	ThemeOf	Here, we used knock-in (KI) mice expressing an Itgb3 variant that phenocopies the human Pro33 variant to elucidate the consequences of constitutively enhanced v3 signaling to the 5-HT system in the brain.
Serotonin System	MPA	(58, 74)	Gain-of-Function	PosReg	(4, 20)	ThemeOf	The Gain-of-Function Integrin 3 Pro33 Variant Alters the Serotonin System in the Mouse Brain.
ITGB3	Gene	(462, 467)	Leu33Pro	Var	(488, 496)	ThemeOf	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
Leu33Pro	Var	(488, 496)	hyperactive	PosReg	(521, 532)	CauseOf	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
v3 receptors	Protein	(533, 547)	hyperactive	PosReg	(521, 532)	ThemeOf	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
v3 receptors	Protein	(533, 547)	influence	Reg	(553, 562)	CauseOf	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
whole-blood 5-HT levels	MPA	(563, 586)	influence	Reg	(553, 562)	ThemeOf	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
Leu33Pro	Var	(488, 496)	influence	Reg	(595, 604)	CauseOf	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
autism spectrum disorder	Disease	(618, 642)	influence	Reg	(595, 604)	ThemeOf	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
whole-blood 5-HT levels	MPA	(105, 128)	hyperactive	PosReg	(63, 74)	NoRelation	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
v3 receptors	Protein	(75, 89)	whole-blood 5-HT levels	MPA	(105, 128)	NoRelation	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
autism spectrum disorder	Disease	(160, 184)	influence	Reg	(95, 104)	NoRelation	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
autism spectrum disorder	Disease	(160, 184)	hyperactive	PosReg	(63, 74)	NoRelation	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
whole-blood 5-HT levels	MPA	(105, 128)	influence	Reg	(137, 146)	NoRelation	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
Leu33Pro	Var	(30, 38)	influence	Reg	(95, 104)	NoRelation	The ITGB3 coding polymorphism Leu33Pro (rs5918, PlA2) produces hyperactive v3 receptors that influence whole-blood 5-HT levels and may influence the risk for autism spectrum disorder (ASD).
Parkin	Gene	(0, 6)	absence	Var	(7, 14)	ThemeOf	Parkin absence accelerates microtubule aging in dopaminergic neurons.
loss	Var	(739, 743)	affects	Reg	(754, 761)	CauseOf	Moreover, in-cell experiments confirmed that loss of parkin affects mitochondria mobility and showed that this defect depends on MT system as it is rescued by paclitaxel, a well-known MT-targeted agent.
mitochondria mobility	MPA	(762, 783)	affects	Reg	(754, 761)	ThemeOf	Moreover, in-cell experiments confirmed that loss of parkin affects mitochondria mobility and showed that this defect depends on MT system as it is rescued by paclitaxel, a well-known MT-targeted agent.
parkin	Gene	(747, 753)	loss	Var	(739, 743)	ThemeOf	Moreover, in-cell experiments confirmed that loss of parkin affects mitochondria mobility and showed that this defect depends on MT system as it is rescued by paclitaxel, a well-known MT-targeted agent.
absence	Var	(7, 14)	accelerates	PosReg	(15, 26)	CauseOf	Parkin absence accelerates microtubule aging in dopaminergic neurons.
microtubule aging in dopaminergic neurons	MPA	(27, 68)	accelerates	PosReg	(15, 26)	ThemeOf	Parkin absence accelerates microtubule aging in dopaminergic neurons.
mutations	Var	(97, 106)	Loss-of-function	NegReg	(70, 86)	CauseOf	Loss-of-function caused by mutations in the parkin gene (PARK2) lead to early-onset familial Parkinson's disease.
early-onset familial Parkinson's disease	Disease	(142, 182)	Loss-of-function	NegReg	(70, 86)	ThemeOf	Loss-of-function caused by mutations in the parkin gene (PARK2) lead to early-onset familial Parkinson's disease.
PARK2	Gene	(127, 132)	mutations	Var	(97, 106)	ThemeOf	Loss-of-function caused by mutations in the parkin gene (PARK2) lead to early-onset familial Parkinson's disease.
loss	Var	(390, 394)	accelerated	PosReg	(416, 427)	CauseOf	Looking at these systems during aging of PARK2 knockout mice, we found that loss of parkin induced an accelerated (over)acetylation of MT system both in dopaminergic neuron cell bodies and fibers, localized in the substantia nigra and corpus striatum, respectively.
acetylation	MPA	(434, 445)	accelerated	PosReg	(416, 427)	ThemeOf	Looking at these systems during aging of PARK2 knockout mice, we found that loss of parkin induced an accelerated (over)acetylation of MT system both in dopaminergic neuron cell bodies and fibers, localized in the substantia nigra and corpus striatum, respectively.
parkin	Gene	(398, 404)	loss	Var	(390, 394)	ThemeOf	Looking at these systems during aging of PARK2 knockout mice, we found that loss of parkin induced an accelerated (over)acetylation of MT system both in dopaminergic neuron cell bodies and fibers, localized in the substantia nigra and corpus striatum, respectively.
LRRK2	Gene	(31, 36)	Mutant	Var	(56, 62)	ThemeOf	Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
SV endocytosis in ventral midbrain (MB) neurons, including DA neurons	MPA	(567, 636)	impairs	NegReg	(559, 566)	ThemeOf	Here we show that the most common PD mutation LRRK2 G2019S impairs SV endocytosis in ventral midbrain (MB) neurons, including DA neurons, and the slowed endocytosis can be rescued by inhibition of LRRK2 kinase activity.
SYNJ1	Gene	(1049, 1054)	deletion	Var	(1037, 1045)	ThemeOf	Additionally, we found MB-specific impairment of SV endocytosis in neurons carrying heterozygous deletion of SYNJ1 (PARK20), a gene that is associated with recessive Parkinsonism.
deletion	Var	(1037, 1045)	impairment	NegReg	(975, 985)	CauseOf	Additionally, we found MB-specific impairment of SV endocytosis in neurons carrying heterozygous deletion of SYNJ1 (PARK20), a gene that is associated with recessive Parkinsonism.
SV endocytosis in neurons	MPA	(989, 1014)	impairment	NegReg	(975, 985)	ThemeOf	Additionally, we found MB-specific impairment of SV endocytosis in neurons carrying heterozygous deletion of SYNJ1 (PARK20), a gene that is associated with recessive Parkinsonism.
SYNJ1+/-	Var	(1130, 1138)	impairs	NegReg	(1195, 1202)	CauseOf	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
sustained exocytosis in MB neurons	MPA	(1203, 1237)	impairs	NegReg	(1195, 1202)	ThemeOf	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
LRRK2 G2019S	Var	(1143, 1155)	impairs	NegReg	(1195, 1202)	CauseOf	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
SYNJ1+/-	Var	(1130, 1138)	alters	Reg	(1242, 1248)	CauseOf	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
LRRK2 G2019S	Var	(1143, 1155)	alters	Reg	(1242, 1248)	CauseOf	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
specific motor functions	MPA	(1249, 1273)	alters	Reg	(1242, 1248)	ThemeOf	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
Mutant	Var	(56, 62)	Disrupts	NegReg	(63, 71)	CauseOf	Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
G2019S	Var	(2085, 2091)	enhanced	PosReg	(2027, 2035)	CauseOf	We demonstrate that the enhanced kinase activity resulting from the most frequent G2019S mutation in LRRK2 is the key to this impairment.
kinase activity	MPA	(2036, 2051)	enhanced	PosReg	(2027, 2035)	ThemeOf	We demonstrate that the enhanced kinase activity resulting from the most frequent G2019S mutation in LRRK2 is the key to this impairment.
LRRK2	Gene	(2104, 2109)	G2019S	Var	(2085, 2091)	ThemeOf	We demonstrate that the enhanced kinase activity resulting from the most frequent G2019S mutation in LRRK2 is the key to this impairment.
G2019S	Var	(2183, 2189)	loss of function	NegReg	(2200, 2216)	CauseOf	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
SYNJ1	Gene	(2194, 2199)	loss of function	NegReg	(2200, 2216)	CauseOf	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
deregulating DAergic neuron SV endocytosis	MPA	(2255, 2297)	loss of function	NegReg	(2200, 2216)	ThemeOf	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
SYNJ1	Gene	(2194, 2199)	play additive roles	Reg	(2312, 2331)	CauseOf	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
G2019S	Var	(2183, 2189)	play additive roles	Reg	(2312, 2331)	CauseOf	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
PD	Disease	(2385, 2387)	play additive roles	Reg	(2312, 2331)	ThemeOf	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
LRRK2	Var	(1327, 1332)	resulting in	Reg	(1381, 1393)	CauseOf	Interestingly, we show that LRRK2 directly phosphorylates synaptojanin1 in vitro, resulting in the disruption of endophilin-synaptojanin1 interaction required for SV endocytosis.
Synaptic Vesicle Trafficking in Ventral Midbrain Neurons	MPA	(72, 128)	Disrupts	NegReg	(63, 71)	ThemeOf	Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
disruption of endophilin-synaptojanin1 interaction required for SV endocytosis	MPA	(1398, 1476)	resulting in	Reg	(1381, 1393)	ThemeOf	Interestingly, we show that LRRK2 directly phosphorylates synaptojanin1 in vitro, resulting in the disruption of endophilin-synaptojanin1 interaction required for SV endocytosis.
LRRK2	Gene	(2177, 2182)	G2019S	Var	(2183, 2189)	ThemeOf	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
Mutant	Var	(56, 62)	Parkinson's Disease	Disease	(0, 19)	CauseOf	Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
LRRK2	Gene	(434, 439)	mutants	Var	(440, 447)	ThemeOf	However, the mechanism whereby LRRK2 mutants contribute to nigral vulnerability remains unclear.
mutants	Var	(440, 447)	contribute	Reg	(448, 458)	CauseOf	However, the mechanism whereby LRRK2 mutants contribute to nigral vulnerability remains unclear.
nigral vulnerability	MPA	(462, 482)	contribute	Reg	(448, 458)	ThemeOf	However, the mechanism whereby LRRK2 mutants contribute to nigral vulnerability remains unclear.
LRRK2	Gene	(546, 551)	mutation	Var	(537, 545)	ThemeOf	Here we show that the most common PD mutation LRRK2 G2019S impairs SV endocytosis in ventral midbrain (MB) neurons, including DA neurons, and the slowed endocytosis can be rescued by inhibition of LRRK2 kinase activity.
mutation	Var	(537, 545)	impairs	NegReg	(559, 566)	CauseOf	Here we show that the most common PD mutation LRRK2 G2019S impairs SV endocytosis in ventral midbrain (MB) neurons, including DA neurons, and the slowed endocytosis can be rescued by inhibition of LRRK2 kinase activity.
Parkinson's Disease	Disease	(0, 19)	Disrupts	NegReg	(63, 71)	NoRelation	Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
sustained exocytosis in MB neurons	MPA	(83, 117)	alters	Reg	(122, 128)	NoRelation	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
specific motor functions	MPA	(129, 153)	impairs	NegReg	(75, 82)	NoRelation	Combining SYNJ1+/- and LRRK2 G2019S does not exacerbate SV endocytosis but impairs sustained exocytosis in MB neurons and alters specific motor functions of 1-year-old male mice.
deregulating DAergic neuron SV endocytosis	MPA	(114, 156)	play additive roles	Reg	(171, 190)	NoRelation	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
PD	Disease	(244, 246)	loss of function	NegReg	(59, 75)	NoRelation	We provide evidence suggesting that LRRK2 G2019S and SYNJ1 loss of function share a similar pathogenic pathway in deregulating DAergic neuron SV endocytosis and that they play additive roles in facilitating each other's pathogenic functions in PD.
mutations	Var	(162, 171)	inactivation	NegReg	(218, 230)	CauseOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
p53	Gene	(604, 607)	R273C	Var	(567, 572)	ThemeOf	Here we report the first account of the dynamics of mutation-induced structural transition of native p53 to an aberrant gain-of-function state, studying the wildtype (WT) and high incidence contact (R273C) and structural (R175H) mutant p53 (mutp53) through molecular dynamics simulation.
p53	Gene	(604, 607)	R175H	Var	(590, 595)	ThemeOf	Here we report the first account of the dynamics of mutation-induced structural transition of native p53 to an aberrant gain-of-function state, studying the wildtype (WT) and high incidence contact (R273C) and structural (R175H) mutant p53 (mutp53) through molecular dynamics simulation.
structural distortion	Var	(709, 730)	exhibited	Reg	(699, 708)	ThemeOf	Result analysis revealed that both mutants exhibited structural distortion and reduced flexibility, indicative of rigidity and kinetic stability.
flexibility	MPA	(743, 754)	reduced	NegReg	(735, 742)	ThemeOf	Result analysis revealed that both mutants exhibited structural distortion and reduced flexibility, indicative of rigidity and kinetic stability.
mutation	Var	(1293, 1301)	induced	Reg	(1302, 1309)	CauseOf	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
structural distortion	Var	(1310, 1331)	induced	Reg	(1302, 1309)	ThemeOf	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
flexibility	MPA	(1341, 1352)	loss	NegReg	(1333, 1337)	ThemeOf	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
rigidity	MPA	(1354, 1362)	loss	NegReg	(1333, 1337)	ThemeOf	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
p53	Gene	(175, 178)	mutations	Var	(162, 171)	ThemeOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
stability	MPA	(1373, 1382)	enhanced	PosReg	(1364, 1372)	ThemeOf	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
mutation	Var	(1293, 1301)	enhanced	PosReg	(1364, 1372)	CauseOf	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
mutation	Var	(1293, 1301)	loss	NegReg	(1333, 1337)	CauseOf	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
wildtype functions	MPA	(234, 252)	inactivation	NegReg	(218, 230)	ThemeOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
mutations	Var	(162, 171)	elicits	Reg	(264, 271)	CauseOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
interactions	Interaction	(283, 295)	elicits	Reg	(264, 271)	ThemeOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
mutant	Var	(333, 339)	promote	PosReg	(301, 308)	CauseOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
malignancy	Disease	(309, 319)	promote	PosReg	(301, 308)	ThemeOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
p53	Gene	(340, 343)	mutant	Var	(333, 339)	ThemeOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
mutant	Var	(333, 339)	gain-of-function	PosReg	(344, 360)	CauseOf	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
malignancy	Disease	(182, 192)	inactivation	NegReg	(91, 103)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
mutant	Var	(206, 212)	inactivation	NegReg	(91, 103)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
malignancy	Disease	(182, 192)	elicits	Reg	(137, 144)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
malignancy	Disease	(182, 192)	interactions	Interaction	(156, 168)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
malignancy	Disease	(182, 192)	gain-of-function	PosReg	(217, 233)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
wildtype functions	MPA	(107, 125)	promote	PosReg	(174, 181)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
mutations	Var	(35, 44)	gain-of-function	PosReg	(217, 233)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
mutations	Var	(35, 44)	promote	PosReg	(174, 181)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
wildtype functions	MPA	(107, 125)	elicits	Reg	(137, 144)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
mutant	Var	(206, 212)	elicits	Reg	(137, 144)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
wildtype functions	MPA	(107, 125)	gain-of-function	PosReg	(217, 233)	NoRelation	Various evidence has revealed that mutations in p53 exert activities that go beyond simply inactivation of wildtype functions but rather elicits downstream interactions that promote malignancy described as mutant p53 gain-of-function (GOF).
flexibility	MPA	(87, 98)	exhibited	Reg	(43, 52)	NoRelation	Result analysis revealed that both mutants exhibited structural distortion and reduced flexibility, indicative of rigidity and kinetic stability.
structural distortion	Var	(53, 74)	reduced	NegReg	(79, 86)	NoRelation	Result analysis revealed that both mutants exhibited structural distortion and reduced flexibility, indicative of rigidity and kinetic stability.
stability	MPA	(175, 184)	induced	Reg	(104, 111)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
flexibility	MPA	(143, 154)	enhanced	PosReg	(166, 174)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
structural distortion	Var	(112, 133)	loss	NegReg	(135, 139)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
structural distortion	Var	(112, 133)	enhanced	PosReg	(166, 174)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
rigidity	MPA	(156, 164)	induced	Reg	(104, 111)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
rigidity	MPA	(156, 164)	enhanced	PosReg	(166, 174)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
stability	MPA	(175, 184)	loss	NegReg	(135, 139)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
flexibility	MPA	(143, 154)	induced	Reg	(104, 111)	NoRelation	Taken together, this study complements experimental findings and reveals the interplay between mutation-induced structural distortion, loss of flexibility, rigidity, enhanced stability, protein unfolding and ultimately, exposure of binding surfaces as conformational attributes that characterize mutP53 structure-GOF activities.
p.S632W	Var	(1052, 1059)	activation	PosReg	(1167, 1177)	CauseOf	Functional studies revealed that both p.S632W and p.V246M had an identical functional impact including a depolarizing shift in the voltage dependence of activation that is consistent with a gain-of-function.
p.V246M	Var	(1064, 1071)	activation	PosReg	(1167, 1177)	CauseOf	Functional studies revealed that both p.S632W and p.V246M had an identical functional impact including a depolarizing shift in the voltage dependence of activation that is consistent with a gain-of-function.
depolarizing shift in the voltage dependence	MPA	(1119, 1163)	activation	PosReg	(1167, 1177)	ThemeOf	Functional studies revealed that both p.S632W and p.V246M had an identical functional impact including a depolarizing shift in the voltage dependence of activation that is consistent with a gain-of-function.
HCN2	Gene	(1434, 1438)	variants	Var	(1439, 1447)	ThemeOf	Our data suggest that HCN2 variants can confer susceptibility to GGE via a gain-of-function mechanism.
variants	Var	(1439, 1447)	gain-of-function	PosReg	(1487, 1503)	CauseOf	Our data suggest that HCN2 variants can confer susceptibility to GGE via a gain-of-function mechanism.
susceptibility	MPA	(1459, 1473)	gain-of-function	PosReg	(1487, 1503)	ThemeOf	Our data suggest that HCN2 variants can confer susceptibility to GGE via a gain-of-function mechanism.
HCN2	Gene	(17, 21)	variants	Var	(22, 30)	ThemeOf	Gain-of-function HCN2 variants in genetic epilepsy.
variants	Var	(22, 30)	Gain-of-function	PosReg	(0, 16)	CauseOf	Gain-of-function HCN2 variants in genetic epilepsy.
epilepsy	Disease	(42, 50)	Gain-of-function	PosReg	(0, 16)	ThemeOf	Gain-of-function HCN2 variants in genetic epilepsy.
Polymorphisms	Var	(381, 394)	lead to	Reg	(416, 423)	CauseOf	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
GSTT1	Gene	(1485, 1490)	presence	Var	(1440, 1448)	ThemeOf	The presence of both null genotypes of GSTM1 and GSTT1 further increased the risk of psoriasis (OR = 3.52) when compared with the positive genotypes of GSTM1 and GSTT1.
GSTM1	Gene	(1475, 1480)	presence	Var	(1440, 1448)	ThemeOf	The presence of both null genotypes of GSTM1 and GSTT1 further increased the risk of psoriasis (OR = 3.52) when compared with the positive genotypes of GSTM1 and GSTT1.
imbalance in pro- and antioxidant systems	MPA	(427, 468)	lead to	Reg	(416, 423)	ThemeOf	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
GST	Gene	(402, 405)	Polymorphisms	Var	(381, 394)	ThemeOf	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
imbalance in pro- and antioxidant systems	MPA	(427, 468)	increased	PosReg	(486, 495)	CauseOf	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
production of reactive oxygen species	MPA	(496, 533)	increased	PosReg	(486, 495)	ThemeOf	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
production of reactive oxygen species	MPA	(496, 533)	influence	Reg	(545, 554)	CauseOf	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
psoriasis	Disease	(575, 584)	influence	Reg	(545, 554)	ThemeOf	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
presence	Var	(1440, 1448)	increased	PosReg	(1499, 1508)	CauseOf	The presence of both null genotypes of GSTM1 and GSTT1 further increased the risk of psoriasis (OR = 3.52) when compared with the positive genotypes of GSTM1 and GSTT1.
psoriasis	Disease	(1521, 1530)	increased	PosReg	(1499, 1508)	ThemeOf	The presence of both null genotypes of GSTM1 and GSTT1 further increased the risk of psoriasis (OR = 3.52) when compared with the positive genotypes of GSTM1 and GSTT1.
psoriasis	Disease	(194, 203)	increased	PosReg	(105, 114)	NoRelation	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
imbalance in pro- and antioxidant systems	MPA	(46, 87)	influence	Reg	(164, 173)	NoRelation	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
Polymorphisms	Var	(0, 13)	influence	Reg	(164, 173)	NoRelation	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
psoriasis	Disease	(194, 203)	lead to	Reg	(35, 42)	NoRelation	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
production of reactive oxygen species	MPA	(115, 152)	lead to	Reg	(35, 42)	NoRelation	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
Polymorphisms	Var	(0, 13)	increased	PosReg	(105, 114)	NoRelation	Polymorphisms in the GST genes may lead to an imbalance in pro- and antioxidant systems resulting in the increased production of reactive oxygen species that could influence the pathogenesis of psoriasis.
Fix- mutants	Var	(884, 896)	indicating	Reg	(841, 851)	CauseOf	In these nodules, infected cells disintegrated and successively became necrotic, indicating premature senescence typical of Fix- mutants.
premature senescence	MPA	(852, 872)	indicating	Reg	(841, 851)	ThemeOf	In these nodules, infected cells disintegrated and successively became necrotic, indicating premature senescence typical of Fix- mutants.
Null-mutations	Var	(53, 67)	loss of function	NegReg	(80, 96)	CauseOf	Null-mutations which cause loss of function of the gene encoding filaggrin (FLG) have been strongly linked to the development of atopic disorders, predominantly atopic eczema/dermatitis syndrome (AEDS).
Null-mutations	Var	(53, 67)	linked	Reg	(153, 159)	CauseOf	Null-mutations which cause loss of function of the gene encoding filaggrin (FLG) have been strongly linked to the development of atopic disorders, predominantly atopic eczema/dermatitis syndrome (AEDS).
atopic eczema/dermatitis syndrome	Disease	(214, 247)	linked	Reg	(153, 159)	ThemeOf	Null-mutations which cause loss of function of the gene encoding filaggrin (FLG) have been strongly linked to the development of atopic disorders, predominantly atopic eczema/dermatitis syndrome (AEDS).
FLG	Gene	(1120, 1123)	null-mutations	Var	(1124, 1138)	ThemeOf	Epidemiological studies indicate an association of FLG null-mutations with AEDS, whereas results regarding an association of FLG null-mutations with sensitization to common inhalant allergens and development of rhinitis and asthma are incoherent.
null-mutations	Var	(1124, 1138)	association	Interaction	(1105, 1116)	CauseOf	Epidemiological studies indicate an association of FLG null-mutations with AEDS, whereas results regarding an association of FLG null-mutations with sensitization to common inhalant allergens and development of rhinitis and asthma are incoherent.
AEDS	Disease	(1144, 1148)	association	Interaction	(1105, 1116)	ThemeOf	Epidemiological studies indicate an association of FLG null-mutations with AEDS, whereas results regarding an association of FLG null-mutations with sensitization to common inhalant allergens and development of rhinitis and asthma are incoherent.
FLG	Gene	(839, 842)	null-mutation	Var	(843, 856)	ThemeOf	FLG null-mutation carriers are prone to develop unspecific skin symptoms related to atopic and non-atopic skin disorders due to their defect of epidermal barrier function, which allows greater skin penetration of various hazards.
null-mutation	Var	(843, 856)	develop	PosReg	(879, 886)	CauseOf	FLG null-mutation carriers are prone to develop unspecific skin symptoms related to atopic and non-atopic skin disorders due to their defect of epidermal barrier function, which allows greater skin penetration of various hazards.
unspecific skin symptoms	Disease	(887, 911)	develop	PosReg	(879, 886)	ThemeOf	FLG null-mutation carriers are prone to develop unspecific skin symptoms related to atopic and non-atopic skin disorders due to their defect of epidermal barrier function, which allows greater skin penetration of various hazards.
FLG	Gene	(129, 132)	Null-mutations	Var	(53, 67)	ThemeOf	Null-mutations which cause loss of function of the gene encoding filaggrin (FLG) have been strongly linked to the development of atopic disorders, predominantly atopic eczema/dermatitis syndrome (AEDS).
atopic eczema/dermatitis syndrome	Disease	(161, 194)	loss of function	NegReg	(27, 43)	NoRelation	Null-mutations which cause loss of function of the gene encoding filaggrin (FLG) have been strongly linked to the development of atopic disorders, predominantly atopic eczema/dermatitis syndrome (AEDS).
Deleting	Var	(2134, 2142)	impaired	NegReg	(2162, 2170)	CauseOf	We found that excessive glutamate transmission upregulated mRNA expression of Fgfrs and their ligands Fgfs Deleting Fgfr1/2/3 not only impaired bSC dendritogenesis but also abolished glutamate transmission-induced dendritic overgrowth.
bSC dendritogenesis	MPA	(2171, 2190)	impaired	NegReg	(2162, 2170)	ThemeOf	We found that excessive glutamate transmission upregulated mRNA expression of Fgfrs and their ligands Fgfs Deleting Fgfr1/2/3 not only impaired bSC dendritogenesis but also abolished glutamate transmission-induced dendritic overgrowth.
Deleting	Var	(2134, 2142)	abolished	NegReg	(2200, 2209)	CauseOf	We found that excessive glutamate transmission upregulated mRNA expression of Fgfrs and their ligands Fgfs Deleting Fgfr1/2/3 not only impaired bSC dendritogenesis but also abolished glutamate transmission-induced dendritic overgrowth.
glutamate transmission-induced dendritic overgrowth	MPA	(2210, 2261)	abolished	NegReg	(2200, 2209)	ThemeOf	We found that excessive glutamate transmission upregulated mRNA expression of Fgfrs and their ligands Fgfs Deleting Fgfr1/2/3 not only impaired bSC dendritogenesis but also abolished glutamate transmission-induced dendritic overgrowth.
Fgfr1/2/3	Gene	(2143, 2152)	Deleting	Var	(2134, 2142)	ThemeOf	We found that excessive glutamate transmission upregulated mRNA expression of Fgfrs and their ligands Fgfs Deleting Fgfr1/2/3 not only impaired bSC dendritogenesis but also abolished glutamate transmission-induced dendritic overgrowth.
bSC dendritogenesis	MPA	(144, 163)	abolished	NegReg	(173, 182)	NoRelation	We found that excessive glutamate transmission upregulated mRNA expression of Fgfrs and their ligands Fgfs Deleting Fgfr1/2/3 not only impaired bSC dendritogenesis but also abolished glutamate transmission-induced dendritic overgrowth.
glutamate transmission-induced dendritic overgrowth	MPA	(183, 234)	impaired	NegReg	(135, 143)	NoRelation	We found that excessive glutamate transmission upregulated mRNA expression of Fgfrs and their ligands Fgfs Deleting Fgfr1/2/3 not only impaired bSC dendritogenesis but also abolished glutamate transmission-induced dendritic overgrowth.
mutations	Var	(299, 308)	regulates	Reg	(391, 400)	CauseOf	These mutations produce a protein with a reduced capacity to bind to a specific DNA sequence that regulates the p53 transcriptional pathway.
p53 transcriptional pathway	Pathway	(405, 432)	regulates	Reg	(391, 400)	ThemeOf	These mutations produce a protein with a reduced capacity to bind to a specific DNA sequence that regulates the p53 transcriptional pathway.
mutant	Var	(796, 802)	altered	Reg	(847, 854)	CauseOf	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
structure	MPA	(855, 864)	altered	Reg	(847, 854)	ThemeOf	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
mutant	Var	(1283, 1289)	gain of function	PosReg	(1323, 1339)	CauseOf	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
cancer	Disease	(1354, 1360)	gain of function	PosReg	(1323, 1339)	ThemeOf	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
proteins	Protein	(1290, 1298)	mutant	Var	(1283, 1289)	ThemeOf	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
mutant	Var	(550, 556)	altered	Reg	(114, 121)	NoRelation	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
cancer	Disease	(621, 627)	altered	Reg	(114, 121)	NoRelation	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
structure	MPA	(122, 131)	gain of function	PosReg	(590, 606)	NoRelation	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
mutant	Var	(63, 69)	gain of function	PosReg	(590, 606)	NoRelation	Four possible reasons for this are considered; (1) the hotspot mutant alleles produce a protein that has a highly altered structure, (2) environmental mutagens produce allele-specific changes in the p53 gene, (3) these mutations arise at selected sites in the gene due to a specific DNA sequence, such as a methylated cytosine residue in a CpG dinucleotide, which has a higher mutation rate changing C to T nucleotides, (4) along with the observed change in mutant p53 proteins, which produce a loss of function (DNA binding and transcription), some mutant proteins have an allele-specific gain of function that promotes cancer.
Mutant	Var	(30, 36)	changes	Reg	(57, 64)	CauseOf	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
p53	Gene	(356, 359)	mutant	Var	(349, 355)	ThemeOf	Varying conformations of mutant p53 largely dictate protein-protein interactions as different point mutations within protein-coding regions greatly alter the extent and array of gain-of-function (GOF) activities.
mutant	Var	(885, 891)	activation	PosReg	(914, 924)	CauseOf	In this article, we review known proteins that interact with mutant p53 and result in the activation of genes that contribute to p53 GOF with particular emphasis on context dependency and an evolving appreciation of GOF mechanisms.
genes	Gene	(928, 933)	activation	PosReg	(914, 924)	ThemeOf	In this article, we review known proteins that interact with mutant p53 and result in the activation of genes that contribute to p53 GOF with particular emphasis on context dependency and an evolving appreciation of GOF mechanisms.
p53	Gene	(892, 895)	mutant	Var	(885, 891)	ThemeOf	In this article, we review known proteins that interact with mutant p53 and result in the activation of genes that contribute to p53 GOF with particular emphasis on context dependency and an evolving appreciation of GOF mechanisms.
cellular behavior	MPA	(68, 85)	changes	Reg	(57, 64)	ThemeOf	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
function	MPA	(90, 98)	changes	Reg	(57, 64)	ThemeOf	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
Mutant	Var	(30, 36)	interactions	Interaction	(107, 119)	CauseOf	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
proteins	Protein	(125, 133)	interactions	Interaction	(107, 119)	ThemeOf	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
p53	Gene	(37, 40)	Mutant	Var	(30, 36)	ThemeOf	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
proteins	Protein	(41, 49)	p53	Gene	(37, 40)	ThemeOf	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
mutant	Var	(349, 355)	dictate	Reg	(368, 375)	CauseOf	Varying conformations of mutant p53 largely dictate protein-protein interactions as different point mutations within protein-coding regions greatly alter the extent and array of gain-of-function (GOF) activities.
protein-protein interactions	MPA	(376, 404)	dictate	Reg	(368, 375)	ThemeOf	Varying conformations of mutant p53 largely dictate protein-protein interactions as different point mutations within protein-coding regions greatly alter the extent and array of gain-of-function (GOF) activities.
proteins	Protein	(11, 19)	interactions	Interaction	(77, 89)	NoRelation	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
interactions	Interaction	(77, 89)	changes	Reg	(27, 34)	NoRelation	Mutant p53 proteins impart changes in cellular behavior and function through interactions with proteins that alter gene expression.
MTOR	Gene	(1255, 1259)	variant	Var	(1260, 1267)	ThemeOf	The MTOR mutation was present in all tumor regions, with similar allele frequency as the VHL mutation, and in vitro functional assessment of the MTOR variant demonstrated that it increased mTORC1 activity.
variant	Var	(1260, 1267)	increased	PosReg	(1289, 1298)	CauseOf	The MTOR mutation was present in all tumor regions, with similar allele frequency as the VHL mutation, and in vitro functional assessment of the MTOR variant demonstrated that it increased mTORC1 activity.
mTORC1 activity	MPA	(1299, 1314)	increased	PosReg	(1289, 1298)	ThemeOf	The MTOR mutation was present in all tumor regions, with similar allele frequency as the VHL mutation, and in vitro functional assessment of the MTOR variant demonstrated that it increased mTORC1 activity.
MTOR	Gene	(1467, 1471)	mutation	Var	(1472, 1480)	ThemeOf	In conclusion, multiregion WES identified a novel MTOR mutation acquired early during tumor development as the event leading to a high sensitivity to temsirolimus treatment.
mutation	Var	(1472, 1480)	leading to	Reg	(1534, 1544)	CauseOf	In conclusion, multiregion WES identified a novel MTOR mutation acquired early during tumor development as the event leading to a high sensitivity to temsirolimus treatment.
high sensitivity to temsirolimus treatment	MPA	(1547, 1589)	leading to	Reg	(1534, 1544)	ThemeOf	In conclusion, multiregion WES identified a novel MTOR mutation acquired early during tumor development as the event leading to a high sensitivity to temsirolimus treatment.
frameshift mutations	Var	(1041, 1061)	associated	Reg	(1075, 1085)	CauseOf	Recurrent frameshift mutations in JAK1 were associated with high mutation burden and microsatellite instability.
colorectal	Disease	(1216, 1226)	carcinomas	Disease	(1250, 1260)	ThemeOf	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
stomach	Disease	(1228, 1235)	carcinomas	Disease	(1250, 1260)	ThemeOf	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
prostate	Disease	(1241, 1249)	carcinomas	Disease	(1250, 1260)	ThemeOf	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
JAK1	Gene	(1065, 1069)	frameshift mutations	Var	(1041, 1061)	ThemeOf	Recurrent frameshift mutations in JAK1 were associated with high mutation burden and microsatellite instability.
high mutation burden	MPA	(1091, 1111)	frameshift mutations	Var	(1041, 1061)	ThemeOf	Recurrent frameshift mutations in JAK1 were associated with high mutation burden and microsatellite instability.
microsatellite instability	MPA	(1116, 1142)	frameshift mutations	Var	(1041, 1061)	ThemeOf	Recurrent frameshift mutations in JAK1 were associated with high mutation burden and microsatellite instability.
JAK1	Var	(1965, 1969)	loss of function	NegReg	(1970, 1986)	CauseOf	From these data, we derive two primary conclusions: 1) JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability; 2) The mechanism by which JAK1 loss of function contributes to tumor immune evasion is likely associated with loss of the JAK1-mediated interferon response.
tumor immune evasion	MPA	(2002, 2022)	loss of function	NegReg	(1970, 1986)	ThemeOf	From these data, we derive two primary conclusions: 1) JAK1 frameshifts are loss of function alterations that represent a potential pan-cancer adaptation to immune responses against tumors with microsatellite instability; 2) The mechanism by which JAK1 loss of function contributes to tumor immune evasion is likely associated with loss of the JAK1-mediated interferon response.
mutations	Var	(1150, 1159)	occurred	Reg	(1160, 1168)	CauseOf	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
carcinomas	Disease	(1250, 1260)	occurred	Reg	(1160, 1168)	ThemeOf	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
endometrial	Disease	(1203, 1214)	carcinomas	Disease	(1250, 1260)	ThemeOf	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
high mutation burden	MPA	(60, 80)	associated	Reg	(44, 54)	NoRelation	Recurrent frameshift mutations in JAK1 were associated with high mutation burden and microsatellite instability.
microsatellite instability	MPA	(85, 111)	associated	Reg	(44, 54)	NoRelation	Recurrent frameshift mutations in JAK1 were associated with high mutation burden and microsatellite instability.
colorectal	Disease	(72, 82)	occurred	Reg	(16, 24)	NoRelation	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
stomach	Disease	(84, 91)	occurred	Reg	(16, 24)	NoRelation	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
prostate	Disease	(97, 105)	occurred	Reg	(16, 24)	NoRelation	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
endometrial	Disease	(59, 70)	occurred	Reg	(16, 24)	NoRelation	These mutations occurred in multiple tumor types including endometrial, colorectal, stomach, and prostate carcinomas.
mutation	Var	(65, 73)	Gain of function	PosReg	(0, 16)	CauseOf	Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia.
gnathodiaphyseal dysplasia	Disease	(90, 116)	Gain of function	PosReg	(0, 16)	ThemeOf	Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia.
TMEM16E	Gene	(20, 27)	mutation	Var	(65, 73)	ThemeOf	Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia.
scrambling activity	MPA	(33, 52)	Gain of function	PosReg	(0, 16)	ThemeOf	Gain of function of TMEM16E/ANO5 scrambling activity caused by a mutation associated with gnathodiaphyseal dysplasia.
Mutations	Var	(118, 127)	associated	Reg	(165, 175)	CauseOf	Mutations in the human TMEM16E (ANO5) gene are associated both with the bone disease gnathodiaphyseal dysplasia (GDD; OMIM: 166260) and muscle dystrophies (OMIM: 611307, 613319).
gnathodiaphyseal dysplasia	Disease	(203, 229)	associated	Reg	(165, 175)	ThemeOf	Mutations in the human TMEM16E (ANO5) gene are associated both with the bone disease gnathodiaphyseal dysplasia (GDD; OMIM: 166260) and muscle dystrophies (OMIM: 611307, 613319).
muscle dystrophies	Disease	(254, 272)	associated	Reg	(165, 175)	ThemeOf	Mutations in the human TMEM16E (ANO5) gene are associated both with the bone disease gnathodiaphyseal dysplasia (GDD; OMIM: 166260) and muscle dystrophies (OMIM: 611307, 613319).
TMEM16E	Gene	(141, 148)	Mutations	Var	(118, 127)	ThemeOf	Mutations in the human TMEM16E (ANO5) gene are associated both with the bone disease gnathodiaphyseal dysplasia (GDD; OMIM: 166260) and muscle dystrophies (OMIM: 611307, 613319).
gnathodiaphyseal dysplasia	Disease	(203, 229)	bone disease	Disease	(190, 202)	CauseOf	Mutations in the human TMEM16E (ANO5) gene are associated both with the bone disease gnathodiaphyseal dysplasia (GDD; OMIM: 166260) and muscle dystrophies (OMIM: 611307, 613319).
muscle dystrophies	Disease	(254, 272)	bone disease	Disease	(190, 202)	CauseOf	Mutations in the human TMEM16E (ANO5) gene are associated both with the bone disease gnathodiaphyseal dysplasia (GDD; OMIM: 166260) and muscle dystrophies (OMIM: 611307, 613319).
bone disease	Disease	(72, 84)	associated	Reg	(47, 57)	NoRelation	Mutations in the human TMEM16E (ANO5) gene are associated both with the bone disease gnathodiaphyseal dysplasia (GDD; OMIM: 166260) and muscle dystrophies (OMIM: 611307, 613319).
L. pneumophila	CPA	(1130, 1144)	enhanced	PosReg	(1121, 1129)	ThemeOf	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
LegC4	Var	(1227, 1232)	augments	PosReg	(1233, 1241)	CauseOf	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
bacterial clearance	CPA	(1242, 1261)	augments	PosReg	(1233, 1241)	ThemeOf	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
mutations	Var	(777, 786)	Loss-of-function	NegReg	(760, 776)	CauseOf	Loss-of-function mutations in genes encoding effector proteins resulted in host-specific or broad virulence phenotypes.
host-specific	MPA	(835, 848)	Loss-of-function	NegReg	(760, 776)	ThemeOf	Loss-of-function mutations in genes encoding effector proteins resulted in host-specific or broad virulence phenotypes.
broad virulence phenotypes	MPA	(852, 878)	Loss-of-function	NegReg	(760, 776)	ThemeOf	Loss-of-function mutations in genes encoding effector proteins resulted in host-specific or broad virulence phenotypes.
mutations	Var	(1072, 1081)	loss-of-function	NegReg	(1055, 1071)	CauseOf	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
LegC4	Gene	(1103, 1108)	mutations	Var	(1072, 1081)	ThemeOf	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
mutations	Var	(1072, 1081)	enhanced	PosReg	(1121, 1129)	CauseOf	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
LegC4	Var	(186, 191)	loss-of-function	NegReg	(14, 30)	NoRelation	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
mutations	Var	(31, 40)	augments	PosReg	(192, 200)	NoRelation	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
L. pneumophila	CPA	(89, 103)	augments	PosReg	(192, 200)	NoRelation	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
L. pneumophila	CPA	(89, 103)	loss-of-function	NegReg	(14, 30)	NoRelation	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
LegC4	Var	(186, 191)	enhanced	PosReg	(80, 88)	NoRelation	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
bacterial clearance	CPA	(201, 220)	enhanced	PosReg	(80, 88)	NoRelation	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
bacterial clearance	CPA	(201, 220)	loss-of-function	NegReg	(14, 30)	NoRelation	Specifically, loss-of-function mutations in the gene encoding LegC4 resulted in enhanced L. pneumophila in the lungs of infected mice but not within cultured host cells, which indicates LegC4 augments bacterial clearance by the host immune system.
AKT2	Gene	(38, 42)	Variant	Var	(27, 34)	ThemeOf	A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study.
Variant	Var	(27, 34)	Loss-of-Function	NegReg	(10, 26)	CauseOf	A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study.
Insulin-Mediated Glucose Uptake	CPA	(70, 101)	Reduced	NegReg	(62, 69)	ThemeOf	A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study.
insulin-mediated GU	MPA	(1504, 1523)	influences	Reg	(1493, 1503)	ThemeOf	These data demonstrate that the p.P50T substitution of AKT2 influences insulin-mediated GU in multiple insulin-sensitive tissues and may explain, at least in part, the increased risk of type 2 diabetes in p.P50T/AKT2 carriers.
AKT2	Gene	(1488, 1492)	p.P50T	Var	(1465, 1471)	ThemeOf	These data demonstrate that the p.P50T substitution of AKT2 influences insulin-mediated GU in multiple insulin-sensitive tissues and may explain, at least in part, the increased risk of type 2 diabetes in p.P50T/AKT2 carriers.
Variant	Var	(27, 34)	Reduced	NegReg	(62, 69)	CauseOf	A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study.
p.P50T	Var	(1465, 1471)	influences	Reg	(1493, 1503)	CauseOf	These data demonstrate that the p.P50T substitution of AKT2 influences insulin-mediated GU in multiple insulin-sensitive tissues and may explain, at least in part, the increased risk of type 2 diabetes in p.P50T/AKT2 carriers.
Insulin-Mediated Glucose Uptake	CPA	(70, 101)	Loss-of-Function	NegReg	(10, 26)	NoRelation	A Partial Loss-of-Function Variant in AKT2 Is Associated With Reduced Insulin-Mediated Glucose Uptake in Multiple Insulin-Sensitive Tissues: A Genotype-Based Callback Positron Emission Tomography Study.
TBK1	Gene	(16, 20)	variants	Var	(21, 29)	ThemeOf	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.
early-onset Alzheimer disease	Disease	(33, 62)	in	Reg	(30, 32)	ThemeOf	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.
TBK1	Gene	(108, 112)	mutations	Var	(137, 146)	ThemeOf	TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course.
frontotemporal dementia	Disease	(166, 189)	loss-of-function	NegReg	(114, 130)	ThemeOf	TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course.
amyotrophic lateral sclerosis	Disease	(200, 229)	loss-of-function	NegReg	(114, 130)	ThemeOf	TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course.
variants	Var	(21, 29)	in	Reg	(30, 32)	CauseOf	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.
mutations	Var	(137, 146)	loss-of-function	NegReg	(114, 130)	CauseOf	TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course.
NLRP1	Gene	(435, 440)	variants	Var	(441, 449)	ThemeOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs11651270	Var	(560, 570)	with	Reg	(590, 594)	CauseOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs2670660	Var	(575, 584)	with	Reg	(590, 594)	CauseOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
IgE level	MPA	(621, 630)	with	Reg	(590, 594)	ThemeOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
asthma	Disease	(595, 601)	with	Reg	(590, 594)	ThemeOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
SNPs	Var	(763, 767)	gain-of-function	PosReg	(746, 762)	CauseOf	NLRP1 activators in humans are still unknown, however we hypothesized that individuals with gain-of-function SNPs in NLRP1 could be more prone in activating inflammasome in the presence of asthma-related cell stressors (i.e.
NLRP1	Gene	(771, 776)	SNPs	Var	(763, 767)	ThemeOf	NLRP1 activators in humans are still unknown, however we hypothesized that individuals with gain-of-function SNPs in NLRP1 could be more prone in activating inflammasome in the presence of asthma-related cell stressors (i.e.
activating inflammasome	MPA	(800, 823)	prone	PosReg	(791, 796)	ThemeOf	NLRP1 activators in humans are still unknown, however we hypothesized that individuals with gain-of-function SNPs in NLRP1 could be more prone in activating inflammasome in the presence of asthma-related cell stressors (i.e.
SNPs	Var	(763, 767)	prone	PosReg	(791, 796)	CauseOf	NLRP1 activators in humans are still unknown, however we hypothesized that individuals with gain-of-function SNPs in NLRP1 could be more prone in activating inflammasome in the presence of asthma-related cell stressors (i.e.
NLRP1	Gene	(435, 440)	rs11651270	Var	(450, 460)	ThemeOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
inflammatory response	CPA	(943, 964)	exacerbate	PosReg	(932, 942)	ThemeOf	ER stress or ROS), and this activation contribute to exacerbate inflammatory response and asthma development.
asthma development	CPA	(969, 987)	exacerbate	PosReg	(932, 942)	ThemeOf	ER stress or ROS), and this activation contribute to exacerbate inflammatory response and asthma development.
IL1A	Gene	(1006, 1010)	rs17561	Var	(1011, 1018)	ThemeOf	Gain-of-function IL1A rs17561 resulted significantly associated with a reduced pulmonary capacity in asthmatic children.
rs17561	Var	(1011, 1018)	reduced	NegReg	(1060, 1067)	CauseOf	Gain-of-function IL1A rs17561 resulted significantly associated with a reduced pulmonary capacity in asthmatic children.
pulmonary capacity	CPA	(1068, 1086)	reduced	NegReg	(1060, 1067)	ThemeOf	Gain-of-function IL1A rs17561 resulted significantly associated with a reduced pulmonary capacity in asthmatic children.
IL18	Gene	(1110, 1114)	rs5744256	Var	(1115, 1124)	ThemeOf	IL18 rs5744256 which lead to lower serum level of IL-18 appeared to be associated to a worse response to bronchodilators.
serum level of IL-18	MPA	(1145, 1165)	lower	NegReg	(1139, 1144)	ThemeOf	IL18 rs5744256 which lead to lower serum level of IL-18 appeared to be associated to a worse response to bronchodilators.
rs5744256	Var	(1115, 1124)	lower	NegReg	(1139, 1144)	CauseOf	IL18 rs5744256 which lead to lower serum level of IL-18 appeared to be associated to a worse response to bronchodilators.
NLRP1	Gene	(435, 440)	rs12150220	Var	(462, 472)	ThemeOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
variants	Var	(441, 449)	Gain-of-function	PosReg	(418, 434)	CauseOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs11651270	Var	(450, 460)	Gain-of-function	PosReg	(418, 434)	CauseOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs12150220	Var	(462, 472)	Gain-of-function	PosReg	(418, 434)	CauseOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs2670660	Var	(477, 486)	Gain-of-function	PosReg	(418, 434)	CauseOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
NLRP1	Gene	(435, 440)	rs2670660	Var	(477, 486)	ThemeOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
asthma	Disease	(524, 530)	Gain-of-function	PosReg	(418, 434)	ThemeOf	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
IgE level	MPA	(203, 212)	Gain-of-function	PosReg	(0, 16)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
variants	Var	(23, 31)	with	Reg	(172, 176)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
asthma	Disease	(177, 183)	Gain-of-function	PosReg	(0, 16)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs12150220	Var	(44, 54)	with	Reg	(172, 176)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs11651270	Var	(142, 152)	Gain-of-function	PosReg	(0, 16)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
asthma	Disease	(106, 112)	with	Reg	(172, 176)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs11651270	Var	(32, 42)	with	Reg	(172, 176)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs2670660	Var	(157, 166)	Gain-of-function	PosReg	(0, 16)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
rs2670660	Var	(59, 68)	with	Reg	(172, 176)	NoRelation	Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children.
activating inflammasome	MPA	(146, 169)	gain-of-function	PosReg	(92, 108)	NoRelation	NLRP1 activators in humans are still unknown, however we hypothesized that individuals with gain-of-function SNPs in NLRP1 could be more prone in activating inflammasome in the presence of asthma-related cell stressors (i.e.
MED13L	Gene	(0, 6)	variants	Var	(24, 32)	ThemeOf	MED13L loss-of-function variants in two patients with syndromic Pierre Robin sequence.
variants	Var	(24, 32)	loss-of-function	NegReg	(7, 23)	CauseOf	MED13L loss-of-function variants in two patients with syndromic Pierre Robin sequence.
Pierre Robin sequence	Disease	(64, 85)	loss-of-function	NegReg	(7, 23)	ThemeOf	MED13L loss-of-function variants in two patients with syndromic Pierre Robin sequence.
MED13L	Gene	(627, 633)	Disruption	Var	(613, 623)	ThemeOf	Disruption of MED13L, encoding a component of the Mediator complex, is increasingly recognized as the cause of an intellectual disability syndrome with associated facial dysmorphism.
Disruption	Var	(613, 623)	cause	Reg	(715, 720)	CauseOf	Disruption of MED13L, encoding a component of the Mediator complex, is increasingly recognized as the cause of an intellectual disability syndrome with associated facial dysmorphism.
intellectual disability syndrome	Disease	(727, 759)	cause	Reg	(715, 720)	ThemeOf	Disruption of MED13L, encoding a component of the Mediator complex, is increasingly recognized as the cause of an intellectual disability syndrome with associated facial dysmorphism.
facial dysmorphism	Disease	(776, 794)	cause	Reg	(715, 720)	ThemeOf	Disruption of MED13L, encoding a component of the Mediator complex, is increasingly recognized as the cause of an intellectual disability syndrome with associated facial dysmorphism.
mutation	Var	(17, 25)	Loss-of-activity	NegReg	(0, 16)	CauseOf	Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome.
cardiac chloride-bicarbonate exchanger AE3	MPA	(33, 75)	Loss-of-activity	NegReg	(0, 16)	ThemeOf	Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome.
short QT syndrome	Disease	(83, 100)	Loss-of-activity	NegReg	(0, 16)	ThemeOf	Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger AE3 causes short QT syndrome.
SLC4A3	Gene	(377, 383)	missense mutation	Var	(321, 338)	ThemeOf	Here we identify a missense mutation in the anion exchanger (AE3)-encoding SLC4A3 gene in two unrelated families with SQTS.
surface expression of AE3	MPA	(454, 479)	reduced	NegReg	(446, 453)	ThemeOf	The mutation causes reduced surface expression of AE3 and reduced membrane bicarbonate transport.
membrane bicarbonate transport	MPA	(492, 522)	reduced	NegReg	(484, 491)	ThemeOf	The mutation causes reduced surface expression of AE3 and reduced membrane bicarbonate transport.
membrane bicarbonate transport	MPA	(66, 96)	reduced	NegReg	(20, 27)	NoRelation	The mutation causes reduced surface expression of AE3 and reduced membrane bicarbonate transport.
surface expression of AE3	MPA	(28, 53)	reduced	NegReg	(58, 65)	NoRelation	The mutation causes reduced surface expression of AE3 and reduced membrane bicarbonate transport.
LDLR	Gene	(1081, 1085)	c.1429G>A	Var	(991, 1000)	ThemeOf	Missense variants resulting in amino acid changes, c.1429G>A (p.D477N), c.1474G>A (p.D492N), c.1731G>T (p.W577C), and c.1783C>T (p.R595W) in LDLR gene, in addition to c.9835A>G (p.S3279G) in APOB, were shown to be deleterious by concordant analysis.
functional interaction	Interaction	(1203, 1225)	deformities	Reg	(1226, 1237)	ThemeOf	Furthermore, functional interaction deformities showed a significant loss and gain of energies in the mutated proteins.
energies in the mutated proteins	MPA	(1276, 1308)	loss	NegReg	(1259, 1263)	ThemeOf	Furthermore, functional interaction deformities showed a significant loss and gain of energies in the mutated proteins.
LDLR	Gene	(1081, 1085)	c.1474G>A	Var	(1012, 1021)	ThemeOf	Missense variants resulting in amino acid changes, c.1429G>A (p.D477N), c.1474G>A (p.D492N), c.1731G>T (p.W577C), and c.1783C>T (p.R595W) in LDLR gene, in addition to c.9835A>G (p.S3279G) in APOB, were shown to be deleterious by concordant analysis.
LDLR	Gene	(1081, 1085)	c.1731G>T	Var	(1033, 1042)	ThemeOf	Missense variants resulting in amino acid changes, c.1429G>A (p.D477N), c.1474G>A (p.D492N), c.1731G>T (p.W577C), and c.1783C>T (p.R595W) in LDLR gene, in addition to c.9835A>G (p.S3279G) in APOB, were shown to be deleterious by concordant analysis.
LDLR	Gene	(1081, 1085)	c.1783C>T	Var	(1058, 1067)	ThemeOf	Missense variants resulting in amino acid changes, c.1429G>A (p.D477N), c.1474G>A (p.D492N), c.1731G>T (p.W577C), and c.1783C>T (p.R595W) in LDLR gene, in addition to c.9835A>G (p.S3279G) in APOB, were shown to be deleterious by concordant analysis.
APOB	Gene	(1131, 1135)	c.9835A>G	Var	(1107, 1116)	ThemeOf	Missense variants resulting in amino acid changes, c.1429G>A (p.D477N), c.1474G>A (p.D492N), c.1731G>T (p.W577C), and c.1783C>T (p.R595W) in LDLR gene, in addition to c.9835A>G (p.S3279G) in APOB, were shown to be deleterious by concordant analysis.
energies in the mutated proteins	MPA	(86, 118)	gain	PosReg	(78, 82)	NoRelation	Furthermore, functional interaction deformities showed a significant loss and gain of energies in the mutated proteins.
energies in the mutated proteins	MPA	(86, 118)	deformities	Reg	(36, 47)	NoRelation	Furthermore, functional interaction deformities showed a significant loss and gain of energies in the mutated proteins.
htpG	Gene	(544, 548)	mutant	Var	(549, 555)	ThemeOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
amount of rhamnolipids and pyoverdine/pyocyanin	MPA	(713, 760)	diminished	NegReg	(702, 712)	ThemeOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
mutant	Var	(549, 555)	decreased	NegReg	(605, 614)	CauseOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
activity	MPA	(615, 623)	decreased	NegReg	(605, 614)	ThemeOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
LasA protease	Enzyme	(631, 644)	activity	MPA	(615, 623)	ThemeOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
mutant	Var	(549, 555)	reduction	NegReg	(646, 655)	CauseOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
biofilm formation	MPA	(659, 676)	reduction	NegReg	(646, 655)	ThemeOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
mutant	Var	(549, 555)	decreased	NegReg	(678, 687)	CauseOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
motility	CPA	(688, 696)	decreased	NegReg	(678, 687)	ThemeOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
mutant	Var	(549, 555)	diminished	NegReg	(702, 712)	CauseOf	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
LasA protease	Enzyme	(112, 125)	biofilm formation	MPA	(140, 157)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
activity	MPA	(96, 104)	decreased	NegReg	(159, 168)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
motility	CPA	(169, 177)	reduction	NegReg	(127, 136)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
biofilm formation	MPA	(140, 157)	decreased	NegReg	(86, 95)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
biofilm formation	MPA	(140, 157)	diminished	NegReg	(183, 193)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
LasA protease	Enzyme	(112, 125)	amount of rhamnolipids and pyoverdine/pyocyanin	MPA	(194, 241)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
motility	CPA	(169, 177)	decreased	NegReg	(86, 95)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
activity	MPA	(96, 104)	reduction	NegReg	(127, 136)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
amount of rhamnolipids and pyoverdine/pyocyanin	MPA	(194, 241)	decreased	NegReg	(86, 95)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
biofilm formation	MPA	(140, 157)	decreased	NegReg	(159, 168)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
amount of rhamnolipids and pyoverdine/pyocyanin	MPA	(194, 241)	decreased	NegReg	(159, 168)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
amount of rhamnolipids and pyoverdine/pyocyanin	MPA	(194, 241)	reduction	NegReg	(127, 136)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
activity	MPA	(96, 104)	diminished	NegReg	(183, 193)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
motility	CPA	(169, 177)	diminished	NegReg	(183, 193)	NoRelation	RESULTS: We showed that htpG mutant affects many physiological processes containing: decreased activity of the LasA protease, reduction of biofilm formation, decreased motility, and diminished amount of rhamnolipids and pyoverdine/pyocyanin.
KMT2A	Gene	(33, 38)	variants	Var	(39, 47)	ThemeOf	Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome.
variants	Var	(239, 247)	causing	Reg	(286, 293)	CauseOf	Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann-Steiner syndrome.
Wiedemann-Steiner syndrome	Disease	(312, 338)	causing	Reg	(286, 293)	ThemeOf	Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann-Steiner syndrome.
KMT2A	Gene	(659, 664)	variants	Var	(647, 655)	ThemeOf	We used primary cells from the patients and molecular approaches to determine the deleterious effects of those variants on KMT2A expression and function.
variants	Var	(647, 655)	effects	Reg	(630, 637)	CauseOf	We used primary cells from the patients and molecular approaches to determine the deleterious effects of those variants on KMT2A expression and function.
expression	MPA	(665, 675)	effects	Reg	(630, 637)	ThemeOf	We used primary cells from the patients and molecular approaches to determine the deleterious effects of those variants on KMT2A expression and function.
function	MPA	(680, 688)	effects	Reg	(630, 637)	ThemeOf	We used primary cells from the patients and molecular approaches to determine the deleterious effects of those variants on KMT2A expression and function.
c.11322-1G>A	Var	(722, 734)	loss	NegReg	(794, 798)	CauseOf	For the putative splice variant c.11322-1G>A, we showed that it led to only one nucleotide deletion and loss of the C-terminal part of the protein.
C-terminal part of the protein	MPA	(806, 836)	loss	NegReg	(794, 798)	ThemeOf	For the putative splice variant c.11322-1G>A, we showed that it led to only one nucleotide deletion and loss of the C-terminal part of the protein.
KMT2A	Gene	(854, 859)	c.3460C>T	Var	(879, 888)	ThemeOf	For two studied KMT2A missense variants, c.3460C>T (p.(Arg1154Trp)) and c.8558T>G (p.(Met2853Arg)), located at the cysteine-rich CXXC domain and the transactivation domain of the protein, respectively, we found altered KMT2A target genes expression in patient's fibroblasts compared to controls.
KMT2A	Gene	(854, 859)	c.8558T>G	Var	(910, 919)	ThemeOf	For two studied KMT2A missense variants, c.3460C>T (p.(Arg1154Trp)) and c.8558T>G (p.(Met2853Arg)), located at the cysteine-rich CXXC domain and the transactivation domain of the protein, respectively, we found altered KMT2A target genes expression in patient's fibroblasts compared to controls.
variants	Var	(39, 47)	involved in	Reg	(48, 59)	CauseOf	Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome.
c.8558T>G	Var	(910, 919)	altered	Reg	(1049, 1056)	CauseOf	For two studied KMT2A missense variants, c.3460C>T (p.(Arg1154Trp)) and c.8558T>G (p.(Met2853Arg)), located at the cysteine-rich CXXC domain and the transactivation domain of the protein, respectively, we found altered KMT2A target genes expression in patient's fibroblasts compared to controls.
c.3460C>T	Var	(879, 888)	altered	Reg	(1049, 1056)	CauseOf	For two studied KMT2A missense variants, c.3460C>T (p.(Arg1154Trp)) and c.8558T>G (p.(Met2853Arg)), located at the cysteine-rich CXXC domain and the transactivation domain of the protein, respectively, we found altered KMT2A target genes expression in patient's fibroblasts compared to controls.
expression	MPA	(1076, 1086)	altered	Reg	(1049, 1056)	ThemeOf	For two studied KMT2A missense variants, c.3460C>T (p.(Arg1154Trp)) and c.8558T>G (p.(Met2853Arg)), located at the cysteine-rich CXXC domain and the transactivation domain of the protein, respectively, we found altered KMT2A target genes expression in patient's fibroblasts compared to controls.
KMT2A	Gene	(1196, 1201)	c.3460C>T	Var	(1210, 1219)	ThemeOf	Furthermore, we found a disturbed subcellular distribution of KMT2A for the c.3460C>T mutant.
c.3460C>T	Var	(1210, 1219)	disturbed	Reg	(1158, 1167)	CauseOf	Furthermore, we found a disturbed subcellular distribution of KMT2A for the c.3460C>T mutant.
subcellular distribution	MPA	(1168, 1192)	disturbed	Reg	(1158, 1167)	ThemeOf	Furthermore, we found a disturbed subcellular distribution of KMT2A for the c.3460C>T mutant.
Wiedemann-Steiner syndrome	Disease	(60, 86)	involved in	Reg	(48, 59)	ThemeOf	Molecular and cellular issues of KMT2A variants involved in Wiedemann-Steiner syndrome.
KMT2A	Gene	(100, 105)	Variants	Var	(88, 96)	ThemeOf	Variants in KMT2A, encoding the histone methyltransferase KMT2A, are a growing cause of intellectual disability (ID).
intellectual disability	Disease	(176, 199)	cause	Reg	(167, 172)	ThemeOf	Variants in KMT2A, encoding the histone methyltransferase KMT2A, are a growing cause of intellectual disability (ID).
Variants	Var	(88, 96)	cause	Reg	(167, 172)	CauseOf	Variants in KMT2A, encoding the histone methyltransferase KMT2A, are a growing cause of intellectual disability (ID).
KMT2A	Gene	(233, 238)	variants	Var	(239, 247)	ThemeOf	Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann-Steiner syndrome.
non-sense	Var	(252, 261)	variants	Var	(239, 247)	ThemeOf	Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann-Steiner syndrome.
frameshift	Var	(266, 276)	variants	Var	(239, 247)	ThemeOf	Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann-Steiner syndrome.
frameshift	Var	(60, 70)	causing	Reg	(80, 87)	NoRelation	Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann-Steiner syndrome.
non-sense	Var	(46, 55)	causing	Reg	(80, 87)	NoRelation	Up to now, the majority of KMT2A variants are non-sense and frameshift variants causing a typical form of Wiedemann-Steiner syndrome.
Abnormalities	Var	(222, 235)	associated	Reg	(249, 259)	CauseOf	Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features.
SOX10	Gene	(239, 244)	Abnormalities	Var	(222, 235)	ThemeOf	Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features.
Waardenburg syndrome	Disease	(265, 285)	associated	Reg	(249, 259)	ThemeOf	Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features.
Types II	Disease	(286, 294)	Waardenburg syndrome	Disease	(265, 285)	ThemeOf	Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features.
IV	Disease	(299, 301)	Waardenburg syndrome	Disease	(265, 285)	ThemeOf	Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features.
Types II	Disease	(64, 72)	associated	Reg	(27, 37)	NoRelation	Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features.
IV	Disease	(77, 79)	associated	Reg	(27, 37)	NoRelation	Abnormalities in SOX10 are associated with Waardenburg syndrome Types II and IV, and these patients have recognizable clinical features.
NR2F2	Gene	(8, 13)	mutation	Var	(31, 39)	ThemeOf	A novel NR2F2 loss-of-function mutation predisposes to congenital heart defect.
NR2F2	Gene	(1523, 1528)	synergistic transcriptional activation	MPA	(1476, 1514)	ThemeOf	Furthermore, the mutation abrogated the synergistic transcriptional activation between NR2F2 and GATA4, another core cardiac transcription factor associated with CHD.
GATA4	Gene	(1533, 1538)	synergistic transcriptional activation	MPA	(1476, 1514)	ThemeOf	Furthermore, the mutation abrogated the synergistic transcriptional activation between NR2F2 and GATA4, another core cardiac transcription factor associated with CHD.
mutation	Var	(31, 39)	loss-of-function	NegReg	(14, 30)	CauseOf	A novel NR2F2 loss-of-function mutation predisposes to congenital heart defect.
congenital heart defect	Disease	(55, 78)	loss-of-function	NegReg	(14, 30)	ThemeOf	A novel NR2F2 loss-of-function mutation predisposes to congenital heart defect.
NR2F2	Gene	(1346, 1351)	mutant	Var	(1339, 1345)	ThemeOf	Functional deciphers by using a dual-luciferase reporter assay system revealed that the mutant NR2F2 protein had no transcriptional activity as compared with its wild-type counterpart.
mutant	Var	(1339, 1345)	no	NegReg	(1364, 1366)	CauseOf	Functional deciphers by using a dual-luciferase reporter assay system revealed that the mutant NR2F2 protein had no transcriptional activity as compared with its wild-type counterpart.
transcriptional activity	MPA	(1367, 1391)	no	NegReg	(1364, 1366)	ThemeOf	Functional deciphers by using a dual-luciferase reporter assay system revealed that the mutant NR2F2 protein had no transcriptional activity as compared with its wild-type counterpart.
mutation	Var	(1453, 1461)	abrogated	NegReg	(1462, 1471)	CauseOf	Furthermore, the mutation abrogated the synergistic transcriptional activation between NR2F2 and GATA4, another core cardiac transcription factor associated with CHD.
synergistic transcriptional activation	MPA	(1476, 1514)	abrogated	NegReg	(1462, 1471)	ThemeOf	Furthermore, the mutation abrogated the synergistic transcriptional activation between NR2F2 and GATA4, another core cardiac transcription factor associated with CHD.
FMR1	Gene	(276, 280)	expansion of 55-200 CGG repeats	Var	(229, 260)	ThemeOf	Fragile X-associated tremor/ataxia syndrome (FXTAS) is an inherited neurodegenerative disease caused by an expansion of 55-200 CGG repeats located in the FMR1 gene.
expansion of 55-200 CGG repeats	Var	(229, 260)	caused by	Reg	(216, 225)	CauseOf	Fragile X-associated tremor/ataxia syndrome (FXTAS) is an inherited neurodegenerative disease caused by an expansion of 55-200 CGG repeats located in the FMR1 gene.
Fragile X-associated tremor/ataxia syndrome	Disease	(122, 165)	caused by	Reg	(216, 225)	ThemeOf	Fragile X-associated tremor/ataxia syndrome (FXTAS) is an inherited neurodegenerative disease caused by an expansion of 55-200 CGG repeats located in the FMR1 gene.
DCHS1	Gene	(24, 29)	variants	Var	(12, 20)	ThemeOf	Deleterious variants in DCHS1 are prevalent in sporadic cases of mitral valve prolapse.
variants	Var	(12, 20)	prevalent	Reg	(34, 43)	CauseOf	Deleterious variants in DCHS1 are prevalent in sporadic cases of mitral valve prolapse.
mitral valve prolapse	Disease	(65, 86)	prevalent	Reg	(34, 43)	ThemeOf	Deleterious variants in DCHS1 are prevalent in sporadic cases of mitral valve prolapse.
DCHS1	Gene	(524, 529)	p.R2330C	Var	(481, 489)	ThemeOf	METHODS: DNA sequencing assays were developed for two previously identified functional missense variants, namely p.R2330C and p.R2513H, and all 21 exons of DCHS1.
DCHS1	Gene	(524, 529)	p.R2513H	Var	(494, 502)	ThemeOf	METHODS: DNA sequencing assays were developed for two previously identified functional missense variants, namely p.R2330C and p.R2513H, and all 21 exons of DCHS1.
PSMC3IP	Gene	(74, 81)	Mutation	Var	(92, 100)	ThemeOf	Primary Ovarian Insufficiency and Azoospermia in Carriers of a Homozygous PSMC3IP Stop Gain Mutation.
Mutation	Var	(92, 100)	Carriers	Reg	(49, 57)	CauseOf	Primary Ovarian Insufficiency and Azoospermia in Carriers of a Homozygous PSMC3IP Stop Gain Mutation.
Azoospermia	Disease	(34, 45)	Carriers	Reg	(49, 57)	ThemeOf	Primary Ovarian Insufficiency and Azoospermia in Carriers of a Homozygous PSMC3IP Stop Gain Mutation.
Primary Ovarian Insufficiency	Disease	(0, 29)	Carriers	Reg	(49, 57)	ThemeOf	Primary Ovarian Insufficiency and Azoospermia in Carriers of a Homozygous PSMC3IP Stop Gain Mutation.
CLPP	Gene	(1225, 1229)	mutation	Var	(1230, 1238)	ThemeOf	Functional studies demonstrated mitochondrial fragmentation in cells infected with the CLPP mutation.
mutation	Var	(1230, 1238)	demonstrated	Reg	(1157, 1169)	CauseOf	Functional studies demonstrated mitochondrial fragmentation in cells infected with the CLPP mutation.
mitochondrial fragmentation	CPA	(1170, 1197)	demonstrated	Reg	(1157, 1169)	ThemeOf	Functional studies demonstrated mitochondrial fragmentation in cells infected with the CLPP mutation.
hop-1	Gene	(1100, 1105)	mutants	Var	(1106, 1113)	ThemeOf	The low-fecundity phenotype of hop-1 mutants can be phenocopied by switching off glp-1/Notch function during the last stage of larval development.
production	CPA	(1450, 1460)	defects	NegReg	(1423, 1430)	ThemeOf	Additional defects in oocyte size and production rate in hop-1 and glp-1 mutants indicate that the process of oogenesis is compromised when germline Notch signaling is switched off.
oocyte size	CPA	(1434, 1445)	defects	NegReg	(1423, 1430)	ThemeOf	Additional defects in oocyte size and production rate in hop-1 and glp-1 mutants indicate that the process of oogenesis is compromised when germline Notch signaling is switched off.
fecundity	CPA	(1077, 1086)	low	NegReg	(1073, 1076)	ThemeOf	The low-fecundity phenotype of hop-1 mutants can be phenocopied by switching off glp-1/Notch function during the last stage of larval development.
mutants	Var	(1106, 1113)	switching off	NegReg	(1136, 1149)	CauseOf	The low-fecundity phenotype of hop-1 mutants can be phenocopied by switching off glp-1/Notch function during the last stage of larval development.
glp-1/Notch function	MPA	(1150, 1170)	switching off	NegReg	(1136, 1149)	ThemeOf	The low-fecundity phenotype of hop-1 mutants can be phenocopied by switching off glp-1/Notch function during the last stage of larval development.
switching off	NegReg	(1136, 1149)	fecundity	CPA	(1077, 1086)	CauseOf	The low-fecundity phenotype of hop-1 mutants can be phenocopied by switching off glp-1/Notch function during the last stage of larval development.
glp-1	Gene	(1479, 1484)	mutants	Var	(1485, 1492)	ThemeOf	Additional defects in oocyte size and production rate in hop-1 and glp-1 mutants indicate that the process of oogenesis is compromised when germline Notch signaling is switched off.
hop-1	Gene	(1469, 1474)	mutants	Var	(1485, 1492)	ThemeOf	Additional defects in oocyte size and production rate in hop-1 and glp-1 mutants indicate that the process of oogenesis is compromised when germline Notch signaling is switched off.
mutants	Var	(1485, 1492)	defects	NegReg	(1423, 1430)	CauseOf	Additional defects in oocyte size and production rate in hop-1 and glp-1 mutants indicate that the process of oogenesis is compromised when germline Notch signaling is switched off.
glp-1/Notch function	MPA	(81, 101)	low	NegReg	(4, 7)	NoRelation	The low-fecundity phenotype of hop-1 mutants can be phenocopied by switching off glp-1/Notch function during the last stage of larval development.
mutants	Var	(37, 44)	low	NegReg	(4, 7)	NoRelation	The low-fecundity phenotype of hop-1 mutants can be phenocopied by switching off glp-1/Notch function during the last stage of larval development.
lac4	Gene	(1006, 1010)	mutants	Var	(1011, 1018)	ThemeOf	All lac4 mutants examined from strains with severe telomere dysfunction underwent terminal deletion/duplication events consistent with being due to break-induced replication.
mutants	Var	(1011, 1018)	underwent	Reg	(1074, 1083)	CauseOf	All lac4 mutants examined from strains with severe telomere dysfunction underwent terminal deletion/duplication events consistent with being due to break-induced replication.
terminal deletion/duplication	MPA	(1084, 1113)	underwent	Reg	(1074, 1083)	ThemeOf	All lac4 mutants examined from strains with severe telomere dysfunction underwent terminal deletion/duplication events consistent with being due to break-induced replication.
lac4	Gene	(1314, 1318)	mutants	Var	(1319, 1326)	ThemeOf	In contrast, although cells with mild telomere dysfunction also exhibited similar terminal deletion and duplication events, up to 50% of lac4 mutants from this background unexpectedly contained base changes within the LAC4 coding region.
mutants	Var	(1319, 1326)	contained	Reg	(1361, 1370)	CauseOf	In contrast, although cells with mild telomere dysfunction also exhibited similar terminal deletion and duplication events, up to 50% of lac4 mutants from this background unexpectedly contained base changes within the LAC4 coding region.
base changes	MPA	(1371, 1383)	contained	Reg	(1361, 1370)	ThemeOf	In contrast, although cells with mild telomere dysfunction also exhibited similar terminal deletion and duplication events, up to 50% of lac4 mutants from this background unexpectedly contained base changes within the LAC4 coding region.
variants	Var	(152, 160)	loss of function	NegReg	(135, 151)	CauseOf	Kabuki syndrome is a monogenic disorder caused by loss of function variants in either of two genes encoding histone-modifying enzymes.
Kabuki syndrome	Disease	(85, 100)	loss of function	NegReg	(135, 151)	ThemeOf	Kabuki syndrome is a monogenic disorder caused by loss of function variants in either of two genes encoding histone-modifying enzymes.
variants	Var	(459, 467)	associated	Reg	(590, 600)	CauseOf	In 2, we identified presumptive loss of function de novo variants in KMT2A (missense and splice site variants), a gene that encodes another histone modifying enzyme previously exclusively associated with Wiedermann-Steiner syndrome.
Wiedermann-Steiner syndrome	Disease	(606, 633)	associated	Reg	(590, 600)	ThemeOf	In 2, we identified presumptive loss of function de novo variants in KMT2A (missense and splice site variants), a gene that encodes another histone modifying enzyme previously exclusively associated with Wiedermann-Steiner syndrome.
KMT2A	Gene	(471, 476)	variants	Var	(459, 467)	ThemeOf	In 2, we identified presumptive loss of function de novo variants in KMT2A (missense and splice site variants), a gene that encodes another histone modifying enzyme previously exclusively associated with Wiedermann-Steiner syndrome.
ARL13B	Gene	(19, 25)	variant	Var	(26, 33)	ThemeOf	A novel homozygous ARL13B variant in patients with Joubert syndrome impairs its guanine nucleotide-exchange factor activity.
variant	Var	(26, 33)	impairs	NegReg	(68, 75)	CauseOf	A novel homozygous ARL13B variant in patients with Joubert syndrome impairs its guanine nucleotide-exchange factor activity.
guanine nucleotide-exchange factor activity	MPA	(80, 123)	impairs	NegReg	(68, 75)	ThemeOf	A novel homozygous ARL13B variant in patients with Joubert syndrome impairs its guanine nucleotide-exchange factor activity.
ARL13B	Gene	(1217, 1223)	c.[223G>A]	Var	(1224, 1234)	ThemeOf	In contrast, ARL13B-c.[223G>A] (p.(Gly75Arg) displayed a marked loss of ARL3 guanine nucleotide-exchange factor activity, with retention of its GTPase activities, highlighting the correlation between its loss of function as an ARL3 guanine nucleotide-exchange factor and Joubert syndrome.
c.[223G>A]	Var	(1224, 1234)	loss	NegReg	(1268, 1272)	CauseOf	In contrast, ARL13B-c.[223G>A] (p.(Gly75Arg) displayed a marked loss of ARL3 guanine nucleotide-exchange factor activity, with retention of its GTPase activities, highlighting the correlation between its loss of function as an ARL3 guanine nucleotide-exchange factor and Joubert syndrome.
ARL3 guanine nucleotide-exchange factor activity	MPA	(1276, 1324)	loss	NegReg	(1268, 1272)	ThemeOf	In contrast, ARL13B-c.[223G>A] (p.(Gly75Arg) displayed a marked loss of ARL3 guanine nucleotide-exchange factor activity, with retention of its GTPase activities, highlighting the correlation between its loss of function as an ARL3 guanine nucleotide-exchange factor and Joubert syndrome.
Joubert syndrome	Disease	(1475, 1491)	loss	NegReg	(1268, 1272)	ThemeOf	In contrast, ARL13B-c.[223G>A] (p.(Gly75Arg) displayed a marked loss of ARL3 guanine nucleotide-exchange factor activity, with retention of its GTPase activities, highlighting the correlation between its loss of function as an ARL3 guanine nucleotide-exchange factor and Joubert syndrome.
ABCC9	Gene	(32, 37)	mutations	Var	(39, 48)	ThemeOf	Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms.
channel activity	MPA	(417, 433)	increase	PosReg	(408, 416)	ThemeOf	Recent reports indicate that such mutations can increase channel activity by multiple molecular mechanisms.
mutations	Var	(394, 403)	increase	PosReg	(408, 416)	CauseOf	Recent reports indicate that such mutations can increase channel activity by multiple molecular mechanisms.
SUR2	Gene	(604, 608)	D207E	Var	(610, 615)	ThemeOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
SUR2	Gene	(604, 608)	Y985S	Var	(651, 656)	ThemeOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
SUR2	Gene	(604, 608)	G989E	Var	(658, 663)	ThemeOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
SUR2	Gene	(604, 608)	M1060I	Var	(665, 671)	ThemeOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
SUR2	Gene	(604, 608)	R1154Q	Var	(677, 683)	ThemeOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
SUR2	Gene	(604, 608)	R1154W	Var	(684, 690)	ThemeOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
R1154W	Var	(684, 690)	altered	Reg	(537, 544)	CauseOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
R1154Q	Var	(677, 683)	altered	Reg	(537, 544)	CauseOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
mutations	Var	(39, 48)	gain-of-function	PosReg	(103, 119)	CauseOf	Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms.
Y985S	Var	(651, 656)	altered	Reg	(537, 544)	CauseOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
G989E	Var	(658, 663)	altered	Reg	(537, 544)	CauseOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
M1060I	Var	(665, 671)	altered	Reg	(537, 544)	CauseOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
KATP function	MPA	(520, 533)	altered	Reg	(537, 544)	ThemeOf	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
D207E	Var	(971, 976)	increasing	PosReg	(1012, 1022)	CauseOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
intrinsic stability of the open state	MPA	(1023, 1060)	increasing	PosReg	(1012, 1022)	ThemeOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
increasing	PosReg	(1012, 1022)	increases	PosReg	(977, 986)	CauseOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
KATP channel activity	MPA	(987, 1008)	increases	PosReg	(977, 986)	ThemeOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
Y981S	Var	(1085, 1090)	augmented	PosReg	(1145, 1154)	CauseOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
G985E	Var	(1091, 1096)	augmented	PosReg	(1145, 1154)	CauseOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
KATP channel	MPA	(90, 102)	gain-of-function	PosReg	(103, 119)	ThemeOf	Cantu syndrome-associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms.
M1056I	Var	(1097, 1103)	augmented	PosReg	(1145, 1154)	CauseOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
R1150Q	Var	(1130, 1136)	augmented	PosReg	(1145, 1154)	CauseOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
R1150W	Var	(1137, 1143)	augmented	PosReg	(1145, 1154)	CauseOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
Mg-nucleotide activation	MPA	(1155, 1179)	augmented	PosReg	(1145, 1154)	ThemeOf	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
KCNJ8	Gene	(238, 243)	mutations	Var	(218, 227)	ThemeOf	The complex disorder Cantu syndrome (CS) arises from gain-of-function mutations in either KCNJ8 or ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potassium (KATP) channels, respectively.
ABCC9	Gene	(247, 252)	mutations	Var	(218, 227)	ThemeOf	The complex disorder Cantu syndrome (CS) arises from gain-of-function mutations in either KCNJ8 or ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potassium (KATP) channels, respectively.
Cantu syndrome	Disease	(169, 183)	gain-of-function	PosReg	(201, 217)	ThemeOf	The complex disorder Cantu syndrome (CS) arises from gain-of-function mutations in either KCNJ8 or ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potassium (KATP) channels, respectively.
mutations	Var	(218, 227)	gain-of-function	PosReg	(201, 217)	CauseOf	The complex disorder Cantu syndrome (CS) arises from gain-of-function mutations in either KCNJ8 or ABCC9, the genes encoding the Kir6.1 and SUR2 subunits of ATP-sensitive potassium (KATP) channels, respectively.
D207E	Var	(142, 147)	altered	Reg	(69, 76)	NoRelation	In this study, we determined the mechanism by which KATP function is altered by several substitutions in distinct structural domains of SUR2: D207E in the intracellular L0-linker and Y985S, G989E, M1060I, and R1154Q/R1154W in TMD2.
R1150W	Var	(192, 198)	increasing	PosReg	(67, 77)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
G985E	Var	(146, 151)	increasing	PosReg	(67, 77)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
KATP channel activity	MPA	(42, 63)	augmented	PosReg	(200, 209)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
Mg-nucleotide activation	MPA	(210, 234)	increasing	PosReg	(67, 77)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
R1150W	Var	(192, 198)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
M1056I	Var	(152, 158)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
R1150Q	Var	(185, 191)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
M1056I	Var	(152, 158)	increasing	PosReg	(67, 77)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
intrinsic stability of the open state	MPA	(78, 115)	augmented	PosReg	(200, 209)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
R1150Q	Var	(185, 191)	increasing	PosReg	(67, 77)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
G985E	Var	(146, 151)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
Y981S	Var	(140, 145)	increasing	PosReg	(67, 77)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
Mg-nucleotide activation	MPA	(210, 234)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
intrinsic stability of the open state	MPA	(78, 115)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
D207E	Var	(26, 31)	augmented	PosReg	(200, 209)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
KATP channel activity	MPA	(42, 63)	increasing	PosReg	(67, 77)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
Y981S	Var	(140, 145)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
D207E	Var	(26, 31)	increases	PosReg	(32, 41)	NoRelation	Our results indicate that D207E increases KATP channel activity by increasing intrinsic stability of the open state, whereas the cluster of Y981S/G985E/M1056I substitutions, as well as R1150Q/R1150W, augmented Mg-nucleotide activation.
knock-down mutants	Var	(886, 904)	reduced	NegReg	(947, 954)	CauseOf	Two independent knock-down mutants, plc3-2 and plc3-3, were found to exhibit reduced lateral root densities by 10-20%.
lateral root densities	CPA	(955, 977)	reduced	NegReg	(947, 954)	ThemeOf	Two independent knock-down mutants, plc3-2 and plc3-3, were found to exhibit reduced lateral root densities by 10-20%.
Mutant	Var	(989, 995)	slowly	NegReg	(1018, 1024)	CauseOf	Mutant seeds germinated more slowly but were less sensitive to ABA to prevent germination.
germinated	CPA	(1002, 1012)	slowly	NegReg	(1018, 1024)	ThemeOf	Mutant seeds germinated more slowly but were less sensitive to ABA to prevent germination.
plc3	Gene	(1558, 1562)	mutants	Var	(1563, 1570)	ThemeOf	In vivo 32Pi labeling revealed that ABA stimulated the formation of PIP2 in germinating seeds and guard cell-enriched leaf peels, which was significantly reduced in plc3 mutants.
mutants	Var	(1563, 1570)	reduced	NegReg	(1547, 1554)	CauseOf	In vivo 32Pi labeling revealed that ABA stimulated the formation of PIP2 in germinating seeds and guard cell-enriched leaf peels, which was significantly reduced in plc3 mutants.
formation of PIP2	MPA	(1448, 1465)	reduced	NegReg	(1547, 1554)	ThemeOf	In vivo 32Pi labeling revealed that ABA stimulated the formation of PIP2 in germinating seeds and guard cell-enriched leaf peels, which was significantly reduced in plc3 mutants.
N-methyl-D-aspartate glutamate receptors	Protein	(35, 75)	mutations	Var	(22, 31)	ThemeOf	Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility.
mutations	Var	(22, 31)	loss of function	NegReg	(5, 21)	CauseOf	Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility.
schizophrenia	Disease	(103, 116)	loss of function	NegReg	(5, 21)	ThemeOf	Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility.
NMDARs	Gene	(1402, 1408)	nonsense or splice site	Var	(1374, 1397)	ThemeOf	Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.
NMDARs	Gene	(1402, 1408)	frameshift	Var	(1362, 1372)	ThemeOf	Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.
frameshift	Var	(1362, 1372)	loss of function	NegReg	(1344, 1360)	CauseOf	Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.
nonsense or splice site	Var	(1374, 1397)	loss of function	NegReg	(1344, 1360)	CauseOf	Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.
SCZ	Disease	(1450, 1453)	loss of function	NegReg	(1344, 1360)	ThemeOf	Our study gives evidence in support of the view that ultra-rare variants with loss of function (frameshift, nonsense or splice site) in NMDARs genes may contribute to possible risk of SCZ.
fln1	Gene	(1485, 1489)	mutants	Var	(1499, 1506)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
stability of the transcriptionally active chromosome complex	CPA	(1585, 1645)	perturbs	NegReg	(1572, 1580)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
mutants	Var	(1499, 1506)	inhibited	NegReg	(1472, 1481)	CauseOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
transcription	MPA	(1405, 1418)	inhibited	NegReg	(1472, 1481)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
translation	MPA	(1423, 1434)	inhibited	NegReg	(1472, 1481)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
PEP-dependent genes	Gene	(1438, 1457)	translation	MPA	(1423, 1434)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
PEP-dependent genes	Gene	(1438, 1457)	transcription	MPA	(1405, 1418)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
inhibited	NegReg	(1472, 1481)	perturbs	NegReg	(1572, 1580)	CauseOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
PEP	Enzyme	(1650, 1653)	activity	MPA	(1654, 1662)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
activity	MPA	(1654, 1662)	perturbs	NegReg	(1572, 1580)	ThemeOf	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
transcription	MPA	(103, 116)	perturbs	NegReg	(270, 278)	NoRelation	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
stability of the transcriptionally active chromosome complex	CPA	(283, 343)	inhibited	NegReg	(170, 179)	NoRelation	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
activity	MPA	(352, 360)	inhibited	NegReg	(170, 179)	NoRelation	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
mutants	Var	(197, 204)	perturbs	NegReg	(270, 278)	NoRelation	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
translation	MPA	(121, 132)	perturbs	NegReg	(270, 278)	NoRelation	Quantitative reverse transcription polymerase chain reaction and immunoblot analysis revealed that the transcription and translation of PEP-dependent genes were strongly inhibited in fln1 and trxz mutants, indicating that loss of OsFLN1, HSA1/OsFLN2, or OsTRXz function perturbs the stability of the transcriptionally active chromosome complex and PEP activity.
SHP2	Gene	(38, 42)	E76K	Var	(30, 34)	ThemeOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
E76K	Var	(983, 987)	aggravated	PosReg	(1024, 1034)	CauseOf	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
inflammation	CPA	(1035, 1047)	aggravated	PosReg	(1024, 1034)	ThemeOf	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
E76K	Var	(983, 987)	increased	PosReg	(1052, 1061)	CauseOf	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
SHP2	Gene	(1091, 1095)	E76K	Var	(1095, 1099)	ThemeOf	In vitro, SHP2E76K and SHP2WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/-catenin signaling pathway.
E76K	Var	(1095, 1099)	promoted	PosReg	(1111, 1119)	CauseOf	In vitro, SHP2E76K and SHP2WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/-catenin signaling pathway.
E76K	Var	(1095, 1099)	induced	PosReg	(1168, 1175)	CauseOf	In vitro, SHP2E76K and SHP2WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/-catenin signaling pathway.
malignant biological behaviors of CRC cells	CPA	(1120, 1163)	promoted	PosReg	(1111, 1119)	ThemeOf	In vitro, SHP2E76K and SHP2WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/-catenin signaling pathway.
epithelial-mesenchymal transition	CPA	(1176, 1209)	induced	PosReg	(1168, 1175)	ThemeOf	In vitro, SHP2E76K and SHP2WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/-catenin signaling pathway.
E76K	Var	(30, 34)	gain-of-function	PosReg	(4, 20)	CauseOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
SHP2	Gene	(1291, 1295)	E76K	Var	(1295, 1299)	ThemeOf	Together, our results showed that SHP2E76K acts as an oncogene that promotes the tumorigenesis and metastasis of CRC.
E76K	Var	(1295, 1299)	promotes	PosReg	(1325, 1333)	CauseOf	Together, our results showed that SHP2E76K acts as an oncogene that promotes the tumorigenesis and metastasis of CRC.
tumorigenesis	CPA	(1338, 1351)	promotes	PosReg	(1325, 1333)	ThemeOf	Together, our results showed that SHP2E76K acts as an oncogene that promotes the tumorigenesis and metastasis of CRC.
metastasis	CPA	(1356, 1366)	promotes	PosReg	(1325, 1333)	ThemeOf	Together, our results showed that SHP2E76K acts as an oncogene that promotes the tumorigenesis and metastasis of CRC.
CRC	Disease	(1370, 1373)	metastasis	CPA	(1356, 1366)	ThemeOf	Together, our results showed that SHP2E76K acts as an oncogene that promotes the tumorigenesis and metastasis of CRC.
CRC	Disease	(1370, 1373)	tumorigenesis	CPA	(1338, 1351)	ThemeOf	Together, our results showed that SHP2E76K acts as an oncogene that promotes the tumorigenesis and metastasis of CRC.
tumorigenesis	CPA	(1066, 1079)	increased	PosReg	(1052, 1061)	ThemeOf	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
CAC	Disease	(1062, 1065)	tumorigenesis	CPA	(1066, 1079)	ThemeOf	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
CAC	Disease	(52, 55)	tumorigenesis	CPA	(56, 69)	ThemeOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
tumorigenesis	CPA	(56, 69)	promotes	PosReg	(43, 51)	ThemeOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
gain-of-function	PosReg	(4, 20)	promotes	PosReg	(43, 51)	CauseOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
SHP2	Gene	(358, 362)	mutation	Var	(340, 348)	ThemeOf	In addition, the mutation rate for SHP2 is the highest for colorectal cancer (CRC) among solid tumors.
mutation	Var	(340, 348)	highest	Reg	(370, 377)	CauseOf	In addition, the mutation rate for SHP2 is the highest for colorectal cancer (CRC) among solid tumors.
colorectal cancer	Disease	(382, 399)	highest	Reg	(370, 377)	ThemeOf	In addition, the mutation rate for SHP2 is the highest for colorectal cancer (CRC) among solid tumors.
Wnt/-catenin signaling pathway	Pathway	(94, 125)	induces	PosReg	(74, 81)	ThemeOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
EMT	CPA	(82, 85)	induces	PosReg	(74, 81)	ThemeOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
gain-of-function	PosReg	(4, 20)	induces	PosReg	(74, 81)	CauseOf	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
Ptpn11	Gene	(977, 983)	E76K	Var	(983, 987)	ThemeOf	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
E76K	Var	(30, 34)	promotes	PosReg	(43, 51)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
tumorigenesis	CPA	(56, 69)	gain-of-function	PosReg	(4, 20)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
CAC	Disease	(52, 55)	promotes	PosReg	(43, 51)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
CAC	Disease	(52, 55)	induces	PosReg	(74, 81)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
tumorigenesis	CPA	(56, 69)	induces	PosReg	(74, 81)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
EMT	CPA	(82, 85)	promotes	PosReg	(43, 51)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
EMT	CPA	(82, 85)	gain-of-function	PosReg	(4, 20)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
CAC	Disease	(52, 55)	gain-of-function	PosReg	(4, 20)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
E76K	Var	(30, 34)	induces	PosReg	(74, 81)	NoRelation	The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/-catenin signaling pathway.
tumorigenesis	CPA	(89, 102)	aggravated	PosReg	(47, 57)	NoRelation	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
CAC	Disease	(85, 88)	aggravated	PosReg	(47, 57)	NoRelation	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
CAC	Disease	(85, 88)	increased	PosReg	(75, 84)	NoRelation	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
inflammation	CPA	(58, 70)	increased	PosReg	(75, 84)	NoRelation	Ptpn11E76K conditional knock-in mice exhibited aggravated inflammation and increased CAC tumorigenesis.
epithelial-mesenchymal transition	CPA	(95, 128)	promoted	PosReg	(30, 38)	NoRelation	In vitro, SHP2E76K and SHP2WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/-catenin signaling pathway.
malignant biological behaviors of CRC cells	CPA	(39, 82)	induced	PosReg	(87, 94)	NoRelation	In vitro, SHP2E76K and SHP2WT promoted malignant biological behaviors of CRC cells and induced epithelial-mesenchymal transition (EMT) via the Wnt/-catenin signaling pathway.
CRC	Disease	(113, 116)	promotes	PosReg	(68, 76)	NoRelation	Together, our results showed that SHP2E76K acts as an oncogene that promotes the tumorigenesis and metastasis of CRC.
PIGN	Gene	(796, 800)	missense	Var	(812, 820)	ThemeOf	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
compound missense	Var	(824, 841)	truncating	MPA	(847, 857)	CauseOf	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
truncating	MPA	(847, 857)	cause	Reg	(864, 869)	CauseOf	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
PIGN	Gene	(796, 800)	compound missense	Var	(824, 841)	ThemeOf	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
multiple congenital anomalies-hypotonia-seizures syndrome 1	Disease	(870, 929)	cause	Reg	(864, 869)	ThemeOf	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
PIGN	Gene	(589, 593)	biallelic truncating variants	Var	(556, 585)	ThemeOf	Although no major genetic cause has been identified for FS, biallelic truncating variants in PIGN, encoding a component of the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway, have been identified in a limited number of cases with a phenotype compatible with FS.
biallelic truncating variants	Var	(556, 585)	identified	Reg	(697, 707)	CauseOf	Although no major genetic cause has been identified for FS, biallelic truncating variants in PIGN, encoding a component of the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway, have been identified in a limited number of cases with a phenotype compatible with FS.
FS	Disease	(770, 772)	identified	Reg	(697, 707)	ThemeOf	Although no major genetic cause has been identified for FS, biallelic truncating variants in PIGN, encoding a component of the glycosylphosphatidylinositol (GPI)-anchor biosynthesis pathway, have been identified in a limited number of cases with a phenotype compatible with FS.
missense	Var	(812, 820)	truncating	MPA	(847, 857)	CauseOf	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
missense	Var	(38, 46)	cause	Reg	(90, 95)	NoRelation	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
compound missense	Var	(50, 67)	cause	Reg	(90, 95)	NoRelation	Biallelic variants in PIGN, typically missense or compound missense with truncating, also cause multiple congenital anomalies-hypotonia-seizures syndrome 1 (MCAHS1).
ANGPTL3	Gene	(1047, 1054)	mutations	Var	(1034, 1043)	ThemeOf	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
mutations	Var	(1034, 1043)	LOF	NegReg	(1030, 1033)	CauseOf	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
plasma LDL-C	MPA	(1066, 1078)	lower	NegReg	(1060, 1065)	ThemeOf	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
TG levels	MPA	(1080, 1089)	lower	NegReg	(1060, 1065)	ThemeOf	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
LOF	NegReg	(1030, 1033)	lower	NegReg	(1060, 1065)	CauseOf	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
mutations	Var	(54, 63)	lower	NegReg	(80, 85)	NoRelation	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
TG levels	MPA	(100, 109)	LOF	NegReg	(50, 53)	NoRelation	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
plasma LDL-C	MPA	(86, 98)	LOF	NegReg	(50, 53)	NoRelation	Additionally, in humans, carriers with homozygous LOF mutations in ANGPTL3 have lower plasma LDL-C, TG levels and lower risk of atherosclerosis compared to the non-carriers.
NT5C2	Gene	(260, 265)	mutations	Var	(212, 221)	ThemeOf	Gain-of-function mutations in the 5'-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine and are selectively present in relapsed ALL.
depletion of the intracellular purine-nucleotide pool	MPA	(939, 992)	excess	PosReg	(883, 889)	ThemeOf	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
R367Q	Var	(606, 611)	induces	PosReg	(662, 669)	CauseOf	Here we use a conditional-and-inducible leukaemia model to demonstrate that expression of NT5C2(R367Q), a highly prevalent relapsed-ALL NT5C2 mutation, induces resistance to chemotherapy with 6-mercaptopurine at the cost of impaired leukaemia cell growth and leukaemia-initiating cell activity.
R367Q	Var	(845, 850)	excess	PosReg	(883, 889)	CauseOf	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
excess	PosReg	(883, 889)	loss-of-fitness	NegReg	(809, 824)	CauseOf	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
induces	PosReg	(662, 669)	relapsed-ALL	Disease	(633, 645)	CauseOf	Here we use a conditional-and-inducible leukaemia model to demonstrate that expression of NT5C2(R367Q), a highly prevalent relapsed-ALL NT5C2 mutation, induces resistance to chemotherapy with 6-mercaptopurine at the cost of impaired leukaemia cell growth and leukaemia-initiating cell activity.
NT5C2	Gene	(31, 36)	mutant	Var	(37, 43)	ThemeOf	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
mutant	Var	(37, 43)	mechanisms	Reg	(17, 27)	CauseOf	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
relapsed acute lymphoblastic leukaemia	Disease	(44, 82)	mechanisms	Reg	(17, 27)	ThemeOf	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
resistance to 6-mercaptopurine	MPA	(279, 309)	induce	PosReg	(272, 278)	ThemeOf	Gain-of-function mutations in the 5'-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine and are selectively present in relapsed ALL.
mutations	Var	(212, 221)	Gain-of-function	PosReg	(195, 211)	CauseOf	Gain-of-function mutations in the 5'-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine and are selectively present in relapsed ALL.
Gain-of-function	PosReg	(195, 211)	induce	PosReg	(272, 278)	CauseOf	Gain-of-function mutations in the 5'-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine and are selectively present in relapsed ALL.
NT5C2	Gene	(646, 651)	R367Q	Var	(606, 611)	ThemeOf	Here we use a conditional-and-inducible leukaemia model to demonstrate that expression of NT5C2(R367Q), a highly prevalent relapsed-ALL NT5C2 mutation, induces resistance to chemotherapy with 6-mercaptopurine at the cost of impaired leukaemia cell growth and leukaemia-initiating cell activity.
resistance to chemotherapy with 6-mercaptopurine	MPA	(670, 718)	induces	PosReg	(662, 669)	ThemeOf	Here we use a conditional-and-inducible leukaemia model to demonstrate that expression of NT5C2(R367Q), a highly prevalent relapsed-ALL NT5C2 mutation, induces resistance to chemotherapy with 6-mercaptopurine at the cost of impaired leukaemia cell growth and leukaemia-initiating cell activity.
NT5C2	Gene	(838, 843)	R367Q	Var	(845, 850)	ThemeOf	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
export of purines to the extracellular space	MPA	(890, 934)	excess	PosReg	(883, 889)	ThemeOf	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
phenotype	CPA	(825, 834)	loss-of-fitness	NegReg	(809, 824)	ThemeOf	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
mutations	Var	(17, 26)	induce	PosReg	(77, 83)	NoRelation	Gain-of-function mutations in the 5'-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine and are selectively present in relapsed ALL.
resistance to 6-mercaptopurine	MPA	(84, 114)	Gain-of-function	PosReg	(0, 16)	NoRelation	Gain-of-function mutations in the 5'-nucleotidase, cytosolic II (NT5C2) gene induce resistance to 6-mercaptopurine and are selectively present in relapsed ALL.
phenotype	CPA	(20, 29)	excess	PosReg	(78, 84)	NoRelation	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
depletion of the intracellular purine-nucleotide pool	MPA	(134, 187)	loss-of-fitness	NegReg	(4, 19)	NoRelation	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
export of purines to the extracellular space	MPA	(85, 129)	loss-of-fitness	NegReg	(4, 19)	NoRelation	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
R367Q	Var	(40, 45)	loss-of-fitness	NegReg	(4, 19)	NoRelation	The loss-of-fitness phenotype of NT5C2+/R367Q mutant cells is associated with excess export of purines to the extracellular space and depletion of the intracellular purine-nucleotide pool.
melanoma development	CPA	(691, 711)	promotes	PosReg	(682, 690)	ThemeOf	Importantly, in the absence of DOT1L, UVR-induced DNA damage is inefficiently repaired, so that DOT1L loss promotes melanoma development in mice after exposure to UVR.
loss	NegReg	(677, 681)	promotes	PosReg	(682, 690)	CauseOf	Importantly, in the absence of DOT1L, UVR-induced DNA damage is inefficiently repaired, so that DOT1L loss promotes melanoma development in mice after exposure to UVR.
DOT1L	Gene	(497, 502)	methyltransferase enzyme	Enzyme	(503, 527)	ThemeOf	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
methyltransferase enzyme	Enzyme	(503, 527)	activity	MPA	(528, 536)	ThemeOf	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
H3K79	Protein	(556, 561)	methylation	MPA	(562, 573)	ThemeOf	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
methylation	MPA	(562, 573)	reduced	NegReg	(548, 555)	ThemeOf	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
activity	MPA	(528, 536)	compromise	NegReg	(486, 496)	ThemeOf	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
mutations	Var	(463, 472)	compromise	NegReg	(486, 496)	CauseOf	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
compromise	NegReg	(486, 496)	reduced	NegReg	(548, 555)	CauseOf	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
DOT1L	Gene	(671, 676)	loss	NegReg	(677, 681)	ThemeOf	Importantly, in the absence of DOT1L, UVR-induced DNA damage is inefficiently repaired, so that DOT1L loss promotes melanoma development in mice after exposure to UVR.
activity	MPA	(74, 82)	reduced	NegReg	(94, 101)	NoRelation	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
methylation	MPA	(108, 119)	compromise	NegReg	(32, 42)	NoRelation	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
mutations	Var	(9, 18)	reduced	NegReg	(94, 101)	NoRelation	Specific mutations functionally compromise DOT1L methyltransferase enzyme activity leading to reduced H3K79 methylation.
melanoma development	CPA	(116, 136)	loss	NegReg	(102, 106)	NoRelation	Importantly, in the absence of DOT1L, UVR-induced DNA damage is inefficiently repaired, so that DOT1L loss promotes melanoma development in mice after exposure to UVR.
KIF14	Gene	(22, 27)	Biallelic variants	Var	(0, 18)	ThemeOf	Biallelic variants in KIF14 cause intellectual disability with microcephaly.
p.Asn83Ilefs*3	Var	(538, 552)	loss-of-function	NegReg	(520, 536)	CauseOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
p.Ser1478fs	Var	(557, 568)	loss-of-function	NegReg	(520, 536)	CauseOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
pathogenic	CPA	(472, 482)	loss-of-function	NegReg	(520, 536)	ThemeOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
KIF14	Gene	(495, 500)	p.Ser841Phe	Var	(603, 614)	ThemeOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
KIF14	Gene	(495, 500)	p.Gly459Arg	Var	(619, 630)	ThemeOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
pathogenic	CPA	(472, 482)	missense substitutions	Reg	(579, 601)	ThemeOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
p.Ser841Phe	Var	(603, 614)	missense substitutions	Reg	(579, 601)	CauseOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
p.Gly459Arg	Var	(619, 630)	missense substitutions	Reg	(579, 601)	CauseOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
intellectual disability	Disease	(34, 57)	cause	Reg	(28, 33)	ThemeOf	Biallelic variants in KIF14 cause intellectual disability with microcephaly.
microcephaly	Disease	(63, 75)	cause	Reg	(28, 33)	ThemeOf	Biallelic variants in KIF14 cause intellectual disability with microcephaly.
Biallelic variants	Var	(0, 18)	cause	Reg	(28, 33)	CauseOf	Biallelic variants in KIF14 cause intellectual disability with microcephaly.
CIT	Gene	(754, 757)	mutated	Var	(764, 771)	ThemeOf	KIF14 is a mitotic motor protein that is required for spindle localization of the mitotic citron rho-interacting kinase, CIT, also mutated in microcephaly.
microcephaly	Disease	(775, 787)	in	Reg	(772, 774)	ThemeOf	KIF14 is a mitotic motor protein that is required for spindle localization of the mitotic citron rho-interacting kinase, CIT, also mutated in microcephaly.
mutated	Var	(764, 771)	in	Reg	(772, 774)	CauseOf	KIF14 is a mitotic motor protein that is required for spindle localization of the mitotic citron rho-interacting kinase, CIT, also mutated in microcephaly.
KIF14	Gene	(495, 500)	p.Asn83Ilefs*3	Var	(538, 552)	ThemeOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
KIF14	Gene	(495, 500)	p.Ser1478fs	Var	(557, 568)	ThemeOf	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
p.Asn83Ilefs*3	Var	(134, 148)	missense substitutions	Reg	(175, 197)	NoRelation	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
p.Ser841Phe	Var	(199, 210)	loss-of-function	NegReg	(116, 132)	NoRelation	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
p.Ser1478fs	Var	(153, 164)	missense substitutions	Reg	(175, 197)	NoRelation	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
p.Gly459Arg	Var	(215, 226)	loss-of-function	NegReg	(116, 132)	NoRelation	In the affected individuals of each family, homozygosity for likely pathogenic variants in KIF14 were detected; two loss-of-function (p.Asn83Ilefs*3 and p.Ser1478fs), and two missense substitutions (p.Ser841Phe and p.Gly459Arg).
APOC3	Gene	(211, 216)	mutations	Var	(198, 207)	ThemeOf	OBJECTIVE: Loss-of-function mutations in APOC3 associate with low remnant cholesterol levels and low risk of ischemic vascular disease (IVD).
APOC3	Gene	(0, 5)	Mutations	Var	(23, 32)	ThemeOf	APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137895 Individuals.
Mutations	Var	(23, 32)	Loss-of-Function	NegReg	(6, 22)	CauseOf	APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137895 Individuals.
mutations	Var	(198, 207)	Loss-of-function	NegReg	(181, 197)	CauseOf	OBJECTIVE: Loss-of-function mutations in APOC3 associate with low remnant cholesterol levels and low risk of ischemic vascular disease (IVD).
Loss-of-function	NegReg	(181, 197)	low	NegReg	(232, 235)	CauseOf	OBJECTIVE: Loss-of-function mutations in APOC3 associate with low remnant cholesterol levels and low risk of ischemic vascular disease (IVD).
remnant cholesterol levels	MPA	(236, 262)	low	NegReg	(232, 235)	ThemeOf	OBJECTIVE: Loss-of-function mutations in APOC3 associate with low remnant cholesterol levels and low risk of ischemic vascular disease (IVD).
APOC3	Gene	(1716, 1721)	loss-of-function	NegReg	(1722, 1738)	ThemeOf	CONCLUSIONS: The low risk of IVD observed in APOC3 loss-of-function heterozygotes is mainly mediated by the associated low remnant cholesterol and not by low LDL-C.
loss-of-function	NegReg	(1722, 1738)	low	NegReg	(1790, 1793)	CauseOf	CONCLUSIONS: The low risk of IVD observed in APOC3 loss-of-function heterozygotes is mainly mediated by the associated low remnant cholesterol and not by low LDL-C.
remnant cholesterol	MPA	(1794, 1813)	low	NegReg	(1790, 1793)	ThemeOf	CONCLUSIONS: The low risk of IVD observed in APOC3 loss-of-function heterozygotes is mainly mediated by the associated low remnant cholesterol and not by low LDL-C.
remnant cholesterol levels	MPA	(66, 92)	Loss-of-function	NegReg	(11, 27)	NoRelation	OBJECTIVE: Loss-of-function mutations in APOC3 associate with low remnant cholesterol levels and low risk of ischemic vascular disease (IVD).
mutations	Var	(28, 37)	low	NegReg	(62, 65)	NoRelation	OBJECTIVE: Loss-of-function mutations in APOC3 associate with low remnant cholesterol levels and low risk of ischemic vascular disease (IVD).
remnant cholesterol	MPA	(123, 142)	loss-of-function	NegReg	(51, 67)	NoRelation	CONCLUSIONS: The low risk of IVD observed in APOC3 loss-of-function heterozygotes is mainly mediated by the associated low remnant cholesterol and not by low LDL-C.
APAF1	Gene	(20, 25)	apoptotic genes	Gene	(4, 19)	ThemeOf	Key apoptotic genes APAF1 and CASP9 implicated in recurrent folate-resistant neural tube defects.
CASP9	Gene	(30, 35)	apoptotic genes	Gene	(4, 19)	ThemeOf	Key apoptotic genes APAF1 and CASP9 implicated in recurrent folate-resistant neural tube defects.
variants	Var	(540, 548)	loss-of-function	NegReg	(553, 569)	CauseOf	Functional studies in fibroblasts indicate that these variants are loss-of-function, as apoptosis is significantly reduced.
variants	Var	(540, 548)	reduced	NegReg	(601, 608)	CauseOf	Functional studies in fibroblasts indicate that these variants are loss-of-function, as apoptosis is significantly reduced.
apoptosis	CPA	(574, 583)	reduced	NegReg	(601, 608)	ThemeOf	Functional studies in fibroblasts indicate that these variants are loss-of-function, as apoptosis is significantly reduced.
variants	Var	(638, 646)	contributing	Reg	(666, 678)	CauseOf	This is the first report of variants in apoptotic genes contributing to neural tube defect risk in humans.
neural tube defect	Disease	(682, 700)	contributing	Reg	(666, 678)	ThemeOf	This is the first report of variants in apoptotic genes contributing to neural tube defect risk in humans.
apoptotic genes	Gene	(650, 665)	variants	Var	(638, 646)	ThemeOf	This is the first report of variants in apoptotic genes contributing to neural tube defect risk in humans.
apoptosis	CPA	(88, 97)	loss-of-function	NegReg	(67, 83)	NoRelation	Functional studies in fibroblasts indicate that these variants are loss-of-function, as apoptosis is significantly reduced.
NHS	Gene	(324, 327)	nonsense	Var	(315, 323)	ThemeOf	Here, we identify a patient with Nance-Horan syndrome caused by a new nonsense NHS variant.
nonsense	Var	(315, 323)	caused by	Reg	(299, 308)	CauseOf	Here, we identify a patient with Nance-Horan syndrome caused by a new nonsense NHS variant.
Nance-Horan syndrome	Disease	(278, 298)	caused by	Reg	(299, 308)	ThemeOf	Here, we identify a patient with Nance-Horan syndrome caused by a new nonsense NHS variant.
NHS	Gene	(586, 589)	loss of function	NegReg	(590, 606)	ThemeOf	Congenital diaphragmatic hernia could result from NHS loss of function in pleuroperitoneal fold or in somites-derived muscle progenitor cells leading to an impairment of their cells migration.
loss of function	NegReg	(590, 606)	cells migration	CPA	(712, 727)	CauseOf	Congenital diaphragmatic hernia could result from NHS loss of function in pleuroperitoneal fold or in somites-derived muscle progenitor cells leading to an impairment of their cells migration.
cells migration	CPA	(712, 727)	Congenital diaphragmatic hernia	Disease	(536, 567)	CauseOf	Congenital diaphragmatic hernia could result from NHS loss of function in pleuroperitoneal fold or in somites-derived muscle progenitor cells leading to an impairment of their cells migration.
Congenital diaphragmatic hernia	Disease	(0, 31)	loss of function	NegReg	(54, 70)	NoRelation	Congenital diaphragmatic hernia could result from NHS loss of function in pleuroperitoneal fold or in somites-derived muscle progenitor cells leading to an impairment of their cells migration.
Congenital diaphragmatic hernia	Disease	(0, 31)	result from	Reg	(38, 49)	NoRelation	Congenital diaphragmatic hernia could result from NHS loss of function in pleuroperitoneal fold or in somites-derived muscle progenitor cells leading to an impairment of their cells migration.
cells migration	CPA	(176, 191)	result from	Reg	(38, 49)	NoRelation	Congenital diaphragmatic hernia could result from NHS loss of function in pleuroperitoneal fold or in somites-derived muscle progenitor cells leading to an impairment of their cells migration.
FLG	Gene	(146, 149)	mutations	Var	(122, 131)	ThemeOf	Since the discovery of loss-of-function mutations in filaggrin (FLG) gene in atopic dermatitis (AD) individuals, significant attention has been paid against the skin barrier as an initial starting point of atopic march.
mutations	Var	(122, 131)	loss-of-function	NegReg	(105, 121)	CauseOf	Since the discovery of loss-of-function mutations in filaggrin (FLG) gene in atopic dermatitis (AD) individuals, significant attention has been paid against the skin barrier as an initial starting point of atopic march.
atopic dermatitis	Disease	(159, 176)	loss-of-function	NegReg	(105, 121)	ThemeOf	Since the discovery of loss-of-function mutations in filaggrin (FLG) gene in atopic dermatitis (AD) individuals, significant attention has been paid against the skin barrier as an initial starting point of atopic march.
TRH	Gene	(24, 27)	mutations	Var	(46, 55)	ThemeOf	Tryptophan hydroxylase (TRH) loss of function mutations induce growth and behavioral defects in Daphnia magna.
lacking	NegReg	(660, 667)	reproduced	CPA	(698, 708)	CauseOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
offspring	CPA	(754, 763)	smaller	NegReg	(746, 753)	ThemeOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
smaller	NegReg	(746, 753)	clutches	CPA	(734, 742)	ThemeOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
clutches	CPA	(734, 742)	smaller	NegReg	(726, 733)	ThemeOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
lacking	NegReg	(660, 667)	smaller	NegReg	(726, 733)	CauseOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
growth and behavioral defects	CPA	(63, 92)	loss of function	NegReg	(29, 45)	ThemeOf	Tryptophan hydroxylase (TRH) loss of function mutations induce growth and behavioral defects in Daphnia magna.
mutations	Var	(46, 55)	loss of function	NegReg	(29, 45)	CauseOf	Tryptophan hydroxylase (TRH) loss of function mutations induce growth and behavioral defects in Daphnia magna.
serotonin	MPA	(668, 677)	lacking	NegReg	(660, 667)	ThemeOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
Mutants	Var	(652, 659)	lacking	NegReg	(660, 667)	CauseOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
lacking	NegReg	(660, 667)	less	NegReg	(683, 687)	CauseOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
grew	CPA	(678, 682)	less	NegReg	(683, 687)	ThemeOf	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
offspring	CPA	(102, 111)	smaller	NegReg	(74, 81)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
grew	CPA	(26, 30)	smaller	NegReg	(94, 101)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
reproduced	CPA	(46, 56)	smaller	NegReg	(74, 81)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
clutches	CPA	(82, 90)	lacking	NegReg	(8, 15)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
grew	CPA	(26, 30)	smaller	NegReg	(74, 81)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
Mutants	Var	(0, 7)	less	NegReg	(31, 35)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
reproduced	CPA	(46, 56)	less	NegReg	(31, 35)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
Mutants	Var	(0, 7)	smaller	NegReg	(74, 81)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
reproduced	CPA	(46, 56)	smaller	NegReg	(94, 101)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
offspring	CPA	(102, 111)	lacking	NegReg	(8, 15)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
offspring	CPA	(102, 111)	less	NegReg	(31, 35)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
Mutants	Var	(0, 7)	smaller	NegReg	(94, 101)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
grew	CPA	(26, 30)	lacking	NegReg	(8, 15)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
clutches	CPA	(82, 90)	less	NegReg	(31, 35)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
serotonin	MPA	(16, 25)	smaller	NegReg	(94, 101)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
serotonin	MPA	(16, 25)	smaller	NegReg	(74, 81)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
serotonin	MPA	(16, 25)	less	NegReg	(31, 35)	NoRelation	Mutants lacking serotonin grew less and hence reproduced latter, produced smaller clutches of smaller offspring and responded to a greater extent to light than wild type individuals.
FLT3	Gene	(71, 75)	Internal tandem duplication mutations	Var	(0, 37)	ThemeOf	Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
STAT5	Protein	(1831, 1836)	phosphorylation	MPA	(1812, 1827)	ThemeOf	Furthermore, TKD-ITD is capable of inducing phosphorylation of STAT5, while D835Y/FLT3 fails to induce tyrosine phosphorylation of STAT5.
phosphorylation	MPA	(1812, 1827)	inducing	PosReg	(1803, 1811)	ThemeOf	Furthermore, TKD-ITD is capable of inducing phosphorylation of STAT5, while D835Y/FLT3 fails to induce tyrosine phosphorylation of STAT5.
Mutations	Var	(303, 312)	prevalent	Reg	(369, 378)	CauseOf	Mutations in FMS-like tyrosine kinase 3 (FLT3) is one of the most prevalent findings in this heterogeneous disease.
FLT3	Gene	(344, 348)	Mutations	Var	(303, 312)	ThemeOf	Mutations in FMS-like tyrosine kinase 3 (FLT3) is one of the most prevalent findings in this heterogeneous disease.
Internal tandem duplication mutations	Var	(0, 37)	higher	PosReg	(86, 92)	CauseOf	Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
oncogenic potential	CPA	(93, 112)	higher	PosReg	(86, 92)	ThemeOf	Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
TKD-ITD	Var	(1701, 1708)	higher	PosReg	(1691, 1697)	CauseOf	Cell proliferation and cell survival was also significantly higher in TKD-ITD expressing cells, compared to cells expressing D835Y/FLT3.
cell survival	CPA	(1654, 1667)	higher	PosReg	(1691, 1697)	ThemeOf	Cell proliferation and cell survival was also significantly higher in TKD-ITD expressing cells, compared to cells expressing D835Y/FLT3.
Cell proliferation	CPA	(1631, 1649)	higher	PosReg	(1691, 1697)	ThemeOf	Cell proliferation and cell survival was also significantly higher in TKD-ITD expressing cells, compared to cells expressing D835Y/FLT3.
TKD-ITD	Var	(1781, 1788)	inducing	PosReg	(1803, 1811)	CauseOf	Furthermore, TKD-ITD is capable of inducing phosphorylation of STAT5, while D835Y/FLT3 fails to induce tyrosine phosphorylation of STAT5.
HJV	Gene	(996, 999)	mutation	Var	(976, 984)	ThemeOf	Targeted gene sequencing revealed a loss-of-function mutation within the HJV gene, which is consistent with juvenile hemochromatosis.
mutation	Var	(976, 984)	loss-of-function	NegReg	(959, 975)	CauseOf	Targeted gene sequencing revealed a loss-of-function mutation within the HJV gene, which is consistent with juvenile hemochromatosis.
loss-of-function	NegReg	(959, 975)	juvenile hemochromatosis	Disease	(1031, 1055)	CauseOf	Targeted gene sequencing revealed a loss-of-function mutation within the HJV gene, which is consistent with juvenile hemochromatosis.
juvenile hemochromatosis	Disease	(1103, 1127)	associated	Reg	(1128, 1138)	ThemeOf	CONCLUSIONS: This rare case of a patient with juvenile hemochromatosis associated with a HJV mutation provides histologic evidence documenting the reversal of associated end-stage heart failure, requiring emergent mechanical circulatory support, with iron chelation therapy.
HJV	Gene	(1146, 1149)	mutation	Var	(1150, 1158)	ThemeOf	CONCLUSIONS: This rare case of a patient with juvenile hemochromatosis associated with a HJV mutation provides histologic evidence documenting the reversal of associated end-stage heart failure, requiring emergent mechanical circulatory support, with iron chelation therapy.
mutation	Var	(1150, 1158)	associated	Reg	(1128, 1138)	CauseOf	CONCLUSIONS: This rare case of a patient with juvenile hemochromatosis associated with a HJV mutation provides histologic evidence documenting the reversal of associated end-stage heart failure, requiring emergent mechanical circulatory support, with iron chelation therapy.
TRPV1	Gene	(0, 5)	mutation	Var	(23, 31)	ThemeOf	TRPV1 gain-of-function mutation impairs pain and itch sensations in mice.
thermosensory	CPA	(726, 739)	defect	NegReg	(740, 746)	ThemeOf	Intriguingly, using behavioral analysis, we found that knock-in mice showed a thermosensory defect, impaired inflammatory thermal pain, and capsaicin sensitivity.
inflammatory thermal pain	MPA	(757, 782)	impaired	NegReg	(748, 756)	ThemeOf	Intriguingly, using behavioral analysis, we found that knock-in mice showed a thermosensory defect, impaired inflammatory thermal pain, and capsaicin sensitivity.
G564S	Var	(1087, 1092)	reduced	NegReg	(1100, 1107)	CauseOf	Western blot analysis revealed that the G564S mutant reduced TRPV1 phosphorylation and cell membrane trafficking.
TRPV1	Protein	(1108, 1113)	phosphorylation	MPA	(1114, 1129)	ThemeOf	Western blot analysis revealed that the G564S mutant reduced TRPV1 phosphorylation and cell membrane trafficking.
phosphorylation	MPA	(1114, 1129)	reduced	NegReg	(1100, 1107)	ThemeOf	Western blot analysis revealed that the G564S mutant reduced TRPV1 phosphorylation and cell membrane trafficking.
cell membrane trafficking	CPA	(1134, 1159)	reduced	NegReg	(1100, 1107)	ThemeOf	Western blot analysis revealed that the G564S mutant reduced TRPV1 phosphorylation and cell membrane trafficking.
Trpv1	Gene	(1239, 1244)	mutation	Var	(1227, 1235)	ThemeOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
mutation	Var	(1227, 1235)	gain-of-function	PosReg	(1210, 1226)	CauseOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
mutation	Var	(23, 31)	gain-of-function	PosReg	(6, 22)	CauseOf	TRPV1 gain-of-function mutation impairs pain and itch sensations in mice.
gain-of-function	PosReg	(1210, 1226)	decreased	NegReg	(1357, 1366)	CauseOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
gain-of-function	PosReg	(1210, 1226)	reduced	NegReg	(1393, 1400)	CauseOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
phosphorylation level	MPA	(1367, 1388)	decreased	NegReg	(1357, 1366)	ThemeOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
TRPV1	Protein	(1426, 1431)	membrane localization	MPA	(1401, 1422)	ThemeOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
membrane localization	MPA	(1401, 1422)	reduced	NegReg	(1393, 1400)	ThemeOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
decreased	NegReg	(1357, 1366)	impaired	NegReg	(1339, 1347)	CauseOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
reduced	NegReg	(1393, 1400)	impaired	NegReg	(1339, 1347)	CauseOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
pain and histamine-dependent itch sensations	CPA	(1276, 1320)	impaired	NegReg	(1339, 1347)	ThemeOf	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
gain-of-function	PosReg	(6, 22)	impairs	NegReg	(32, 39)	CauseOf	TRPV1 gain-of-function mutation impairs pain and itch sensations in mice.
pain and itch sensations	CPA	(40, 64)	impairs	NegReg	(32, 39)	ThemeOf	TRPV1 gain-of-function mutation impairs pain and itch sensations in mice.
TRPV1	Gene	(567, 572)	G564S	Var	(543, 548)	ThemeOf	In the heterologous expression system, an electrophysiological study showed that the G564S mutation in mouse TRPV1 caused increased basal current and a leftward shift of voltage dependence.
G564S	Var	(543, 548)	increased	PosReg	(580, 589)	CauseOf	In the heterologous expression system, an electrophysiological study showed that the G564S mutation in mouse TRPV1 caused increased basal current and a leftward shift of voltage dependence.
basal current	CPA	(590, 603)	increased	PosReg	(580, 589)	ThemeOf	In the heterologous expression system, an electrophysiological study showed that the G564S mutation in mouse TRPV1 caused increased basal current and a leftward shift of voltage dependence.
G564S	Var	(543, 548)	leftward shift of voltage dependence	CPA	(610, 646)	CauseOf	In the heterologous expression system, an electrophysiological study showed that the G564S mutation in mouse TRPV1 caused increased basal current and a leftward shift of voltage dependence.
mutation	Var	(23, 31)	impairs	NegReg	(32, 39)	NoRelation	TRPV1 gain-of-function mutation impairs pain and itch sensations in mice.
pain and itch sensations	CPA	(40, 64)	gain-of-function	PosReg	(6, 22)	NoRelation	TRPV1 gain-of-function mutation impairs pain and itch sensations in mice.
inflammatory thermal pain	MPA	(109, 134)	defect	NegReg	(92, 98)	NoRelation	Intriguingly, using behavioral analysis, we found that knock-in mice showed a thermosensory defect, impaired inflammatory thermal pain, and capsaicin sensitivity.
capsaicin sensitivity	CPA	(140, 161)	impaired	NegReg	(100, 108)	NoRelation	Intriguingly, using behavioral analysis, we found that knock-in mice showed a thermosensory defect, impaired inflammatory thermal pain, and capsaicin sensitivity.
capsaicin sensitivity	CPA	(140, 161)	defect	NegReg	(92, 98)	NoRelation	Intriguingly, using behavioral analysis, we found that knock-in mice showed a thermosensory defect, impaired inflammatory thermal pain, and capsaicin sensitivity.
thermosensory	CPA	(78, 91)	impaired	NegReg	(100, 108)	NoRelation	Intriguingly, using behavioral analysis, we found that knock-in mice showed a thermosensory defect, impaired inflammatory thermal pain, and capsaicin sensitivity.
mutation	Var	(66, 74)	reduced	NegReg	(232, 239)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
membrane localization	MPA	(240, 261)	impaired	NegReg	(178, 186)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
membrane localization	MPA	(240, 261)	decreased	NegReg	(196, 205)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
mutation	Var	(66, 74)	impaired	NegReg	(178, 186)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
pain and histamine-dependent itch sensations	CPA	(115, 159)	decreased	NegReg	(196, 205)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
pain and histamine-dependent itch sensations	CPA	(115, 159)	reduced	NegReg	(232, 239)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
membrane localization	MPA	(240, 261)	gain-of-function	PosReg	(49, 65)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
phosphorylation level	MPA	(206, 227)	gain-of-function	PosReg	(49, 65)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
mutation	Var	(66, 74)	decreased	NegReg	(196, 205)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
phosphorylation level	MPA	(206, 227)	impaired	NegReg	(178, 186)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
phosphorylation level	MPA	(206, 227)	reduced	NegReg	(232, 239)	NoRelation	Together, we have generated a mouse model with a gain-of-function mutation in Trpv1 gene and demonstrated that the pain and histamine-dependent itch sensations in these mice are impaired due to a decreased phosphorylation level and reduced membrane localization of TRPV1.
UNC45A	Gene	(30, 36)	Mutations	Var	(17, 26)	ThemeOf	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
protein	Protein	(750, 757)	activity	MPA	(758, 766)	ThemeOf	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
activity	MPA	(758, 766)	abolished	NegReg	(740, 749)	ThemeOf	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
activity	MPA	(758, 766)	attenuated	NegReg	(726, 736)	ThemeOf	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
gut development	CPA	(795, 810)	defects	NegReg	(784, 791)	CauseOf	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
Mutations	Var	(17, 26)	Loss-of-Function	NegReg	(0, 16)	CauseOf	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Loss-of-Function	NegReg	(0, 16)	Syndrome	Disease	(45, 53)	CauseOf	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Cholestasis	Disease	(66, 77)	Syndrome	Disease	(45, 53)	ThemeOf	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Diarrhea	Disease	(79, 87)	Syndrome	Disease	(45, 53)	ThemeOf	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Impaired Hearing	Disease	(89, 105)	Syndrome	Disease	(45, 53)	ThemeOf	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Bone Fragility	Disease	(111, 125)	Syndrome	Disease	(45, 53)	ThemeOf	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
UNC45A	Gene	(550, 556)	biallelic mutations	Var	(500, 519)	ThemeOf	Whole-exome sequencing of all affected individuals and their parents identified biallelic mutations in Unc-45 Myosin Chaperone A (UNC45A) as a likely driver for this disorder.
Impaired Hearing	Disease	(89, 105)	Loss-of-Function	NegReg	(0, 16)	NoRelation	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Cholestasis	Disease	(66, 77)	Loss-of-Function	NegReg	(0, 16)	NoRelation	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Bone Fragility	Disease	(111, 125)	Loss-of-Function	NegReg	(0, 16)	NoRelation	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
Diarrhea	Disease	(79, 87)	Loss-of-Function	NegReg	(0, 16)	NoRelation	Loss-of-Function Mutations in UNC45A Cause a Syndrome Associating Cholestasis, Diarrhea, Impaired Hearing, and Bone Fragility.
gut development	CPA	(199, 214)	abolished	NegReg	(144, 153)	NoRelation	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
activity	MPA	(162, 170)	loss-of-function	NegReg	(85, 101)	NoRelation	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
activity	MPA	(162, 170)	defects	NegReg	(188, 195)	NoRelation	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
gut development	CPA	(199, 214)	attenuated	NegReg	(130, 140)	NoRelation	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
gut development	CPA	(199, 214)	loss-of-function	NegReg	(85, 101)	NoRelation	Subsequent invitro and invivo functional studies of the candidate gene indicated a loss-of-function paradigm, wherein mutations attenuated or abolished protein activity with concomitant defects in gut development and function.
AI domain mutations	Var	(1287, 1306)	increased	PosReg	(1339, 1348)	CauseOf	Using a yeast model system, we showed that the catalytic and AI domain mutations visibly result in decreased and increased calcineurin signaling, respectively.
calcineurin signaling	MPA	(1349, 1370)	increased	PosReg	(1339, 1348)	ThemeOf	Using a yeast model system, we showed that the catalytic and AI domain mutations visibly result in decreased and increased calcineurin signaling, respectively.
catalytic domain mutations	Var	(746, 772)	found	Reg	(815, 820)	CauseOf	First, the catalytic domain mutations and frameshift mutation were consistently found in patients with nonsyndromic early onset epileptic encephalopathy.
frameshift mutation	Var	(777, 796)	found	Reg	(815, 820)	CauseOf	First, the catalytic domain mutations and frameshift mutation were consistently found in patients with nonsyndromic early onset epileptic encephalopathy.
nonsyndromic early onset epileptic encephalopathy	Disease	(838, 887)	found	Reg	(815, 820)	ThemeOf	First, the catalytic domain mutations and frameshift mutation were consistently found in patients with nonsyndromic early onset epileptic encephalopathy.
AI domain mutations	Var	(906, 925)	associated	Reg	(931, 941)	CauseOf	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
multiple congenital abnormalities	Disease	(947, 980)	associated	Reg	(931, 941)	ThemeOf	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
craniofacial dysmorphism	Disease	(991, 1015)	multiple congenital abnormalities	Disease	(947, 980)	ThemeOf	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
arthrogryposis	Disease	(1017, 1031)	multiple congenital abnormalities	Disease	(947, 980)	ThemeOf	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
short stature	Disease	(1036, 1049)	multiple congenital abnormalities	Disease	(947, 980)	ThemeOf	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
short stature	Disease	(147, 160)	associated	Reg	(42, 52)	NoRelation	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
craniofacial dysmorphism	Disease	(102, 126)	associated	Reg	(42, 52)	NoRelation	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
arthrogryposis	Disease	(128, 142)	associated	Reg	(42, 52)	NoRelation	In contrast, the AI domain mutations were associated with multiple congenital abnormalities including craniofacial dysmorphism, arthrogryposis and short stature.
Caenorhabditis elegans peroxidasin PXN-2	Enzyme	(408, 448)	Loss of function	NegReg	(384, 400)	ThemeOf	Loss of function in the Caenorhabditis elegans peroxidasin PXN-2 results in fully penetrant embryonic or larval lethality.
Loss of function	NegReg	(384, 400)	fully penetrant embryonic	CPA	(460, 485)	CauseOf	Loss of function in the Caenorhabditis elegans peroxidasin PXN-2 results in fully penetrant embryonic or larval lethality.
Loss of function	NegReg	(384, 400)	larval lethality	CPA	(489, 505)	CauseOf	Loss of function in the Caenorhabditis elegans peroxidasin PXN-2 results in fully penetrant embryonic or larval lethality.
let-805	Gene	(951, 958)	missense alterations	Var	(984, 1004)	ThemeOf	We identify multiple alleles of let-805, encoding the transmembrane protein myotactin, which suppress phenotypes of pxn-2 null mutants and of other basement membrane mutants such as F-spondin/spon-1 These let-805 suppressor alleles cause missense alterations in two pairs of FNIII repeats in the extracellular domain; they act dominantly and have no detectable phenotypes alone, suggesting they cause gain of function.
missense alterations	Var	(984, 1004)	gain of function	PosReg	(1147, 1163)	CauseOf	We identify multiple alleles of let-805, encoding the transmembrane protein myotactin, which suppress phenotypes of pxn-2 null mutants and of other basement membrane mutants such as F-spondin/spon-1 These let-805 suppressor alleles cause missense alterations in two pairs of FNIII repeats in the extracellular domain; they act dominantly and have no detectable phenotypes alone, suggesting they cause gain of function.
GTPBP2	Gene	(39, 45)	Biallelic inactivating variants	Var	(0, 31)	ThemeOf	Biallelic inactivating variants in the GTPBP2 gene cause a neurodevelopmental disorder with severe intellectual disability.
agenesis of the corpus callosum	CPA	(903, 934)	structural brain abnormalities	CPA	(865, 895)	ThemeOf	Notable differences include structural brain abnormalities (e.g., agenesis of the corpus callosum, exclusive to our patients), and evidence for brain iron accumulation (exclusive to the previously described family).
brain iron accumulation	CPA	(981, 1004)	structural brain abnormalities	CPA	(865, 895)	ThemeOf	Notable differences include structural brain abnormalities (e.g., agenesis of the corpus callosum, exclusive to our patients), and evidence for brain iron accumulation (exclusive to the previously described family).
neurodevelopmental disorder	Disease	(59, 86)	cause	Reg	(51, 56)	ThemeOf	Biallelic inactivating variants in the GTPBP2 gene cause a neurodevelopmental disorder with severe intellectual disability.
Biallelic inactivating variants	Var	(0, 31)	cause	Reg	(51, 56)	CauseOf	Biallelic inactivating variants in the GTPBP2 gene cause a neurodevelopmental disorder with severe intellectual disability.
GTPBP2	Gene	(600, 606)	c.1408[C>T];[C>T] p.(Arg470*)	Var	(567, 596)	ThemeOf	We present three unrelated families in which whole-exome sequencing identified the homozygous non-sense variants c.430[C>T];[C>T] p.(Arg144*), c.1219[C>T];[C>T] p.(Gln407*) and c.1408[C>T];[C>T] p.(Arg470*) in GTPBP2.
GTPBP2	Gene	(600, 606)	c.1219[C>T];[C>T] p.(Gln407*)	Var	(533, 562)	ThemeOf	We present three unrelated families in which whole-exome sequencing identified the homozygous non-sense variants c.430[C>T];[C>T] p.(Arg144*), c.1219[C>T];[C>T] p.(Gln407*) and c.1408[C>T];[C>T] p.(Arg470*) in GTPBP2.
GTPBP2	Gene	(600, 606)	c.430[C>T];[C>T] p.(Arg144*)	Var	(503, 531)	ThemeOf	We present three unrelated families in which whole-exome sequencing identified the homozygous non-sense variants c.430[C>T];[C>T] p.(Arg144*), c.1219[C>T];[C>T] p.(Gln407*) and c.1408[C>T];[C>T] p.(Arg470*) in GTPBP2.
COCH	Gene	(40, 44)	Bi-allelic inactivating variants	Var	(0, 32)	ThemeOf	Bi-allelic inactivating variants in the COCH gene cause autosomal recessive prelingual hearing impairment.
Bi-allelic inactivating variants	Var	(0, 32)	cause	Reg	(50, 55)	CauseOf	Bi-allelic inactivating variants in the COCH gene cause autosomal recessive prelingual hearing impairment.
autosomal recessive prelingual hearing impairment	Disease	(56, 105)	cause	Reg	(50, 55)	ThemeOf	Bi-allelic inactivating variants in the COCH gene cause autosomal recessive prelingual hearing impairment.
COCH	Gene	(514, 518)	c.292C>T(p.Arg98*)	Var	(495, 513)	ThemeOf	Here, we describe two brothers with congenital prelingual deafness and a homozygous nonsense c.292C>T(p.Arg98*) COCH variant, suggesting a loss-of-function effect.
c.292C>T(p.Arg98*)	Var	(495, 513)	loss-of-function	NegReg	(541, 557)	CauseOf	Here, we describe two brothers with congenital prelingual deafness and a homozygous nonsense c.292C>T(p.Arg98*) COCH variant, suggesting a loss-of-function effect.
RecQ-family DNA helicase	Protein	(229, 253)	mutations	Var	(214, 223)	ThemeOf	Werner syndrome (WS) is a premature aging disorder caused by mutations in a RecQ-family DNA helicase (WRN).
mutations	Var	(214, 223)	caused by	Reg	(204, 213)	CauseOf	Werner syndrome (WS) is a premature aging disorder caused by mutations in a RecQ-family DNA helicase (WRN).
Werner syndrome	Disease	(153, 168)	caused by	Reg	(204, 213)	ThemeOf	Werner syndrome (WS) is a premature aging disorder caused by mutations in a RecQ-family DNA helicase (WRN).
CgPDR1	Gene	(0, 6)	mutations	Var	(24, 33)	ThemeOf	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
drug resistance	MPA	(1500, 1515)	conferred	Reg	(1490, 1499)	ThemeOf	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
mutations	Var	(1470, 1479)	increased	PosReg	(1520, 1529)	CauseOf	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
adherence	MPA	(1530, 1539)	increased	PosReg	(1520, 1529)	ThemeOf	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
mutations	Var	(911, 920)	elevated	PosReg	(876, 884)	CauseOf	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
CDR1, CDR2 and SNQ2 efflux pump gene expression levels	MPA	(816, 870)	elevated	PosReg	(876, 884)	ThemeOf	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
CgPDR1	Gene	(924, 930)	mutations	Var	(911, 920)	ThemeOf	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
mutations	Var	(911, 920)	GOF	PosReg	(907, 910)	CauseOf	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
mutations	Var	(911, 920)	decreased	NegReg	(945, 954)	CauseOf	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
azole susceptibility	MPA	(955, 975)	decreased	NegReg	(945, 954)	ThemeOf	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
CgPDR1	Gene	(1088, 1094)	mutations	Var	(1098, 1107)	ThemeOf	CgPDR1GOF mutations led to increased efflux pumps expression levels in a strain background independent way.
mutations	Var	(24, 33)	gain-of-function	PosReg	(7, 23)	CauseOf	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
mutations	Var	(1098, 1107)	GOF	PosReg	(1094, 1097)	CauseOf	CgPDR1GOF mutations led to increased efflux pumps expression levels in a strain background independent way.
mutations	Var	(1098, 1107)	increased	PosReg	(1115, 1124)	CauseOf	CgPDR1GOF mutations led to increased efflux pumps expression levels in a strain background independent way.
efflux pumps expression levels	MPA	(1125, 1155)	increased	PosReg	(1115, 1124)	ThemeOf	CgPDR1GOF mutations led to increased efflux pumps expression levels in a strain background independent way.
mutations	Var	(24, 33)	lead to	Reg	(34, 41)	CauseOf	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
azole-resistance	MPA	(42, 58)	lead to	Reg	(34, 41)	ThemeOf	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
mutations	Var	(24, 33)	increased	PosReg	(63, 72)	CauseOf	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
adhesion	MPA	(73, 81)	increased	PosReg	(63, 72)	ThemeOf	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
mutations	Var	(1470, 1479)	GOF	PosReg	(1466, 1469)	CauseOf	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
CgPDR1	Gene	(1483, 1489)	mutations	Var	(1470, 1479)	ThemeOf	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
mutations	Var	(1470, 1479)	conferred	Reg	(1490, 1499)	CauseOf	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
azole-resistance	MPA	(42, 58)	increased	PosReg	(63, 72)	NoRelation	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
adhesion	MPA	(73, 81)	gain-of-function	PosReg	(7, 23)	NoRelation	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
adhesion	MPA	(73, 81)	lead to	Reg	(34, 41)	NoRelation	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
azole-resistance	MPA	(42, 58)	gain-of-function	PosReg	(7, 23)	NoRelation	CgPDR1 gain-of-function mutations lead to azole-resistance and increased adhesion in clinical Candida glabrata strains.
CDR1, CDR2 and SNQ2 efflux pump gene expression levels	MPA	(0, 54)	decreased	NegReg	(129, 138)	NoRelation	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
CDR1, CDR2 and SNQ2 efflux pump gene expression levels	MPA	(0, 54)	GOF	PosReg	(91, 94)	NoRelation	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
azole susceptibility	MPA	(139, 159)	elevated	PosReg	(60, 68)	NoRelation	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
azole susceptibility	MPA	(139, 159)	GOF	PosReg	(91, 94)	NoRelation	CDR1, CDR2 and SNQ2 efflux pump gene expression levels were elevated in strains harbouring GOF mutations in CgPDR1, resulting in decreased azole susceptibility.
efflux pumps expression levels	MPA	(37, 67)	GOF	PosReg	(6, 9)	NoRelation	CgPDR1GOF mutations led to increased efflux pumps expression levels in a strain background independent way.
drug resistance	MPA	(34, 49)	GOF	PosReg	(0, 3)	NoRelation	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
adherence	MPA	(64, 73)	GOF	PosReg	(0, 3)	NoRelation	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
drug resistance	MPA	(34, 49)	increased	PosReg	(54, 63)	NoRelation	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
adherence	MPA	(64, 73)	conferred	Reg	(24, 33)	NoRelation	GOF mutations in CgPDR1 conferred drug resistance and increased adherence in the clinical strains, possibly endowing C.glabrata with increased viability and pathogenicity.
mutations	Var	(1435, 1444)	loss-of-function	NegReg	(1418, 1434)	CauseOf	We demonstrate a highly significant association between the NR2F2 loss-of-function mutations and this syndromic form of DSD (p = 2.44 10-8).
syndromic form of DSD	Disease	(1454, 1475)	loss-of-function	NegReg	(1418, 1434)	ThemeOf	We demonstrate a highly significant association between the NR2F2 loss-of-function mutations and this syndromic form of DSD (p = 2.44 10-8).
congenital heart disease	Disease	(1040, 1064)	presented with	Reg	(1025, 1039)	ThemeOf	All three children presented with congenital heart disease (CHD), one child with congenital diaphragmatic hernia (CDH), and two children with blepharophimosis-ptosis-epicanthus inversus syndrome (BPES).
NR2F2	Gene	(1412, 1417)	mutations	Var	(1435, 1444)	ThemeOf	We demonstrate a highly significant association between the NR2F2 loss-of-function mutations and this syndromic form of DSD (p = 2.44 10-8).
ATP5F1D	Gene	(23, 30)	Biallelic Mutations	Var	(0, 19)	ThemeOf	Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder.
Mendelian mitochondrial disease	Disease	(1513, 1544)	leading to	Reg	(1500, 1510)	ThemeOf	Ourdata establish c.245C>T (p.Pro82Leu) and c.317T>G (p.Val106Gly) in ATP5F1D as pathogenic variants leading to a Mendelian mitochondrial disease featuring episodic metabolic decompensation.
missense variants	Var	(374, 391)	presented	Reg	(408, 417)	CauseOf	Here, we describe two individuals, each with homozygous missense variants in ATP5F1D, who presented with episodic lethargy, metabolic acidosis, 3-methylglutaconic aciduria, and hyperammonemia.
episodic lethargy	MPA	(423, 440)	presented	Reg	(408, 417)	ThemeOf	Here, we describe two individuals, each with homozygous missense variants in ATP5F1D, who presented with episodic lethargy, metabolic acidosis, 3-methylglutaconic aciduria, and hyperammonemia.
metabolic acidosis	MPA	(442, 460)	presented	Reg	(408, 417)	ThemeOf	Here, we describe two individuals, each with homozygous missense variants in ATP5F1D, who presented with episodic lethargy, metabolic acidosis, 3-methylglutaconic aciduria, and hyperammonemia.
3-methylglutaconic aciduria	MPA	(462, 489)	presented	Reg	(408, 417)	ThemeOf	Here, we describe two individuals, each with homozygous missense variants in ATP5F1D, who presented with episodic lethargy, metabolic acidosis, 3-methylglutaconic aciduria, and hyperammonemia.
hyperammonemia	Disease	(495, 509)	presented	Reg	(408, 417)	ThemeOf	Here, we describe two individuals, each with homozygous missense variants in ATP5F1D, who presented with episodic lethargy, metabolic acidosis, 3-methylglutaconic aciduria, and hyperammonemia.
ATP5F1D	Gene	(395, 402)	missense variants	Var	(374, 391)	ThemeOf	Here, we describe two individuals, each with homozygous missense variants in ATP5F1D, who presented with episodic lethargy, metabolic acidosis, 3-methylglutaconic aciduria, and hyperammonemia.
Biallelic Mutations	Var	(0, 19)	Cause	Reg	(73, 78)	CauseOf	Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder.
Metabolic Disorder	MPA	(81, 99)	Cause	Reg	(73, 78)	ThemeOf	Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder.
variants	Var	(1226, 1234)	rescued	PosReg	(1235, 1242)	CauseOf	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
head-size phenotype	MPA	(1247, 1266)	rescued	PosReg	(1235, 1242)	ThemeOf	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
variants	Var	(1226, 1234)	recapitulated	NegReg	(1271, 1284)	CauseOf	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
eye	MPA	(1289, 1292)	recapitulated	NegReg	(1271, 1284)	ThemeOf	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
antennae defects	MPA	(1297, 1313)	recapitulated	NegReg	(1271, 1284)	ThemeOf	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
variants	Var	(1491, 1499)	leading to	Reg	(1500, 1510)	CauseOf	Ourdata establish c.245C>T (p.Pro82Leu) and c.317T>G (p.Val106Gly) in ATP5F1D as pathogenic variants leading to a Mendelian mitochondrial disease featuring episodic metabolic decompensation.
eye	MPA	(124, 127)	rescued	PosReg	(70, 77)	NoRelation	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
antennae defects	MPA	(132, 148)	rescued	PosReg	(70, 77)	NoRelation	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
head-size phenotype	MPA	(82, 101)	recapitulated	NegReg	(106, 119)	NoRelation	In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
Nav1.5	Gene	(118, 124)	G213D	Var	(152, 157)	ThemeOf	Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a Nav1.5 gain-of-function mutation (G213D).
G213D	Var	(152, 157)	gain-of-function	PosReg	(125, 141)	CauseOf	Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a Nav1.5 gain-of-function mutation (G213D).
G213D	Var	(847, 852)	resulting in	Reg	(781, 793)	ThemeOf	Screening of the SCN5A gene revealed a missense mutation in the linker between segments 3 and 4 in domain 1 of the Nav1.5 protein, resulting in a glycine to aspartate substitution at position 213 (G213D).
Nav1.5	Gene	(1605, 1611)	G213D	Var	(1612, 1617)	ThemeOf	CONCLUSION: The Nav1.5_G213D mutation is associated with a gain-of-function phenotype, multifocal atrial and ventricular ectopy and dilated cardiomyopathy.
G213D	Var	(1612, 1617)	gain-of-function	PosReg	(1648, 1664)	CauseOf	CONCLUSION: The Nav1.5_G213D mutation is associated with a gain-of-function phenotype, multifocal atrial and ventricular ectopy and dilated cardiomyopathy.
dilated cardiomyopathy	Disease	(1721, 1743)	gain-of-function	PosReg	(1648, 1664)	ThemeOf	CONCLUSION: The Nav1.5_G213D mutation is associated with a gain-of-function phenotype, multifocal atrial and ventricular ectopy and dilated cardiomyopathy.
dilated cardiomyopathy	Disease	(83, 105)	gain-of-function	PosReg	(125, 141)	ThemeOf	Multifocal atrial and ventricular premature contractions with an increased risk of dilated cardiomyopathy caused by a Nav1.5 gain-of-function mutation (G213D).
mutations	Var	(178, 187)	lead to	Reg	(192, 199)	CauseOf	BACKGROUND: SCN5A mutations can lead to different cardiac diseases.
cardiac diseases	Disease	(210, 226)	lead to	Reg	(192, 199)	ThemeOf	BACKGROUND: SCN5A mutations can lead to different cardiac diseases.
SCN5A	Gene	(667, 672)	missense mutation	Var	(689, 706)	ThemeOf	Screening of the SCN5A gene revealed a missense mutation in the linker between segments 3 and 4 in domain 1 of the Nav1.5 protein, resulting in a glycine to aspartate substitution at position 213 (G213D).
missense mutation	Var	(689, 706)	resulting in	Reg	(781, 793)	CauseOf	Screening of the SCN5A gene revealed a missense mutation in the linker between segments 3 and 4 in domain 1 of the Nav1.5 protein, resulting in a glycine to aspartate substitution at position 213 (G213D).
ego-3	Gene	(282, 287)	om40	Var	(288, 292)	ThemeOf	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
om40	Var	(288, 292)	causes	Reg	(294, 300)	CauseOf	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
defects	MPA	(309, 316)	causes	Reg	(294, 300)	ThemeOf	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
paralysis	Disease	(357, 366)	defects	MPA	(309, 316)	ThemeOf	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
sterility	Disease	(394, 403)	defects	MPA	(309, 316)	ThemeOf	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
delayed proliferation	CPA	(405, 426)	defects	MPA	(309, 316)	ThemeOf	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
ectopic germline stem cell proliferation	CPA	(455, 495)	defects	MPA	(309, 316)	ThemeOf	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
ectopic germline stem cell proliferation	CPA	(173, 213)	causes	Reg	(12, 18)	NoRelation	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
delayed proliferation	CPA	(123, 144)	causes	Reg	(12, 18)	NoRelation	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
sterility	Disease	(112, 121)	causes	Reg	(12, 18)	NoRelation	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
paralysis	Disease	(75, 84)	causes	Reg	(12, 18)	NoRelation	ego-3(om40) causes several defects in the soma and the germline, including paralysis during larval development, sterility, delayed proliferation of germline stem cells, and ectopic germline stem cell proliferation.
Platelet activity	MPA	(1690, 1707)	associated	Interaction	(1721, 1731)	ThemeOf	Platelet activity was strongly associated with allele *2 status (rs = 0.21, P = 0.016) but not with other genetic polymorphisms.
allele *2 status	Var	(1737, 1753)	associated	Interaction	(1721, 1731)	CauseOf	Platelet activity was strongly associated with allele *2 status (rs = 0.21, P = 0.016) but not with other genetic polymorphisms.
allele	Var	(1441, 1447)	loss-of-function	NegReg	(1424, 1440)	CauseOf	The risk of major adverse clinical events was nearly 3-fold in loss-of-function allele carriers (hazard ratio = 2.904; 95% confidence interval, 1.083-7.786; P = 0.013), whereas the risk of ischemic stroke or transient ischemic attack alone was also higher (hazard ratio = 3.170; 95% confidence interval, 1.281-7.849; P = 0.034).
allele	Var	(1441, 1447)	major adverse clinical events	MPA	(1373, 1402)	CauseOf	The risk of major adverse clinical events was nearly 3-fold in loss-of-function allele carriers (hazard ratio = 2.904; 95% confidence interval, 1.083-7.786; P = 0.013), whereas the risk of ischemic stroke or transient ischemic attack alone was also higher (hazard ratio = 3.170; 95% confidence interval, 1.281-7.849; P = 0.034).
allele	Var	(1441, 1447)	ischemic stroke	MPA	(1550, 1565)	CauseOf	The risk of major adverse clinical events was nearly 3-fold in loss-of-function allele carriers (hazard ratio = 2.904; 95% confidence interval, 1.083-7.786; P = 0.013), whereas the risk of ischemic stroke or transient ischemic attack alone was also higher (hazard ratio = 3.170; 95% confidence interval, 1.281-7.849; P = 0.034).
allele	Var	(1441, 1447)	transient ischemic attack alone	MPA	(1569, 1600)	CauseOf	The risk of major adverse clinical events was nearly 3-fold in loss-of-function allele carriers (hazard ratio = 2.904; 95% confidence interval, 1.083-7.786; P = 0.013), whereas the risk of ischemic stroke or transient ischemic attack alone was also higher (hazard ratio = 3.170; 95% confidence interval, 1.281-7.849; P = 0.034).
ischemic stroke	MPA	(189, 204)	loss-of-function	NegReg	(63, 79)	NoRelation	The risk of major adverse clinical events was nearly 3-fold in loss-of-function allele carriers (hazard ratio = 2.904; 95% confidence interval, 1.083-7.786; P = 0.013), whereas the risk of ischemic stroke or transient ischemic attack alone was also higher (hazard ratio = 3.170; 95% confidence interval, 1.281-7.849; P = 0.034).
major adverse clinical events	MPA	(12, 41)	loss-of-function	NegReg	(63, 79)	NoRelation	The risk of major adverse clinical events was nearly 3-fold in loss-of-function allele carriers (hazard ratio = 2.904; 95% confidence interval, 1.083-7.786; P = 0.013), whereas the risk of ischemic stroke or transient ischemic attack alone was also higher (hazard ratio = 3.170; 95% confidence interval, 1.281-7.849; P = 0.034).
transient ischemic attack alone	MPA	(208, 239)	loss-of-function	NegReg	(63, 79)	NoRelation	The risk of major adverse clinical events was nearly 3-fold in loss-of-function allele carriers (hazard ratio = 2.904; 95% confidence interval, 1.083-7.786; P = 0.013), whereas the risk of ischemic stroke or transient ischemic attack alone was also higher (hazard ratio = 3.170; 95% confidence interval, 1.281-7.849; P = 0.034).
fama	Gene	(1074, 1078)	mutants	Var	(1096, 1103)	ThemeOf	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
mutants	Var	(1096, 1103)	loss-of-function	NegReg	(1079, 1095)	CauseOf	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
mutants	Var	(1096, 1103)	increased	PosReg	(1124, 1133)	CauseOf	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
susceptibility to B. cinerea infection	MPA	(1134, 1172)	increased	PosReg	(1124, 1133)	ThemeOf	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
mutants	Var	(1096, 1103)	reduced	NegReg	(1177, 1184)	CauseOf	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
defense-gene expression	MPA	(1185, 1208)	reduced	NegReg	(1177, 1184)	ThemeOf	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
susceptibility to B. cinerea infection	MPA	(64, 102)	reduced	NegReg	(107, 114)	NoRelation	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
defense-gene expression	MPA	(115, 138)	loss-of-function	NegReg	(9, 25)	NoRelation	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
defense-gene expression	MPA	(115, 138)	increased	PosReg	(54, 63)	NoRelation	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
susceptibility to B. cinerea infection	MPA	(64, 102)	loss-of-function	NegReg	(9, 25)	NoRelation	The fama loss-of-function mutants (fama-1 and fama-2) increased susceptibility to B. cinerea infection and reduced defense-gene expression.
mutations	Var	(147, 156)	caused	Reg	(137, 143)	CauseOf	Familial erythrocytosis with elevated erythropoietin levels is frequently caused by mutations in genes that regulate oxygen-dependent transcription of the gene encoding erythropoietin ( EPO).
Familial erythrocytosis	Disease	(63, 86)	caused	Reg	(137, 143)	ThemeOf	Familial erythrocytosis with elevated erythropoietin levels is frequently caused by mutations in genes that regulate oxygen-dependent transcription of the gene encoding erythropoietin ( EPO).
EPO	Gene	(249, 252)	mutations	Var	(147, 156)	ThemeOf	Familial erythrocytosis with elevated erythropoietin levels is frequently caused by mutations in genes that regulate oxygen-dependent transcription of the gene encoding erythropoietin ( EPO).
mutation	Var	(423, 431)	interrupts	NegReg	(513, 523)	CauseOf	This mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2 that interrupts translation of the main EPO messenger RNA (mRNA) transcript but initiates excess production of erythropoietin from what is normally a noncoding EPO mRNA transcribed from an alternative promoter located in intron 1.
main EPO messenger RNA (mRNA) transcript	MPA	(543, 583)	interrupts	NegReg	(513, 523)	ThemeOf	This mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2 that interrupts translation of the main EPO messenger RNA (mRNA) transcript but initiates excess production of erythropoietin from what is normally a noncoding EPO mRNA transcribed from an alternative promoter located in intron 1.
Fgfr2	Gene	(16, 21)	Inactivation	Var	(0, 12)	ThemeOf	Inactivation of Fgfr2 gene in mouse secondary palate mesenchymal cells leads to cleft palate.
Inactivation	Var	(0, 12)	leads to	Reg	(71, 79)	CauseOf	Inactivation of Fgfr2 gene in mouse secondary palate mesenchymal cells leads to cleft palate.
cleft palate	Disease	(80, 92)	leads to	Reg	(71, 79)	ThemeOf	Inactivation of Fgfr2 gene in mouse secondary palate mesenchymal cells leads to cleft palate.
inactivation	Var	(669, 681)	leads to	Reg	(762, 770)	CauseOf	Fgfr2 continues to express in palate on E12.5 and E13.5 in both epithelial and mesenchymal cells, and inactivation of Fgfr2 expression in mesenchymal cells using floxed Fgfr2 allele and Osr2-Cre leads to cleft palate at various stages including reorientation, horizontal growth and fusion.
cleft palate	Disease	(771, 783)	leads to	Reg	(762, 770)	ThemeOf	Fgfr2 continues to express in palate on E12.5 and E13.5 in both epithelial and mesenchymal cells, and inactivation of Fgfr2 expression in mesenchymal cells using floxed Fgfr2 allele and Osr2-Cre leads to cleft palate at various stages including reorientation, horizontal growth and fusion.
Fgfr2	Gene	(685, 690)	inactivation	Var	(669, 681)	ThemeOf	Fgfr2 continues to express in palate on E12.5 and E13.5 in both epithelial and mesenchymal cells, and inactivation of Fgfr2 expression in mesenchymal cells using floxed Fgfr2 allele and Osr2-Cre leads to cleft palate at various stages including reorientation, horizontal growth and fusion.
mib-1	Gene	(1464, 1469)	mutants	Var	(1470, 1477)	ThemeOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
oocyte production	MPA	(1644, 1661)	restoring	PosReg	(1554, 1563)	ThemeOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
mib-1	Gene	(639, 644)	mutants	Var	(650, 657)	ThemeOf	Here, we show that C. elegans mib-1 null mutants have a spermatogenesis-defective phenotype that results in a heterogeneous mixture of arrested spermatocytes, defective spermatids, and motility-impaired spermatozoa.
mutants	Var	(650, 657)	results in	Reg	(706, 716)	CauseOf	Here, we show that C. elegans mib-1 null mutants have a spermatogenesis-defective phenotype that results in a heterogeneous mixture of arrested spermatocytes, defective spermatids, and motility-impaired spermatozoa.
heterogeneous mixture of arrested spermatocytes	MPA	(719, 766)	results in	Reg	(706, 716)	ThemeOf	Here, we show that C. elegans mib-1 null mutants have a spermatogenesis-defective phenotype that results in a heterogeneous mixture of arrested spermatocytes, defective spermatids, and motility-impaired spermatozoa.
heterogeneous mixture of arrested spermatocytes	MPA	(719, 766)	spermatogenesis-defective phenotype	Disease	(665, 700)	CauseOf	Here, we show that C. elegans mib-1 null mutants have a spermatogenesis-defective phenotype that results in a heterogeneous mixture of arrested spermatocytes, defective spermatids, and motility-impaired spermatozoa.
mutants	Var	(1470, 1477)	suppress	NegReg	(1478, 1486)	CauseOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
lin-12	Gene	(1492, 1498)	mutants	Var	(1545, 1552)	ThemeOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
glp-1	Gene	(1503, 1508)	mutants	Var	(1545, 1552)	ThemeOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
mutants	Var	(1545, 1552)	gain-of-function	PosReg	(1528, 1544)	CauseOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
mutants	Var	(1545, 1552)	suppress	NegReg	(1478, 1486)	ThemeOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
mutants	Var	(1470, 1477)	restoring	PosReg	(1554, 1563)	CauseOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
anchor cell formation	MPA	(1564, 1585)	restoring	PosReg	(1554, 1563)	ThemeOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
functional vulva	MPA	(1592, 1608)	restoring	PosReg	(1554, 1563)	ThemeOf	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
spermatogenesis-defective phenotype	Disease	(56, 91)	results in	Reg	(97, 107)	NoRelation	Here, we show that C. elegans mib-1 null mutants have a spermatogenesis-defective phenotype that results in a heterogeneous mixture of arrested spermatocytes, defective spermatids, and motility-impaired spermatozoa.
functional vulva	MPA	(147, 163)	suppress	NegReg	(33, 41)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
functional vulva	MPA	(147, 163)	gain-of-function	PosReg	(83, 99)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
mutants	Var	(25, 32)	gain-of-function	PosReg	(83, 99)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
anchor cell formation	MPA	(119, 140)	gain-of-function	PosReg	(83, 99)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
anchor cell formation	MPA	(119, 140)	suppress	NegReg	(33, 41)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
oocyte production	MPA	(199, 216)	suppress	NegReg	(33, 41)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
mutants	Var	(100, 107)	restoring	PosReg	(109, 118)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
oocyte production	MPA	(199, 216)	gain-of-function	PosReg	(83, 99)	NoRelation	Here, we show that mib-1 mutants suppress both lin-12 and glp-1 (C. elegans Notch) gain-of-function mutants, restoring anchor cell formation and a functional vulva to the former and partly restoring oocyte production to the latter.
Mutations	Var	(67, 76)	activating	PosReg	(77, 87)	CauseOf	BACKGROUND: Mutations activating the  subunit of heterotrimeric Gs protein are associated with a number of highly specific pathological molecular phenotypes.
Gs	Gene	(975, 978)	mutations	Var	(962, 971)	ThemeOf	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
mutations	Var	(962, 971)	interfere	NegReg	(979, 988)	CauseOf	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
microenvironment of permissive	MPA	(1009, 1039)	interfere	NegReg	(979, 988)	ThemeOf	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
mutations	Var	(962, 971)	lead to	Reg	(1052, 1059)	CauseOf	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
transversal neoplastic phenotype	MPA	(1062, 1094)	lead to	Reg	(1052, 1059)	ThemeOf	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
heterotrimeric Gs protein	Protein	(105, 130)	activating	PosReg	(77, 87)	ThemeOf	BACKGROUND: Mutations activating the  subunit of heterotrimeric Gs protein are associated with a number of highly specific pathological molecular phenotypes.
Gs	Gene	(648, 651)	mutations	Var	(652, 661)	ThemeOf	High frequency of activating Gs mutations is associated with precise diagnoses (e.g., IPMN, Pyloric gland adenoma, pituitary toxic adenoma).
mutations	Var	(652, 661)	activating	PosReg	(637, 647)	CauseOf	High frequency of activating Gs mutations is associated with precise diagnoses (e.g., IPMN, Pyloric gland adenoma, pituitary toxic adenoma).
IPMN	Disease	(706, 710)	activating	PosReg	(637, 647)	ThemeOf	High frequency of activating Gs mutations is associated with precise diagnoses (e.g., IPMN, Pyloric gland adenoma, pituitary toxic adenoma).
Pyloric gland adenoma	Disease	(712, 733)	activating	PosReg	(637, 647)	ThemeOf	High frequency of activating Gs mutations is associated with precise diagnoses (e.g., IPMN, Pyloric gland adenoma, pituitary toxic adenoma).
pituitary toxic adenoma	Disease	(735, 758)	activating	PosReg	(637, 647)	ThemeOf	High frequency of activating Gs mutations is associated with precise diagnoses (e.g., IPMN, Pyloric gland adenoma, pituitary toxic adenoma).
mutations	Var	(962, 971)	gain-of-function	PosReg	(945, 961)	CauseOf	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
transversal neoplastic phenotype	MPA	(167, 199)	gain-of-function	PosReg	(50, 66)	NoRelation	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
microenvironment of permissive	MPA	(114, 144)	gain-of-function	PosReg	(50, 66)	NoRelation	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
microenvironment of permissive	MPA	(114, 144)	lead to	Reg	(157, 164)	NoRelation	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
transversal neoplastic phenotype	MPA	(167, 199)	interfere	NegReg	(84, 93)	NoRelation	CONCLUSIONS: Here we propose the possibility that gain-of-function mutations of Gs interfere with signals in the microenvironment of permissive tissues and lead to a transversal neoplastic phenotype.
mutations	Var	(861, 870)	responsible	Reg	(923, 934)	CauseOf	Here, we report that the combination of loss-of-function mutations in Grain number 1a (Gn1a) and Grain Size 3 (GS3) is responsible for the heavy panicle phenotype of the elite hybrid rice restorer line Shuhui498 (R498).
heavy panicle phenotype	MPA	(943, 966)	responsible	Reg	(923, 934)	ThemeOf	Here, we report that the combination of loss-of-function mutations in Grain number 1a (Gn1a) and Grain Size 3 (GS3) is responsible for the heavy panicle phenotype of the elite hybrid rice restorer line Shuhui498 (R498).
GS3	Gene	(915, 918)	mutations	Var	(861, 870)	ThemeOf	Here, we report that the combination of loss-of-function mutations in Grain number 1a (Gn1a) and Grain Size 3 (GS3) is responsible for the heavy panicle phenotype of the elite hybrid rice restorer line Shuhui498 (R498).
Gn1a	Gene	(891, 895)	mutations	Var	(861, 870)	ThemeOf	Here, we report that the combination of loss-of-function mutations in Grain number 1a (Gn1a) and Grain Size 3 (GS3) is responsible for the heavy panicle phenotype of the elite hybrid rice restorer line Shuhui498 (R498).
mutations	Var	(861, 870)	loss-of-function	NegReg	(844, 860)	CauseOf	Here, we report that the combination of loss-of-function mutations in Grain number 1a (Gn1a) and Grain Size 3 (GS3) is responsible for the heavy panicle phenotype of the elite hybrid rice restorer line Shuhui498 (R498).
heavy panicle phenotype	MPA	(139, 162)	loss-of-function	NegReg	(40, 56)	NoRelation	Here, we report that the combination of loss-of-function mutations in Grain number 1a (Gn1a) and Grain Size 3 (GS3) is responsible for the heavy panicle phenotype of the elite hybrid rice restorer line Shuhui498 (R498).
Variants	Var	(457, 465)	association	Interaction	(551, 562)	CauseOf	Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples.
nonalcoholic cirrhosis	Disease	(1471, 1493)	reduced	NegReg	(1069, 1076)	ThemeOf	Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes).
variant	Var	(1664, 1671)	reduced	NegReg	(1694, 1701)	CauseOf	The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples.
nonalcoholic steatohepatitis	Disease	(1710, 1738)	reduced	NegReg	(1694, 1701)	ThemeOf	The rs72613567:TA variant was associated with a reduced risk of nonalcoholic steatohepatitis, but not steatosis, in human liver samples.
variant	Var	(1801, 1808)	mitigated	NegReg	(1809, 1818)	CauseOf	The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity.
liver injury	Disease	(1819, 1831)	mitigated	NegReg	(1809, 1818)	ThemeOf	The rs72613567:TA variant mitigated liver injury associated with the risk-increasing PNPLA3 p.I148M allele and resulted in an unstable and truncated protein with reduced enzymatic activity.
variant	Var	(2005, 2012)	loss-of-function	NegReg	(1988, 2004)	CauseOf	CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.
HSD17B13	Gene	(2016, 2024)	variant	Var	(2005, 2012)	ThemeOf	CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.
variant	Var	(2005, 2012)	reduced	NegReg	(2047, 2054)	CauseOf	CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.
chronic liver disease	Disease	(2063, 2084)	reduced	NegReg	(2047, 2054)	ThemeOf	CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.
AST	MPA	(979, 982)	reduced	NegReg	(939, 946)	ThemeOf	RESULTS: A splice variant (rs72613567:TA) in HSD17B13, encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13, was associated with reduced levels of ALT (P=4.210-12) and AST (P=6.210-10).
chronic liver disease	Disease	(590, 611)	association	Interaction	(551, 562)	ThemeOf	Variants that were replicated in three additional cohorts (12,527 persons) were evaluated for association with clinical diagnoses of chronic liver disease in DiscovEHR study participants and two independent cohorts (total of 37,173 persons) and with histopathological severity of liver disease in 2391 human liver samples.
splice variant	Var	(791, 805)	reduced	NegReg	(939, 946)	CauseOf	RESULTS: A splice variant (rs72613567:TA) in HSD17B13, encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13, was associated with reduced levels of ALT (P=4.210-12) and AST (P=6.210-10).
HSD17B13	Gene	(825, 833)	splice variant	Var	(791, 805)	ThemeOf	RESULTS: A splice variant (rs72613567:TA) in HSD17B13, encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13, was associated with reduced levels of ALT (P=4.210-12) and AST (P=6.210-10).
ALT	MPA	(957, 960)	reduced	NegReg	(939, 946)	ThemeOf	RESULTS: A splice variant (rs72613567:TA) in HSD17B13, encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13, was associated with reduced levels of ALT (P=4.210-12) and AST (P=6.210-10).
variant	Var	(1039, 1046)	reduced	NegReg	(1069, 1076)	CauseOf	Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes).
alcoholic liver disease	Disease	(1085, 1108)	reduced	NegReg	(1069, 1076)	ThemeOf	Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes).
nonalcoholic liver disease	Disease	(1227, 1253)	reduced	NegReg	(1069, 1076)	ThemeOf	Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes).
alcoholic cirrhosis	Disease	(1350, 1369)	reduced	NegReg	(1069, 1076)	ThemeOf	Among DiscovEHR study participants, this variant was associated with a reduced risk of alcoholic liver disease (by 42% [95% confidence interval {CI}, 20 to 58] among heterozygotes and by 53% [95% CI, 3 to 77] among homozygotes), nonalcoholic liver disease (by 17% [95% CI, 8 to 25] among heterozygotes and by 30% [95% CI, 13 to 43] among homozygotes), alcoholic cirrhosis (by 42% [95% CI, 14 to 61] among heterozygotes and by 73% [95% CI, 15 to 91] among homozygotes), and nonalcoholic cirrhosis (by 26% [95% CI, 7 to 40] among heterozygotes and by 49% [95% CI, 15 to 69] among homozygotes).
chronic liver disease	Disease	(90, 111)	loss-of-function	NegReg	(15, 31)	NoRelation	CONCLUSIONS: A loss-of-function variant in HSD17B13 was associated with a reduced risk of chronic liver disease and of progression from steatosis to steatohepatitis.
CSF3R	Gene	(366, 371)	mutations	Var	(349, 358)	ThemeOf	Recent studies have uncovered an oncogenic role of mutations in the CSF3R gene in many hematologic malignancies.
missense mutations	Var	(1599, 1617)	exhibit	PosReg	(1618, 1625)	CauseOf	Cumulatively, we have expanded the regions of the CSF3R extracellular and transmembrane domains in which missense mutations exhibit leukemogenic capacity and have further elucidated the mechanistic underpinnings that underlie altered CSF3R expression, dimerization, and signaling activation.
leukemogenic	Disease	(1626, 1638)	exhibit	PosReg	(1618, 1625)	ThemeOf	Cumulatively, we have expanded the regions of the CSF3R extracellular and transmembrane domains in which missense mutations exhibit leukemogenic capacity and have further elucidated the mechanistic underpinnings that underlie altered CSF3R expression, dimerization, and signaling activation.
mutations	Var	(349, 358)	hematologic malignancies	Disease	(385, 409)	CauseOf	Recent studies have uncovered an oncogenic role of mutations in the CSF3R gene in many hematologic malignancies.
mutations	Var	(809, 818)	transform	Reg	(844, 853)	CauseOf	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
cells	CPA	(854, 859)	transform	Reg	(844, 853)	ThemeOf	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
mutations	Var	(809, 818)	cysteine- and disulfide bond-mediated dimerization	MPA	(893, 943)	CauseOf	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
mutations	Var	(809, 818)	polar, noncharged amino acid substitution	Var	(956, 997)	CauseOf	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
mutations	Var	(809, 818)	increased	PosReg	(1064, 1073)	CauseOf	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
internalization	MPA	(1074, 1089)	increased	PosReg	(1064, 1073)	ThemeOf	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
mutations	Var	(809, 818)	hydrophobic amino acid substitutions	Var	(1153, 1189)	CauseOf	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
cysteine- and disulfide bond-mediated dimerization	MPA	(112, 162)	transform	Reg	(63, 72)	NoRelation	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
internalization	MPA	(293, 308)	transform	Reg	(63, 72)	NoRelation	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
polar, noncharged amino acid substitution	Var	(175, 216)	increased	PosReg	(283, 292)	NoRelation	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
cysteine- and disulfide bond-mediated dimerization	MPA	(112, 162)	increased	PosReg	(283, 292)	NoRelation	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
hydrophobic amino acid substitutions	Var	(372, 408)	increased	PosReg	(283, 292)	NoRelation	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
hydrophobic amino acid substitutions	Var	(372, 408)	transform	Reg	(63, 72)	NoRelation	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
polar, noncharged amino acid substitution	Var	(175, 216)	transform	Reg	(63, 72)	NoRelation	We identified several novel mutations and determined that they transform cells via four distinct mechanisms: 1) cysteine- and disulfide bond-mediated dimerization (S581C); 2) polar, noncharged amino acid substitution at the transmembrane helix dimer interface at residue Thr-640; 3) increased internalization by a Glu-524 substitution that mimics a low G-CSF dose; and 4) hydrophobic amino acid substitutions in the membrane-proximal residues Thr-612, Thr-615, and Thr-618.
WNT5A	Gene	(27, 32)	mutations	Var	(33, 42)	ThemeOf	Biallelic loss-of-function WNT5A mutations in an infant with severe and atypical manifestations of Robinow syndrome.
WNT5A	Gene	(613, 618)	homozygous frameshifting single nucleotide deletion	Var	(558, 609)	ThemeOf	Through trio whole genome sequencing, we identified a homozygous frameshifting single nucleotide deletion in WNT5A in a previously reported, deceased infant with a unique constellation of features comprising a 46,XY disorder of sex development with multiple congenital malformations including congenital diaphragmatic hernia, ambiguous genitalia, dysmorphic facies, shortened long bones, adactyly, and ventricular septal defect.
homozygous frameshifting single nucleotide deletion	Var	(558, 609)	congenital diaphragmatic hernia	Disease	(797, 828)	CauseOf	Through trio whole genome sequencing, we identified a homozygous frameshifting single nucleotide deletion in WNT5A in a previously reported, deceased infant with a unique constellation of features comprising a 46,XY disorder of sex development with multiple congenital malformations including congenital diaphragmatic hernia, ambiguous genitalia, dysmorphic facies, shortened long bones, adactyly, and ventricular septal defect.
homozygous frameshifting single nucleotide deletion	Var	(558, 609)	ambiguous genitalia	Disease	(830, 849)	CauseOf	Through trio whole genome sequencing, we identified a homozygous frameshifting single nucleotide deletion in WNT5A in a previously reported, deceased infant with a unique constellation of features comprising a 46,XY disorder of sex development with multiple congenital malformations including congenital diaphragmatic hernia, ambiguous genitalia, dysmorphic facies, shortened long bones, adactyly, and ventricular septal defect.
homozygous frameshifting single nucleotide deletion	Var	(558, 609)	ventricular septal defect	Disease	(906, 931)	CauseOf	Through trio whole genome sequencing, we identified a homozygous frameshifting single nucleotide deletion in WNT5A in a previously reported, deceased infant with a unique constellation of features comprising a 46,XY disorder of sex development with multiple congenital malformations including congenital diaphragmatic hernia, ambiguous genitalia, dysmorphic facies, shortened long bones, adactyly, and ventricular septal defect.
homozygous frameshifting single nucleotide deletion	Var	(558, 609)	adactyly	Disease	(892, 900)	CauseOf	Through trio whole genome sequencing, we identified a homozygous frameshifting single nucleotide deletion in WNT5A in a previously reported, deceased infant with a unique constellation of features comprising a 46,XY disorder of sex development with multiple congenital malformations including congenital diaphragmatic hernia, ambiguous genitalia, dysmorphic facies, shortened long bones, adactyly, and ventricular septal defect.
homozygous frameshifting single nucleotide deletion	Var	(558, 609)	shortened long bones	Disease	(870, 890)	CauseOf	Through trio whole genome sequencing, we identified a homozygous frameshifting single nucleotide deletion in WNT5A in a previously reported, deceased infant with a unique constellation of features comprising a 46,XY disorder of sex development with multiple congenital malformations including congenital diaphragmatic hernia, ambiguous genitalia, dysmorphic facies, shortened long bones, adactyly, and ventricular septal defect.
homozygous frameshifting single nucleotide deletion	Var	(558, 609)	dysmorphic facies	Disease	(851, 868)	CauseOf	Through trio whole genome sequencing, we identified a homozygous frameshifting single nucleotide deletion in WNT5A in a previously reported, deceased infant with a unique constellation of features comprising a 46,XY disorder of sex development with multiple congenital malformations including congenital diaphragmatic hernia, ambiguous genitalia, dysmorphic facies, shortened long bones, adactyly, and ventricular septal defect.
mutations	Var	(33, 42)	loss-of-function	NegReg	(10, 26)	CauseOf	Biallelic loss-of-function WNT5A mutations in an infant with severe and atypical manifestations of Robinow syndrome.
mutations	Var	(33, 42)	Robinow syndrome.	Disease	(99, 116)	CauseOf	Biallelic loss-of-function WNT5A mutations in an infant with severe and atypical manifestations of Robinow syndrome.
Robinow syndrome.	Disease	(99, 116)	loss-of-function	NegReg	(10, 26)	NoRelation	Biallelic loss-of-function WNT5A mutations in an infant with severe and atypical manifestations of Robinow syndrome.
SYNGAP1	Gene	(83, 90)	loss-of-function	NegReg	(91, 107)	CauseOf	SYNGAP1 loss-of-function variants are causally associated with intellectual disability, severe epilepsy, autism spectrum disorder and schizophrenia.
variants	Var	(108, 116)	loss-of-function	NegReg	(91, 107)	ThemeOf	SYNGAP1 loss-of-function variants are causally associated with intellectual disability, severe epilepsy, autism spectrum disorder and schizophrenia.
intellectual disability	Disease	(146, 169)	loss-of-function	NegReg	(91, 107)	ThemeOf	SYNGAP1 loss-of-function variants are causally associated with intellectual disability, severe epilepsy, autism spectrum disorder and schizophrenia.
severe epilepsy	Disease	(171, 186)	loss-of-function	NegReg	(91, 107)	ThemeOf	SYNGAP1 loss-of-function variants are causally associated with intellectual disability, severe epilepsy, autism spectrum disorder and schizophrenia.
autism spectrum disorder	Disease	(188, 212)	loss-of-function	NegReg	(91, 107)	ThemeOf	SYNGAP1 loss-of-function variants are causally associated with intellectual disability, severe epilepsy, autism spectrum disorder and schizophrenia.
schizophrenia	Disease	(217, 230)	loss-of-function	NegReg	(91, 107)	ThemeOf	SYNGAP1 loss-of-function variants are causally associated with intellectual disability, severe epilepsy, autism spectrum disorder and schizophrenia.
PCSK9	Var	(194, 199)	degrading	NegReg	(257, 266)	CauseOf	The proprotein convertase subtilisin/kexin type-9 (PCSK9) plays a central role in cardiovascular disease (CVD) by degrading hepatic low-density lipoprotein receptor (LDLR).
PCSK9	Gene	(772, 777)	variants	Var	(778, 786)	ThemeOf	Although overexpression of these PCSK9 variants caused an accumulation in the ER of hepatocytes, UPR activation or apoptosis was not observed.
variants	Var	(778, 786)	accumulation	PosReg	(797, 809)	CauseOf	Although overexpression of these PCSK9 variants caused an accumulation in the ER of hepatocytes, UPR activation or apoptosis was not observed.
ER of hepatocytes	MPA	(817, 834)	accumulation	PosReg	(797, 809)	ThemeOf	Although overexpression of these PCSK9 variants caused an accumulation in the ER of hepatocytes, UPR activation or apoptosis was not observed.
overexpression	PosReg	(748, 762)	variants	Var	(778, 786)	ThemeOf	Although overexpression of these PCSK9 variants caused an accumulation in the ER of hepatocytes, UPR activation or apoptosis was not observed.
hepatic low-density lipoprotein receptor	MPA	(267, 307)	degrading	NegReg	(257, 266)	ThemeOf	The proprotein convertase subtilisin/kexin type-9 (PCSK9) plays a central role in cardiovascular disease (CVD) by degrading hepatic low-density lipoprotein receptor (LDLR).
cardiovascular disease	Disease	(225, 247)	hepatic low-density lipoprotein receptor	MPA	(267, 307)	ThemeOf	The proprotein convertase subtilisin/kexin type-9 (PCSK9) plays a central role in cardiovascular disease (CVD) by degrading hepatic low-density lipoprotein receptor (LDLR).
PCSK9	Gene	(348, 353)	variants	Var	(354, 362)	ThemeOf	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
variants	Var	(354, 362)	loss-of-function	NegReg	(325, 341)	CauseOf	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
variants	Var	(354, 362)	increase	PosReg	(412, 420)	CauseOf	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
hepatic LDLR levels	MPA	(421, 440)	increase	PosReg	(412, 420)	ThemeOf	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
variants	Var	(354, 362)	lower	NegReg	(445, 450)	CauseOf	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
risk of developing CVD	MPA	(455, 477)	lower	NegReg	(445, 450)	ThemeOf	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
cardiovascular disease	Disease	(82, 104)	degrading	NegReg	(114, 123)	NoRelation	The proprotein convertase subtilisin/kexin type-9 (PCSK9) plays a central role in cardiovascular disease (CVD) by degrading hepatic low-density lipoprotein receptor (LDLR).
risk of developing CVD	MPA	(139, 161)	loss-of-function	NegReg	(9, 25)	NoRelation	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
risk of developing CVD	MPA	(139, 161)	increase	PosReg	(96, 104)	NoRelation	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
hepatic LDLR levels	MPA	(105, 124)	lower	NegReg	(129, 134)	NoRelation	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
hepatic LDLR levels	MPA	(105, 124)	loss-of-function	NegReg	(9, 25)	NoRelation	As such, loss-of-function (LOF) PCSK9 variants that fail to exit the endoplasmic reticulum (ER) increase hepatic LDLR levels and lower the risk of developing CVD.
ER of hepatocytes	MPA	(78, 95)	overexpression	PosReg	(9, 23)	NoRelation	Although overexpression of these PCSK9 variants caused an accumulation in the ER of hepatocytes, UPR activation or apoptosis was not observed.
CBL	Gene	(0, 3)	mutation	Var	(4, 12)	ThemeOf	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
mutation	Var	(1025, 1033)	prolonged	PosReg	(1034, 1043)	CauseOf	A loss-of-function CBL mutation prolonged STAT5 phosphorylation after GM-CSF stimulation, which was rapidly terminated in both patient samples and GDM-1 cells.
STAT5 phosphorylation	MPA	(1044, 1065)	prolonged	PosReg	(1034, 1043)	ThemeOf	A loss-of-function CBL mutation prolonged STAT5 phosphorylation after GM-CSF stimulation, which was rapidly terminated in both patient samples and GDM-1 cells.
MEFV	Gene	(17, 21)	single-nucleotide variant	Var	(22, 47)	ThemeOf	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
single-nucleotide variant	Var	(22, 47)	reduction	NegReg	(90, 99)	CauseOf	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
mutation	Var	(4, 12)	reduction	NegReg	(90, 99)	CauseOf	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
tumor	Disease	(84, 89)	reduction	NegReg	(90, 99)	ThemeOf	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
chronic myelomonocytic leukemia	Disease	(140, 171)	tumor	Disease	(84, 89)	ThemeOf	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
mutation	Var	(1025, 1033)	loss-of-function	NegReg	(1004, 1020)	CauseOf	A loss-of-function CBL mutation prolonged STAT5 phosphorylation after GM-CSF stimulation, which was rapidly terminated in both patient samples and GDM-1 cells.
CBL	Gene	(1021, 1024)	mutation	Var	(1025, 1033)	ThemeOf	A loss-of-function CBL mutation prolonged STAT5 phosphorylation after GM-CSF stimulation, which was rapidly terminated in both patient samples and GDM-1 cells.
chronic myelomonocytic leukemia	Disease	(140, 171)	reduction	NegReg	(90, 99)	NoRelation	CBL mutation and MEFV single-nucleotide variant are important genetic predictors of tumor reduction in glucocorticoid-treated patients with chronic myelomonocytic leukemia.
STAT5 phosphorylation	MPA	(42, 63)	loss-of-function	NegReg	(2, 18)	NoRelation	A loss-of-function CBL mutation prolonged STAT5 phosphorylation after GM-CSF stimulation, which was rapidly terminated in both patient samples and GDM-1 cells.
IGF1R	Gene	(56, 61)	mutation	Var	(44, 52)	ThemeOf	Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/-catenin signaling pathways.
mutation	Var	(44, 52)	loss-of-function	NegReg	(27, 43)	CauseOf	Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/-catenin signaling pathways.
mutation	Var	(44, 52)	crosstalk	Reg	(68, 77)	CauseOf	Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/-catenin signaling pathways.
Wnt/-catenin signaling pathways	Pathway	(96, 128)	crosstalk	Reg	(68, 77)	ThemeOf	Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/-catenin signaling pathways.
IGF1R	Gene	(86, 91)	crosstalk	Reg	(68, 77)	ThemeOf	Identification of a unique loss-of-function mutation in IGF1R and a crosstalk between IGF1R and Wnt/-catenin signaling pathways.
GRN	Gene	(123, 126)	mutation	Var	(133, 141)	ThemeOf	We previously reported a granulin (GRN) null mutation, originating from a common founder, in multiple Belgian families with frontotemporal dementia.
mutation	Var	(133, 141)	reported	Reg	(102, 110)	CauseOf	We previously reported a granulin (GRN) null mutation, originating from a common founder, in multiple Belgian families with frontotemporal dementia.
frontotemporal dementia	Disease	(212, 235)	reported	Reg	(102, 110)	ThemeOf	We previously reported a granulin (GRN) null mutation, originating from a common founder, in multiple Belgian families with frontotemporal dementia.
MLKL	Gene	(18, 22)	variant	Var	(7, 14)	ThemeOf	A rare variant in MLKL confers susceptibility to ApoE 4-negative Alzheimer's disease in Hong Kong Chinese population.
variant	Var	(7, 14)	susceptibility	Reg	(31, 45)	CauseOf	A rare variant in MLKL confers susceptibility to ApoE 4-negative Alzheimer's disease in Hong Kong Chinese population.
Alzheimer's disease	Disease	(66, 85)	susceptibility	Reg	(31, 45)	ThemeOf	A rare variant in MLKL confers susceptibility to ApoE 4-negative Alzheimer's disease in Hong Kong Chinese population.
MLKL	Gene	(810, 814)	p.Q48X	Var	(877, 883)	ThemeOf	MLKL is expressed in neurons, and the its expression levels in the p.Q48X carriers were significantly lower than that in age-matched wild-type controls.
p.Q48X	Var	(877, 883)	lower	NegReg	(912, 917)	CauseOf	MLKL is expressed in neurons, and the its expression levels in the p.Q48X carriers were significantly lower than that in age-matched wild-type controls.
expression levels	MPA	(852, 869)	lower	NegReg	(912, 917)	ThemeOf	MLKL is expressed in neurons, and the its expression levels in the p.Q48X carriers were significantly lower than that in age-matched wild-type controls.
MLKL	Gene	(1068, 1072)	mutation	Var	(1090, 1098)	ThemeOf	MLKL loss-of-function mutation might contribute to late-onset ApoE 4-negative AD in the Hong Kong Chinese population.
mutation	Var	(1090, 1098)	loss-of-function	NegReg	(1073, 1089)	CauseOf	MLKL loss-of-function mutation might contribute to late-onset ApoE 4-negative AD in the Hong Kong Chinese population.
AD	Disease	(1147, 1149)	loss-of-function	NegReg	(1073, 1089)	ThemeOf	MLKL loss-of-function mutation might contribute to late-onset ApoE 4-negative AD in the Hong Kong Chinese population.
Leu206Stop	Var	(338, 348)	loss-of-function	NegReg	(371, 387)	CauseOf	A transversion from TA in exon 4 led to a Leu206Stop mutation generating a loss-of-function mutant.
TRPV1	Gene	(658, 663)	Leu206Stop	Var	(664, 674)	ThemeOf	Capsaicin-induced [Ca2+]i changes in small diameter DRG neurons were significantly diminished in TRPV1 Leu206Stop mice and administration of capsaicin induced neither hypothermia nor nocifensive behaviour invivo.
Leu206Stop	Var	(664, 674)	diminished	NegReg	(644, 654)	CauseOf	Capsaicin-induced [Ca2+]i changes in small diameter DRG neurons were significantly diminished in TRPV1 Leu206Stop mice and administration of capsaicin induced neither hypothermia nor nocifensive behaviour invivo.
Capsaicin-induced [Ca2+]i	MPA	(561, 586)	diminished	NegReg	(644, 654)	ThemeOf	Capsaicin-induced [Ca2+]i changes in small diameter DRG neurons were significantly diminished in TRPV1 Leu206Stop mice and administration of capsaicin induced neither hypothermia nor nocifensive behaviour invivo.
DRG neurons	CPA	(613, 624)	Capsaicin-induced [Ca2+]i	MPA	(561, 586)	ThemeOf	Capsaicin-induced [Ca2+]i changes in small diameter DRG neurons were significantly diminished in TRPV1 Leu206Stop mice and administration of capsaicin induced neither hypothermia nor nocifensive behaviour invivo.
TRPV1	Gene	(1023, 1028)	Leu206Stop	Var	(1029, 1039)	ThemeOf	In the open field test, a significant increase in spontaneous locomotion was detected in TRPV1 Leu206Stop mice as compared to wildtype controls.
Leu206Stop	Var	(1029, 1039)	increase	PosReg	(972, 980)	CauseOf	In the open field test, a significant increase in spontaneous locomotion was detected in TRPV1 Leu206Stop mice as compared to wildtype controls.
spontaneous locomotion	CPA	(984, 1006)	increase	PosReg	(972, 980)	ThemeOf	In the open field test, a significant increase in spontaneous locomotion was detected in TRPV1 Leu206Stop mice as compared to wildtype controls.
DRG neurons	CPA	(52, 63)	diminished	NegReg	(83, 93)	NoRelation	Capsaicin-induced [Ca2+]i changes in small diameter DRG neurons were significantly diminished in TRPV1 Leu206Stop mice and administration of capsaicin induced neither hypothermia nor nocifensive behaviour invivo.
TP53	Gene	(10, 14)	mutations	Var	(32, 41)	ThemeOf	Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
p.P278S	Var	(986, 993)	GOF	PosReg	(995, 998)	CauseOf	The third patient, a 62-year-old female with metastatic lung adenocarcinoma, had allelic p.P278S (GOF) and p.R283L (non-GOF) variants at frequencies of 61% but with null staining for p53.
metastatic lung adenocarcinoma	Disease	(942, 972)	GOF	PosReg	(995, 998)	ThemeOf	The third patient, a 62-year-old female with metastatic lung adenocarcinoma, had allelic p.P278S (GOF) and p.R283L (non-GOF) variants at frequencies of 61% but with null staining for p53.
p.R283L	Var	(1004, 1011)	non-GOF	Reg	(1013, 1020)	CauseOf	The third patient, a 62-year-old female with metastatic lung adenocarcinoma, had allelic p.P278S (GOF) and p.R283L (non-GOF) variants at frequencies of 61% but with null staining for p53.
metastatic lung adenocarcinoma	Disease	(942, 972)	non-GOF	Reg	(1013, 1020)	ThemeOf	The third patient, a 62-year-old female with metastatic lung adenocarcinoma, had allelic p.P278S (GOF) and p.R283L (non-GOF) variants at frequencies of 61% but with null staining for p53.
mutations	Var	(32, 41)	gain of function	PosReg	(15, 31)	CauseOf	Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
rapidly progressing solid tumors	Disease	(45, 77)	gain of function	PosReg	(15, 31)	ThemeOf	Biallelic TP53 gain of function mutations in rapidly progressing solid tumors.
TP53	Gene	(110, 114)	mutations	Var	(115, 124)	ThemeOf	Recent studies are discovering TP53 mutations with gain of function (GOF) properties that promote tumorigenesis via a variety of mechanisms.
mutations	Var	(115, 124)	gain of function	PosReg	(130, 146)	CauseOf	Recent studies are discovering TP53 mutations with gain of function (GOF) properties that promote tumorigenesis via a variety of mechanisms.
tumorigenesis	CPA	(177, 190)	gain of function	PosReg	(130, 146)	ThemeOf	Recent studies are discovering TP53 mutations with gain of function (GOF) properties that promote tumorigenesis via a variety of mechanisms.
p.R273H	Var	(638, 645)	GOF	PosReg	(623, 626)	CauseOf	Biallelic GOF mutations (p.R273H and p.R273C) were identified in a 19-year-old male with glioblastoma (allele frequencies 94% and 48%) and a 54-year-old with pT3 penile squamous cell carcinoma (allele frequencies 19% and 27%).
p.R273C	Var	(650, 657)	GOF	PosReg	(623, 626)	CauseOf	Biallelic GOF mutations (p.R273H and p.R273C) were identified in a 19-year-old male with glioblastoma (allele frequencies 94% and 48%) and a 54-year-old with pT3 penile squamous cell carcinoma (allele frequencies 19% and 27%).
glioblastoma	Disease	(702, 714)	GOF	PosReg	(623, 626)	ThemeOf	Biallelic GOF mutations (p.R273H and p.R273C) were identified in a 19-year-old male with glioblastoma (allele frequencies 94% and 48%) and a 54-year-old with pT3 penile squamous cell carcinoma (allele frequencies 19% and 27%).
p.P278S	Var	(89, 96)	non-GOF	Reg	(116, 123)	NoRelation	The third patient, a 62-year-old female with metastatic lung adenocarcinoma, had allelic p.P278S (GOF) and p.R283L (non-GOF) variants at frequencies of 61% but with null staining for p53.
p.R283L	Var	(107, 114)	GOF	PosReg	(98, 101)	NoRelation	The third patient, a 62-year-old female with metastatic lung adenocarcinoma, had allelic p.P278S (GOF) and p.R283L (non-GOF) variants at frequencies of 61% but with null staining for p53.
CDH1	Gene	(245, 249)	variants	Var	(212, 220)	ThemeOf	BACKGROUND: Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the development of hereditary diffuse gastric cancer.
variants	Var	(212, 220)	associated with	Reg	(264, 279)	CauseOf	BACKGROUND: Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the development of hereditary diffuse gastric cancer.
hereditary diffuse gastric cancer	Disease	(299, 332)	associated with	Reg	(264, 279)	ThemeOf	BACKGROUND: Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the development of hereditary diffuse gastric cancer.
PALB2	Gene	(1450, 1455)	frameshift deletion	Var	(1427, 1446)	ThemeOf	A frameshift deletion in PALB2 was found in one member of a family with a history of gastric and breast cancer.
frameshift deletion	Var	(1427, 1446)	found	Reg	(1460, 1465)	CauseOf	A frameshift deletion in PALB2 was found in one member of a family with a history of gastric and breast cancer.
gastric	Disease	(1510, 1517)	found	Reg	(1460, 1465)	ThemeOf	A frameshift deletion in PALB2 was found in one member of a family with a history of gastric and breast cancer.
breast cancer	Disease	(1522, 1535)	found	Reg	(1460, 1465)	ThemeOf	A frameshift deletion in PALB2 was found in one member of a family with a history of gastric and breast cancer.
mutations	Var	(250, 259)	Loss of function	NegReg	(227, 243)	CauseOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
POMC	Gene	(330, 334)	MC4R pathway	Pathway	(267, 279)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
early-onset severe obesity	Disease	(434, 460)	Loss of function	NegReg	(227, 243)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
PCSK1	Gene	(362, 367)	mutations	Var	(250, 259)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
LEPR	Gene	(387, 391)	mutations	Var	(250, 259)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
MC4R	Gene	(397, 401)	mutations	Var	(250, 259)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
POMC	Gene	(330, 334)	mutations	Var	(250, 259)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
PCSK1	Gene	(362, 367)	MC4R pathway	Pathway	(267, 279)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
LEPR	Gene	(387, 391)	MC4R pathway	Pathway	(267, 279)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
MC4R	Gene	(397, 401)	MC4R pathway	Pathway	(267, 279)	ThemeOf	Loss of function (LoF) mutations in the MC4R pathway, including mutations in the pro-opiomelanocortin (POMC), prohormone convertase 1 (PCSK1), leptin receptor (LEPR), or MC4R genes, have been shown to cause early-onset severe obesity.
C11orf70	Gene	(13, 21)	Mutations	Var	(0, 9)	ThemeOf	Mutations in C11orf70 Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry Due to Defects of Outer and Inner Dynein Arms.
respiratory cilia	CPA	(642, 659)	immotility	CPA	(628, 638)	ThemeOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
sperm flagella	CPA	(664, 678)	immotility	CPA	(628, 638)	ThemeOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
axonemal outer	Protein	(721, 735)	loss	NegReg	(713, 717)	ThemeOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
inner dynein arms	Protein	(747, 764)	loss	NegReg	(713, 717)	ThemeOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
loss	NegReg	(713, 717)	loss-of-function	NegReg	(583, 599)	CauseOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
mutations	Var	(600, 609)	loss	NegReg	(713, 717)	ThemeOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
Primary Ciliary Dyskinesia	Disease	(28, 54)	Cause	Reg	(22, 27)	ThemeOf	Mutations in C11orf70 Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry Due to Defects of Outer and Inner Dynein Arms.
Mutations	Var	(0, 9)	Defects	NegReg	(110, 117)	CauseOf	Mutations in C11orf70 Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry Due to Defects of Outer and Inner Dynein Arms.
Outer and Inner Dynein Arms	Protein	(121, 148)	Defects	NegReg	(110, 117)	ThemeOf	Mutations in C11orf70 Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry Due to Defects of Outer and Inner Dynein Arms.
Defects	NegReg	(110, 117)	Cause	Reg	(22, 27)	CauseOf	Mutations in C11orf70 Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry Due to Defects of Outer and Inner Dynein Arms.
C11orf70	Gene	(613, 621)	mutations	Var	(600, 609)	ThemeOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
immotility	CPA	(628, 638)	loss-of-function	NegReg	(583, 599)	ThemeOf	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
Primary Ciliary Dyskinesia	Disease	(28, 54)	Defects	NegReg	(110, 117)	NoRelation	Mutations in C11orf70 Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry Due to Defects of Outer and Inner Dynein Arms.
Mutations	Var	(0, 9)	Cause	Reg	(22, 27)	NoRelation	Mutations in C11orf70 Cause Primary Ciliary Dyskinesia with Randomization of Left/Right Body Asymmetry Due to Defects of Outer and Inner Dynein Arms.
sperm flagella	CPA	(190, 204)	loss-of-function	NegReg	(109, 125)	NoRelation	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
sperm flagella	CPA	(190, 204)	loss	NegReg	(239, 243)	NoRelation	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
immotility	CPA	(154, 164)	loss	NegReg	(239, 243)	NoRelation	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
respiratory cilia	CPA	(168, 185)	loss-of-function	NegReg	(109, 125)	NoRelation	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
mutations	Var	(126, 135)	loss-of-function	NegReg	(109, 125)	NoRelation	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
respiratory cilia	CPA	(168, 185)	loss	NegReg	(239, 243)	NoRelation	Transmission electron microscopy analyses and high-resolution immunofluorescence microscopy demonstrate that loss-of-function mutations in C11orf70 cause immotility of respiratory cilia and sperm flagella, respectively, as a result of the loss of axonemal outer (ODAs) and inner dynein arms (IDAs), indicating that C11orf70 is involved in cytoplasmic assembly of dynein arms.
MAP1B	Gene	(42, 47)	variants	Var	(30, 38)	ThemeOf	De novo and inherited private variants in MAP1B in periventricular nodular heterotopia.
MAP1B	Gene	(846, 851)	variants	Var	(834, 842)	ThemeOf	Using a gene-level collapsing analysis comparing cases and controls, we identified a genome-wide significant signal driven by four ultra-rare loss-of-function heterozygous variants in MAP1B, including one de novo variant.
variants	Var	(834, 842)	loss-of-function	NegReg	(804, 820)	CauseOf	Using a gene-level collapsing analysis comparing cases and controls, we identified a genome-wide significant signal driven by four ultra-rare loss-of-function heterozygous variants in MAP1B, including one de novo variant.
MAP1B	Gene	(914, 919)	variant	Var	(920, 927)	ThemeOf	In at least one instance, the MAP1B variant was inherited from a parent with previously undiagnosed PVNH.
variant	Var	(920, 927)	inherited from	Reg	(932, 946)	CauseOf	In at least one instance, the MAP1B variant was inherited from a parent with previously undiagnosed PVNH.
PVNH	Disease	(984, 988)	inherited from	Reg	(932, 946)	ThemeOf	In at least one instance, the MAP1B variant was inherited from a parent with previously undiagnosed PVNH.
variant	Var	(35, 42)	gain-of-function	PosReg	(18, 34)	CauseOf	Protein kinase C gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
signaling	MPA	(654, 663)	enhances	PosReg	(645, 653)	ThemeOf	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
mutation	Var	(780, 788)	increase	PosReg	(808, 816)	CauseOf	Biochemical analyses of purified protein demonstrate that this mutation results in an 30% increase in the catalytic rate of the activated enzyme, with no changes in the concentrations of Ca2+ or lipid required for half-maximal activation.
catalytic	MPA	(824, 833)	increase	PosReg	(808, 816)	ThemeOf	Biochemical analyses of purified protein demonstrate that this mutation results in an 30% increase in the catalytic rate of the activated enzyme, with no changes in the concentrations of Ca2+ or lipid required for half-maximal activation.
mutation	Var	(1005, 1013)	decreasing	NegReg	(1070, 1080)	CauseOf	Molecular dynamics simulations reveal that this mutation has both localized and allosteric effects, most notably decreasing the dynamics of the C-helix, a key determinant in the catalytic turnover of kinases.
dynamics of the C-helix	MPA	(1085, 1108)	decreasing	NegReg	(1070, 1080)	ThemeOf	Molecular dynamics simulations reveal that this mutation has both localized and allosteric effects, most notably decreasing the dynamics of the C-helix, a key determinant in the catalytic turnover of kinases.
enzyme	Enzyme	(1350, 1356)	mutant	Var	(1343, 1349)	ThemeOf	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
mutant	Var	(1343, 1349)	increased	PosReg	(1375, 1384)	CauseOf	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
sensitivity	MPA	(1385, 1396)	increased	PosReg	(1375, 1384)	ThemeOf	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
protein	Protein	(1523, 1530)	interactions	Interaction	(1531, 1543)	ThemeOf	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
interactions	Interaction	(1531, 1543)	influence	Reg	(1513, 1522)	ThemeOf	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
Alzheimer's disease	Disease	(46, 65)	gain-of-function	PosReg	(18, 34)	ThemeOf	Protein kinase C gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
increased	PosReg	(1375, 1384)	influence	Reg	(1513, 1522)	CauseOf	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
PKC	Enzyme	(1726, 1730)	M489V mutation	Var	(1731, 1745)	ThemeOf	Finally, we show that phosphorylation of a key PKC substrate, myristoylated alanine-rich C-kinase substrate, is increased in brains of CRISPR-Cas9 genome-edited mice containing the PKC-M489V mutation.
M489V mutation	Var	(1731, 1745)	increased	PosReg	(1657, 1666)	CauseOf	Finally, we show that phosphorylation of a key PKC substrate, myristoylated alanine-rich C-kinase substrate, is increased in brains of CRISPR-Cas9 genome-edited mice containing the PKC-M489V mutation.
phosphorylation	MPA	(1567, 1582)	increased	PosReg	(1657, 1666)	ThemeOf	Finally, we show that phosphorylation of a key PKC substrate, myristoylated alanine-rich C-kinase substrate, is increased in brains of CRISPR-Cas9 genome-edited mice containing the PKC-M489V mutation.
myristoylated alanine-rich C-kinase substrate	MPA	(1607, 1652)	phosphorylation	MPA	(1567, 1582)	ThemeOf	Finally, we show that phosphorylation of a key PKC substrate, myristoylated alanine-rich C-kinase substrate, is increased in brains of CRISPR-Cas9 genome-edited mice containing the PKC-M489V mutation.
mutation	Var	(1787, 1795)	associated	Reg	(1776, 1786)	CauseOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
AD	Disease	(1773, 1775)	associated	Reg	(1776, 1786)	ThemeOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
PKC	Enzyme	(1799, 1803)	mutation	Var	(1787, 1795)	ThemeOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
mutation	Var	(1787, 1795)	evades	NegReg	(1870, 1876)	CauseOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
homeostatic down-regulation	MPA	(1888, 1915)	evades	NegReg	(1870, 1876)	ThemeOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
Protein kinase C	Enzyme	(0, 17)	variant	Var	(35, 42)	ThemeOf	Protein kinase C gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
constitutively active PKC	Enzyme	(1919, 1945)	homeostatic down-regulation	MPA	(1888, 1915)	ThemeOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
evades	NegReg	(1870, 1876)	enhanced	PosReg	(1812, 1820)	CauseOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
agonist-dependent signaling	MPA	(1821, 1848)	enhanced	PosReg	(1812, 1820)	ThemeOf	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
variant	Var	(35, 42)	enhanced	PosReg	(75, 83)	CauseOf	Protein kinase C gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
catalysis	MPA	(84, 93)	enhanced	PosReg	(75, 83)	ThemeOf	Protein kinase C gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
germline mutation	Var	(591, 608)	gain-of-function	PosReg	(574, 590)	CauseOf	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
PKC	Enzyme	(612, 616)	germline mutation	Var	(591, 608)	ThemeOf	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
Alzheimer's disease	Disease	(620, 639)	gain-of-function	PosReg	(574, 590)	ThemeOf	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
gain-of-function	PosReg	(574, 590)	enhances	PosReg	(645, 653)	CauseOf	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
Alzheimer's disease	Disease	(46, 65)	enhanced	PosReg	(75, 83)	NoRelation	Protein kinase C gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
catalysis	MPA	(84, 93)	gain-of-function	PosReg	(18, 34)	NoRelation	Protein kinase C gain-of-function variant in Alzheimer's disease displays enhanced catalysis by a mechanism that evades down-regulation.
germline mutation	Var	(40, 57)	enhances	PosReg	(94, 102)	NoRelation	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
Alzheimer's disease	Disease	(69, 88)	enhances	PosReg	(94, 102)	NoRelation	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
signaling	MPA	(103, 112)	gain-of-function	PosReg	(23, 39)	NoRelation	Here, we address how a gain-of-function germline mutation in PKC in Alzheimer's disease (AD) enhances signaling without increasing vulnerability to down-regulation.
mutant	Var	(13, 19)	influence	Reg	(183, 192)	NoRelation	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
sensitivity	MPA	(55, 66)	influence	Reg	(183, 192)	NoRelation	However, the mutant enzyme in cells displays increased sensitivity to an inhibitor that is ineffective toward scaffolded PKC, suggesting the altered dynamics of the kinase domain may influence protein interactions.
myristoylated alanine-rich C-kinase substrate	MPA	(62, 107)	increased	PosReg	(112, 121)	NoRelation	Finally, we show that phosphorylation of a key PKC substrate, myristoylated alanine-rich C-kinase substrate, is increased in brains of CRISPR-Cas9 genome-edited mice containing the PKC-M489V mutation.
agonist-dependent signaling	MPA	(74, 101)	associated	Reg	(29, 39)	NoRelation	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
homeostatic down-regulation	MPA	(141, 168)	associated	Reg	(29, 39)	NoRelation	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
mutation	Var	(40, 48)	enhanced	PosReg	(65, 73)	NoRelation	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
homeostatic down-regulation	MPA	(141, 168)	enhanced	PosReg	(65, 73)	NoRelation	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
AD	Disease	(26, 28)	enhanced	PosReg	(65, 73)	NoRelation	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
agonist-dependent signaling	MPA	(74, 101)	evades	NegReg	(123, 129)	NoRelation	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
AD	Disease	(26, 28)	evades	NegReg	(123, 129)	NoRelation	Our results unveil how an AD-associated mutation in PKC permits enhanced agonist-dependent signaling via a mechanism that evades the cell's homeostatic down-regulation of constitutively active PKC.
KCNJ6	Gene	(17, 22)	Mutation	Var	(23, 31)	ThemeOf	Gain-of-function KCNJ6 Mutation in a Severe Hyperkinetic Movement Disorder Phenotype.
GIRK2	Gene	(619, 624)	mutant	Var	(612, 618)	ThemeOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
mutant	Var	(612, 618)	produced	PosReg	(639, 647)	CauseOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
basal inward current	MPA	(660, 680)	produced	PosReg	(639, 647)	ThemeOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
produced	PosReg	(639, 647)	lacked	NegReg	(686, 692)	CauseOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
G protein	Protein	(693, 702)	activation	MPA	(703, 713)	ThemeOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
activation	MPA	(703, 713)	lacked	NegReg	(686, 692)	ThemeOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
produced	PosReg	(639, 647)	lost	NegReg	(715, 719)	CauseOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
K+ selectivity	MPA	(720, 734)	lost	NegReg	(715, 719)	ThemeOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
produced	PosReg	(639, 647)	gained	PosReg	(739, 745)	CauseOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
Ca2+ permeability	MPA	(746, 763)	gained	PosReg	(739, 745)	ThemeOf	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
Mutation	Var	(23, 31)	Gain-of-function	PosReg	(0, 16)	CauseOf	Gain-of-function KCNJ6 Mutation in a Severe Hyperkinetic Movement Disorder Phenotype.
GIRK2	Gene	(1090, 1095)	p.Leu171Arg	Var	(1078, 1089)	ThemeOf	In neurons expressing p.Leu171Arg GIRK2 channels, these changes in channel properties would be expected to generate a sustained depolarization, instead of the normal G protein-gated inhibitory response, which could be mitigated by expression of other GIRK subunits.
p.Leu171Arg	Var	(1078, 1089)	depolarization	NegReg	(1184, 1198)	CauseOf	In neurons expressing p.Leu171Arg GIRK2 channels, these changes in channel properties would be expected to generate a sustained depolarization, instead of the normal G protein-gated inhibitory response, which could be mitigated by expression of other GIRK subunits.
G protein-gated inhibitory response	MPA	(1222, 1257)	depolarization	NegReg	(1184, 1198)	ThemeOf	In neurons expressing p.Leu171Arg GIRK2 channels, these changes in channel properties would be expected to generate a sustained depolarization, instead of the normal G protein-gated inhibitory response, which could be mitigated by expression of other GIRK subunits.
Severe Hyperkinetic Movement Disorder	Disease	(37, 74)	Gain-of-function	PosReg	(0, 16)	ThemeOf	Gain-of-function KCNJ6 Mutation in a Severe Hyperkinetic Movement Disorder Phenotype.
KCNJ6	Gene	(144, 149)	mutation	Var	(158, 166)	ThemeOf	Here, we describe a fourth case of a human with a de novo KCNJ6 (GIRK2) mutation, who presented with clinical findings of severe hyperkinetic movement disorder and developmental delay, similar to the Keppen-Lubinsky syndrome but without lipodystrophy.
mutation	Var	(158, 166)	presented	Reg	(172, 181)	CauseOf	Here, we describe a fourth case of a human with a de novo KCNJ6 (GIRK2) mutation, who presented with clinical findings of severe hyperkinetic movement disorder and developmental delay, similar to the Keppen-Lubinsky syndrome but without lipodystrophy.
severe hyperkinetic movement disorder	Disease	(208, 245)	presented	Reg	(172, 181)	ThemeOf	Here, we describe a fourth case of a human with a de novo KCNJ6 (GIRK2) mutation, who presented with clinical findings of severe hyperkinetic movement disorder and developmental delay, similar to the Keppen-Lubinsky syndrome but without lipodystrophy.
developmental delay	CPA	(250, 269)	presented	Reg	(172, 181)	ThemeOf	Here, we describe a fourth case of a human with a de novo KCNJ6 (GIRK2) mutation, who presented with clinical findings of severe hyperkinetic movement disorder and developmental delay, similar to the Keppen-Lubinsky syndrome but without lipodystrophy.
KCNJ6	Gene	(429, 434)	c.512T>G	Var	(436, 444)	ThemeOf	Whole-exome sequencing of the patient's DNA revealed a heterozygous de novo variant in the KCNJ6 (c.512T>G, p.Leu171Arg).
KCNJ6	Gene	(429, 434)	p.Leu171Arg	Var	(446, 457)	ThemeOf	Whole-exome sequencing of the patient's DNA revealed a heterozygous de novo variant in the KCNJ6 (c.512T>G, p.Leu171Arg).
Ca2+ permeability	MPA	(165, 182)	lost	NegReg	(134, 138)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
Ca2+ permeability	MPA	(165, 182)	produced	PosReg	(58, 66)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
activation	MPA	(122, 132)	gained	PosReg	(158, 164)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
basal inward current	MPA	(79, 99)	lost	NegReg	(134, 138)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
Ca2+ permeability	MPA	(165, 182)	lacked	NegReg	(105, 111)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
basal inward current	MPA	(79, 99)	lacked	NegReg	(105, 111)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
mutant	Var	(31, 37)	lacked	NegReg	(105, 111)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
mutant	Var	(31, 37)	lost	NegReg	(134, 138)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
basal inward current	MPA	(79, 99)	gained	PosReg	(158, 164)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
activation	MPA	(122, 132)	lost	NegReg	(134, 138)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
mutant	Var	(31, 37)	gained	PosReg	(158, 164)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
K+ selectivity	MPA	(139, 153)	produced	PosReg	(58, 66)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
activation	MPA	(122, 132)	produced	PosReg	(58, 66)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
K+ selectivity	MPA	(139, 153)	lacked	NegReg	(105, 111)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
K+ selectivity	MPA	(139, 153)	gained	PosReg	(158, 164)	NoRelation	Heterologous expression of the mutant GIRK2 channel alone produced an aberrant basal inward current that lacked G protein activation, lost K+ selectivity and gained Ca2+ permeability.
Variants	Var	(39, 47)	Loss-of-Function	NegReg	(22, 38)	CauseOf	De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder.
TLK2	Gene	(51, 55)	Variants	Var	(39, 47)	ThemeOf	De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder.
Distinct Neurodevelopmental Disorder	Disease	(105, 141)	Loss-of-Function	NegReg	(22, 38)	ThemeOf	De Novo and Inherited Loss-of-Function Variants in TLK2: Clinical and Genotype-Phenotype Evaluation of a Distinct Neurodevelopmental Disorder.
mutations	Var	(318, 327)	cases	Reg	(407, 412)	CauseOf	In 2006, mutations in progranulin gene (GRN) that cause haploinsufficiency were found in familial cases of frontotemporal dementia (FTD).
frontotemporal dementia	Disease	(416, 439)	cases	Reg	(407, 412)	ThemeOf	In 2006, mutations in progranulin gene (GRN) that cause haploinsufficiency were found in familial cases of frontotemporal dementia (FTD).
GRN	Gene	(349, 352)	mutations	Var	(318, 327)	ThemeOf	In 2006, mutations in progranulin gene (GRN) that cause haploinsufficiency were found in familial cases of frontotemporal dementia (FTD).
Sik3	Gene	(684, 688)	mutation	Var	(668, 676)	ThemeOf	Sleepy mice, owing to a gain-of-function mutation in the Sik3 gene 12 , have a constitutively high sleep need despite increased sleep amount.
SNIPPs	Protein	(1148, 1154)	phosphorylates	MPA	(1133, 1147)	ThemeOf	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
mutation	Var	(668, 676)	gain-of-function	PosReg	(651, 667)	CauseOf	Sleepy mice, owing to a gain-of-function mutation in the Sik3 gene 12 , have a constitutively high sleep need despite increased sleep amount.
hyperphosphorylation	MPA	(811, 831)	brain proteome	Protein	(773, 787)	ThemeOf	The brain proteome of these mice exhibits hyperphosphorylation, similar to that seen in the brain of sleep-deprived mice.
SIK3	Gene	(1084, 1088)	mutant	Var	(1077, 1083)	ThemeOf	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
protein	Protein	(1089, 1096)	SIK3	Gene	(1084, 1088)	ThemeOf	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
mutant	Var	(1077, 1083)	preferentially	PosReg	(1098, 1112)	CauseOf	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
associates with	Interaction	(1113, 1128)	preferentially	PosReg	(1098, 1112)	ThemeOf	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
phosphorylates	MPA	(1133, 1147)	associates with	Interaction	(1113, 1128)	ThemeOf	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
SNIPPs	Protein	(83, 89)	associates with	Interaction	(48, 63)	NoRelation	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
protein	Protein	(24, 31)	associates with	Interaction	(48, 63)	NoRelation	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
phosphorylates	MPA	(68, 82)	preferentially	PosReg	(33, 47)	NoRelation	SLEEPY, the mutant SIK3 protein, preferentially associates with and phosphorylates SNIPPs.
mutations	Var	(318, 327)	loss of function	NegReg	(301, 317)	CauseOf	Here we report that germline loss of function mutations in TRIM28 predispose children to Wilms tumour.
Wilms tumour	Disease	(361, 373)	loss of function	NegReg	(301, 317)	ThemeOf	Here we report that germline loss of function mutations in TRIM28 predispose children to Wilms tumour.
TRIM28	Gene	(331, 337)	mutations	Var	(318, 327)	ThemeOf	Here we report that germline loss of function mutations in TRIM28 predispose children to Wilms tumour.
loss of heterozygosity	Var	(606, 628)	Inactivation	NegReg	(513, 525)	CauseOf	Inactivation of TRIM28, either germline or somatic, occurred through inactivating mutations, loss of heterozygosity or epigenetic silencing.
inactivating mutations	Var	(582, 604)	Inactivation	NegReg	(513, 525)	CauseOf	Inactivation of TRIM28, either germline or somatic, occurred through inactivating mutations, loss of heterozygosity or epigenetic silencing.
epigenetic silencing	Var	(632, 652)	Inactivation	NegReg	(513, 525)	CauseOf	Inactivation of TRIM28, either germline or somatic, occurred through inactivating mutations, loss of heterozygosity or epigenetic silencing.
TRIM28	Gene	(529, 535)	Inactivation	NegReg	(513, 525)	ThemeOf	Inactivation of TRIM28, either germline or somatic, occurred through inactivating mutations, loss of heterozygosity or epigenetic silencing.
mutations	Var	(132, 141)	loss of function	NegReg	(115, 131)	CauseOf	Mutational and functional studies on NR5A1 gene in 46,XY disorders of sex development: identification of six novel loss of function mutations.
p.Q460R	Var	(968, 975)	identified in	Reg	(863, 876)	CauseOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
p.T40R	Var	(921, 927)	identified in	Reg	(863, 876)	CauseOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
p.R427W	Var	(955, 962)	identified in	Reg	(863, 876)	CauseOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
p.A351E	Var	(946, 953)	identified in	Reg	(863, 876)	CauseOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
p.G328W	Var	(937, 944)	identified in	Reg	(863, 876)	CauseOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
p.T47C	Var	(929, 935)	identified in	Reg	(863, 876)	CauseOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
46,XY DSD	Disease	(881, 890)	identified in	Reg	(863, 876)	ThemeOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
NR5A1	Gene	(37, 42)	mutations	Var	(132, 141)	ThemeOf	Mutational and functional studies on NR5A1 gene in 46,XY disorders of sex development: identification of six novel loss of function mutations.
DNA-binding	Interaction	(1104, 1115)	loss	NegReg	(1096, 1100)	ThemeOf	Functional analysis revealed a significant loss of DNA-binding and transactivation ability for all variants, except for p.Q460R, which showed a modest reduced activity compared with that of the wild-type protein.
transactivation	MPA	(1120, 1135)	loss	NegReg	(1096, 1100)	ThemeOf	Functional analysis revealed a significant loss of DNA-binding and transactivation ability for all variants, except for p.Q460R, which showed a modest reduced activity compared with that of the wild-type protein.
NR5A1	Gene	(1526, 1531)	mutations	Var	(1513, 1522)	ThemeOf	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
mutations	Var	(1513, 1522)	affect	Reg	(1564, 1570)	CauseOf	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
protein structure	MPA	(1571, 1588)	affect	Reg	(1564, 1570)	ThemeOf	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
affect	Reg	(1564, 1570)	compromising	NegReg	(1600, 1612)	CauseOf	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
SF-1	MPA	(1627, 1631)	compromising	NegReg	(1600, 1612)	ThemeOf	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
gonadal development	CPA	(1651, 1670)	compromising	NegReg	(1600, 1612)	ThemeOf	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
46,XY disorders of sex development	Disease	(51, 85)	loss of function	NegReg	(115, 131)	ThemeOf	Mutational and functional studies on NR5A1 gene in 46,XY disorders of sex development: identification of six novel loss of function mutations.
NR5A1	Gene	(840, 845)	p.T40R	Var	(921, 927)	ThemeOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
NR5A1	Gene	(840, 845)	p.Q460R	Var	(968, 975)	ThemeOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
NR5A1	Gene	(840, 845)	p.R427W	Var	(955, 962)	ThemeOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
NR5A1	Gene	(840, 845)	p.A351E	Var	(946, 953)	ThemeOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
NR5A1	Gene	(840, 845)	p.G328W	Var	(937, 944)	ThemeOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
NR5A1	Gene	(840, 845)	p.T47C	Var	(929, 935)	ThemeOf	RESULT(S): NR5A1 exons sequencing identified in six 46,XY DSD patients six novel mutations: p.T40R, p.T47C, p.G328W, p.A351E, p.R427W, and p.Q460R.
SF-1	MPA	(151, 155)	affect	Reg	(88, 94)	NoRelation	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
protein structure	MPA	(95, 112)	compromising	NegReg	(124, 136)	NoRelation	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
gonadal development	CPA	(175, 194)	affect	Reg	(88, 94)	NoRelation	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
mutations	Var	(37, 46)	compromising	NegReg	(124, 136)	NoRelation	CONCLUSION(S): We describe six novel mutations in NR5A1 gene and showed that they might affect protein structure, therefore compromising seriously the SF-1 role in regulating gonadal development.
Substitution	Var	(1005, 1017)	loss	NegReg	(1083, 1087)	CauseOf	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
function	MPA	(1091, 1099)	loss	NegReg	(1083, 1087)	ThemeOf	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
Substitution	Var	(1005, 1017)	increased	PosReg	(1117, 1126)	CauseOf	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
EC50	MPA	(1131, 1135)	increased	PosReg	(1117, 1126)	ThemeOf	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
Substitution	Var	(1005, 1017)	altered	Reg	(1145, 1152)	CauseOf	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
maximal response to the partial GlyR agonist taurine	MPA	(1157, 1209)	altered	Reg	(1145, 1152)	ThemeOf	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
EC50	MPA	(126, 130)	loss	NegReg	(78, 82)	NoRelation	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
function	MPA	(86, 94)	increased	PosReg	(112, 121)	NoRelation	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
EC50	MPA	(126, 130)	altered	Reg	(140, 147)	NoRelation	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
maximal response to the partial GlyR agonist taurine	MPA	(152, 204)	loss	NegReg	(78, 82)	NoRelation	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
function	MPA	(86, 94)	altered	Reg	(140, 147)	NoRelation	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
maximal response to the partial GlyR agonist taurine	MPA	(152, 204)	increased	PosReg	(112, 121)	NoRelation	Substitution of six of the eight Phe residues in the ECD with Ala resulted in loss of function or significantly increased the EC50 and also altered the maximal response to the partial GlyR agonist taurine compared with glycine in those receptor variants that were functional.
mutants	Var	(674, 681)	loss-of-function	NegReg	(657, 673)	CauseOf	In this study, we have generated loss-of-function mutants for the three components of the RES complex in zebrafish and showed that they are required during early development.
intron splicing	MPA	(1026, 1041)	defect	NegReg	(1016, 1022)	ThemeOf	Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns.
mis-splicing of a subset of introns	MPA	(1055, 1090)	intron splicing	MPA	(1026, 1041)	ThemeOf	Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns.
differentiated neurons	CPA	(901, 923)	decrease	NegReg	(889, 897)	ThemeOf	The mutants showed a marked neural phenotype with increased cell death in the brain and a decrease in differentiated neurons.
rbmx2	Gene	(976, 981)	mutants	Var	(990, 997)	ThemeOf	Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns.
snip1	Gene	(959, 964)	mutants	Var	(990, 997)	ThemeOf	Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns.
bud13	Gene	(952, 957)	mutants	Var	(990, 997)	ThemeOf	Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns.
mutants	Var	(990, 997)	defect	NegReg	(1016, 1022)	CauseOf	Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns.
mis-splicing of a subset of introns	MPA	(130, 165)	defect	NegReg	(91, 97)	NoRelation	Transcriptomic analysis of bud13, snip1 (pml1) and rbmx2 (snu17) mutants revealed a global defect in intron splicing, with strong mis-splicing of a subset of introns.
p53	Gene	(7, 10)	Mutant	Var	(0, 6)	ThemeOf	Mutant p53 gain of function induces HER2 over-expression in cancer cells.
mtp53	Var	(1049, 1054)	Higher	PosReg	(991, 997)	CauseOf	RESULTS: Higher HER2 expression in cell lines harboring endogenous mtp53 compared with wt or null expression of p53 cell lines.
HER2	Protein	(998, 1002)	expression	MPA	(1003, 1013)	ThemeOf	RESULTS: Higher HER2 expression in cell lines harboring endogenous mtp53 compared with wt or null expression of p53 cell lines.
expression	MPA	(1003, 1013)	Higher	PosReg	(991, 997)	ThemeOf	RESULTS: Higher HER2 expression in cell lines harboring endogenous mtp53 compared with wt or null expression of p53 cell lines.
p53	Gene	(1126, 1129)	R248Q	Var	(1139, 1144)	ThemeOf	Transfection of p53 mutants (R248Q and R273C) in cell lines increased the expression of HER2.
p53	Gene	(1126, 1129)	R273C	Var	(1149, 1154)	ThemeOf	Transfection of p53 mutants (R248Q and R273C) in cell lines increased the expression of HER2.
R273C	Var	(1149, 1154)	increased	PosReg	(1170, 1179)	CauseOf	Transfection of p53 mutants (R248Q and R273C) in cell lines increased the expression of HER2.
R248Q	Var	(1139, 1144)	increased	PosReg	(1170, 1179)	CauseOf	Transfection of p53 mutants (R248Q and R273C) in cell lines increased the expression of HER2.
HER2	Protein	(1198, 1202)	expression	MPA	(1184, 1194)	ThemeOf	Transfection of p53 mutants (R248Q and R273C) in cell lines increased the expression of HER2.
expression	MPA	(1184, 1194)	increased	PosReg	(1170, 1179)	ThemeOf	Transfection of p53 mutants (R248Q and R273C) in cell lines increased the expression of HER2.
p53	Gene	(1260, 1263)	R248Q	Var	(1272, 1277)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
Mutant	Var	(0, 6)	gain of function	PosReg	(11, 27)	CauseOf	Mutant p53 gain of function induces HER2 over-expression in cancer cells.
p53	Gene	(1260, 1263)	R273C	Var	(1282, 1287)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
R248Q	Var	(1272, 1277)	increase	PosReg	(1302, 1310)	CauseOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
R273C	Var	(1282, 1287)	increase	PosReg	(1302, 1310)	CauseOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
luciferase	Enzyme	(1315, 1325)	activity	MPA	(1326, 1334)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
activity	MPA	(1326, 1334)	increase	PosReg	(1302, 1310)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
H3	Protein	(1402, 1404)	binding	Interaction	(1421, 1428)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
H4 histones	Protein	(1409, 1420)	binding	Interaction	(1421, 1428)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
binding	Interaction	(1421, 1428)	acetylation	MPA	(1387, 1398)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
acetylation	MPA	(1387, 1398)	promote	PosReg	(1379, 1386)	ThemeOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
R248Q	Var	(1272, 1277)	promote	PosReg	(1379, 1386)	CauseOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
gain of function	PosReg	(11, 27)	induces	Reg	(28, 35)	CauseOf	Mutant p53 gain of function induces HER2 over-expression in cancer cells.
R273C	Var	(1282, 1287)	promote	PosReg	(1379, 1386)	CauseOf	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
HER2	Protein	(36, 40)	over-expression	MPA	(41, 56)	ThemeOf	Mutant p53 gain of function induces HER2 over-expression in cancer cells.
over-expression	MPA	(41, 56)	induces	Reg	(28, 35)	ThemeOf	Mutant p53 gain of function induces HER2 over-expression in cancer cells.
p53	Gene	(1493, 1496)	mutants	Var	(1497, 1504)	ThemeOf	CONCLUSIONS: These findings show for the first time that p53 mutants induce over-expression of HER2 at transcriptional level of the HER2 protein.
mutants	Var	(1497, 1504)	induce	Reg	(1505, 1511)	CauseOf	CONCLUSIONS: These findings show for the first time that p53 mutants induce over-expression of HER2 at transcriptional level of the HER2 protein.
HER2	Protein	(1531, 1535)	over-expression	MPA	(1512, 1527)	ThemeOf	CONCLUSIONS: These findings show for the first time that p53 mutants induce over-expression of HER2 at transcriptional level of the HER2 protein.
over-expression	MPA	(1512, 1527)	induce	Reg	(1505, 1511)	ThemeOf	CONCLUSIONS: These findings show for the first time that p53 mutants induce over-expression of HER2 at transcriptional level of the HER2 protein.
over-expression	MPA	(41, 56)	gain of function	PosReg	(11, 27)	NoRelation	Mutant p53 gain of function induces HER2 over-expression in cancer cells.
Mutant	Var	(0, 6)	induces	Reg	(28, 35)	NoRelation	Mutant p53 gain of function induces HER2 over-expression in cancer cells.
acetylation	MPA	(131, 142)	increase	PosReg	(46, 54)	NoRelation	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
activity	MPA	(70, 78)	promote	PosReg	(123, 130)	NoRelation	The p53 mutants R248Q and R273C significantly increase the luciferase activity on the HER2 promoter, and both mutants also promote acetylation of H3 and H4 histones binding in it.
SLC30A8	Gene	(25, 32)	R138X	Var	(33, 38)	ThemeOf	Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity.
secrete insulin	MPA	(951, 966)	increasing	PosReg	(913, 923)	ThemeOf	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
increasing	PosReg	(913, 923)	beneficial effects	PosReg	(869, 887)	CauseOf	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
glucose metabolism	MPA	(891, 909)	beneficial effects	PosReg	(869, 887)	ThemeOf	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
R138X	Var	(33, 38)	loss-of-function	NegReg	(39, 55)	CauseOf	Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity.
loss-of-function	NegReg	(39, 55)	increased	PosReg	(70, 79)	CauseOf	Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity.
insulin secretory capacity	MPA	(80, 106)	increased	PosReg	(70, 79)	ThemeOf	Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity.
R138X	Var	(676, 681)	increase	PosReg	(700, 708)	CauseOf	Interestingly, in hyperglycemic conditions induced by the insulin receptor antagonist S961, the R138X mice showed a 50% increase in insulin secretion.
insulin secretion	MPA	(712, 729)	increase	PosReg	(700, 708)	ThemeOf	Interestingly, in hyperglycemic conditions induced by the insulin receptor antagonist S961, the R138X mice showed a 50% increase in insulin secretion.
SLC30A8	Gene	(832, 839)	mutation	Var	(850, 858)	ThemeOf	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
mutation	Var	(850, 858)	LOF	NegReg	(846, 849)	CauseOf	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
LOF	NegReg	(846, 849)	increasing	PosReg	(913, 923)	CauseOf	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
R138X	Var	(33, 38)	increased	PosReg	(70, 79)	NoRelation	Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity.
insulin secretory capacity	MPA	(80, 106)	loss-of-function	NegReg	(39, 55)	NoRelation	Mice harboring the human SLC30A8 R138X loss-of-function mutation have increased insulin secretory capacity.
mutation	Var	(44, 52)	beneficial effects	PosReg	(63, 81)	NoRelation	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
secrete insulin	MPA	(145, 160)	beneficial effects	PosReg	(63, 81)	NoRelation	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
mutation	Var	(44, 52)	increasing	PosReg	(107, 117)	NoRelation	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
glucose metabolism	MPA	(85, 103)	increasing	PosReg	(107, 117)	NoRelation	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
secrete insulin	MPA	(145, 160)	LOF	NegReg	(40, 43)	NoRelation	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
glucose metabolism	MPA	(85, 103)	LOF	NegReg	(40, 43)	NoRelation	Our data suggest that the SLC30A8 R138X LOF mutation may exert beneficial effects on glucose metabolism by increasing the capacity of -cells to secrete insulin under hyperglycemic conditions.
NOTCH3	Gene	(247, 253)	mutations in exon 33	Var	(223, 243)	ThemeOf	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
osteoblast proliferation	CPA	(1864, 1888)	increase	PosReg	(1852, 1860)	ThemeOf	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
function	CPA	(1893, 1901)	increase	PosReg	(1852, 1860)	ThemeOf	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
Notch3tm1.1Ecan mutation	Var	(1798, 1822)	enhanced	PosReg	(1925, 1933)	CauseOf	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
Tnfsf11	Gene	(1934, 1941)	expression	MPA	(1942, 1952)	ThemeOf	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
expression	MPA	(1942, 1952)	enhanced	PosReg	(1925, 1933)	ThemeOf	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
Notch3tm1.1Ecan	Var	(660, 675)	osteopenia	NegReg	(714, 724)	CauseOf	One-month-old male and female heterozygous Notch3tm1.1Ecan mice had cancellous and cortical bone osteopenia but exhibited no obvious neurological alterations, and histopathology of multiple organs revealed no abnormalities.
cancellous and cortical bone	CPA	(685, 713)	osteopenia	NegReg	(714, 724)	ThemeOf	One-month-old male and female heterozygous Notch3tm1.1Ecan mice had cancellous and cortical bone osteopenia but exhibited no obvious neurological alterations, and histopathology of multiple organs revealed no abnormalities.
mutants	Var	(875, 882)	reduction	NegReg	(954, 963)	CauseOf	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
trabecular number	CPA	(967, 984)	reduction	NegReg	(954, 963)	ThemeOf	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
mutants	Var	(875, 882)	decreased	NegReg	(989, 998)	CauseOf	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
mutations in exon 33	Var	(223, 243)	truncated	MPA	(267, 276)	CauseOf	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
connectivity	CPA	(999, 1011)	decreased	NegReg	(989, 998)	ThemeOf	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
cancellous bone volume	CPA	(913, 935)	decrease	NegReg	(901, 909)	ThemeOf	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
reduction	NegReg	(954, 963)	decrease	NegReg	(901, 909)	CauseOf	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
decreased	NegReg	(989, 998)	decrease	NegReg	(901, 909)	CauseOf	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
calvarial osteoblasts	CPA	(1334, 1355)	increased	PosReg	(1360, 1369)	ThemeOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
Notch3tm1.1Ecan	Var	(1318, 1333)	increased	PosReg	(1360, 1369)	CauseOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
Notch3tm1.1Ecan	Var	(1318, 1333)	increased	PosReg	(1388, 1397)	CauseOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
protein	Protein	(277, 284)	truncated	MPA	(267, 276)	ThemeOf	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
bone -carboxyglutamate protein (Bglap)	Protein	(1398, 1437)	increased	PosReg	(1388, 1397)	ThemeOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
TNF superfamily member 11 (Tnfsf11)	Gene	(1442, 1477)	mRNA levels	MPA	(1478, 1489)	ThemeOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
mRNA levels	MPA	(1478, 1489)	increased	PosReg	(1388, 1397)	ThemeOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
Notch3tm1.1Ecan	Var	(1318, 1333)	lower	NegReg	(1494, 1499)	CauseOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
Tnfrsf11b levels	MPA	(1500, 1516)	lower	NegReg	(1494, 1499)	ThemeOf	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
truncated	MPA	(267, 276)	lacking	NegReg	(285, 292)	CauseOf	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
sequences for NOTCH3 degradation	MPA	(293, 325)	lacking	NegReg	(285, 292)	ThemeOf	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
mutations in exon 33	Var	(223, 243)	gain of function	PosReg	(356, 372)	CauseOf	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
NOTCH3	Gene	(349, 355)	gain of function	PosReg	(356, 372)	ThemeOf	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
Notch3tm1.1Ecan mutation	Var	(1798, 1822)	osteopenia	Disease	(1830, 1840)	CauseOf	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
Notch3tm1.1Ecan mutation	Var	(1798, 1822)	increase	PosReg	(1852, 1860)	CauseOf	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
truncated	MPA	(67, 76)	gain of function	PosReg	(156, 172)	NoRelation	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
LMS	Disease	(0, 3)	gain of function	PosReg	(156, 172)	NoRelation	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
LMS	Disease	(0, 3)	lacking	NegReg	(85, 92)	NoRelation	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
sequences for NOTCH3 degradation	MPA	(93, 125)	gain of function	PosReg	(156, 172)	NoRelation	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
mutations in exon 33	Var	(23, 43)	lacking	NegReg	(85, 92)	NoRelation	LMS is associated with mutations in exon 33 of NOTCH3 leading to a truncated protein lacking sequences for NOTCH3 degradation and presumably causing NOTCH3 gain of function.
mutants	Var	(34, 41)	decrease	NegReg	(60, 68)	NoRelation	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
connectivity	CPA	(158, 170)	decrease	NegReg	(60, 68)	NoRelation	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
cancellous bone volume	CPA	(72, 94)	decreased	NegReg	(148, 157)	NoRelation	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
trabecular number	CPA	(126, 143)	decrease	NegReg	(60, 68)	NoRelation	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
trabecular number	CPA	(126, 143)	decreased	NegReg	(148, 157)	NoRelation	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
cancellous bone volume	CPA	(72, 94)	reduction	NegReg	(113, 122)	NoRelation	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
connectivity	CPA	(158, 170)	reduction	NegReg	(113, 122)	NoRelation	Microcomputed tomography of these mutants revealed a 35-60% decrease in cancellous bone volume associated with a reduction in trabecular number and decreased connectivity.
mRNA levels	MPA	(160, 171)	lower	NegReg	(176, 181)	NoRelation	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
Tnfrsf11b levels	MPA	(182, 198)	increased	PosReg	(42, 51)	NoRelation	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
mRNA levels	MPA	(160, 171)	increased	PosReg	(42, 51)	NoRelation	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
Tnfrsf11b levels	MPA	(182, 198)	increased	PosReg	(70, 79)	NoRelation	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
calvarial osteoblasts	CPA	(16, 37)	lower	NegReg	(176, 181)	NoRelation	Notch3tm1.1Ecan calvarial osteoblasts had increased proliferation and increased bone -carboxyglutamate protein (Bglap) and TNF superfamily member 11 (Tnfsf11) mRNA levels and lower Tnfrsf11b levels.
expression	MPA	(163, 173)	increase	PosReg	(73, 81)	NoRelation	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
osteopenia	Disease	(51, 61)	enhanced	PosReg	(146, 154)	NoRelation	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
osteopenia	Disease	(51, 61)	increase	PosReg	(73, 81)	NoRelation	In conclusion, the Notch3tm1.1Ecan mutation causes osteopenia despite an increase in osteoblast proliferation and function and is associated with enhanced Tnfsf11 expression in osteoblasts and osteocytes.
ABCC8	Gene	(201, 206)	mutations	Var	(208, 217)	ThemeOf	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
mutations	Var	(208, 217)	Gain-of-function	PosReg	(141, 157)	CauseOf	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
Gain-of-function	PosReg	(141, 157)	cause	Reg	(231, 236)	CauseOf	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
neonatal diabetes mellitus	Disease	(237, 263)	cause	Reg	(231, 236)	ThemeOf	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
maturity-onset diabetes	Disease	(268, 291)	cause	Reg	(231, 236)	ThemeOf	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
ABCC8	Gene	(128, 133)	mutation	Var	(69, 77)	ThemeOf	Heterogeneous nature of diabetes in a family with a gain-of-function mutation in the ATP-binding cassette subfamily C member 8 (ABCC8) gene.
mutation	Var	(69, 77)	gain-of-function	PosReg	(52, 68)	CauseOf	Heterogeneous nature of diabetes in a family with a gain-of-function mutation in the ATP-binding cassette subfamily C member 8 (ABCC8) gene.
diabetes	Disease	(24, 32)	gain-of-function	PosReg	(52, 68)	ThemeOf	Heterogeneous nature of diabetes in a family with a gain-of-function mutation in the ATP-binding cassette subfamily C member 8 (ABCC8) gene.
neonatal diabetes mellitus	Disease	(96, 122)	Gain-of-function	PosReg	(0, 16)	NoRelation	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
maturity-onset diabetes	Disease	(127, 150)	Gain-of-function	PosReg	(0, 16)	NoRelation	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
mutations	Var	(67, 76)	cause	Reg	(90, 95)	NoRelation	Gain-of-function ATP-binding cassette subfamily C member 8 (ABCC8) mutations are known to cause neonatal diabetes mellitus and maturity-onset diabetes in the young.
ERBB2	Gene	(219, 224)	point mutations	Var	(142, 157)	ThemeOf	In addition to amplification, point mutations of the human epidermal growth factor receptor 2 (HER2) gene (ERBB2) have been shown to activate the corresponding signaling pathway in breast cancer.
point mutations	Var	(142, 157)	activate	PosReg	(245, 253)	CauseOf	In addition to amplification, point mutations of the human epidermal growth factor receptor 2 (HER2) gene (ERBB2) have been shown to activate the corresponding signaling pathway in breast cancer.
signaling pathway	Pathway	(272, 289)	activate	PosReg	(245, 253)	ThemeOf	In addition to amplification, point mutations of the human epidermal growth factor receptor 2 (HER2) gene (ERBB2) have been shown to activate the corresponding signaling pathway in breast cancer.
breast cancer	Disease	(293, 306)	signaling pathway	Pathway	(272, 289)	ThemeOf	In addition to amplification, point mutations of the human epidermal growth factor receptor 2 (HER2) gene (ERBB2) have been shown to activate the corresponding signaling pathway in breast cancer.
mutation	Var	(1478, 1486)	activating	PosReg	(1462, 1472)	CauseOf	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
activating	PosReg	(1462, 1472)	higher rates	PosReg	(1569, 1581)	CauseOf	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
breast cancers	Disease	(1534, 1548)	bone metastases	CPA	(1513, 1528)	ThemeOf	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
bone metastases	CPA	(1513, 1528)	higher rates	PosReg	(1569, 1581)	ThemeOf	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
HER2	Gene	(1473, 1477)	mutation	Var	(1478, 1486)	ThemeOf	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
breast cancer	Disease	(181, 194)	activate	PosReg	(133, 141)	NoRelation	In addition to amplification, point mutations of the human epidermal growth factor receptor 2 (HER2) gene (ERBB2) have been shown to activate the corresponding signaling pathway in breast cancer.
breast cancers	Disease	(89, 103)	higher rates	PosReg	(124, 136)	NoRelation	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
breast cancers	Disease	(89, 103)	activating	PosReg	(17, 27)	NoRelation	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
mutation	Var	(33, 41)	higher rates	PosReg	(124, 136)	NoRelation	We conclude that activating HER2 mutation is present in about 3% of bone metastases from breast cancers, with significantly higher rates in the pleomorphic subtype of lobular cancer.
PINK1	Gene	(758, 763)	mutant	Var	(764, 770)	ThemeOf	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mutant	Var	(764, 770)	strengthened	PosReg	(796, 808)	CauseOf	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mutant	Var	(764, 770)	elevated	PosReg	(832, 840)	CauseOf	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
elevated	PosReg	(832, 840)	enlargement	PosReg	(869, 880)	CauseOf	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
ERMCS	MPA	(787, 792)	strengthened	PosReg	(796, 808)	ThemeOf	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mito-Ca2+ level	MPA	(813, 828)	elevated	PosReg	(832, 840)	ThemeOf	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mitochondrial	MPA	(855, 868)	enlargement	PosReg	(869, 880)	ThemeOf	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mutant	Var	(9, 15)	enlargement	PosReg	(114, 125)	NoRelation	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mitochondrial	MPA	(100, 113)	strengthened	PosReg	(41, 53)	NoRelation	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
ERMCS	MPA	(32, 37)	enlargement	PosReg	(114, 125)	NoRelation	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
ERMCS	MPA	(32, 37)	elevated	PosReg	(77, 85)	NoRelation	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mito-Ca2+ level	MPA	(58, 73)	strengthened	PosReg	(41, 53)	NoRelation	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mito-Ca2+ level	MPA	(58, 73)	enlargement	PosReg	(114, 125)	NoRelation	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
mitochondrial	MPA	(100, 113)	elevated	PosReg	(77, 85)	NoRelation	In PINK1 mutant DA neurons, the ERMCS is strengthened and mito-Ca2+ level is elevated, resulting in mitochondrial enlargement and neuronal death.
STAT1	Gene	(67, 72)	Variant	Var	(90, 97)	ThemeOf	Bronchiectasis and Recurrent Respiratory Infections with a De Novo STAT1 Gain-of-Function Variant: First Case in Korea.
c.800C>T	Var	(1075, 1083)	revealed	Reg	(1064, 1072)	CauseOf	Whole-exome sequencing revealed a c.800C>T (p.Ala267Val) heterozygous mutation in the STAT1 gene.
STAT1	Gene	(590, 595)	alleles	Var	(575, 582)	ThemeOf	Heterozygotes for gain-of-function (GOF) alleles of the STAT1 gene usually display autosomal dominant chronic mucocutaneous candidiasis (CMC) and a wide range of clinical features, such as bronchiectasis.
alleles	Var	(575, 582)	gain-of-function	PosReg	(552, 568)	CauseOf	Heterozygotes for gain-of-function (GOF) alleles of the STAT1 gene usually display autosomal dominant chronic mucocutaneous candidiasis (CMC) and a wide range of clinical features, such as bronchiectasis.
autosomal dominant chronic mucocutaneous candidiasis	Disease	(617, 669)	gain-of-function	PosReg	(552, 568)	ThemeOf	Heterozygotes for gain-of-function (GOF) alleles of the STAT1 gene usually display autosomal dominant chronic mucocutaneous candidiasis (CMC) and a wide range of clinical features, such as bronchiectasis.
bronchiectasis	Disease	(723, 737)	gain-of-function	PosReg	(552, 568)	ThemeOf	Heterozygotes for gain-of-function (GOF) alleles of the STAT1 gene usually display autosomal dominant chronic mucocutaneous candidiasis (CMC) and a wide range of clinical features, such as bronchiectasis.
Variant	Var	(90, 97)	Gain-of-Function	PosReg	(73, 89)	CauseOf	Bronchiectasis and Recurrent Respiratory Infections with a De Novo STAT1 Gain-of-Function Variant: First Case in Korea.
Bronchiectasis	Disease	(0, 14)	Gain-of-Function	PosReg	(73, 89)	ThemeOf	Bronchiectasis and Recurrent Respiratory Infections with a De Novo STAT1 Gain-of-Function Variant: First Case in Korea.
Recurrent Respiratory Infections	Disease	(19, 51)	Gain-of-Function	PosReg	(73, 89)	ThemeOf	Bronchiectasis and Recurrent Respiratory Infections with a De Novo STAT1 Gain-of-Function Variant: First Case in Korea.
STAT1	Gene	(1127, 1132)	c.800C>T	Var	(1075, 1083)	ThemeOf	Whole-exome sequencing revealed a c.800C>T (p.Ala267Val) heterozygous mutation in the STAT1 gene.
SOD1	Gene	(212, 216)	Mutations	Var	(169, 178)	ThemeOf	Mutations in Cu/Zn superoxide dismutase 1 (SOD1) lead to Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease that disproportionately affects glutamatergic and cholinergic motor neurons.
Mutations	Var	(169, 178)	lead to	Reg	(218, 225)	CauseOf	Mutations in Cu/Zn superoxide dismutase 1 (SOD1) lead to Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease that disproportionately affects glutamatergic and cholinergic motor neurons.
Amyotrophic Lateral Sclerosis	Disease	(226, 255)	lead to	Reg	(218, 225)	ThemeOf	Mutations in Cu/Zn superoxide dismutase 1 (SOD1) lead to Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease that disproportionately affects glutamatergic and cholinergic motor neurons.
CYBC1	Gene	(50, 55)	mutation	Var	(30, 38)	ThemeOf	A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease.
chronic granulomatous disease	Disease	(74, 103)	loss-of-function	NegReg	(13, 29)	ThemeOf	A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease.
CYBC1	Gene	(577, 582)	p.Tyr2Ter	Var	(563, 572)	ThemeOf	Analyzing two brothers diagnosed with CGD we identify a homozygous loss-of-function mutation, p.Tyr2Ter, in CYBC1.
p.Tyr2Ter	Var	(563, 572)	loss-of-function	NegReg	(536, 552)	CauseOf	Analyzing two brothers diagnosed with CGD we identify a homozygous loss-of-function mutation, p.Tyr2Ter, in CYBC1.
p.Tyr2Ter	Var	(824, 833)	associates with	Reg	(847, 862)	CauseOf	Homozygosity for p.Tyr2Ter consequently associates with inflammatory bowel disease (IBD) in Iceland (P=8.310-8; OR=67.6), as well as reduced height (P=3.310-4; -8.5cm).
inflammatory bowel disease	Disease	(863, 889)	associates with	Reg	(847, 862)	ThemeOf	Homozygosity for p.Tyr2Ter consequently associates with inflammatory bowel disease (IBD) in Iceland (P=8.310-8; OR=67.6), as well as reduced height (P=3.310-4; -8.5cm).
mutation	Var	(30, 38)	loss-of-function	NegReg	(13, 29)	CauseOf	A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease.
Mutations	Var	(105, 114)	cause	Reg	(199, 204)	CauseOf	Mutations in genes encoding subunits of the phagocyte NADPH oxidase complex are recognized to cause chronic granulomatous disease (CGD), a severe primary immunodeficiency.
chronic granulomatous disease	Disease	(205, 234)	cause	Reg	(199, 204)	ThemeOf	Mutations in genes encoding subunits of the phagocyte NADPH oxidase complex are recognized to cause chronic granulomatous disease (CGD), a severe primary immunodeficiency.
single amino acid mutation	Var	(1229, 1255)	conformational change	MPA	(1194, 1215)	CauseOf	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
glycine to aspartate in a highly conserved region in the catalytic domain	MPA	(586, 659)	change	Reg	(576, 582)	ThemeOf	We found that the zea1 mutant has a point mutation of the 1337th nucleotide of the ZEP sequence (a change from guanine to adenine), resulting in a change of glycine to aspartate in a highly conserved region in the catalytic domain.
ZEP	Enzyme	(1160, 1163)	conformational change	MPA	(1194, 1215)	ThemeOf	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
conformational change	MPA	(1194, 1215)	impact	NegReg	(1262, 1268)	CauseOf	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
interaction between the substrate and substrate-binding site	Interaction	(1273, 1333)	impact	NegReg	(1262, 1268)	ThemeOf	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
impact	NegReg	(1262, 1268)	loss	NegReg	(1348, 1352)	CauseOf	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
zeaxanthin epoxidase	Enzyme	(1356, 1376)	function	MPA	(1377, 1385)	ThemeOf	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
function	MPA	(1377, 1385)	loss	NegReg	(1348, 1352)	ThemeOf	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
ZEP	Gene	(512, 515)	point mutation	Var	(465, 479)	ThemeOf	We found that the zea1 mutant has a point mutation of the 1337th nucleotide of the ZEP sequence (a change from guanine to adenine), resulting in a change of glycine to aspartate in a highly conserved region in the catalytic domain.
point mutation	Var	(465, 479)	change	Reg	(576, 582)	CauseOf	We found that the zea1 mutant has a point mutation of the 1337th nucleotide of the ZEP sequence (a change from guanine to adenine), resulting in a change of glycine to aspartate in a highly conserved region in the catalytic domain.
function	MPA	(247, 255)	impact	NegReg	(132, 138)	NoRelation	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
conformational change	MPA	(64, 85)	loss	NegReg	(218, 222)	NoRelation	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
single amino acid mutation	Var	(99, 125)	loss	NegReg	(218, 222)	NoRelation	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
single amino acid mutation	Var	(99, 125)	impact	NegReg	(132, 138)	NoRelation	A comparative analysis of the ZEP structures suggested that the conformational change induced by a single amino acid mutation might impact the interaction between the substrate and substrate-binding site, resulting in loss of zeaxanthin epoxidase function.
LZTR1	Gene	(263, 268)	inactivation	Var	(162, 174)	ThemeOf	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
Inactivation	Var	(571, 583)	enhanced	PosReg	(629, 637)	CauseOf	Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog).
plasma membrane localization	MPA	(638, 666)	enhanced	PosReg	(629, 637)	ThemeOf	Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog).
inactivation	Var	(162, 174)	enhanced	PosReg	(282, 290)	CauseOf	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
activity	MPA	(339, 347)	enhanced	PosReg	(282, 290)	ThemeOf	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
mitogen-activated protein kinase (MAPK) pathway	Pathway	(291, 338)	activity	MPA	(339, 347)	ThemeOf	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
inactivation	Var	(162, 174)	reduced	NegReg	(352, 359)	CauseOf	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
sensitivity to tyrosine kinase inhibitors	MPA	(360, 401)	reduced	NegReg	(352, 359)	ThemeOf	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
LZTR1	Gene	(587, 592)	Inactivation	Var	(571, 583)	ThemeOf	Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog).
Inactivation	Var	(571, 583)	decreased	NegReg	(600, 609)	CauseOf	Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog).
ubiquitination	MPA	(610, 624)	decreased	NegReg	(600, 609)	ThemeOf	Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog).
activity	MPA	(281, 289)	reduced	NegReg	(294, 301)	NoRelation	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
sensitivity to tyrosine kinase inhibitors	MPA	(302, 343)	enhanced	PosReg	(224, 232)	NoRelation	In genetic screens aimed at understanding drug resistance mechanisms in chronic myeloid leukemia cells, inactivation of the cullin 3 adapter protein-encoding leucine zipper-like transcription regulator 1 (LZTR1) gene led to enhanced mitogen-activated protein kinase (MAPK) pathway activity and reduced sensitivity to tyrosine kinase inhibitors.
plasma membrane localization	MPA	(67, 95)	decreased	NegReg	(29, 38)	NoRelation	Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog).
ubiquitination	MPA	(39, 53)	enhanced	PosReg	(58, 66)	NoRelation	Inactivation of LZTR1 led to decreased ubiquitination and enhanced plasma membrane localization of endogenous KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog).
TTN	Gene	(1888, 1891)	variant	Var	(1877, 1884)	ThemeOf	The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased with an earlier age of AF onset (P value for trend, 4.9210-4), and 6.5% of individuals with AF onset prior to age 30 carried a TTN LOF variant (OR, 5.94 [95% CI, 2.64-13.35]; P=1.6510-5).
variant	Var	(1877, 1884)	LOF	PosReg	(1873, 1876)	CauseOf	The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased with an earlier age of AF onset (P value for trend, 4.9210-4), and 6.5% of individuals with AF onset prior to age 30 carried a TTN LOF variant (OR, 5.94 [95% CI, 2.64-13.35]; P=1.6510-5).
LOF	PosReg	(1873, 1876)	increased	PosReg	(1892, 1901)	CauseOf	The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased with an earlier age of AF onset (P value for trend, 4.9210-4), and 6.5% of individuals with AF onset prior to age 30 carried a TTN LOF variant (OR, 5.94 [95% CI, 2.64-13.35]; P=1.6510-5).
early-onset AF	Disease	(1844, 1858)	increased	PosReg	(1892, 1901)	ThemeOf	The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased with an earlier age of AF onset (P value for trend, 4.9210-4), and 6.5% of individuals with AF onset prior to age 30 carried a TTN LOF variant (OR, 5.94 [95% CI, 2.64-13.35]; P=1.6510-5).
TTN	Gene	(2435, 2438)	variant	Var	(2420, 2427)	ThemeOf	Conclusions and Relevance: In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group).
variant	Var	(2420, 2427)	LOF	NegReg	(2416, 2419)	CauseOf	Conclusions and Relevance: In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group).
LOF	NegReg	(2416, 2419)	significant association	Reg	(2381, 2404)	CauseOf	Conclusions and Relevance: In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group).
early-onset AF	Disease	(2448, 2462)	significant association	Reg	(2381, 2404)	ThemeOf	Conclusions and Relevance: In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group).
variant	Var	(68, 75)	increased	PosReg	(83, 92)	NoRelation	The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased with an earlier age of AF onset (P value for trend, 4.9210-4), and 6.5% of individuals with AF onset prior to age 30 carried a TTN LOF variant (OR, 5.94 [95% CI, 2.64-13.35]; P=1.6510-5).
early-onset AF	Disease	(35, 49)	LOF	PosReg	(64, 67)	NoRelation	The proportion of individuals with early-onset AF who carried a LOF variant in TTN increased with an earlier age of AF onset (P value for trend, 4.9210-4), and 6.5% of individuals with AF onset prior to age 30 carried a TTN LOF variant (OR, 5.94 [95% CI, 2.64-13.35]; P=1.6510-5).
early-onset AF	Disease	(145, 159)	LOF	NegReg	(113, 116)	NoRelation	Conclusions and Relevance: In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group).
variant	Var	(117, 124)	significant association	Reg	(78, 101)	NoRelation	Conclusions and Relevance: In a case-control study, there was a statistically significant association between an LOF variant in the TTN gene and early-onset AF, with the variant present in a small percentage of participants with early-onset AF (the case group).
RIG-I	Gene	(260, 265)	C268F	Var	(267, 272)	ThemeOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
H830A mutation	Var	(797, 811)	restores	PosReg	(812, 820)	CauseOf	RIG-I H830A mutation restores Cap1-helicase engagement as well as CARDs partial opening event to a level comparable to that of 5'ppp.
Cap1-helicase	Protein	(821, 834)	engagement	MPA	(835, 845)	ThemeOf	RIG-I H830A mutation restores Cap1-helicase engagement as well as CARDs partial opening event to a level comparable to that of 5'ppp.
engagement	MPA	(835, 845)	restores	PosReg	(812, 820)	ThemeOf	RIG-I H830A mutation restores Cap1-helicase engagement as well as CARDs partial opening event to a level comparable to that of 5'ppp.
CARDs partial opening event	MPA	(857, 884)	restores	PosReg	(812, 820)	ThemeOf	RIG-I H830A mutation restores Cap1-helicase engagement as well as CARDs partial opening event to a level comparable to that of 5'ppp.
RIG-I	Gene	(940, 945)	E373A	Var	(934, 939)	ThemeOf	However, E373A RIG-I locks the receptor in an ATP-bound state, resulting in enhanced Cap1-helicase engagement and a sequential CARDs stimulation.
E373A	Var	(934, 939)	enhanced	PosReg	(1001, 1009)	CauseOf	However, E373A RIG-I locks the receptor in an ATP-bound state, resulting in enhanced Cap1-helicase engagement and a sequential CARDs stimulation.
Cap1-helicase	Protein	(1010, 1023)	engagement	MPA	(1024, 1034)	ThemeOf	However, E373A RIG-I locks the receptor in an ATP-bound state, resulting in enhanced Cap1-helicase engagement and a sequential CARDs stimulation.
engagement	MPA	(1024, 1034)	enhanced	PosReg	(1001, 1009)	ThemeOf	However, E373A RIG-I locks the receptor in an ATP-bound state, resulting in enhanced Cap1-helicase engagement and a sequential CARDs stimulation.
sequential CARDs stimulation	MPA	(1041, 1069)	enhanced	PosReg	(1001, 1009)	ThemeOf	However, E373A RIG-I locks the receptor in an ATP-bound state, resulting in enhanced Cap1-helicase engagement and a sequential CARDs stimulation.
C268F mutation	Var	(1071, 1085)	more	PosReg	(1096, 1100)	CauseOf	C268F mutation renders a more tethered ring architecture and results in constitutive CARDs signaling in an ATP-independent manner.
RIG-I	Gene	(260, 265)	E373A	Var	(277, 282)	ThemeOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
tethered ring architecture	MPA	(1101, 1127)	more	PosReg	(1096, 1100)	ThemeOf	C268F mutation renders a more tethered ring architecture and results in constitutive CARDs signaling in an ATP-independent manner.
C268F mutation	Var	(1071, 1085)	results in	Reg	(1132, 1142)	CauseOf	C268F mutation renders a more tethered ring architecture and results in constitutive CARDs signaling in an ATP-independent manner.
constitutive CARDs signaling	MPA	(1143, 1171)	results in	Reg	(1132, 1142)	ThemeOf	C268F mutation renders a more tethered ring architecture and results in constitutive CARDs signaling in an ATP-independent manner.
C268F	Var	(267, 272)	impaired	NegReg	(292, 300)	CauseOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
E373A	Var	(277, 282)	impaired	NegReg	(292, 300)	CauseOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
ATPase	Protein	(301, 307)	activity	MPA	(308, 316)	ThemeOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
activity	MPA	(308, 316)	impaired	NegReg	(292, 300)	ThemeOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
impaired	NegReg	(292, 300)	hyperactive	PosReg	(334, 345)	CauseOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
signaling	MPA	(346, 355)	hyperactive	PosReg	(334, 345)	ThemeOf	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
RIG-I	Gene	(791, 796)	H830A mutation	Var	(797, 811)	ThemeOf	RIG-I H830A mutation restores Cap1-helicase engagement as well as CARDs partial opening event to a level comparable to that of 5'ppp.
E373A	Var	(30, 35)	hyperactive	PosReg	(87, 98)	NoRelation	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
activity	MPA	(61, 69)	hyperactive	PosReg	(87, 98)	NoRelation	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
C268F	Var	(20, 25)	hyperactive	PosReg	(87, 98)	NoRelation	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
signaling	MPA	(99, 108)	impaired	NegReg	(45, 53)	NoRelation	Mutations in RIG-I (C268F and E373A) lead to impaired ATPase activity, thereby driving hyperactive signaling associated with autoimmune diseases.
constitutive CARDs signaling	MPA	(72, 100)	more	PosReg	(25, 29)	NoRelation	C268F mutation renders a more tethered ring architecture and results in constitutive CARDs signaling in an ATP-independent manner.
tethered ring architecture	MPA	(30, 56)	results in	Reg	(61, 71)	NoRelation	C268F mutation renders a more tethered ring architecture and results in constitutive CARDs signaling in an ATP-independent manner.
PRLR	Gene	(523, 527)	variants	Var	(511, 519)	ThemeOf	She is a compound heterozygote for loss-of-function variants of PRLR.
variants	Var	(511, 519)	loss-of-function	NegReg	(494, 510)	CauseOf	She is a compound heterozygote for loss-of-function variants of PRLR.
lactate	CPA	(674, 681)	not	NegReg	(670, 673)	ThemeOf	These findings are consistent with previous work showing that mice deficient in functional Prlr do not lactate.
Cd tolerance	CPA	(817, 829)	Enhanced	PosReg	(808, 816)	ThemeOf	Enhanced Cd tolerance was observed in the WRKY12 loss-of-function mutants, whereas increased Cd sensitivity was found in the WRKY12-overexpressing plants.
WRKY12	Gene	(850, 856)	mutants	Var	(874, 881)	ThemeOf	Enhanced Cd tolerance was observed in the WRKY12 loss-of-function mutants, whereas increased Cd sensitivity was found in the WRKY12-overexpressing plants.
mutants	Var	(874, 881)	loss-of-function	NegReg	(857, 873)	CauseOf	Enhanced Cd tolerance was observed in the WRKY12 loss-of-function mutants, whereas increased Cd sensitivity was found in the WRKY12-overexpressing plants.
loss-of-function	NegReg	(857, 873)	Enhanced	PosReg	(808, 816)	CauseOf	Enhanced Cd tolerance was observed in the WRKY12 loss-of-function mutants, whereas increased Cd sensitivity was found in the WRKY12-overexpressing plants.
WRKY12	Gene	(1002, 1008)	loss-of-function	NegReg	(982, 998)	ThemeOf	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
loss-of-function	NegReg	(982, 998)	releasing	PosReg	(1100, 1109)	CauseOf	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
expression	MPA	(1114, 1124)	releasing	PosReg	(1100, 1109)	ThemeOf	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
releasing	PosReg	(1100, 1109)	decreased	NegReg	(1057, 1066)	CauseOf	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
Cd accumulation	CPA	(1067, 1082)	decreased	NegReg	(1057, 1066)	ThemeOf	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
mutants	Var	(66, 73)	Enhanced	PosReg	(0, 8)	NoRelation	Enhanced Cd tolerance was observed in the WRKY12 loss-of-function mutants, whereas increased Cd sensitivity was found in the WRKY12-overexpressing plants.
Cd tolerance	CPA	(9, 21)	loss-of-function	NegReg	(49, 65)	NoRelation	Enhanced Cd tolerance was observed in the WRKY12 loss-of-function mutants, whereas increased Cd sensitivity was found in the WRKY12-overexpressing plants.
Cd accumulation	CPA	(104, 119)	loss-of-function	NegReg	(19, 35)	NoRelation	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
expression	MPA	(151, 161)	decreased	NegReg	(94, 103)	NoRelation	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
expression	MPA	(151, 161)	loss-of-function	NegReg	(19, 35)	NoRelation	Overexpression and loss-of-function of WRKY12 were associated respectively with increased and decreased Cd accumulation by repressing or releasing the expression of the genes involved in the PC synthesis pathway.
QRICH2	Gene	(30, 36)	mutations	Var	(17, 26)	ThemeOf	Loss-of-function mutations in QRICH2 cause male infertility with multiple morphological abnormalities of the sperm flagella.
male infertility	Disease	(181, 197)	cause	Reg	(175, 180)	ThemeOf	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
QRICH2	Gene	(1075, 1081)	mutations	Var	(1056, 1065)	ThemeOf	Our findings strongly suggest that the genetic mutations of human QRICH2 can lead to male infertility with MMAF and that QRICH2 is essential for sperm flagellar formation.
mutations	Var	(1056, 1065)	lead to	Reg	(1086, 1093)	CauseOf	Our findings strongly suggest that the genetic mutations of human QRICH2 can lead to male infertility with MMAF and that QRICH2 is essential for sperm flagellar formation.
male infertility	Disease	(1094, 1110)	lead to	Reg	(1086, 1093)	ThemeOf	Our findings strongly suggest that the genetic mutations of human QRICH2 can lead to male infertility with MMAF and that QRICH2 is essential for sperm flagellar formation.
MMAF	CPA	(1116, 1120)	lead to	Reg	(1086, 1093)	ThemeOf	Our findings strongly suggest that the genetic mutations of human QRICH2 can lead to male infertility with MMAF and that QRICH2 is essential for sperm flagellar formation.
mutations	Var	(17, 26)	Loss-of-function	NegReg	(0, 16)	CauseOf	Loss-of-function mutations in QRICH2 cause male infertility with multiple morphological abnormalities of the sperm flagella.
Loss-of-function	NegReg	(0, 16)	cause	Reg	(37, 42)	CauseOf	Loss-of-function mutations in QRICH2 cause male infertility with multiple morphological abnormalities of the sperm flagella.
male infertility	Disease	(43, 59)	cause	Reg	(37, 42)	ThemeOf	Loss-of-function mutations in QRICH2 cause male infertility with multiple morphological abnormalities of the sperm flagella.
sperm flagella	CPA	(134, 148)	Aberrant	Var	(125, 133)	ThemeOf	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
Aberrant	Var	(125, 133)	impair	NegReg	(149, 155)	CauseOf	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
sperm motility	CPA	(156, 170)	impair	NegReg	(149, 155)	ThemeOf	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
impair	NegReg	(149, 155)	cause	Reg	(175, 180)	CauseOf	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
mutations	Var	(17, 26)	cause	Reg	(37, 42)	NoRelation	Loss-of-function mutations in QRICH2 cause male infertility with multiple morphological abnormalities of the sperm flagella.
male infertility	Disease	(43, 59)	Loss-of-function	NegReg	(0, 16)	NoRelation	Loss-of-function mutations in QRICH2 cause male infertility with multiple morphological abnormalities of the sperm flagella.
sperm flagella	CPA	(9, 23)	cause	Reg	(50, 55)	NoRelation	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
sperm flagella	CPA	(9, 23)	impair	NegReg	(24, 30)	NoRelation	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
male infertility	Disease	(56, 72)	impair	NegReg	(24, 30)	NoRelation	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
Aberrant	Var	(0, 8)	cause	Reg	(50, 55)	NoRelation	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
sperm motility	CPA	(31, 45)	cause	Reg	(50, 55)	NoRelation	Aberrant sperm flagella impair sperm motility and cause male infertility, yet the genes which have been identified in multiple morphological abnormalities of the flagella (MMAF) can only explain the pathogenic mechanisms of MMAF in a small number of cases.
phosphatase	Enzyme	(19, 30)	juvenile myelomonocytic leukemia	Disease	(138, 170)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
leukemias	Disease	(114, 123)	phosphatase	Enzyme	(19, 30)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
SHP-2	Gene	(13, 18)	juvenile myelomonocytic leukemia	Disease	(138, 170)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
leukemias	Disease	(114, 123)	SHP-2	Gene	(13, 18)	NoRelation	Mutations in SHP-2 phosphatase that cause hyperactivation of its catalytic activity have been identified in human leukemias, particularly juvenile myelomonocytic leukemia, which is characterized by hypersensitivity of myeloid progenitor cells to granulocyte macrophage colony-stimulating factor and interleukin (IL)-3.
myeloproliferative disease	Disease	(51, 77)	SHP-2	Gene	(24, 29)	NoRelation	Our results showed that SHP-2 E76K mutation caused myeloproliferative disease in mice, while overexpression of WT SHP-2 decreased hematopoietic potential of the transduced cells in recipient animals.
IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways	Pathway	(153, 219)	mutant	Var	(84, 90)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
E76K	Var	(4, 8)	IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways	Pathway	(153, 219)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways	Pathway	(153, 219)	interactions	Interaction	(68, 80)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
Grb2	Protein	(102, 106)	IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways	Pathway	(153, 219)	NoRelation	The E76K mutation in the N-terminal Src homology 2 domain increased interactions of mutant SHP-2 with Grb2, Gab2, and p85, leading to hyperactivation of IL-3-induced Erk and phosphatidylinositol 3-kinase (PI3K) pathways.
E76K	Var	(42, 46)	PI3K pathway	Pathway	(180, 192)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
PI3K pathway	Pathway	(180, 192)	Gab2	Protein	(138, 142)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
C459S	Var	(66, 71)	PI3K pathway	Pathway	(180, 192)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
enhance	PosReg	(150, 157)	SHP-2	Gene	(36, 41)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
PI3K pathway	Pathway	(180, 192)	interaction	Interaction	(121, 132)	NoRelation	Furthermore, catalytically inactive SHP-2 E76K with an additional C459S mutation retained the capability to increase the interaction with Gab2 and to enhance the activation of the PI3K pathway.
bchs	Gene	(99, 103)	increased	PosReg	(138, 147)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
bchs	Gene	(99, 103)	neuronal death	CPA	(148, 162)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life span	CPA	(121, 136)	bchs	Gene	(99, 103)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
bchs	Gene	(99, 103)	widespread CNS	CPA	(168, 182)	NoRelation	Previously we have found that loss-of-function (LOF) mutations in the Drosophila gene blue cheese (bchs) lead to reduced adult life span, increased neuronal death, and widespread CNS degeneration that is associated with the formation of ubiquitinated-protein aggregates.
adult life spans	CPA	(85, 101)	lysosomal trafficking genes	Gene	(21, 48)	NoRelation	Mutations in several lysosomal trafficking genes resulted in significantly decreased adult life spans and several mutants showed changes in ubiquitinated protein profiles as young adults.
G protein-coupled receptors	Protein	(113, 140)	heterotrimeric G proteins	Protein	(145, 170)	NoRelation	Regulator of G protein signaling (RGS) proteins play a crucial role in the adaptation of cells to stimulation by G protein-coupled receptors via heterotrimeric G proteins.
Galpha(o1) subunit contained in an alpha(2A)-adrenoreceptor-Galpha(o1)(C351I) fusion protein	Protein	(112, 204)	yeast-based signalling pathway	Pathway	(56, 86)	NoRelation	RGS4(S30C) demonstrates GOF activity both in an in vivo yeast-based signalling pathway and in vitro against the Galpha(o1) subunit contained in an alpha(2A)-adrenoreceptor-Galpha(o1)(C351I) fusion protein.
gain of function	PosReg	(52, 68)	p53	Gene	(7, 10)	NoRelation	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
tumor aggressiveness	CPA	(112, 132)	p53	Gene	(7, 10)	NoRelation	Mutant p53 proteins are thought to have acquired a "gain of function" (GOF) activity that mainly contributes to tumor aggressiveness.
p53	Gene	(66, 69)	tumorigenicity of cancer cells in an animal model	CPA	(102, 151)	NoRelation	Previously we reported that constitutive downregulation of mutant p53 by RNA interference reduces the tumorigenicity of cancer cells in an animal model; however, effects of adaptation to long-term mutant p53 inhibition could not be excluded.
p53	Gene	(50, 53)	tumor malignancy	CPA	(73, 89)	NoRelation	Results are confirmatory that depletion of mutant p53 protein impacts on tumor malignancy and validated the inducible lentiviral-based system as an efficient tool to study the gain of function activity of human tumor derived p53 mutants.
melanoma	Disease	(79, 87)	MC1R	Gene	(49, 53)	NoRelation	We report the functional characterization of six MC1R alleles found in Spanish melanoma patients.
p.Val38Met	Var	(140, 150)	cAMP pathway	Pathway	(126, 138)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Ser41Phe	Var	(218, 228)	cAMP pathway	Pathway	(126, 138)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(230, 241)	cAMP pathway	Pathway	(126, 138)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	cAMP pathway	Pathway	(126, 138)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
cAMP pathway	Pathway	(126, 138)	p.Cys289Arg	Var	(247, 258)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Ser41Phe	Var	(218, 228)	functional coupling	MPA	(197, 216)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Met128Thr	Var	(230, 241)	functional coupling	MPA	(197, 216)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	p.Ser41Phe	Var	(218, 228)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	p.Val38Met	Var	(140, 150)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	p.Cys289Arg	Var	(247, 258)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Val51Ala	Var	(155, 165)	functional coupling	MPA	(197, 216)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
functional coupling	MPA	(197, 216)	p.Cys289Arg	Var	(247, 258)	NoRelation	The other mutations are associated with varying degrees of loss of function (LOF), from moderate decreases in coupling to the cAMP pathway (p.Val38Met and p.Val51Ala) to nearly complete absence of functional coupling (p.Ser41Phe, p.Met128Thr, and p.Cys289Arg).
p.Cys289Arg	Var	(24, 35)	p.Met128Thr	Var	(8, 19)	NoRelation	The LOF p.Met128Thr and p.Cys289Arg mutants are trafficked to the cell surface, but are unable to bind agonists efficiently.
p.Ser41Phe,	Var	(31, 42)	p.Val51Ala	Var	(47, 57)	NoRelation	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p.Val38Met	Var	(19, 29)	p.Val51Ala	Var	(47, 57)	NoRelation	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p.Ser41Phe,	Var	(31, 42)	p.Val38Met	Var	(19, 29)	NoRelation	Conversely, LOF of p.Val38Met, p.Ser41Phe, and p.Val51Ala is due to reduced cell surface expression as a consequence of retention in the endoplasmic reticulum (ER).
p53	Gene	(23, 26)	gain-of-function	PosReg	(27, 43)	NoRelation	Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
R175H	Var	(53, 58)	EGFR/PI3K/AKT pathway	Pathway	(145, 166)	NoRelation	Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
p53	Gene	(29, 32)	aggressive nonendometrioid cancer	Disease	(72, 105)	NoRelation	In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer.
p53 gene	Gene	(299, 307)	inducing	Reg	(243, 251)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
up-regulation	PosReg	(180, 193)	p53 gene	Gene	(299, 307)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
tested	Reg	(153, 159)	inducing	Reg	(243, 251)	NoRelation	METHODS: To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.
p53	Gene	(49, 52)	promoted	PosReg	(73, 81)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	cell migration	CPA	(82, 96)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
activation	PosReg	(123, 133)	p53	Gene	(49, 52)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	invasion	CPA	(101, 109)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
p53	Gene	(49, 52)	invasion	CPA	(101, 109)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
p53	Gene	(49, 52)	epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	invasion	CPA	(101, 109)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
R175H	Var	(53, 58)	epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
R175H	Var	(53, 58)	cell migration	CPA	(82, 96)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	cell migration	CPA	(82, 96)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
R175H	Var	(53, 58)	epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway	Pathway	(141, 229)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
over-expression	PosReg	(30, 45)	p53	Gene	(49, 52)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
p53	Gene	(49, 52)	cell migration	CPA	(82, 96)	NoRelation	RESULTS: We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway.
EGFR/PI3K/AKT pathway.	Pathway	(144, 166)	p53-R175H	Protein	(27, 36)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
short hairpin RNA	Gene	(42, 59)	EGFR/PI3K/AKT pathway.	Pathway	(144, 166)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
short hairpin RNA	Gene	(42, 59)	cell migration and invasion	CPA	(84, 111)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
cell migration and invasion	CPA	(84, 111)	EGFR/PI3K/AKT pathway.	Pathway	(144, 166)	NoRelation	Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.
R175H	Var	(83, 88)	function activity	MPA	(114, 131)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
R175H	Var	(83, 88)	EGFR/PI3K/AKT pathway	Pathway	(148, 169)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
p53	Gene	(79, 82)	activate	PosReg	(135, 143)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
R175H	Var	(83, 88)	expression	MPA	(65, 75)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
gain	PosReg	(106, 110)	p53	Gene	(79, 82)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
p53	Gene	(79, 82)	EGFR/PI3K/AKT pathway	Pathway	(148, 169)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
p53	Gene	(79, 82)	elevated	PosReg	(56, 64)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
endometrial cancer	Disease	(223, 241)	p53	Gene	(79, 82)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
contribute	Reg	(183, 193)	p53	Gene	(79, 82)	NoRelation	CONCLUSION: These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
Shp2	Gene	(8, 12)	juvenile myelomonocytic leukemia	Disease	(128, 160)	NoRelation	Somatic Shp2 mutations are also associated with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).
Shp2	Gene	(8, 12)	associated	Reg	(32, 42)	NoRelation	Somatic Shp2 mutations are also associated with several types of human malignancies, such as the most common juvenile leukemia, juvenile myelomonocytic leukemia (JMML).
LEOPARD syndrome	Disease	(143, 159)	Shp2	Gene	(70, 74)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
mutations	Var	(99, 108)	mutations	Var	(57, 66)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
NS	Disease	(8, 10)	Shp2	Gene	(70, 74)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
Shp2	Gene	(70, 74)	gain-of-function	PosReg	(34, 50)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
JMML	Disease	(15, 19)	Shp2	Gene	(70, 74)	NoRelation	Whereas NS and JMML are caused by gain-of-function (GOF) mutations of Shp2, loss-of-function (LOF) mutations are thought to be associated with LEOPARD syndrome.
somatic cell reprogramming	CPA	(23, 49)	p53	Gene	(7, 10)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
malignant potential of reprogrammed cells	CPA	(67, 108)	Mutant	Var	(0, 6)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
facilitates	PosReg	(11, 22)	p53	Gene	(7, 10)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
somatic cell reprogramming	CPA	(23, 49)	Mutant	Var	(0, 6)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
malignant potential of reprogrammed cells	CPA	(67, 108)	p53	Gene	(7, 10)	NoRelation	Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.
p53	Gene	(0, 3)	somatic cell reprogramming	CPA	(42, 68)	NoRelation	p53 deficiency enhances the efficiency of somatic cell reprogramming to a pluripotent state.
p53	Gene	(0, 3)	enhances	PosReg	(15, 23)	NoRelation	p53 deficiency enhances the efficiency of somatic cell reprogramming to a pluripotent state.
deficiency	Var	(4, 14)	somatic cell reprogramming	CPA	(42, 68)	NoRelation	p53 deficiency enhances the efficiency of somatic cell reprogramming to a pluripotent state.
mutated	Var	(51, 58)	activities	MPA	(83, 93)	NoRelation	As p53 is usually mutated in human tumors and many mutated forms of p53 gain novel activities, we studied the influence of mutant p53 (mut-p53) on somatic cell reprogramming.
p53	Gene	(68, 71)	gain	PosReg	(72, 76)	NoRelation	As p53 is usually mutated in human tumors and many mutated forms of p53 gain novel activities, we studied the influence of mutant p53 (mut-p53) on somatic cell reprogramming.
function	MPA	(34, 42)	mut-p53	Var	(62, 69)	NoRelation	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
mut-p53	Var	(62, 69)	reprogramming process	CPA	(117, 138)	NoRelation	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
function	MPA	(34, 42)	reprogramming process	CPA	(117, 138)	NoRelation	Our data indicate a novel gain of function (GOF) property for mut-p53, which markedly enhanced the efficiency of the reprogramming process compared with p53 deficiency.
alterations	Reg	(52, 63)	p53	Gene	(40, 43)	NoRelation	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
characteristics of the reprogrammed cells	CPA	(71, 112)	p53	Gene	(40, 43)	NoRelation	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
characteristics of the reprogrammed cells	CPA	(71, 112)	mut	Var	(36, 39)	NoRelation	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
characteristics of the reprogrammed cells	CPA	(71, 112)	activity	MPA	(24, 32)	NoRelation	Importantly, this novel activity of mut-p53 induced alterations in the characteristics of the reprogrammed cells.
p53	Gene	(154, 157)	malignant tumors	CPA	(196, 212)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
pluripotent capacity	MPA	(87, 107)	malignant tumors	CPA	(196, 212)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
malignant tumors	CPA	(196, 212)	mutant	Var	(147, 153)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
p53	Gene	(154, 157)	gave rise	Reg	(183, 192)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
pluripotent capacity	MPA	(87, 107)	mutant	Var	(147, 153)	NoRelation	Although p53 knockout (KO) cells reprogrammed with only Oct4 and Sox2 maintained their pluripotent capacity in vivo, reprogrammed cells expressing mutant p53 lost this capability and gave rise to malignant tumors.
p53	Gene	(105, 108)	overexpression	PosReg	(66, 80)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
aggressive tumors	CPA	(123, 140)	oncogenic activity	MPA	(31, 49)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
induced	PosReg	(115, 122)	p53	Gene	(105, 108)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
aggressive tumors	CPA	(123, 140)	p53	Gene	(105, 108)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
mut	Var	(101, 104)	aggressive tumors	CPA	(123, 140)	NoRelation	In addition, we demonstrate an oncogenic activity of Klf4, as its overexpression in either p53 KO or mut-p53 cells induced aggressive tumors.
cells with malignant tumor-forming potential	CPA	(277, 321)	p53	Gene	(215, 218)	NoRelation	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
p53	Gene	(215, 218)	reprogramming	CPA	(231, 244)	NoRelation	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
p53	Gene	(215, 218)	result in	Reg	(249, 258)	NoRelation	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
mutated	Var	(222, 229)	cells with malignant tumor-forming potential	CPA	(277, 321)	NoRelation	Overall, our data show that reprogrammed cells with the capacity to differentiate into the three germ layers in vitro can form malignant tumors, suggesting that in genetically unstable cells, such as those in which p53 is mutated, reprogramming may result in the generation of cells with malignant tumor-forming potential.
 combine	Interaction	(107, 115)	 CYP2C1	Var	(130, 137)	NoRelation	RESULTS: In livers of known CYP2C19 and CYP2B6 genotype and protein expression we observed that there was a combined role for both CYP2C19 and CYP2B6 in the bioactivation of cyclophosphamide in vitro.
 combine	Interaction	(107, 115)	 CYP2B	Var	(142, 148)	NoRelation	RESULTS: In livers of known CYP2C19 and CYP2B6 genotype and protein expression we observed that there was a combined role for both CYP2C19 and CYP2B6 in the bioactivation of cyclophosphamide in vitro.
 CYP2B	Var	(142, 148)	 CYP2C1	Var	(130, 137)	NoRelation	RESULTS: In livers of known CYP2C19 and CYP2B6 genotype and protein expression we observed that there was a combined role for both CYP2C19 and CYP2B6 in the bioactivation of cyclophosphamide in vitro.
 CYP2C1	Var	(68, 75)	 V(max) (P= 0.028) and CL(int) (P= 0.0017	MPA	(129, 170)	NoRelation	The presence of at least one loss of function (LoF) allele at either CYP2C19 or CYP2B6 resulted in a significant decrease in both V(max) (P= 0.028) and CL(int) (P= 0.0017) compared with livers with no LoF alleles.
 CYP2C1	Var	(68, 75)	 CYP2B	Var	(79, 85)	NoRelation	The presence of at least one loss of function (LoF) allele at either CYP2C19 or CYP2B6 resulted in a significant decrease in both V(max) (P= 0.028) and CL(int) (P= 0.0017) compared with livers with no LoF alleles.
 CYP2B	Var	(79, 85)	 V(max) (P= 0.028) and CL(int) (P= 0.0017	MPA	(129, 170)	NoRelation	The presence of at least one loss of function (LoF) allele at either CYP2C19 or CYP2B6 resulted in a significant decrease in both V(max) (P= 0.028) and CL(int) (P= 0.0017) compared with livers with no LoF alleles.
 CYP2B	Var	(139, 145)	 bioactivation of cyclophosphamid	MPA	(194, 227)	NoRelation	This dual genotype relationship was also observed in a preliminary clinical study, with patients who had 1 LoF allele at either CYP2C19 or CYP2B6 also displaying significantly (P= 0.0316) lower bioactivation of cyclophosphamide.
 bioactivation of cyclophosphamid	MPA	(194, 227)	 CYP2C1	Var	(128, 135)	NoRelation	This dual genotype relationship was also observed in a preliminary clinical study, with patients who had 1 LoF allele at either CYP2C19 or CYP2B6 also displaying significantly (P= 0.0316) lower bioactivation of cyclophosphamide.
 CYP2B	Var	(139, 145)	 CYP2C1	Var	(128, 135)	NoRelation	This dual genotype relationship was also observed in a preliminary clinical study, with patients who had 1 LoF allele at either CYP2C19 or CYP2B6 also displaying significantly (P= 0.0316) lower bioactivation of cyclophosphamide.
 bioactivation of cyclophosphamid	MPA	(105, 138)	 CYP2B	Var	(55, 61)	NoRelation	CONCLUSIONS: The presence of 1 LoF allele(s) at either CYP2B6 or CYP2C19 appeared to result in decreased bioactivation of cyclophosphamide both in vitro and in patients.
 CYP2C1	Var	(65, 72)	 bioactivation of cyclophosphamid	MPA	(105, 138)	NoRelation	CONCLUSIONS: The presence of 1 LoF allele(s) at either CYP2B6 or CYP2C19 appeared to result in decreased bioactivation of cyclophosphamide both in vitro and in patients.
 CYP2C1	Var	(65, 72)	 CYP2B	Var	(55, 61)	NoRelation	CONCLUSIONS: The presence of 1 LoF allele(s) at either CYP2B6 or CYP2C19 appeared to result in decreased bioactivation of cyclophosphamide both in vitro and in patients.
associated	Reg	(40, 50)	TP53	Gene	(73, 77)	NoRelation	More than half of all human cancers are associated with mutations of the TP53 gene.
human cancers	Disease	(22, 35)	TP53	Gene	(73, 77)	NoRelation	More than half of all human cancers are associated with mutations of the TP53 gene.
'gain-of-function (GOF)' activity	PosReg	(281, 314)	p53	Gene	(273, 276)	NoRelation	We previously showed that the DN p53 mutant was useful as a predictor of poor outcome or a risk factor for metastatic recurrence in patients with some types of cancers, regardless of the presence or absence of loss of heterozygosity (LOH) of WT p53, suggesting that the DN p53 had 'gain-of-function (GOF)' activity besides the transdominance function.
R248Q-transfectants	Var	(69, 88)	vitro invasions of Matrigel and type I collagen gel	CPA	(14, 65)	NoRelation	Meanwhile, in vitro invasions of Matrigel and type I collagen gel by R248Q-transfectants were significantly higher than those by R248W-transfectants or the control cells.
cell migration	CPA	(68, 82)	p53	Gene	(24, 27)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
CXC chemokines	MPA	(40, 54)	cell migration	CPA	(68, 82)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
CXC chemokines	MPA	(40, 54)	mutant	Var	(17, 23)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
enhances	PosReg	(59, 67)	p53	Gene	(24, 27)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
upregulates	PosReg	(28, 39)	p53	Gene	(24, 27)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
cell migration	CPA	(68, 82)	mutant	Var	(17, 23)	NoRelation	Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
aberrant	Var	(33, 41)	tumorigenesis and metastasis	CPA	(67, 95)	NoRelation	Our previous data suggested that aberrant p53 proteins can enhance tumorigenesis and metastasis.
p53 -R175H, -R273H and -D281G	Var	(21, 50)	migration	CPA	(67, 76)	NoRelation	Cells expressing GOF p53 -R175H, -R273H and -D281G showed enhanced migration, which was reversed by RNA interference (RNAi) or transactivation-deficient mutants.
GOF p53	Var	(14, 21)	CXC-chemokine expression	MPA	(42, 66)	NoRelation	We found that GOF p53 proteins upregulate CXC-chemokine expression, the inflammatory mediators that contribute to multiple aspects of tumorigenesis.
oncogenic p53	Var	(77, 90)	expression	MPA	(9, 19)	NoRelation	Elevated expression of CXCL5, CXCL8 and CXCL12 was found in cells expressing oncogenic p53.
GOF p53	Var	(95, 102)	Transcription	MPA	(0, 13)	NoRelation	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
CXCL5 and CXCL8 promoter activity	MPA	(30, 63)	GOF p53	Var	(95, 102)	NoRelation	Transcription was elevated as CXCL5 and CXCL8 promoter activity was higher in cells expressing GOF p53, whereas wild-type p53 repressed promoter activity.
CXCL5 expression	MPA	(102, 118)	cell migration	CPA	(123, 137)	NoRelation	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
p53	Gene	(57, 60)	reduced	NegReg	(94, 101)	NoRelation	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
p53	Gene	(57, 60)	cell migration	CPA	(123, 137)	NoRelation	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
endogenous mutant	Var	(39, 56)	cell migration	CPA	(123, 137)	NoRelation	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
endogenous mutant	Var	(39, 56)	CXCL5 expression	MPA	(102, 118)	NoRelation	Consistent with this, knockdown of the endogenous mutant p53 in lung cancer or melanoma cells reduced CXCL5 expression and cell migration.
p53	Gene	(51, 54)	reduced	NegReg	(75, 82)	NoRelation	Furthermore, short hairpin RNA knockdown of mutant p53 in MDA-MB-231 cells reduced expression of a number of key targets, including several chemokines and other inflammatory mediators.
mutant	Var	(44, 50)	expression of a number of key targets	MPA	(83, 120)	NoRelation	Furthermore, short hairpin RNA knockdown of mutant p53 in MDA-MB-231 cells reduced expression of a number of key targets, including several chemokines and other inflammatory mediators.
CXCL5 expression	MPA	(9, 25)	GOF p53	Var	(77, 84)	NoRelation	Finally, CXCL5 expression was also elevated in lung tumor samples containing GOF p53, indicating relevance to human cancer.
lung cancer	Disease	(60, 71)	activity	MPA	(33, 41)	NoRelation	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
activity	MPA	(33, 41)	mutants	Var	(49, 56)	NoRelation	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
p53	Gene	(45, 48)	gain-of-function	PosReg	(16, 32)	NoRelation	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
lung cancer	Disease	(60, 71)	p53	Gene	(45, 48)	NoRelation	Allele specific gain-of-function activity of p53 mutants in lung cancer cells.
p53	Gene	(0, 3)	gain of function	PosReg	(108, 124)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
mutations	Var	(4, 13)	activity	MPA	(132, 140)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
p53	Gene	(0, 3)	resulting in	Reg	(51, 63)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
mutations	Var	(4, 13)	expression	MPA	(64, 74)	NoRelation	p53 mutations are mostly single amino acid changes resulting in expression of a stable mutant protein with "gain of function" (GOF) activity having a dominant oncogenic role rather than simple loss of function of wild-type p53.
mutants	Var	(87, 94)	activity	MPA	(118, 126)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
loss	NegReg	(106, 110)	p53	Gene	(83, 86)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
p53	Gene	(83, 86)	cell growth rate	CPA	(151, 167)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
p53	Gene	(83, 86)	lowering	NegReg	(139, 147)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
mutants	Var	(87, 94)	cell growth rate	CPA	(151, 167)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
activity	MPA	(118, 126)	cell growth rate	CPA	(151, 167)	NoRelation	Knock-down of mutant p53 in human lung cancer cell lines with different endogenous p53 mutants results in loss of GOF activity as shown by lowering of cell growth rate.
mutants p53-P278S and -R267P	Var	(64, 92)	growth rate	MPA	(112, 123)	NoRelation	Two lung cancer cell lines, ABC1 and H1437, carrying endogenous mutants p53-P278S and -R267P, show reduction in growth rate on knock-down on p53 levels.
tumorigenicity	MPA	(60, 74)	p53	Var	(34, 37)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
p53	Var	(34, 37)	tumorigenicity	MPA	(117, 131)	NoRelation	However, whereas reduction of the p53 level induces loss of tumorigenicity in nude mice for ABC1 cells, it escalates tumorigenicity for H1437 cells.
p53	Gene	(18, 21)	aggressively	PosReg	(55, 67)	NoRelation	Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53.
mutations	Var	(22, 31)	grow	CPA	(45, 49)	NoRelation	Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53.
p53	Gene	(18, 21)	grow	CPA	(45, 49)	NoRelation	Cancer cells with p53 mutations, in general, grow more aggressively than those with wild-type p53 or no p53.
cell growth	CPA	(106, 117)	p53	Gene	(35, 38)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
p53	Gene	(35, 38)	affect	Reg	(99, 105)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
expression of genes	MPA	(70, 89)	cell growth	CPA	(106, 117)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
up-regulated	PosReg	(57, 69)	p53	Gene	(35, 38)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
expression of genes	MPA	(70, 89)	mutant	Var	(28, 34)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
cell growth	CPA	(106, 117)	mutant	Var	(28, 34)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
oncogenesis	CPA	(122, 133)	p53	Gene	(35, 38)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
oncogenesis	CPA	(122, 133)	expression of genes	MPA	(70, 89)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
oncogenesis	CPA	(122, 133)	mutant	Var	(28, 34)	NoRelation	Expression of tumor-derived mutant p53 in cells leads to up-regulated expression of genes that may affect cell growth and oncogenesis.
p53	Gene	(131, 134)	up-regulated	PosReg	(115, 127)	NoRelation	In our study of this aggressive phenotype, we have investigated the receptor protein tyrosine kinase Axl, which is up-regulated by p53 mutants at both RNA and protein levels in H1299 lung cancer cells expressing mutants p53-R175H, -R273H, and -D281G.
acetylation on the Axl promoter region	MPA	(120, 158)	p53	Gene	(169, 172)	NoRelation	Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53.
histone	Reg	(112, 119)	p53	Gene	(169, 172)	NoRelation	Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53.
acetylation on the Axl promoter region	MPA	(120, 158)	mutant	Var	(162, 168)	NoRelation	Chromatin immunoprecipitation (ChIP) assays carried out with acetylated histone antibodies demonstrated induced histone acetylation on the Axl promoter region by mutant p53.
mediated	Reg	(83, 91)	p53	Gene	(59, 62)	NoRelation	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
activities	MPA	(68, 78)	p53	Gene	(59, 62)	NoRelation	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
mutant	Var	(52, 58)	activities	MPA	(68, 78)	NoRelation	This indicates that for lung cancer cell lines with mutant p53, GOF activities are mediated in part through Axl.
CgPDR1	Gene	(47, 53)	virulence	MPA	(128, 137)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
mutations	Var	(34, 43)	virulence	MPA	(128, 137)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
CgPDR1	Gene	(47, 53)	lead	PosReg	(73, 77)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
mutations	Var	(34, 43)	azole resistance	MPA	(90, 106)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
CgPDR1	Gene	(47, 53)	azole resistance	MPA	(90, 106)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
virulence	MPA	(128, 137)	azole resistance	MPA	(90, 106)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
CgPDR1	Gene	(47, 53)	enhanced	PosReg	(119, 127)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
CgPDR1	Gene	(47, 53)	gain-of-function	PosReg	(11, 27)	NoRelation	A range of gain-of-function (GOF) mutations in CgPDR1 have been found to lead not only to azole resistance but also to enhanced virulence.
implicates	Reg	(5, 15)	CgPDR1	Gene	(16, 22)	NoRelation	This implicates CgPDR1 in the regulation of the interaction of C. glabrata with the host.
regulation	MPA	(30, 40)	CgPDR1	Gene	(16, 22)	NoRelation	This implicates CgPDR1 in the regulation of the interaction of C. glabrata with the host.
adherence to and uptake by macrophages	CPA	(130, 168)	mutations	Var	(4, 13)	NoRelation	GOF mutations in CgPDR1 did not influence survival and replication within macrophages following phagocytosis but led to decreased adherence to and uptake by macrophages.
adherence to and uptake by macrophages	CPA	(130, 168)	CgPDR1	Gene	(17, 23)	NoRelation	GOF mutations in CgPDR1 did not influence survival and replication within macrophages following phagocytosis but led to decreased adherence to and uptake by macrophages.
decreased	NegReg	(120, 129)	CgPDR1	Gene	(17, 23)	NoRelation	GOF mutations in CgPDR1 did not influence survival and replication within macrophages following phagocytosis but led to decreased adherence to and uptake by macrophages.
CgPDR1	Gene	(99, 105)	epithelial colonization	CPA	(116, 139)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
CgPDR1	Gene	(99, 105)	increased	PosReg	(175, 184)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
adherence	CPA	(185, 194)	CgPDR1	Gene	(99, 105)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
epithelial colonization	CPA	(116, 139)	mutations	Var	(86, 95)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
CgPDR1	Gene	(99, 105)	favor	PosReg	(110, 115)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
adherence	CPA	(185, 194)	mutations	Var	(86, 95)	NoRelation	The interaction with epithelial cells revealed an opposite trend, suggesting that GOF mutations in CgPDR1 may favor epithelial colonization of the host by C. glabrata through increased adherence to epithelial cell layers.
interaction	Interaction	(60, 71)	mutations	Var	(27, 36)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
CgPDR1	Gene	(40, 46)	increased	PosReg	(119, 128)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
CgPDR1	Gene	(40, 46)	modulate	Reg	(47, 55)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
virulence	MPA	(129, 138)	mutations	Var	(27, 36)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
CgPDR1	Gene	(40, 46)	virulence	MPA	(129, 138)	NoRelation	These data reveal that GOF mutations in CgPDR1 modulate the interaction with host cells in ways that may contribute to increased virulence.
mutp53	Var	(113, 119)	invasive carcinoma	Disease	(89, 107)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
mutp53	Var	(113, 119)	colitis-associated colorectal cancer	Disease	(229, 265)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
NF-B	Protein	(147, 152)	invasive carcinoma	Disease	(89, 107)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
NF-B	Protein	(147, 152)	colitis-associated colorectal cancer	Disease	(229, 265)	NoRelation	This mutp53 GOF is manifested by rapid onset of flat dysplastic lesions that progress to invasive carcinoma with mutp53 accumulation and augmented NF-B activation, faithfully recapitulating features frequently observed in human colitis-associated colorectal cancer (CAC).
high-grade serous ovarian carcinoma	Disease	(59, 94)	p53	Gene	(52, 55)	NoRelation	Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
high-grade serous ovarian carcinoma	Disease	(59, 94)	mutations	Var	(39, 48)	NoRelation	Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
gain-of-function	PosReg	(22, 38)	p53	Gene	(52, 55)	NoRelation	Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
p53	Gene	(70, 73)	oncogenic activity	CPA	(84, 102)	NoRelation	In spite of growing evidence that gain-of-function (GOF) mutations of p53 also have oncogenic activity, little is known about the clinical relevance of these mutations.
mutations	Var	(57, 66)	oncogenic activity	CPA	(84, 102)	NoRelation	In spite of growing evidence that gain-of-function (GOF) mutations of p53 also have oncogenic activity, little is known about the clinical relevance of these mutations.
gain-of-function	PosReg	(34, 50)	p53	Gene	(70, 73)	NoRelation	In spite of growing evidence that gain-of-function (GOF) mutations of p53 also have oncogenic activity, little is known about the clinical relevance of these mutations.
higher	PosReg	(80, 86)	p53 protein	Protein	(32, 43)	NoRelation	RESULTS: Patients with a mutant p53 protein (mutp53) with a GOF mutation showed higher p53 mRNA and protein expression levels than patients with p53 mutation with no evidence of GOF (NE-GOF).
mutation	Var	(64, 72)	p53 mRNA and protein expression levels	MPA	(87, 125)	NoRelation	RESULTS: Patients with a mutant p53 protein (mutp53) with a GOF mutation showed higher p53 mRNA and protein expression levels than patients with p53 mutation with no evidence of GOF (NE-GOF).
platinum resistance	CPA	(69, 88)	mutations	Var	(30, 39)	NoRelation	Clinically, patients with GOF mutations showed a higher frequency of platinum resistance (22/58, 37.9%) than patients with NE-GOF mutations (12/56, 21.4%) (p=0.054).
distant metastasis	CPA	(69, 87)	mutations	Var	(31, 40)	NoRelation	Furthermore, patients with GOF mutations were more likely to develop distant metastasis (36/55, 65.5%) than local recurrence (19/55, 34.5%), whereas patients with NE-GOF mutations showed a higher frequency of locoregional recurrence (26/47, 55.3%) than distant metastasis (21/47, 44.7%) (p=0.035).
platinum treatment resistance	CPA	(109, 138)	mutp53	Var	(58, 64)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
distant metastatic properties	CPA	(143, 172)	mutp53	Var	(58, 64)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
mutp53	Var	(58, 64)	HGS-OvCa	Disease	(176, 184)	NoRelation	CONCLUSION: This study demonstrates that patient with GOF mutp53 is characterized by a greater likelihood of platinum treatment resistance and distant metastatic properties in HGS-OvCa.
promoting tumorigenesis	CPA	(58, 81)	p53	Protein	(7, 10)	NoRelation	Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF).
promoting tumorigenesis	CPA	(58, 81)	Mutant	Var	(0, 6)	NoRelation	Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF).
gain new activities	PosReg	(35, 54)	p53	Protein	(7, 10)	NoRelation	Mutant p53 (Mutp53) proteins often gain new activities in promoting tumorigenesis, defined as gain-of-function (GOF).
tumorigenesis	CPA	(78, 91)	mutp53	Var	(64, 70)	NoRelation	Mutp53 can accumulate to high levels in tumours, which promotes mutp53 GOF in tumorigenesis.
mutp53	Var	(95, 101)	tumorigenesis	CPA	(109, 122)	NoRelation	Thus, overexpression of MDM2 isoforms promotes mutp53 accumulation in tumours, contributing to mutp53 GOF in tumorigenesis.
human osteosarcoma	Disease	(71, 89)	p53	Gene	(7, 10)	NoRelation	Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
gain of function	PosReg	(11, 27)	p53	Gene	(7, 10)	NoRelation	Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
human osteosarcoma	Disease	(71, 89)	Mutant	Var	(0, 6)	NoRelation	Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
clonogenic growth	CPA	(161, 178)	p53-R248W/P72R	Var	(50, 64)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(256, 283)	p53-R248W/P72R	Var	(50, 64)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
invasive ability	CPA	(199, 215)	p53-R248W/P72R	Var	(50, 64)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	levels of stemness proteins	MPA	(256, 283)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(256, 283)	invasive ability	CPA	(199, 215)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(256, 283)	clonogenic growth	CPA	(161, 178)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
sphere formation	CPA	(143, 159)	p53-R248W/P72R	Var	(50, 64)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
cancer stem-like features	CPA	(88, 113)	p53-R248W/P72R	Var	(50, 64)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	clonogenic growth	CPA	(161, 178)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high migration	CPA	(180, 194)	p53-R248W/P72R	Var	(50, 64)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(256, 283)	high migration	CPA	(180, 194)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(256, 283)	cancer stem-like features	CPA	(88, 113)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
high proliferation rate	CPA	(118, 141)	p53-R248W/P72R	Var	(50, 64)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
sphere formation	CPA	(143, 159)	clonogenic growth	CPA	(161, 178)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
sphere formation	CPA	(143, 159)	invasive ability	CPA	(199, 215)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
clonogenic growth	CPA	(161, 178)	invasive ability	CPA	(199, 215)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
levels of stemness proteins	MPA	(256, 283)	sphere formation	CPA	(143, 159)	NoRelation	We have also found that the ectopic expression of p53-R248W/P72R in MG63 cells promoted cancer stem-like features, as high proliferation rate, sphere formation, clonogenic growth, high migration and invasive ability; furthermore, it strongly increased the levels of stemness proteins.
p53-R248W/P72R	Var	(49, 63)	origin of the aberrant characters of the 3AB-OS cells	CPA	(71, 124)	NoRelation	Overall, the findings suggest the involvement of p53-R248W/P72R at the origin of the aberrant characters of the 3AB-OS cells with the hypothesis that its GOF can be at the root of the dedifferentiation of MG63 cells into CSCs.
activity	MPA	(64, 72)	mutations	Var	(38, 47)	NoRelation	Gene set enrichment analysis on these mutations revealed higher activity of drug-metabolizing enzymes, including the CYP3A4 cytochrome P450.
mutations	Var	(177, 186)	resistance	CPA	(224, 234)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
Ectopic expression	MPA	(0, 18)	p53	Gene	(173, 176)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
Ectopic expression	MPA	(0, 18)	CYP3A4 mRNA and protein levels	MPA	(90, 120)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutations	Var	(177, 186)	expression	MPA	(209, 219)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(22, 25)	expression	MPA	(209, 219)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
resistance	CPA	(224, 234)	expression	MPA	(209, 219)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(173, 176)	higher	PosReg	(195, 201)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(22, 25)	resistance	CPA	(224, 234)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
Ectopic expression	MPA	(0, 18)	mutations	Var	(177, 186)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(173, 176)	expression	MPA	(209, 219)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4 mRNA and protein levels	MPA	(90, 120)	expression	MPA	(209, 219)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
upregulated	PosReg	(78, 89)	p53	Gene	(173, 176)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutant R282W	Var	(26, 38)	expression	MPA	(209, 219)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(22, 25)	CYP3A4 mRNA and protein levels	MPA	(90, 120)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
resistance	CPA	(224, 234)	mutant R282W	Var	(26, 38)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	resistance	CPA	(224, 234)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
Ectopic expression	MPA	(0, 18)	expression	MPA	(209, 219)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4	Enzyme	(202, 208)	upregulated	PosReg	(78, 89)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(173, 176)	resistance	CPA	(224, 234)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutations	Var	(177, 186)	mutant R282W	Var	(26, 38)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(22, 25)	higher	PosReg	(195, 201)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
mutations	Var	(177, 186)	CYP3A4 mRNA and protein levels	MPA	(90, 120)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
resistance	CPA	(224, 234)	CYP3A4 mRNA and protein levels	MPA	(90, 120)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(173, 176)	mutant R282W	Var	(26, 38)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
Ectopic expression	MPA	(0, 18)	resistance	CPA	(224, 234)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(22, 25)	upregulated	PosReg	(78, 89)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(173, 176)	CYP3A4 mRNA and protein levels	MPA	(90, 120)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
CYP3A4 mRNA and protein levels	MPA	(90, 120)	mutant R282W	Var	(26, 38)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
p53	Gene	(22, 25)	Ectopic expression	MPA	(0, 18)	NoRelation	Ectopic expression of p53 mutant R282W in H1299 and SaOS2 cells significantly upregulated CYP3A4 mRNA and protein levels, and cancer cell lines bearing mortality-associated p53 mutations display higher CYP3A4 expression and resistance to several CYP3A4-metabolized chemotherapeutic drugs.
clefts in the perineal region	CPA	(83, 112)	hypoplastic elongation of the URS	CPA	(117, 150)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
-catenin	Protein	(5, 14)	hypoplastic elongation of the URS	CPA	(117, 150)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
clefts in the perineal region	CPA	(83, 112)	mutants	Var	(56, 63)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
mutants	Var	(56, 63)	hypoplastic elongation of the URS	CPA	(117, 150)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
-catenin	Protein	(5, 14)	clefts in the perineal region	CPA	(83, 112)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
-catenin	Protein	(5, 14)	gain-of-function	PosReg	(25, 41)	NoRelation	Both -catenin loss- and gain-of-function (LOF and GOF) mutants displayed abnormal clefts in the perineal region and hypoplastic elongation of the URS.
mutants	Var	(4, 11)	cell proliferation in the URS mesenchyme	CPA	(35, 75)	NoRelation	The mutants also displayed reduced cell proliferation in the URS mesenchyme.
filaggrin	Protein	(114, 123)	keratin 1	Protein	(100, 109)	NoRelation	This instability possibly resulted in reduced expression levels of differentiation markers, such as keratin 1 and filaggrin, in the perineal epithelia.
-catenin	Protein	(145, 154)	induced	PosReg	(102, 109)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
expression	MPA	(4, 14)	mutants	Var	(159, 166)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
expression	MPA	(4, 14)	Bmp4	Gene	(66, 70)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
mutants	Var	(159, 166)	Bmp4	Gene	(66, 70)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
mutants	Var	(159, 166)	Bmp7	Gene	(75, 79)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
expression	MPA	(4, 14)	Bmp7	Gene	(75, 79)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Bmp4	Gene	(66, 70)	induced	PosReg	(102, 109)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Bmp7	Gene	(75, 79)	induced	PosReg	(102, 109)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
mutants	Var	(159, 166)	bone morphogenetic protein (Bmp) genes	Gene	(18, 56)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
induced	PosReg	(102, 109)	bone morphogenetic protein (Bmp) genes	Gene	(18, 56)	NoRelation	The expression of bone morphogenetic protein (Bmp) genes, such as Bmp4 and Bmp7, was also ectopically induced in the epithelia of the URS in the -catenin GOF mutants.
Msx2 gene	Gene	(22, 31)	readouts of Bmp signaling	MPA	(71, 96)	NoRelation	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
Msx2 gene	Gene	(22, 31)	increased	PosReg	(107, 116)	NoRelation	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
expression	MPA	(4, 14)	readouts of Bmp signaling	MPA	(71, 96)	NoRelation	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
mutants	Var	(124, 131)	Msx2 gene	Gene	(22, 31)	NoRelation	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
mutants	Var	(124, 131)	readouts of Bmp signaling	MPA	(71, 96)	NoRelation	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
mutants	Var	(124, 131)	expression	MPA	(4, 14)	NoRelation	The expression of the Msx2 gene and phosphorylated-Smad1/5/8, possible readouts of Bmp signaling, was also increased in the mutants.
Bmp signaling	MPA	(101, 114)	mutants	Var	(69, 76)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
ARM	Disease	(33, 36)	Bmp signaling	MPA	(101, 114)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
ARM	Disease	(33, 36)	mutants	Var	(69, 76)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
ARM	Disease	(33, 36)	-catenin	Protein	(55, 64)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
GOF	PosReg	(65, 68)	-catenin	Protein	(55, 64)	NoRelation	These results indicate that some ARM phenotypes in the -catenin GOF mutants were caused by abnormal Bmp signaling.
endodermal -catenin	Protein	(58, 78)	apoptotic cells	CPA	(13, 28)	NoRelation	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
endodermal -catenin	Protein	(58, 78)	GOF	PosReg	(79, 82)	NoRelation	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
mutant	Var	(83, 89)	apoptotic cells	CPA	(13, 28)	NoRelation	Furthermore, apoptotic cells were markedly reduced in the endodermal -catenin GOF mutant embryos, which counteracted the inhibitory effects of Wif1.
MC1R	Protein	(141, 145)	genomic stability of melanocytes	CPA	(170, 202)	NoRelation	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
LOF	Var	(134, 137)	DDR	MPA	(162, 165)	NoRelation	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
genomic stability of melanocytes	CPA	(170, 202)	LOF	Var	(134, 137)	NoRelation	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
genomic stability of melanocytes	CPA	(170, 202)	DDR	MPA	(162, 165)	NoRelation	We propose that -MSH increases UV-induced H2AX to facilitate formation of DNA repair complexes and repair of DNA photoproducts, and LOF of MC1R compromises the DDR and genomic stability of melanocytes.
PCSK9	Gene	(75, 80)	LOF	NegReg	(54, 57)	NoRelation	Here, we show that two hypocholesterolemia-associated LOF mutations in the PCSK9 gene can be accurately imputed into large-scale GWAS datasets which raises the possibility of assessing LOFs through genomics-linked medical records.
hypocholesterolemia	Disease	(23, 42)	PCSK9	Gene	(75, 80)	NoRelation	Here, we show that two hypocholesterolemia-associated LOF mutations in the PCSK9 gene can be accurately imputed into large-scale GWAS datasets which raises the possibility of assessing LOFs through genomics-linked medical records.
hypocholesterolemia	Disease	(23, 42)	mutations	Var	(58, 67)	NoRelation	Here, we show that two hypocholesterolemia-associated LOF mutations in the PCSK9 gene can be accurately imputed into large-scale GWAS datasets which raises the possibility of assessing LOFs through genomics-linked medical records.
cause	Reg	(44, 49)	contribute	Reg	(53, 63)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
ectopic	Var	(13, 20)	cancer	Disease	(84, 90)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
PDGF	Protein	(21, 25)	tissue fibrosis	Disease	(95, 110)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
activity	MPA	(26, 34)	tissue fibrosis	Disease	(95, 110)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
ectopic	Var	(13, 20)	tissue fibrosis	Disease	(95, 110)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
activity	MPA	(26, 34)	cancer	Disease	(84, 90)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
PDGF	Protein	(21, 25)	cancer	Disease	(84, 90)	NoRelation	Increased or ectopic PDGF activity may also cause or contribute to diseases such as cancer and tissue fibrosis.
PDGF-R	Gene	(135, 142)	familial idiopathic basal ganglia calcification	Disease	(147, 194)	NoRelation	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
PDGF-R	Gene	(135, 142)	LOF	NegReg	(55, 58)	NoRelation	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
familial idiopathic basal ganglia calcification	Disease	(147, 194)	mutations	Var	(59, 68)	NoRelation	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
PDGF-B	Gene	(91, 97)	LOF	NegReg	(55, 58)	NoRelation	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
familial idiopathic basal ganglia calcification	Disease	(147, 194)	PDGF-B	Gene	(91, 97)	NoRelation	This changed in 2013 when reports appeared on presumed LOF mutations in the genes encoding PDGF-B and its receptor PDGF receptor-beta (PDGF-R) in familial idiopathic basal ganglia calcification (IBGC), a brain disease characterized by anatomically localized calcifications in or near the blood microvessels.
p53	Gene	(7, 10)	inflammatory signals	MPA	(43, 63)	NoRelation	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
promoting	PosReg	(33, 42)	p53	Gene	(7, 10)	NoRelation	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
inflammatory signals	MPA	(43, 63)	Mutant	Var	(0, 6)	NoRelation	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
p53	Gene	(7, 10)	repression	NegReg	(67, 77)	NoRelation	Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Missense mutations	Var	(0, 18)	tumor malignancy	CPA	(80, 96)	NoRelation	Missense mutations can add novel functions (gain-of-function, GOF) that promote tumor malignancy.
p53	Gene	(33, 36)	tumor malignancy	CPA	(46, 62)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
p53	Gene	(33, 36)	suppressing	NegReg	(66, 77)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
expression	MPA	(82, 92)	tumor malignancy	CPA	(46, 62)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
p53	Gene	(33, 36)	expression	MPA	(82, 92)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
mutant	Var	(20, 26)	expression	MPA	(82, 92)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
p53	Gene	(33, 36)	promotes	PosReg	(37, 45)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
mutant	Var	(20, 26)	tumor malignancy	CPA	(46, 62)	NoRelation	Here we report that mutant (mut) p53 promotes tumor malignancy by suppressing the expression of a natural occurring anti-inflammatory cytokine, the secreted interleukin-1 receptor antagonist (sIL-1Ra, IL1RN).
mutp53	Var	(13, 19)	sIL-1Ra production	MPA	(62, 80)	NoRelation	We show that mutp53 but not wild-type (wt) p53 suppresses the sIL-1Ra production in conditioned media of cancer cells.
PPARG	Gene	(54, 59)	type 2 diabetes	Disease	(218, 233)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
PPARG	Gene	(54, 59)	lipodystrophy	Disease	(90, 103)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
PPARG	Gene	(54, 59)	insulin resistance	Disease	(108, 126)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
mutations	Var	(41, 50)	P12A	Var	(166, 170)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
mutations	Var	(41, 50)	type 2 diabetes	Disease	(218, 233)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
mutations	Var	(41, 50)	insulin resistance	Disease	(108, 126)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
P12A	Var	(166, 170)	insulin resistance	Disease	(108, 126)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
P12A	Var	(166, 170)	type 2 diabetes	Disease	(218, 233)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
lipodystrophy	Disease	(90, 103)	P12A	Var	(166, 170)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
lipodystrophy	Disease	(90, 103)	mutations	Var	(41, 50)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
PPARG	Gene	(54, 59)	decreased	NegReg	(200, 209)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
PPARG	Gene	(54, 59)	loss-of-function	NegReg	(18, 34)	NoRelation	In rare families, loss-of-function (LOF) mutations in PPARG are known to cosegregate with lipodystrophy and insulin resistance; in the general population, the common P12A variant is associated with a decreased risk of type 2 diabetes (T2D).
associated	Reg	(236, 246)	PPARG	Gene	(158, 163)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
variant	Var	(147, 154)	function in a human adipocyte differentiation assay	CPA	(177, 228)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
T2D	Disease	(274, 277)	PPARG	Gene	(158, 163)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
function in a human adipocyte differentiation assay	CPA	(177, 228)	PPARG	Gene	(158, 163)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
reduces	NegReg	(169, 176)	PPARG	Gene	(158, 163)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
T2D	Disease	(274, 277)	variant	Var	(147, 154)	NoRelation	The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.
SHROOM3	Gene	(79, 86)	truncating	NegReg	(35, 45)	NoRelation	Notably, we identified two protein-truncating DNMs in two independent cases in SHROOM3, previously associated with NTDs only in animal models.
NTDs	Disease	(74, 78)	DNMs	Var	(53, 57)	NoRelation	We have demonstrated a significant enrichment of LoF DNMs in this gene in NTDs compared with the gene specific DNM rate and to the DNM rate estimated from control cohorts.
LoF	NegReg	(57, 60)	SHROOM3	Gene	(117, 124)	NoRelation	CONCLUSIONS: Our study demonstrates an important role of LoF DNMs in the development of NTDs and strongly implicates SHROOM3 in its aetiology.
SHROOM3	Gene	(117, 124)	NTDs	Disease	(88, 92)	NoRelation	CONCLUSIONS: Our study demonstrates an important role of LoF DNMs in the development of NTDs and strongly implicates SHROOM3 in its aetiology.
DNMs	Var	(61, 65)	NTDs	Disease	(88, 92)	NoRelation	CONCLUSIONS: Our study demonstrates an important role of LoF DNMs in the development of NTDs and strongly implicates SHROOM3 in its aetiology.
TXNDC5	Gene	(112, 118)	LOF	NegReg	(95, 98)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
variation	Var	(99, 108)	C1QTNF8	Gene	(213, 220)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
glucose	MPA	(59, 66)	C1QTNF8	Gene	(213, 220)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
TXNDC5	Gene	(112, 118)	serum magnesium levels	MPA	(224, 246)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
elevated	PosReg	(42, 50)	TXNDC5	Gene	(112, 118)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
variation	Var	(99, 108)	serum magnesium levels	MPA	(224, 246)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
elevated	PosReg	(42, 50)	C1QTNF8	Gene	(213, 220)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
LOF	NegReg	(95, 98)	C1QTNF8	Gene	(213, 220)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
recessive effects	NegReg	(192, 209)	TXNDC5	Gene	(112, 118)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
C1QTNF8	Gene	(213, 220)	serum magnesium levels	MPA	(224, 246)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
glucose	MPA	(59, 66)	variation	Var	(99, 108)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
glucose	MPA	(59, 66)	serum magnesium levels	MPA	(224, 246)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
glucose	MPA	(59, 66)	TXNDC5	Gene	(112, 118)	NoRelation	Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels.
mutant	Var	(13, 19)	tumor development	CPA	(128, 145)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
tumor suppressor activity	CPA	(72, 97)	tumor development	CPA	(128, 145)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
lose	NegReg	(51, 55)	p53	Gene	(20, 23)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
proteins	Protein	(33, 41)	tumor development	CPA	(128, 145)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
p53	Gene	(20, 23)	mutant	Var	(13, 19)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
promote	PosReg	(120, 127)	p53	Gene	(20, 23)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
promote	PosReg	(120, 127)	proteins	Protein	(33, 41)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
tumor suppressor activity	CPA	(72, 97)	proteins	Protein	(33, 41)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
tumor suppressor activity	CPA	(72, 97)	mutant	Var	(13, 19)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
p53	Gene	(20, 23)	tumor development	CPA	(128, 145)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
tumor suppressor activity	CPA	(72, 97)	p53	Gene	(20, 23)	NoRelation	Importantly, mutant p53 (mutp53) proteins not only lose their wild-type tumor suppressor activity but also can actively promote tumor development.
mutp53	Var	(35, 41)	oncogenic activities	CPA	(157, 177)	NoRelation	Two main mechanisms accounting for mutp53 proto-oncogenic activity are inhibition of the wild-type p53 in a dominant-negative fashion and gain of additional oncogenic activities known as gain-of-function (GOF).
resistant	CPA	(62, 71)	survival advantage	CPA	(122, 140)	NoRelation	This coordinated adaptive mechanism renders cancer cells more resistant to proteotoxic stress and provides both, a strong survival advantage to cancer cells and a promising means for therapeutic intervention.
no	NegReg	(22, 24)	MC1R	Gene	(10, 14)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
p.Tyr298*	Var	(0, 9)	ERK pathways	Pathway	(66, 78)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
MC1R	Gene	(10, 14)	nor	NegReg	(80, 83)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cAMP	Pathway	(58, 62)	p.Tyr298*	Var	(0, 9)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cAMP	Pathway	(58, 62)	agonist binding	Interaction	(95, 110)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
MC1R	Gene	(10, 14)	ERK pathways	Pathway	(66, 78)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
ERK pathways	Pathway	(66, 78)	agonist binding	Interaction	(95, 110)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cAMP	Pathway	(58, 62)	MC1R	Gene	(10, 14)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cAMP	Pathway	(58, 62)	ERK pathways	Pathway	(66, 78)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
p.Tyr298*	Var	(0, 9)	agonist binding	Interaction	(95, 110)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cAMP	Pathway	(58, 62)	nor	NegReg	(80, 83)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
ERK pathways	Pathway	(66, 78)	nor	NegReg	(80, 83)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
agonist-induced signaling	MPA	(25, 50)	MC1R	Gene	(10, 14)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
agonist-induced signaling	MPA	(25, 50)	p.Tyr298*	Var	(0, 9)	NoRelation	p.Tyr298* MC1R showed no agonist-induced signaling to the cAMP or ERK pathways, nor detectable agonist binding.
cell surface expression	MPA	(149, 172)	p.Val174del	Var	(41, 52)	NoRelation	Conversely, signaling was comparable for p.Val174del and wild-type in HEK cells overexpressing the proteins, but binding analysis suggested impaired cell surface expression.
p.Tyr298*	Var	(107, 116)	plasma membrane expression	MPA	(61, 87)	NoRelation	Flow cytometry and confocal imaging studies revealed reduced plasma membrane expression of p.Val174del and p.Tyr298*.
p.Val174del	Var	(91, 102)	plasma membrane expression	MPA	(61, 87)	NoRelation	Flow cytometry and confocal imaging studies revealed reduced plasma membrane expression of p.Val174del and p.Tyr298*.
p.Tyr298*	Var	(107, 116)	p.Val174del	Var	(91, 102)	NoRelation	Flow cytometry and confocal imaging studies revealed reduced plasma membrane expression of p.Val174del and p.Tyr298*.
p.Tyr298*	Var	(11, 20)	p.Val174del	Var	(70, 81)	NoRelation	Therefore, p.Tyr298* was a total loss-of-function (LOF) allele, while p.Val174del displayed a partial LOF attribute.
tumour suppressive function	CPA	(46, 73)	missense mutations	Var	(14, 32)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
p53	Gene	(10, 13)	abrogate	NegReg	(33, 41)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
p53	Gene	(10, 13)	promotes	PosReg	(118, 126)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
tumour suppressive function	CPA	(46, 73)	p53	Gene	(10, 13)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
p53	Gene	(10, 13)	cancer	Disease	(127, 133)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
missense mutations	Var	(14, 32)	cancer	Disease	(127, 133)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
gain-of-function	PosReg	(89, 105)	p53	Gene	(10, 13)	NoRelation	Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a 'gain-of-function' (GOF) that promotes cancer.
acetylation	MPA	(294, 305)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
chromatin regulatory genes	Gene	(57, 83)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	mutants	Var	(26, 33)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
mutants	Var	(26, 33)	acetylation	MPA	(294, 305)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
increases	PosReg	(257, 266)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
mutants	Var	(26, 33)	methyltransferases MLL1	Enzyme	(99, 122)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
p53	Gene	(18, 21)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
chromatin regulatory genes	Gene	(57, 83)	mutants	Var	(26, 33)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(146, 150)	upregulate	PosReg	(46, 56)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
chromatin regulatory genes	Gene	(57, 83)	increases	PosReg	(257, 266)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
methyltransferases MLL1	Enzyme	(99, 122)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
histone methylation	MPA	(270, 289)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
mutants	Var	(26, 33)	histone methylation	MPA	(270, 289)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
upregulate	PosReg	(46, 56)	methyltransferases MLL1	Enzyme	(99, 122)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	MLL2	Enzyme	(146, 150)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	upregulate	PosReg	(46, 56)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
increases	PosReg	(257, 266)	methyltransferases MLL1	Enzyme	(99, 122)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	increases	PosReg	(257, 266)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
chromatin regulatory genes	Gene	(57, 83)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetylation	MPA	(294, 305)	histone methylation	MPA	(270, 289)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(146, 150)	mutants	Var	(26, 33)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
acetyltransferase MOZ	Enzyme	(178, 199)	methyltransferases MLL1	Enzyme	(99, 122)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
chromatin regulatory genes	Gene	(57, 83)	histone methylation	MPA	(270, 289)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(146, 150)	increases	PosReg	(257, 266)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(146, 150)	GOF	PosReg	(22, 25)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
chromatin regulatory genes	Gene	(57, 83)	acetylation	MPA	(294, 305)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
upregulate	PosReg	(46, 56)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
methyltransferases MLL1	Enzyme	(99, 122)	p53	Gene	(18, 21)	NoRelation	Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation.
MLL2	Enzyme	(73, 77)	GOF	Var	(94, 97)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MLL1	Enzyme	(67, 71)	p53	Gene	(90, 93)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MLL2	Enzyme	(73, 77)	p53	Gene	(90, 93)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
p53	Gene	(90, 93)	MOZ	Enzyme	(83, 86)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MLL2	Enzyme	(73, 77)	MOZ	Enzyme	(83, 86)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MLL1	Enzyme	(67, 71)	GOF	Var	(94, 97)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
upregulation	PosReg	(51, 63)	p53	Gene	(90, 93)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
GOF	Var	(94, 97)	MOZ	Enzyme	(83, 86)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MLL1	Enzyme	(67, 71)	MOZ	Enzyme	(83, 86)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
MLL2	Enzyme	(73, 77)	MLL1	Enzyme	(67, 71)	NoRelation	Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours.
EFNB2	Gene	(71, 76)	p53	Gene	(24, 27)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
response to DNA damage	MPA	(91, 113)	EFNB2	Gene	(71, 76)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
response to DNA damage	MPA	(91, 113)	mutant	Var	(17, 23)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
expression	MPA	(77, 87)	response to DNA damage	MPA	(91, 113)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
upregulates	PosReg	(59, 70)	p53	Gene	(24, 27)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
EFNB2	Gene	(71, 76)	upregulates	PosReg	(59, 70)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
expression	MPA	(77, 87)	p53	Gene	(24, 27)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
EFNB2	Gene	(71, 76)	mutant	Var	(17, 23)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
expression	MPA	(77, 87)	mutant	Var	(17, 23)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
response to DNA damage	MPA	(91, 113)	p53	Gene	(24, 27)	NoRelation	We show that the mutant p53-NF-Y complex transcriptionally upregulates EFNB2 expression in response to DNA damage.
expression	MPA	(116, 126)	mutant	Var	(33, 39)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
mutant	Var	(33, 39)	p53	Gene	(40, 43)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
expression	MPA	(116, 126)	p53	Gene	(40, 43)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
recruited	PosReg	(55, 64)	p53	Gene	(40, 43)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
regulates	Reg	(102, 111)	p53	Gene	(40, 43)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
recruited	PosReg	(55, 64)	protein	Protein	(44, 51)	NoRelation	Moreover, the acetylated form of mutant p53 protein is recruited on the EFNB2 promoter and positively regulates its expression in conjunction with coactivator p300.
ABCG2	Gene	(114, 119)	mutant	Var	(189, 195)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
JNK-c-Jun signaling	MPA	(166, 185)	ABCG2	Gene	(114, 119)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
induces	PosReg	(106, 113)	ABCG2	Gene	(114, 119)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
p53	Gene	(196, 199)	expression	MPA	(120, 130)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
mutant	Var	(189, 195)	expression	MPA	(120, 130)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
JNK-c-Jun signaling	MPA	(166, 185)	p53	Gene	(196, 199)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
JNK-c-Jun signaling	MPA	(166, 185)	mutant	Var	(189, 195)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
induces	PosReg	(106, 113)	p53	Gene	(196, 199)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
ABCG2	Gene	(114, 119)	p53	Gene	(196, 199)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
JNK-c-Jun signaling	MPA	(166, 185)	expression	MPA	(120, 130)	NoRelation	In the course of deciphering the drug resistance mechanism, we also show that ephrin-B2 reverse signaling induces ABCG2 expression after drug treatment that involves JNK-c-Jun signaling in mutant p53 cells.
mutations	Var	(37, 46)	cardio-protective effect	CPA	(190, 214)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	PCSK9	Gene	(144, 149)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(67, 106)	mutations	Var	(37, 46)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(8, 13)	mutations	Var	(173, 182)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
mutations	Var	(37, 46)	mutations	Var	(173, 182)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	cardio-protective effect	CPA	(190, 214)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(67, 106)	mutations	Var	(173, 182)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(67, 106)	PCSK9	Gene	(8, 13)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	gain-of-function	PosReg	(14, 30)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(8, 13)	familial hypobetalipoproteinemia	Disease	(245, 277)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(8, 13)	loss-of-function	NegReg	(150, 166)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
cardio-protective effect	CPA	(190, 214)	mutations	Var	(173, 182)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(8, 13)	gain-of-function	PosReg	(14, 30)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	PCSK9	Gene	(8, 13)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(8, 13)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	mutations	Var	(37, 46)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	loss-of-function	NegReg	(150, 166)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	autosomal dominant hypercholesterolemia	Disease	(67, 106)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
gain-of-function	PosReg	(14, 30)	have	PosReg	(183, 187)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(8, 13)	cardio-protective effect	CPA	(190, 214)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
familial hypobetalipoproteinemia	Disease	(245, 277)	mutations	Var	(37, 46)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	mutations	Var	(37, 46)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
familial hypobetalipoproteinemia	Disease	(245, 277)	mutations	Var	(173, 182)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
PCSK9	Gene	(144, 149)	familial hypobetalipoproteinemia	Disease	(245, 277)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
autosomal dominant hypercholesterolemia	Disease	(67, 106)	cardio-protective effect	CPA	(190, 214)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	mutations	Var	(173, 182)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
premature atherosclerosis	Disease	(117, 142)	PCSK9	Gene	(8, 13)	NoRelation	Whereas PCSK9 gain-of-function (GOF) mutations are associated with autosomal dominant hypercholesterolemia (ADH) and premature atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a cardio-protective effect and in some cases can lead to familial hypobetalipoproteinemia (FHBL).
Suppress	NegReg	(42, 50)	MLK4	Gene	(10, 14)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
MLK4	Gene	(10, 14)	Colon Tumorigenesis	Disease	(76, 95)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
JNK Signaling	Pathway	(51, 64)	Colon Tumorigenesis	Disease	(76, 95)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Promote	PosReg	(68, 75)	MLK4	Gene	(10, 14)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Mutations	Var	(32, 41)	Colon Tumorigenesis	Disease	(76, 95)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
Loss-of-Function	NegReg	(15, 31)	MLK4	Gene	(10, 14)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
JNK Signaling	Pathway	(51, 64)	Mutations	Var	(32, 41)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
JNK Signaling	Pathway	(51, 64)	MLK4	Gene	(10, 14)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
JNK Signaling	Pathway	(51, 64)	Loss-of-Function	NegReg	(15, 31)	NoRelation	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis.
MLK4	Gene	(46, 50)	loss-of-function	NegReg	(65, 81)	NoRelation	Biochemical data indicated that a majority of MLK4 mutations are loss-of-function (LOF) mutations that can exert dominant-negative effects.
JNK pathway	Pathway	(139, 150)	mutations	Var	(88, 97)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
MLK4	Gene	(24, 28)	enhanced	PosReg	(155, 163)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
diminished	NegReg	(111, 121)	MLK4	Gene	(24, 28)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
JNK pathway	Pathway	(139, 150)	proliferation	CPA	(164, 177)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
signaling	MPA	(122, 131)	proliferation	CPA	(164, 177)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
signaling	MPA	(122, 131)	MLK4	Gene	(24, 28)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
signaling	MPA	(122, 131)	mutations	Var	(88, 97)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
diminished	NegReg	(111, 121)	JNK pathway	Pathway	(139, 150)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
MLK4	Gene	(24, 28)	LOF	NegReg	(84, 87)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
JNK pathway	Pathway	(139, 150)	MLK4	Gene	(24, 28)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
JNK pathway	Pathway	(139, 150)	LOF	NegReg	(84, 87)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
mutations	Var	(88, 97)	proliferation	CPA	(164, 177)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
MLK4	Gene	(24, 28)	proliferation	CPA	(164, 177)	NoRelation	Our work indicates that MLK4 is a novel tumor-suppressing kinase harboring frequent LOF mutations that lead to diminished signaling in the JNK pathway and enhanced proliferation in colon cancer.
p53	Gene	(25, 28)	gain-of-function	PosReg	(54, 70)	NoRelation	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
enhanced	PosReg	(130, 138)	gain-of-function	PosReg	(54, 70)	NoRelation	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
chemoresistance	CPA	(139, 154)	missense mutants	Var	(29, 45)	NoRelation	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
enhanced	PosReg	(130, 138)	p53	Gene	(25, 28)	NoRelation	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
chemoresistance	CPA	(139, 154)	p53	Gene	(25, 28)	NoRelation	Certain tumor associated p53 missense mutants acquire gain-of-function (GOF) properties and confer oncogenic phenotypes including enhanced chemoresistance.
GOF	PosReg	(84, 87)	p53	Gene	(95, 98)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
withstand the cytotoxic effect of the drugs	CPA	(137, 180)	mutant	Var	(88, 94)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
key cellular pathways	Pathway	(112, 133)	mutant	Var	(88, 94)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
GOF	PosReg	(84, 87)	modulate	Reg	(103, 111)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
p53	Gene	(95, 98)	modulate	Reg	(103, 111)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
key cellular pathways	Pathway	(112, 133)	p53	Gene	(95, 98)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
GOF	PosReg	(84, 87)	key cellular pathways	Pathway	(112, 133)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
withstand the cytotoxic effect of the drugs	CPA	(137, 180)	p53	Gene	(95, 98)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
withstand the cytotoxic effect of the drugs	CPA	(137, 180)	key cellular pathways	Pathway	(112, 133)	NoRelation	Our data suggest that in response to chemotherapeutics treatment, cancer cells with GOF mutant p53 can modulate key cellular pathways to withstand the cytotoxic effect of the drugs.
autism spectrum disorders	Disease	(126, 151)	variants	Var	(97, 105)	NoRelation	Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including TBR1, a master regulator of cortical development.
loss-of-function	NegReg	(74, 90)	TBR1	Gene	(169, 173)	NoRelation	Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including TBR1, a master regulator of cortical development.
autism spectrum disorders	Disease	(126, 151)	TBR1	Gene	(169, 173)	NoRelation	Exome sequencing studies have identified multiple genes harboring de novo loss-of-function (LoF) variants in individuals with autism spectrum disorders (ASD), including TBR1, a master regulator of cortical development.
p53	Gene	(46, 49)	mutation	Var	(19, 27)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
p53	Gene	(46, 49)	TNFAIP8	Gene	(95, 102)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
gain-of-function	PosReg	(50, 66)	TNFAIP8	Gene	(95, 102)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
tumor cell survival	CPA	(71, 90)	TNFAIP8	Gene	(95, 102)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
TNFAIP8	Gene	(95, 102)	confers	PosReg	(38, 45)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
tumor cell survival	CPA	(71, 90)	mutation	Var	(19, 27)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
p53	Gene	(46, 49)	confers	PosReg	(38, 45)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
tumor cell survival	CPA	(71, 90)	p53	Gene	(46, 49)	NoRelation	A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction.
blocking	NegReg	(179, 187)	p53	Gene	(36, 39)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
tumor suppressive functions	CPA	(195, 222)	binding	Interaction	(157, 164)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
tumor suppressive functions	CPA	(195, 222)	Mutations	Var	(0, 9)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
tumor suppressive functions	CPA	(195, 222)	substitutions	Var	(111, 124)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
substitutions	Var	(111, 124)	p53	Gene	(36, 39)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
binding	Interaction	(157, 164)	Mutations	Var	(0, 9)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
tumor suppressive functions	CPA	(195, 222)	p53	Gene	(36, 39)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
substitutions	Var	(111, 124)	binding	Interaction	(157, 164)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
substitutions	Var	(111, 124)	Mutations	Var	(0, 9)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
result in	Reg	(83, 92)	p53	Gene	(36, 39)	NoRelation	Mutations in the coding sequence of p53 occur frequently in human cancer and often result in single amino acid substitutions (missense mutations) in the DNA binding domain (DBD), blocking normal tumor suppressive functions.
activities to tumor cells	CPA	(109, 134)	missense mutations	Var	(53, 71)	NoRelation	In addition to the loss of canonical functions, some missense mutations in p53 confer gain-of-function (GOF) activities to tumor cells.
p53	Gene	(75, 78)	activities to tumor cells	CPA	(109, 134)	NoRelation	In addition to the loss of canonical functions, some missense mutations in p53 confer gain-of-function (GOF) activities to tumor cells.
p53	Gene	(75, 78)	gain-of-function	PosReg	(86, 102)	NoRelation	In addition to the loss of canonical functions, some missense mutations in p53 confer gain-of-function (GOF) activities to tumor cells.
bind	Interaction	(129, 133)	TNFAIP8	Gene	(185, 192)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
ability	MPA	(118, 125)	transcription	MPA	(151, 164)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
activate	PosReg	(138, 146)	confer	PosReg	(74, 80)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
TNFAIP8	Gene	(185, 192)	ability	MPA	(118, 125)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
p53	Gene	(81, 84)	confer	PosReg	(74, 80)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
TNFAIP8	Gene	(185, 192)	mutations at K120	Var	(20, 37)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
activate	PosReg	(138, 146)	p53	Gene	(81, 84)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
transcription	MPA	(151, 164)	mutations at K120	Var	(20, 37)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
TNFAIP8	Gene	(185, 192)	confer	PosReg	(74, 80)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
activate	PosReg	(138, 146)	TNFAIP8	Gene	(185, 192)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
p53	Gene	(81, 84)	transcription	MPA	(151, 164)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
TNFAIP8	Gene	(185, 192)	p53	Gene	(81, 84)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
bind	Interaction	(129, 133)	p53	Gene	(81, 84)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
ability	MPA	(118, 125)	mutations at K120	Var	(20, 37)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
bind	Interaction	(129, 133)	mutations at K120	Var	(20, 37)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
p53	Gene	(81, 84)	ability	MPA	(118, 125)	NoRelation	We report here that mutations at K120, a non-hotspot DNA contact residue, confer p53 with the previously unrecognized ability to bind and activate the transcription of the pro-survival TNFAIP8 gene.
mutant	Var	(106, 112)	p53	Gene	(113, 116)	NoRelation	These findings identify induction of pro-survival targets as a mechanism of gain-of-function activity for mutant p53 and will likely broaden our understanding of this phenomenon beyond the limited number of GOF activities currently reported for hotspot mutants.
activity	MPA	(93, 101)	mutant	Var	(106, 112)	NoRelation	These findings identify induction of pro-survival targets as a mechanism of gain-of-function activity for mutant p53 and will likely broaden our understanding of this phenomenon beyond the limited number of GOF activities currently reported for hotspot mutants.
gain-of-function	PosReg	(76, 92)	p53	Gene	(113, 116)	NoRelation	These findings identify induction of pro-survival targets as a mechanism of gain-of-function activity for mutant p53 and will likely broaden our understanding of this phenomenon beyond the limited number of GOF activities currently reported for hotspot mutants.
SON	Gene	(21, 24)	Causing	Reg	(103, 110)	NoRelation	De Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development and Metabolism, Causing an Intellectual-Disability Syndrome.
Intellectual-Disability Syndrome	Disease	(114, 146)	SON	Gene	(21, 24)	NoRelation	De Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development and Metabolism, Causing an Intellectual-Disability Syndrome.
Mutations	Var	(8, 17)	Intellectual-Disability Syndrome	Disease	(114, 146)	NoRelation	De Novo Mutations in SON Disrupt RNA Splicing of Genes Essential for Brain Development and Metabolism, Causing an Intellectual-Disability Syndrome.
ID syndrome	Disease	(22, 33)	mutations	Var	(88, 97)	NoRelation	Here, we report on an ID syndrome caused by de novo heterozygous loss-of-function (LoF) mutations in SON.
loss-of-function	NegReg	(65, 81)	SON	Gene	(101, 104)	NoRelation	Here, we report on an ID syndrome caused by de novo heterozygous loss-of-function (LoF) mutations in SON.
ID syndrome	Disease	(22, 33)	SON	Gene	(101, 104)	NoRelation	Here, we report on an ID syndrome caused by de novo heterozygous loss-of-function (LoF) mutations in SON.
neuronal migration	CPA	(88, 106)	cortex organization	CPA	(111, 130)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
erroneous SON-mediated RNA splicing	Var	(327, 362)	metabolism	CPA	(180, 190)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
neuronal migration	CPA	(88, 106)	metabolism	CPA	(180, 190)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
cortex organization	CPA	(111, 130)	erroneous SON-mediated RNA splicing	Var	(327, 362)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
neuronal migration	CPA	(88, 106)	erroneous SON-mediated RNA splicing	Var	(327, 362)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
cortex organization	CPA	(111, 130)	metabolism	CPA	(180, 190)	NoRelation	Importantly, analyses of RNA from affected individuals revealed that genes critical for neuronal migration and cortex organization (TUBG1, FLNA, PNKP, WDR62, PSMD3, andHDAC6) and metabolism (PCK2, PFKL, IDH2, ACY1, and ADA) are significantly downregulated because of the accumulation of mis-spliced transcripts resulting from erroneous SON-mediated RNA splicing.
PCSK9	Gene	(80, 85)	loss-of-function	NegReg	(86, 102)	NoRelation	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
anti-adipogenic effect	MPA	(4, 26)	variants	Var	(103, 111)	NoRelation	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
absent	NegReg	(68, 74)	PCSK9	Gene	(80, 85)	NoRelation	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
anti-adipogenic effect	MPA	(4, 26)	PCSK9	Gene	(80, 85)	NoRelation	The anti-adipogenic effect of peripheral blood mononuclear cells is absent with PCSK9 loss-of-function variants.
variant	Var	(144, 151)	human adipogenesis	MPA	(230, 248)	NoRelation	OBJECTIVE: To determine the effect of (1) an oral fat load and (2) pro-protein convertase subtilisin/kexin type (PCSK) 9 loss-of-function (LOF) variant status on the ability of peripheral blood mononuclear cells (PBMC) to inhibit human adipogenesis.
adipogenesis	MPA	(79, 91)	PCSK9	Gene	(35, 40)	NoRelation	In contrast, PBMC-CM-F or -PP from PCSK9 LOF variant subjects had no effect on adipogenesis.
variant	Var	(45, 52)	adipogenesis	MPA	(79, 91)	NoRelation	In contrast, PBMC-CM-F or -PP from PCSK9 LOF variant subjects had no effect on adipogenesis.
LOF	NegReg	(41, 44)	PCSK9	Gene	(35, 40)	NoRelation	In contrast, PBMC-CM-F or -PP from PCSK9 LOF variant subjects had no effect on adipogenesis.
PCSK9	Gene	(35, 40)	tumor necrosis factor-	MPA	(125, 148)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
sterol regulatory element binding protein-1c	MPA	(150, 194)	tumor necrosis factor-	MPA	(125, 148)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
tumor necrosis factor-	MPA	(125, 148)	variant	Var	(45, 52)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
CD36	MPA	(196, 200)	variant	Var	(45, 52)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
sterol regulatory element binding protein-1c	MPA	(150, 194)	mRNA levels of interleukin-1	MPA	(94, 123)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
PCSK9	Gene	(35, 40)	mRNA levels of interleukin-1	MPA	(94, 123)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
PCSK9	Gene	(35, 40)	CD36	MPA	(196, 200)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
CD36	MPA	(196, 200)	tumor necrosis factor-	MPA	(125, 148)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
sterol regulatory element binding protein-1c	MPA	(150, 194)	variant	Var	(45, 52)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
PCSK9	Gene	(35, 40)	LOF	NegReg	(41, 44)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
PCSK9	Gene	(35, 40)	increases	PosReg	(81, 90)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
mRNA levels of interleukin-1	MPA	(94, 123)	variant	Var	(45, 52)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
CD36	MPA	(196, 200)	mRNA levels of interleukin-1	MPA	(94, 123)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
PCSK9	Gene	(35, 40)	sterol regulatory element binding protein-1c	MPA	(150, 194)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
tumor necrosis factor-	MPA	(125, 148)	mRNA levels of interleukin-1	MPA	(94, 123)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
sterol regulatory element binding protein-1c	MPA	(150, 194)	CD36	MPA	(196, 200)	NoRelation	After the oral fat load, PBMC from PCSK9 LOF variant subjects showed significant increases in mRNA levels of interleukin-1, tumor necrosis factor-, sterol regulatory element binding protein-1c, CD36, and monocyte chemoattractant protein-1 (MCP-1), only MCP-1 mRNA levels increased in PBMC from non-variant controls.
anti-adipogenic action	MPA	(28, 50)	variant	Var	(74, 81)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
anti-adipogenic action	MPA	(28, 50)	PCSK9	Gene	(64, 69)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
novel role	PosReg	(103, 113)	absence	NegReg	(17, 24)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
variant	Var	(74, 81)	interactions	Interaction	(145, 157)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
interactions	Interaction	(145, 157)	PCSK9	Gene	(64, 69)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
absence	NegReg	(17, 24)	PCSK9	Gene	(64, 69)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
novel role	PosReg	(103, 113)	PCSK9	Gene	(64, 69)	NoRelation	CONCLUSIONS: The absence of anti-adipogenic action of PBMC from PCSK9 LOF variant subjects points to a novel role for PCSK9 in PBMC-adipose cell interactions.
atopic dermatitis	Disease	(147, 164)	mutations	Var	(87, 96)	NoRelation	The extensive genetic variation in this gene, especially common loss-of-function (LoF) mutations, has been established as primary risk factors for atopic dermatitis.
atopic dermatitis	Disease	(147, 164)	extensive genetic variation	Var	(4, 31)	NoRelation	The extensive genetic variation in this gene, especially common loss-of-function (LoF) mutations, has been established as primary risk factors for atopic dermatitis.
expression of collagens-TIMPs/MMPs systems	CPA	(85, 127)	variants	Var	(50, 58)	NoRelation	Transcriptome sequencing revealed that identified variants induced dyshomeostasis in expression of collagens-TIMPs/MMPs systems.
Col5a2	Gene	(4, 10)	aortic dysplasia	CPA	(56, 72)	NoRelation	The Col5a2 (-/-) rats manifested growth retardation and aortic dysplasia.
Col5a2	Gene	(4, 10)	growth retardation	CPA	(33, 51)	NoRelation	The Col5a2 (-/-) rats manifested growth retardation and aortic dysplasia.
growth retardation	CPA	(33, 51)	aortic dysplasia	CPA	(56, 72)	NoRelation	The Col5a2 (-/-) rats manifested growth retardation and aortic dysplasia.
loss of function	NegReg	(122, 138)	signal transducer	Gene	(53, 70)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
activator of transcription 1	Gene	(75, 103)	signal transducer	Gene	(53, 70)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
loss of function	NegReg	(122, 138)	activator of transcription 1	Gene	(75, 103)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
signal transducer	Gene	(53, 70)	chronic mucocutaneous candidiasis	Disease	(265, 298)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
gain of function	PosReg	(221, 237)	signal transducer	Gene	(53, 70)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
activator of transcription 1	Gene	(75, 103)	chronic mucocutaneous candidiasis	Disease	(265, 298)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
gain of function	PosReg	(221, 237)	activator of transcription 1	Gene	(75, 103)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
gain of function	PosReg	(221, 237)	loss of function	NegReg	(122, 138)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
mycobacterial diseases	Disease	(194, 216)	activator of transcription 1	Gene	(75, 103)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
mycobacterial diseases	Disease	(194, 216)	signal transducer	Gene	(53, 70)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
Germline heterozygous mutations	Var	(12, 43)	chronic mucocutaneous candidiasis	Disease	(265, 298)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
mycobacterial diseases	Disease	(194, 216)	Germline heterozygous mutations	Var	(12, 43)	NoRelation	BACKGROUND: Germline heterozygous mutations in human signal transducer and activator of transcription 1 (STAT1) can cause loss of function (LOF), as in patients with Mendelian susceptibility to mycobacterial diseases, or gain of function (GOF), as in patients with chronic mucocutaneous candidiasis.
DNA-binding domain	MPA	(125, 143)	coiled-coil domain	MPA	(96, 114)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
DNA-binding domain	MPA	(125, 143)	STAT1	Gene	(74, 79)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
mutations	Var	(12, 21)	domains	MPA	(63, 70)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
coiled-coil domain	MPA	(96, 114)	mutations	Var	(12, 21)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
STAT1	Gene	(74, 79)	mutations	Var	(12, 21)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
STAT1	Gene	(74, 79)	affect	Reg	(47, 53)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
DNA-binding domain	MPA	(125, 143)	mutations	Var	(12, 21)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
coiled-coil domain	MPA	(96, 114)	STAT1	Gene	(74, 79)	NoRelation	LOF and GOF mutations are equally rare and can affect the same domains of STAT1, especially the coiled-coil domain (CCD) and DNA-binding domain (DBD).
Gain-of-function	PosReg	(12, 28)	human signal transducer and activator of transcription 1	Gene	(52, 108)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
impaired	NegReg	(168, 176)	human signal transducer and activator of transcription 1	Gene	(52, 108)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
mutations	Var	(35, 44)	responsiveness to type I and II interferons	Interaction	(219, 262)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH17cell differentiation	CPA	(177, 202)	responsiveness to type I and II interferons	Interaction	(219, 262)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
impaired	NegReg	(168, 176)	Gain-of-function	PosReg	(12, 28)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
human signal transducer and activator of transcription 1	Gene	(52, 108)	responsiveness to type I and II interferons	Interaction	(219, 262)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
exaggerated	PosReg	(207, 218)	Gain-of-function	PosReg	(12, 28)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
exaggerated	PosReg	(207, 218)	human signal transducer and activator of transcription 1	Gene	(52, 108)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
exaggerated	PosReg	(207, 218)	impaired	NegReg	(168, 176)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH17cell differentiation	CPA	(177, 202)	human signal transducer and activator of transcription 1	Gene	(52, 108)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
TH17cell differentiation	CPA	(177, 202)	mutations	Var	(35, 44)	NoRelation	BACKGROUND: Gain-of-function (GOF) mutations in the human signal transducer and activator of transcription 1 (STAT1) manifest in immunodeficiency and autoimmunity with impaired TH17cell differentiation and exaggerated responsiveness to type I and II interferons.
suppressed	NegReg	(101, 111)	increased	PosReg	(54, 63)	NoRelation	Naive lymphocytes from the affected patient displayed increased TH1 and follicular T helper cell and suppressed TH17cell responses.
TH1 and follicular T helper cell	CPA	(64, 96)	TH17cell responses	CPA	(112, 131)	NoRelation	Naive lymphocytes from the affected patient displayed increased TH1 and follicular T helper cell and suppressed TH17cell responses.
cytokine-induced STAT1 phosphorylation	MPA	(23, 61)	mutation	Var	(4, 12)	NoRelation	The mutation augmented cytokine-induced STAT1 phosphorylation without affecting dephosphorylation kinetics.
GOF	PosReg	(56, 59)	STAT1	Gene	(50, 55)	NoRelation	CONCLUSIONS: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses.
T helper cell responses	CPA	(101, 124)	STAT1	Gene	(50, 55)	NoRelation	CONCLUSIONS: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses.
T helper cell responses	CPA	(101, 124)	mutations	Var	(60, 69)	NoRelation	CONCLUSIONS: Autoimmunity and infection caused by STAT1 GOF mutations are the result of dysregulated T helper cell responses.
loss-of-function	NegReg	(159, 175)	gain-of-function	PosReg	(133, 149)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
cardiovascular disease	Disease	(230, 252)	PCSK9	Gene	(110, 115)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
gain-of-function	PosReg	(133, 149)	effects	Reg	(199, 206)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
LDL cholesterol	Disease	(210, 225)	variants	Var	(51, 59)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
loss-of-function	NegReg	(159, 175)	PCSK9	Gene	(110, 115)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
PCSK9	Gene	(110, 115)	gain-of-function	PosReg	(133, 149)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
LDL cholesterol	Disease	(210, 225)	PCSK9	Gene	(110, 115)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
PCSK9	Gene	(110, 115)	effects	Reg	(199, 206)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
cardiovascular disease	Disease	(230, 252)	variants	Var	(51, 59)	NoRelation	PURPOSE OF REVIEW: There are many reports of human variants in proprotein convertase subtilisin-kexin type 9 (PCSK9) that are either gain-of-function (GOF) or loss-of-function (LOF), with downstream effects on LDL cholesterol and cardiovascular disease (CVD) risk.
LDL receptor	Protein	(107, 119)	GOF	PosReg	(17, 20)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
expression	MPA	(120, 130)	familial hypercholesterolemia	Disease	(180, 209)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
affect	Reg	(58, 64)	cause	Reg	(171, 176)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
LDL receptor	Protein	(107, 119)	domains of the protein	Protein	(69, 91)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
affect	Reg	(58, 64)	GOF	PosReg	(17, 20)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
LDL receptor	Protein	(107, 119)	cause	Reg	(171, 176)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
familial hypercholesterolemia	Disease	(180, 209)	variants	Var	(21, 29)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
LDL receptor	Protein	(107, 119)	familial hypercholesterolemia	Disease	(180, 209)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
domains of the protein	Protein	(69, 91)	cause	Reg	(171, 176)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
familial hypercholesterolemia	Disease	(180, 209)	domains of the protein	Protein	(69, 91)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
reduce	NegReg	(100, 106)	GOF	PosReg	(17, 20)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
domains of the protein	Protein	(69, 91)	GOF	PosReg	(17, 20)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
expression	MPA	(120, 130)	variants	Var	(21, 29)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
LDL receptor	Protein	(107, 119)	affect	Reg	(58, 64)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
cause	Reg	(171, 176)	GOF	PosReg	(17, 20)	NoRelation	RECENT FINDINGS: GOF variants are individually ultrarare, affect all domains of the protein, act to reduce LDL receptor expression through several mechanisms, are a minor cause of familial hypercholesterolemia, have been reported mainly within families, have variable LDL cholesterol-raising effects, and are associated with increased CVD risk mainly through observational studies in families and small cohorts.
expression	MPA	(185, 195)	LDL cholesterol	MPA	(238, 253)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	variants	Var	(17, 25)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
lowering	NegReg	(254, 262)	increase	PosReg	(163, 171)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	increase	PosReg	(163, 171)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	domains of the protein	Protein	(132, 154)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	LDL receptor	Protein	(172, 184)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	LDL cholesterol	MPA	(238, 253)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
CVD	Disease	(312, 315)	expression	MPA	(185, 195)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
decreased	NegReg	(302, 311)	increase	PosReg	(163, 171)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
expression	MPA	(185, 195)	variants	Var	(17, 25)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	affect	Reg	(121, 127)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
lowering	NegReg	(254, 262)	domains of the protein	Protein	(132, 154)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
domains of the protein	Protein	(132, 154)	increase	PosReg	(163, 171)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	domains of the protein	Protein	(132, 154)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
increase	PosReg	(163, 171)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
LDL receptor	Protein	(172, 184)	LOF	NegReg	(13, 16)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
variants	Var	(17, 25)	LDL cholesterol	MPA	(238, 253)	NoRelation	In contrast, LOF variants can be either ultrarare mutations or relatively more common polymorphisms seen in populations, affect all domains of the protein, act to increase LDL receptor expression through several mechanisms, have variable LDL cholesterol-lowering effects, and have been associated with decreased CVD risk mainly through Mendelian randomization studies in epidemiologic populations.
elevated	PosReg	(50, 58)	DAT	Gene	(8, 11)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
DAT	Gene	(8, 11)	balance of monoaminergic transmission	MPA	(129, 166)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
subcortical extracellular dopamine concentration	MPA	(59, 107)	balance of monoaminergic transmission	MPA	(129, 166)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
elevated	PosReg	(50, 58)	Loss	NegReg	(0, 4)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
altered	Reg	(117, 124)	DAT	Gene	(8, 11)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
mutant	Var	(29, 35)	balance of monoaminergic transmission	MPA	(129, 166)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
altered	Reg	(117, 124)	Loss	NegReg	(0, 4)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
altered	Reg	(117, 124)	elevated	PosReg	(50, 58)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
subcortical extracellular dopamine concentration	MPA	(59, 107)	mutant	Var	(29, 35)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
subcortical extracellular dopamine concentration	MPA	(59, 107)	DAT	Gene	(8, 11)	NoRelation	Loss of DAT functionality in mutant rats not only elevated subcortical extracellular dopamine concentration but also altered the balance of monoaminergic transmission.
PIK3CD	Gene	(158, 164)	caused	Reg	(75, 81)	NoRelation	Activated PI3K Delta Syndrome (APDS) is a primary immunodeficiency disease caused by activating mutations in either the leukocyte-restricted p110 catalytic (PIK3CD) subunit or the ubiquitously expressed p85 regulatory (PIK3R1) subunit of class IA phosphoinositide 3-kinases (PI3Ks).
PIK3CD	Gene	(158, 164)	Activated PI3K Delta Syndrome	Disease	(0, 29)	NoRelation	Activated PI3K Delta Syndrome (APDS) is a primary immunodeficiency disease caused by activating mutations in either the leukocyte-restricted p110 catalytic (PIK3CD) subunit or the ubiquitously expressed p85 regulatory (PIK3R1) subunit of class IA phosphoinositide 3-kinases (PI3Ks).
mutations	Var	(96, 105)	Activated PI3K Delta Syndrome	Disease	(0, 29)	NoRelation	Activated PI3K Delta Syndrome (APDS) is a primary immunodeficiency disease caused by activating mutations in either the leukocyte-restricted p110 catalytic (PIK3CD) subunit or the ubiquitously expressed p85 regulatory (PIK3R1) subunit of class IA phosphoinositide 3-kinases (PI3Ks).
inhibitory interactions	MPA	(125, 148)	mutation	Var	(36, 44)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
APDS2	Gene	(30, 35)	inhibitory interactions	MPA	(125, 148)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
p110 (>300-fold)	MPA	(94, 111)	mutation	Var	(36, 44)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
APDS2	Gene	(30, 35)	activation	PosReg	(80, 90)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
inhibitory interactions	MPA	(125, 148)	p110 (>300-fold)	MPA	(94, 111)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
disrupts	NegReg	(116, 124)	activation	PosReg	(80, 90)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
APDS2	Gene	(30, 35)	p110 (>300-fold)	MPA	(94, 111)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
APDS2	Gene	(30, 35)	disrupts	NegReg	(116, 124)	NoRelation	Intriguingly, we find that an APDS2 mutation in p85 leads to substantial basal activation of p110 (>300-fold) and disrupts inhibitory interactions from the nSH2, iSH2, and cSH2 domains of p85, whereas p110 is only minimally basally activated (2-fold) when associated with mutated p85.
growth	MPA	(78, 84)	deletion	Var	(40, 48)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
Cdh2	Gene	(35, 39)	osteoprogenitor number	MPA	(113, 135)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
growth	MPA	(78, 84)	osteoprogenitor number	MPA	(113, 135)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
growth	MPA	(78, 84)	Cdh2	Gene	(35, 39)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
deletion	Var	(40, 48)	osteoprogenitor number	MPA	(113, 135)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
Cdh2	Gene	(35, 39)	low	NegReg	(86, 89)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
bone mass	MPA	(90, 99)	growth	MPA	(78, 84)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
reduced	NegReg	(105, 112)	Cdh2	Gene	(35, 39)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
Cdh2	Gene	(35, 39)	defective	NegReg	(68, 77)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
bone mass	MPA	(90, 99)	deletion	Var	(40, 48)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
bone mass	MPA	(90, 99)	osteoprogenitor number	MPA	(113, 135)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
bone mass	MPA	(90, 99)	Cdh2	Gene	(35, 39)	NoRelation	Embryonic conditional osteolineage Cdh2 deletion in mice results in defective growth, low bone mass, and reduced osteoprogenitor number.
NF1	Gene	(13, 16)	KIT	Gene	(0, 3)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
SDH	Gene	(21, 24)	PDGFRA	Gene	(5, 11)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
PDGFRA	Gene	(5, 11)	KIT	Gene	(0, 3)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
NF1	Gene	(13, 16)	PDGFRA	Gene	(5, 11)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
KIT	Gene	(0, 3)	gastrointestinal stromal tumours	MPA	(93, 125)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
mutations	Var	(25, 34)	gastrointestinal stromal tumours	MPA	(93, 125)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
NF1	Gene	(13, 16)	SDH	Gene	(21, 24)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
fostering	Reg	(68, 77)	KIT	Gene	(0, 3)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
NF1	Gene	(13, 16)	gastrointestinal stromal tumours	MPA	(93, 125)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
PDGFRA	Gene	(5, 11)	gastrointestinal stromal tumours	MPA	(93, 125)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
SDH	Gene	(21, 24)	KIT	Gene	(0, 3)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
fostering	Reg	(68, 77)	SDH	Gene	(21, 24)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
fostering	Reg	(68, 77)	PDGFRA	Gene	(5, 11)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
fostering	Reg	(68, 77)	NF1	Gene	(13, 16)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
SDH	Gene	(21, 24)	gastrointestinal stromal tumours	MPA	(93, 125)	NoRelation	KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy.
Melanoma Tumors	Disease	(36, 51)	Mutations	Var	(4, 13)	NoRelation	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
ATR	Gene	(0, 3)	Promote	PosReg	(14, 21)	NoRelation	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Growth	MPA	(26, 32)	Mutations	Var	(4, 13)	NoRelation	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Melanoma Tumors	Disease	(36, 51)	ATR	Gene	(0, 3)	NoRelation	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
Growth	MPA	(26, 32)	ATR	Gene	(0, 3)	NoRelation	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment.
mutations	Var	(38, 47)	neoantigens	MPA	(80, 91)	NoRelation	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
generate	Reg	(71, 79)	suppress	NegReg	(105, 113)	NoRelation	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
immune response to facilitate continued growth	MPA	(118, 164)	neoantigens	MPA	(80, 91)	NoRelation	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
mutations	Var	(38, 47)	immune response to facilitate continued growth	MPA	(118, 164)	NoRelation	Melanomas accumulate a high burden of mutations that could potentially generate neoantigens, yet somehow suppress the immune response to facilitate continued growth.
Tcell recruitment	MPA	(143, 161)	mutant	Var	(4, 10)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
recruitment of macrophages	MPA	(176, 202)	mutant	Var	(4, 10)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
ATR	Gene	(0, 3)	increased	PosReg	(166, 175)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
decreased	NegReg	(133, 142)	ATR	Gene	(0, 3)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
recruitment of macrophages	MPA	(176, 202)	ATR	Gene	(0, 3)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
decreased	NegReg	(133, 142)	increased	PosReg	(166, 175)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
Tcell recruitment	MPA	(143, 161)	ATR	Gene	(0, 3)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
Tcell recruitment	MPA	(143, 161)	recruitment of macrophages	MPA	(176, 202)	NoRelation	ATR mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of inflammatory genes, resulting in decreased Tcell recruitment and increased recruitment of macrophages known to spur tumor invasion.
regulation of endometrial cells growth	MPA	(90, 128)	BDNF	Gene	(24, 28)	NoRelation	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
polymorphism	Var	(70, 82)	polymorphism	Var	(35, 47)	NoRelation	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
regulation of endometrial cells growth	MPA	(90, 128)	polymorphism	Var	(35, 47)	NoRelation	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
loss-of-function	NegReg	(53, 69)	BDNF	Gene	(24, 28)	NoRelation	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
polymorphism	Var	(70, 82)	BDNF	Gene	(24, 28)	NoRelation	The results showed that BDNF(V66M) polymorphism is a loss-of-function polymorphism in the regulation of endometrial cells growth.
gain-of-function	PosReg	(10, 26)	LRP5	Gene	(96, 100)	NoRelation	Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
mutations	Var	(27, 36)	glucose and lipid homeostasis	MPA	(105, 134)	NoRelation	Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
LRP5	Gene	(96, 100)	glucose and lipid homeostasis	MPA	(105, 134)	NoRelation	Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
LRP5	Gene	(0, 4)	profound osteoporosis	MPA	(57, 78)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
LRP5	Gene	(0, 4)	loss-of-function	NegReg	(5, 21)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
dysregulated lipid metabolism	MPA	(142, 171)	mutations	Var	(22, 31)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
LRP5	Gene	(0, 4)	dysregulated lipid metabolism	MPA	(142, 171)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
impaired insulin sensitivity	MPA	(109, 137)	mutations	Var	(22, 31)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
mutations	Var	(22, 31)	profound osteoporosis	MPA	(57, 78)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
dysregulated lipid metabolism	MPA	(142, 171)	profound osteoporosis	MPA	(57, 78)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
LRP5	Gene	(0, 4)	impaired insulin sensitivity	MPA	(109, 137)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
impaired insulin sensitivity	MPA	(109, 137)	profound osteoporosis	MPA	(57, 78)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
dysregulated lipid metabolism	MPA	(142, 171)	impaired insulin sensitivity	MPA	(109, 137)	NoRelation	LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism.
serum LDL	MPA	(224, 233)	LRP5	Gene	(38, 42)	NoRelation	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
serum LDL	MPA	(224, 233)	mutations	Var	(60, 69)	NoRelation	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
gain-of-function	PosReg	(43, 59)	reduction	NegReg	(211, 220)	NoRelation	We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL.
LDL metabolism	MPA	(54, 68)	LRP5	Gene	(29, 33)	NoRelation	However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease.
variants	Var	(34, 42)	LDL metabolism	MPA	(54, 68)	NoRelation	However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease.
LRP5	Gene	(29, 33)	affect	Reg	(47, 53)	NoRelation	However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease.
loss of function	NegReg	(5, 21)	ROP2	Gene	(25, 29)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
MAP18	Gene	(47, 52)	ROP2	Gene	(25, 29)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
root hair length	MPA	(75, 91)	MAP18	Gene	(47, 52)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
knockdown	Var	(34, 43)	ROP2	Gene	(25, 29)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
decrease	NegReg	(63, 71)	MAP18	Gene	(47, 52)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
decrease	NegReg	(63, 71)	ROP2	Gene	(25, 29)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
root hair length	MPA	(75, 91)	knockdown	Var	(34, 43)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
MAP18	Gene	(47, 52)	loss of function	NegReg	(5, 21)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
root hair length	MPA	(75, 91)	ROP2	Gene	(25, 29)	NoRelation	Both loss of function of ROP2 and knockdown of MAP18 lead to a decrease in root hair length, whereas overexpression of either MAP18 or ROP2 causes multiple tips or a branching hair phenotype.
yielding	Reg	(108, 116)	affects	Reg	(72, 79)	NoRelation	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
Deletion	Var	(0, 8)	circadian clock output	MPA	(84, 106)	NoRelation	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
asexual conidiation	MPA	(130, 149)	circadian clock output	MPA	(84, 106)	NoRelation	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
asexual conidiation	MPA	(130, 149)	Deletion	Var	(0, 8)	NoRelation	Deletion of the homolog in the filamentous ascomycete Neurospora crassa affects the circadian clock output, yielding a pattern of asexual conidiation similar to a ras-1 mutant that is used in circadian studies in N. crassa.
mutant	Var	(4, 10)	nonsense-mediated decay	MPA	(24, 47)	NoRelation	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
escaped	NegReg	(16, 23)	lacking	NegReg	(69, 76)	NoRelation	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
two transmembrane domains	MPA	(77, 102)	nonsense-mediated decay	MPA	(24, 47)	NoRelation	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
mutant	Var	(4, 10)	two transmembrane domains	MPA	(77, 102)	NoRelation	The mutant mRNA escaped nonsense-mediated decay and generated a GPCR lacking two transmembrane domains and the carboxyl-terminal tail.
PROKR2	Gene	(43, 49)	functional	MPA	(99, 109)	NoRelation	The results indicate that certain inactive PROKR2 mutants can cause early puberty by enhancing the functional property of coexisting wild-type proteins.
PROKR2	Gene	(43, 49)	enhancing	PosReg	(85, 94)	NoRelation	The results indicate that certain inactive PROKR2 mutants can cause early puberty by enhancing the functional property of coexisting wild-type proteins.
mutants	Var	(50, 57)	functional	MPA	(99, 109)	NoRelation	The results indicate that certain inactive PROKR2 mutants can cause early puberty by enhancing the functional property of coexisting wild-type proteins.
disrupted	NegReg	(85, 94)	MSL8	Gene	(75, 79)	NoRelation	We introduced two point mutations into the predicted pore-lining domain of MSL8 that disrupted normal channel function in different ways.
MSL8	Gene	(75, 79)	normal channel function	MPA	(95, 118)	NoRelation	We introduced two point mutations into the predicted pore-lining domain of MSL8 that disrupted normal channel function in different ways.
mutations	Var	(24, 33)	normal channel function	MPA	(95, 118)	NoRelation	We introduced two point mutations into the predicted pore-lining domain of MSL8 that disrupted normal channel function in different ways.
increased	PosReg	(23, 32)	disrupted	NegReg	(148, 157)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Ile711Ser	Var	(4, 13)	channel	Pathway	(167, 174)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Ile711Ser	Var	(4, 13)	tension threshold	MPA	(37, 54)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Ile711Ser	Var	(4, 13)	conductance unchanged	MPA	(89, 110)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
disrupted	NegReg	(148, 157)	leaving	Reg	(81, 88)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(162, 166)	tension threshold	MPA	(37, 54)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
channel	Pathway	(167, 174)	MSL8	Gene	(62, 66)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Phe720Leu mutation	Var	(120, 138)	conductance unchanged	MPA	(89, 110)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(162, 166)	MSL8	Gene	(62, 66)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
channel	Pathway	(167, 174)	Phe720Leu mutation	Var	(120, 138)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
conductance unchanged	MPA	(89, 110)	tension threshold	MPA	(37, 54)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
increased	PosReg	(23, 32)	leaving	Reg	(81, 88)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(62, 66)	leaving	Reg	(81, 88)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
channel	Pathway	(167, 174)	tension threshold	MPA	(37, 54)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
conductance unchanged	MPA	(89, 110)	MSL8	Gene	(62, 66)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
increased	PosReg	(23, 32)	channel	Pathway	(167, 174)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(162, 166)	disrupted	NegReg	(148, 157)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
increased	PosReg	(23, 32)	MSL8	Gene	(162, 166)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Ile711Ser	Var	(4, 13)	MSL8	Gene	(162, 166)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Phe720Leu mutation	Var	(120, 138)	tension threshold	MPA	(37, 54)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Ile711Ser	Var	(4, 13)	Phe720Leu mutation	Var	(120, 138)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
disrupted	NegReg	(148, 157)	MSL8	Gene	(62, 66)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
Phe720Leu mutation	Var	(120, 138)	MSL8	Gene	(62, 66)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(162, 166)	conductance unchanged	MPA	(89, 110)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
increased	PosReg	(23, 32)	MSL8	Gene	(62, 66)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
tension threshold	MPA	(37, 54)	MSL8	Gene	(62, 66)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(162, 166)	leaving	Reg	(81, 88)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
channel	Pathway	(167, 174)	conductance unchanged	MPA	(89, 110)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
MSL8	Gene	(162, 166)	channel	Pathway	(167, 174)	NoRelation	The Ile711Ser mutation increased the tension threshold of the MSL8 channel while leaving conductance unchanged, and the Phe720Leu mutation severely disrupted the MSL8 channel.
ability	MPA	(37, 44)	mutations	Var	(14, 23)	NoRelation	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
impaired	NegReg	(24, 32)	maintain	Reg	(106, 114)	NoRelation	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
ability	MPA	(37, 44)	integrity	MPA	(119, 128)	NoRelation	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
integrity	MPA	(119, 128)	mutations	Var	(14, 23)	NoRelation	Both of these mutations impaired the ability of MSL8 to preserve pollen viability during hydration and to maintain the integrity of the pollen tube when expressed at endogenous levels.
invasiveness	MPA	(74, 86)	knock-down	Var	(19, 29)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
cell differentiation	MPA	(99, 119)	invasiveness	MPA	(74, 86)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
cell differentiation	MPA	(99, 119)	Rack1	Gene	(13, 18)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
Rack1	Gene	(13, 18)	reduces	NegReg	(66, 73)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
induces	Reg	(91, 98)	reduces	NegReg	(66, 73)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
invasiveness	MPA	(74, 86)	Rack1	Gene	(13, 18)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
induces	Reg	(91, 98)	Rack1	Gene	(13, 18)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
cell differentiation	MPA	(99, 119)	knock-down	Var	(19, 29)	NoRelation	We show that Rack1 knock-down in the mouse melanoma cell line B16 reduces invasiveness and induces cell differentiation.
protein-losing enteropathy	Disease	(93, 119)	DGAT1	Gene	(46, 51)	NoRelation	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
congenital diarrhea	Disease	(69, 88)	mutations	Var	(27, 36)	NoRelation	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
protein-losing enteropathy	Disease	(93, 119)	mutations	Var	(27, 36)	NoRelation	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
loss-of-function	NegReg	(10, 26)	DGAT1	Gene	(46, 51)	NoRelation	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
congenital diarrhea	Disease	(69, 88)	DGAT1	Gene	(46, 51)	NoRelation	Biallelic loss-of-function mutations in human DGAT1 result in severe congenital diarrhea and protein-losing enteropathy.
TG synthesis activity	MPA	(122, 143)	mutant	Var	(61, 67)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
TG synthesis activity	MPA	(122, 143)	DGAT1	Gene	(30, 35)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
formation of lipid droplets	MPA	(158, 185)	mutant	Var	(61, 67)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
decreased	NegReg	(148, 157)	less	NegReg	(78, 82)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
decreased	NegReg	(148, 157)	loss	NegReg	(114, 118)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
less	NegReg	(78, 82)	DGAT1	Gene	(30, 35)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
mutant	Var	(61, 67)	DGAT1	Gene	(30, 35)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
loss	NegReg	(114, 118)	DGAT1	Gene	(30, 35)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
formation of lipid droplets	MPA	(158, 185)	p.L105P	Var	(22, 29)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
formation of lipid droplets	MPA	(158, 185)	TG synthesis activity	MPA	(122, 143)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
decreased	NegReg	(148, 157)	DGAT1	Gene	(30, 35)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
TG synthesis activity	MPA	(122, 143)	p.L105P	Var	(22, 29)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
mutant	Var	(61, 67)	p.L105P	Var	(22, 29)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
formation of lipid droplets	MPA	(158, 185)	DGAT1	Gene	(30, 35)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
loss	NegReg	(114, 118)	less	NegReg	(78, 82)	NoRelation	We show here that the p.L105P DGAT1 enzyme produced from the mutant allele is less abundant, resulting in partial loss of TG synthesis activity and decreased formation of lipid droplets in patient-derived primary dermal fibroblasts.
p.L105P missense	Var	(71, 87)	less severe clinical phenotype	MPA	(148, 178)	NoRelation	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
p.L105P missense	Var	(71, 87)	TG synthesis activity	MPA	(113, 134)	NoRelation	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
less severe clinical phenotype	MPA	(148, 178)	TG synthesis activity	MPA	(113, 134)	NoRelation	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
reduces	NegReg	(105, 112)	causes	Reg	(139, 145)	NoRelation	Thus, in contrast with complete loss-of-function alleles of DGAT1, the p.L105P missense allele partially reduces TG synthesis activity and causes a less severe clinical phenotype.
mutations	Var	(154, 163)	deficiency	Var	(53, 63)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
deficiency	Var	(53, 63)	protein-losing enteropathy	Disease	(103, 129)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
DGAT1	Gene	(148, 153)	spectrum of diseases	Disease	(176, 196)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
deficiency	Var	(53, 63)	DGAT1	Gene	(148, 153)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
protein-losing enteropathy	Disease	(103, 129)	DGAT1	Gene	(47, 52)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
mutations	Var	(154, 163)	DGAT1	Gene	(47, 52)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
mutations	Var	(154, 163)	congenital diarrhea	Disease	(78, 97)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
deficiency	Var	(53, 63)	congenital diarrhea	Disease	(78, 97)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
cause	Reg	(69, 74)	result in	Reg	(164, 173)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
DGAT1	Gene	(47, 52)	DGAT1	Gene	(148, 153)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
congenital diarrhea	Disease	(78, 97)	protein-losing enteropathy	Disease	(103, 129)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
congenital diarrhea	Disease	(78, 97)	DGAT1	Gene	(148, 153)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
congenital diarrhea	Disease	(78, 97)	DGAT1	Gene	(47, 52)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
DGAT1	Gene	(47, 52)	spectrum of diseases	Disease	(176, 196)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
mutations	Var	(154, 163)	spectrum of diseases	Disease	(176, 196)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
result in	Reg	(164, 173)	DGAT1	Gene	(148, 153)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
result in	Reg	(164, 173)	DGAT1	Gene	(47, 52)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
protein-losing enteropathy	Disease	(103, 129)	DGAT1	Gene	(148, 153)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
deficiency	Var	(53, 63)	spectrum of diseases	Disease	(176, 196)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
cause	Reg	(69, 74)	DGAT1	Gene	(47, 52)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
cause	Reg	(69, 74)	DGAT1	Gene	(148, 153)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
mutations	Var	(154, 163)	protein-losing enteropathy	Disease	(103, 129)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
protein-losing enteropathy	Disease	(103, 129)	spectrum of diseases	Disease	(176, 196)	NoRelation	Our findings add to the growing recognition of DGAT1 deficiency as a cause of congenital diarrhea with protein-losing enteropathy and indicate that DGAT1 mutations result in a spectrum of diseases.
Hydrocephalus	Disease	(0, 13)	mutations	Var	(67, 76)	NoRelation	Hydrocephalus due to multiple ependymal malformations is caused by mutations in the MPDZ gene.
caused by	Reg	(57, 66)	MPDZ	Gene	(84, 88)	NoRelation	Hydrocephalus due to multiple ependymal malformations is caused by mutations in the MPDZ gene.
Hydrocephalus	Disease	(0, 13)	MPDZ	Gene	(84, 88)	NoRelation	Hydrocephalus due to multiple ependymal malformations is caused by mutations in the MPDZ gene.
common	Reg	(76, 82)	L1CAM	Gene	(41, 46)	NoRelation	In patients with isolated hydrocephalus, L1CAM mutations represent the most common aetiology.
isolated hydrocephalus	Disease	(17, 39)	L1CAM	Gene	(41, 46)	NoRelation	In patients with isolated hydrocephalus, L1CAM mutations represent the most common aetiology.
mutations	Var	(47, 56)	isolated hydrocephalus	Disease	(17, 39)	NoRelation	In patients with isolated hydrocephalus, L1CAM mutations represent the most common aetiology.
perturb	Reg	(20, 27)	pnt	Gene	(16, 19)	NoRelation	As mutations in pnt perturb the development of several tissues, we wanted to examine the effect and efficacy of using RNAi to target Pnt.
pnt	Gene	(16, 19)	development of several tissues	CPA	(32, 62)	NoRelation	As mutations in pnt perturb the development of several tissues, we wanted to examine the effect and efficacy of using RNAi to target Pnt.
mutations	Var	(3, 12)	development of several tissues	CPA	(32, 62)	NoRelation	As mutations in pnt perturb the development of several tissues, we wanted to examine the effect and efficacy of using RNAi to target Pnt.
CACNA1D	Gene	(36, 43)	gain-of-function	PosReg	(4, 20)	NoRelation	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
epilepsy	Disease	(105, 113)	autism spectrum disorders	Disease	(75, 100)	NoRelation	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
autism spectrum disorders	Disease	(75, 100)	mutation	Var	(21, 29)	NoRelation	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
epilepsy	Disease	(105, 113)	mutation	Var	(21, 29)	NoRelation	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
autism spectrum disorders	Disease	(75, 100)	CACNA1D	Gene	(36, 43)	NoRelation	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
epilepsy	Disease	(105, 113)	CACNA1D	Gene	(36, 43)	NoRelation	New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy.
current densities	MPA	(471, 488)	V401L	Var	(393, 398)	NoRelation	Here we report the discovery and characterization of a third de novo missense mutation in CACNA1D (V401L) in a patient with ASD and epilepsy.For the functional characterization we introduced mutation V401L into two major C-terminal long and short Cav1.3 splice variants, expressed wild-type or mutant channel complexes in tsA-201 cells and performed whole-cell patch-clamp recordings.Mutation V401L, localized within the channel's activation gate, significantly enhanced current densities, shifted voltage dependence of activation and inactivation to more negative voltages and reduced channel inactivation in both Cav1.3 splice variants.
Ca2+-influx through the channel	MPA	(67, 98)	changes	Var	(24, 31)	NoRelation	Altogether these gating changes are expected to result in enhanced Ca2+-influx through the channel, thus representing a strong gain-of-function phenotype.
AE	Disease	(91, 93)	FLG	Gene	(29, 32)	NoRelation	Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood.
AE	Disease	(91, 93)	Null mutations	Var	(0, 14)	NoRelation	Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood.
FLG	Gene	(29, 32)	predispose	Reg	(77, 87)	NoRelation	Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood.
knockdown	Var	(45, 54)	Molecular pathways	Pathway	(0, 18)	NoRelation	Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress.
FLG	Gene	(41, 44)	overrepresented	PosReg	(19, 34)	NoRelation	Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress.
FLG	Gene	(41, 44)	Molecular pathways	Pathway	(0, 18)	NoRelation	Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress.
FLG	Gene	(54, 57)	expression level of proteins	MPA	(116, 144)	NoRelation	CONCLUSIONS: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE.
expression level of proteins	MPA	(116, 144)	loss	Var	(46, 50)	NoRelation	CONCLUSIONS: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE.
alter	Reg	(106, 111)	FLG	Gene	(54, 57)	NoRelation	CONCLUSIONS: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE.
TREM2	Gene	(77, 82)	linked to	Reg	(94, 103)	NoRelation	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
frontotemporal lobar degeneration	Disease	(186, 219)	TREM2	Gene	(77, 82)	NoRelation	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
Alzheimer's disease	Disease	(162, 181)	frontotemporal lobar degeneration	Disease	(186, 219)	NoRelation	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
Alzheimer's disease	Disease	(162, 181)	variations	Var	(9, 19)	NoRelation	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
Alzheimer's disease	Disease	(162, 181)	TREM2	Gene	(77, 82)	NoRelation	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
frontotemporal lobar degeneration	Disease	(186, 219)	variations	Var	(9, 19)	NoRelation	Sequence variations in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to an increased risk for neurodegenerative disorders such as Alzheimer's disease and frontotemporal lobar degeneration.
lipid sensing	MPA	(118, 131)	TREM2	Gene	(27, 32)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
affecting	Reg	(172, 181)	TREM2	Gene	(27, 32)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	TREM2	Gene	(27, 32)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	variants	Var	(33, 41)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
shielding of amyloid plaques	MPA	(182, 210)	variants	Var	(33, 41)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
microglial phagocytosis	CPA	(83, 106)	lipoproteins	Protein	(155, 167)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
preventing	NegReg	(133, 143)	impairing	NegReg	(108, 117)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
microglial phagocytosis	CPA	(83, 106)	TREM2	Gene	(27, 32)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipid sensing	MPA	(118, 131)	microglial phagocytosis	CPA	(83, 106)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
TREM2	Gene	(27, 32)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
impairing	NegReg	(108, 117)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
preventing	NegReg	(133, 143)	TREM2	Gene	(27, 32)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
microglial phagocytosis	CPA	(83, 106)	variants	Var	(33, 41)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
preventing	NegReg	(133, 143)	lipoproteins	Protein	(155, 167)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipoproteins	Protein	(155, 167)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipid sensing	MPA	(118, 131)	shielding of amyloid plaques	MPA	(182, 210)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
affecting	Reg	(172, 181)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
preventing	NegReg	(133, 143)	affecting	Reg	(172, 181)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
impairing	NegReg	(108, 117)	lipoproteins	Protein	(155, 167)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
impairing	NegReg	(108, 117)	TREM2	Gene	(27, 32)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
affecting	Reg	(172, 181)	impairing	NegReg	(108, 117)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
shielding of amyloid plaques	MPA	(182, 210)	TREM2	Gene	(27, 32)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
lipid sensing	MPA	(118, 131)	variants	Var	(33, 41)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
binding	Interaction	(144, 151)	microglial phagocytosis	CPA	(83, 106)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
affecting	Reg	(172, 181)	lipoproteins	Protein	(155, 167)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
preventing	NegReg	(133, 143)	reducing	NegReg	(74, 82)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
shielding of amyloid plaques	MPA	(182, 210)	microglial phagocytosis	CPA	(83, 106)	NoRelation	Several disease-associated TREM2 variants result in a loss of function by reducing microglial phagocytosis, impairing lipid sensing, preventing binding of lipoproteins and affecting shielding of amyloid plaques.
loss	Var	(33, 37)	microglial responses to injury and signals	CPA	(67, 109)	NoRelation	Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels.
microglial responses to injury and signals	CPA	(67, 109)	TREM2	Gene	(41, 46)	NoRelation	Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels.
impairs	NegReg	(47, 54)	TREM2	Gene	(41, 46)	NoRelation	Functional analyses confirm that loss of TREM2 impairs appropriate microglial responses to injury and signals that normally evoke chemotaxis on multiple levels.
loss of function	NegReg	(6, 22)	KRIT1	Gene	(35, 40)	NoRelation	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
associated with	Reg	(49, 64)	KRIT1	Gene	(35, 40)	NoRelation	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
cerebral and spinal cavernous malformations	Disease	(88, 131)	KRIT1	Gene	(35, 40)	NoRelation	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
cerebral and spinal cavernous malformations	Disease	(88, 131)	mutation	Var	(23, 31)	NoRelation	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
associated with	Reg	(49, 64)	loss of function	NegReg	(6, 22)	NoRelation	Novel loss of function mutation in KRIT1/CCM1 is associated with distinctly progressive cerebral and spinal cavernous malformations after radiochemotherapy for intracranial malignant germ cell tumor.
KRIT1 protein	Protein	(136, 149)	leads to	Reg	(14, 22)	NoRelation	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
loss of function	NegReg	(112, 128)	leads to	Reg	(14, 22)	NoRelation	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
premature stop codon	MPA	(43, 63)	frameshift	Var	(25, 35)	NoRelation	This deletion leads to a frameshift with a premature stop codon at nucleotide position 1553 and a highly likely loss of function of the KRIT1 protein.
loss of function	NegReg	(70, 86)	associated with	Reg	(115, 130)	NoRelation	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
KRIT1	Gene	(99, 104)	loss of function	NegReg	(70, 86)	NoRelation	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
CCMs	Disease	(166, 170)	mutation	Var	(87, 95)	NoRelation	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
KRIT1	Gene	(99, 104)	CCMs	Disease	(166, 170)	NoRelation	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
KRIT1	Gene	(99, 104)	associated with	Reg	(115, 130)	NoRelation	CONCLUSION: We describe a patient with a novel heterozygous germ line loss of function mutation in KRIT1, which is associated with rapid-onset and highly progressive CCMs after radiochemotherapy for a malignant brain tumor.
EGFR	Gene	(62, 66)	Non-Small Cell Lung Cancer	Disease	(94, 120)	NoRelation	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Non-Small Cell Lung Cancer	Disease	(94, 120)	Mutation	Var	(67, 75)	NoRelation	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
EGFR	Gene	(62, 66)	Positive	Reg	(76, 84)	NoRelation	Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
leads	Reg	(48, 53)	rad51	Gene	(42, 47)	NoRelation	Loss of the homologous recombination gene rad51 leads to Fanconi anemia-like symptoms in zebrafish.
rad51	Gene	(42, 47)	Fanconi anemia-like symptoms	Disease	(57, 85)	NoRelation	Loss of the homologous recombination gene rad51 leads to Fanconi anemia-like symptoms in zebrafish.
Loss	Var	(0, 4)	Fanconi anemia-like symptoms	Disease	(57, 85)	NoRelation	Loss of the homologous recombination gene rad51 leads to Fanconi anemia-like symptoms in zebrafish.
mutants	Var	(33, 40)	FA	Disease	(67, 69)	NoRelation	Zebrafish rad51 loss-of-function mutants developed key features of FA, including hypocellular kidney marrow, sensitivity to cross-linking agents, and decreased size.
rad51	Gene	(10, 15)	FA	Disease	(67, 69)	NoRelation	Zebrafish rad51 loss-of-function mutants developed key features of FA, including hypocellular kidney marrow, sensitivity to cross-linking agents, and decreased size.
loss-of-function	NegReg	(16, 32)	rad51	Gene	(10, 15)	NoRelation	Zebrafish rad51 loss-of-function mutants developed key features of FA, including hypocellular kidney marrow, sensitivity to cross-linking agents, and decreased size.
CAG repeat expansion	Var	(98, 118)	Spinocerebellar ataxia type 2	Disease	(0, 29)	NoRelation	Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the ATXN2 gene.
Spinocerebellar ataxia type 2	Disease	(0, 29)	ATXN2	Gene	(126, 131)	NoRelation	Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the ATXN2 gene.
ATXN2	Gene	(126, 131)	caused by	Reg	(88, 97)	NoRelation	Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant neurodegenerative disease caused by CAG repeat expansion in the ATXN2 gene.
trans-epidermal penetration	CPA	(114, 141)	mutations	Var	(78, 87)	NoRelation	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
FLG	Gene	(56, 59)	facilitate	PosReg	(103, 113)	NoRelation	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
loss-of function	NegReg	(61, 77)	facilitate	PosReg	(103, 113)	NoRelation	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
trans-epidermal penetration	CPA	(114, 141)	FLG	Gene	(56, 59)	NoRelation	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
loss-of function	NegReg	(61, 77)	FLG	Gene	(56, 59)	NoRelation	Up to 10% of Europeans and Asians carry filaggrin gene (FLG) loss-of function mutations that appear to facilitate trans-epidermal penetration of certain chemicals.
mutations	Var	(25, 34)	infantile spasms	Disease	(177, 193)	NoRelation	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
GRIN2B	Gene	(38, 44)	infantile spasms	Disease	(177, 193)	NoRelation	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
infantile spasms	Disease	(177, 193)	epileptic encephalopathies	Disease	(139, 165)	NoRelation	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
GRIN2B	Gene	(38, 44)	epileptic encephalopathies	Disease	(139, 165)	NoRelation	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
GRIN2B	Gene	(38, 44)	gain of function	PosReg	(8, 24)	NoRelation	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
mutations	Var	(25, 34)	epileptic encephalopathies	Disease	(139, 165)	NoRelation	De novo gain of function mutations in GRIN2B encoding the GluN2B subunit of the N-methyl-d-aspartate (NMDA) receptor have been linked with epileptic encephalopathies, including infantile spasms.
associated with	Reg	(76, 91)	promote	PosReg	(44, 51)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
associated with	Reg	(76, 91)	PAI-1	Gene	(12, 17)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
airway fibrosis	CPA	(52, 67)	variants	Var	(35, 43)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
variants	Var	(35, 43)	asthma	Disease	(92, 98)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
airway fibrosis	CPA	(52, 67)	asthma	Disease	(92, 98)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
promote	PosReg	(44, 51)	PAI-1	Gene	(12, 17)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
PAI-1	Gene	(12, 17)	asthma	Disease	(92, 98)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
airway fibrosis	CPA	(52, 67)	PAI-1	Gene	(12, 17)	NoRelation	BACKGROUND: PAI-1 gain-of-function variants promote airway fibrosis and are associated with asthma and with worse lung function in subjects with asthma.
lipoprotein lipase	Enzyme	(62, 80)	E396V	Var	(103, 108)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
C310R	Var	(97, 102)	recurrent acute pancreatitis	Disease	(146, 174)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
lipoprotein lipase	Enzyme	(62, 80)	recurrent acute pancreatitis	Disease	(146, 174)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
E396V	Var	(103, 108)	recurrent acute pancreatitis	Disease	(146, 174)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
hypertriglyceridemia	Disease	(7, 27)	E396V	Var	(103, 108)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
lipoprotein lipase	Enzyme	(62, 80)	associated with	Reg	(130, 145)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
loss-of-function	NegReg	(45, 61)	associated with	Reg	(130, 145)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
C310R	Var	(97, 102)	E396V	Var	(103, 108)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
hypertriglyceridemia	Disease	(7, 27)	C310R	Var	(97, 102)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
hypertriglyceridemia	Disease	(7, 27)	lipoprotein lipase	Enzyme	(62, 80)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
hypertriglyceridemia	Disease	(7, 27)	recurrent acute pancreatitis	Disease	(146, 174)	NoRelation	Severe hypertriglyceridemia due to two novel loss-of-function lipoprotein lipase gene mutations (C310R/E396V) in a Chinese family associated with recurrent acute pancreatitis.
LPL protein level	MPA	(41, 58)	C310R	Var	(6, 11)	NoRelation	While C310R markedly reduced the overall LPL protein level, COS-1 cells carrying E396V or double mutations contained similar overall LPL protein levels to the wild-type.
mutations	Var	(91, 100)	triglyceride catabolism	MPA	(117, 140)	NoRelation	However, few LPL were detected in the culture medium for the mutants, suggesting that both mutations caused aberrant triglyceride catabolism.
C310R	Var	(111, 116)	E396V	Var	(19, 24)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
LPL protein level	MPA	(136, 153)	E396V	Var	(19, 24)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
double mutations	Var	(29, 45)	C310R	Var	(111, 116)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
double mutations	Var	(29, 45)	LPL protein level	MPA	(136, 153)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
double mutations	Var	(29, 45)	transport of LPL to the cell surface	MPA	(59, 95)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
LPL protein level	MPA	(136, 153)	C310R	Var	(111, 116)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
double mutations	Var	(29, 45)	E396V	Var	(19, 24)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
reducing	NegReg	(127, 135)	dampened	NegReg	(46, 54)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
transport of LPL to the cell surface	MPA	(59, 95)	E396V	Var	(19, 24)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
LPL protein level	MPA	(136, 153)	transport of LPL to the cell surface	MPA	(59, 95)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
C310R	Var	(111, 116)	transport of LPL to the cell surface	MPA	(59, 95)	NoRelation	More specifically, E396V and double mutations dampened the transport of LPL to the cell surface, while for the C310R mutation, reducing LPL protein level might be involved.
ectodermal dysplasia	Disease	(23, 43)	mutation	Var	(7, 15)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
WNT10A	Gene	(0, 6)	causes	Reg	(16, 22)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
mutation	Var	(7, 15)	KLF4-mediated differentiation	CPA	(91, 120)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
ectodermal dysplasia	Disease	(23, 43)	WNT10A	Gene	(0, 6)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
progenitor cell proliferation	CPA	(57, 86)	mutation	Var	(7, 15)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
ectodermal dysplasia	Disease	(23, 43)	KLF4-mediated differentiation	CPA	(91, 120)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
progenitor cell proliferation	CPA	(57, 86)	WNT10A	Gene	(0, 6)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
progenitor cell proliferation	CPA	(57, 86)	KLF4-mediated differentiation	CPA	(91, 120)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
progenitor cell proliferation	CPA	(57, 86)	ectodermal dysplasia	Disease	(23, 43)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
WNT10A	Gene	(0, 6)	KLF4-mediated differentiation	CPA	(91, 120)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
impairing	NegReg	(47, 56)	WNT10A	Gene	(0, 6)	NoRelation	WNT10A mutation causes ectodermal dysplasia by impairing progenitor cell proliferation and KLF4-mediated differentiation.
septal defects	Disease	(69, 83)	ROBO1	Gene	(20, 25)	NoRelation	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
Loss of function	Var	(0, 16)	tetralogy of Fallot	Disease	(45, 64)	NoRelation	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
tetralogy of Fallot	Disease	(45, 64)	ROBO1	Gene	(20, 25)	NoRelation	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
septal defects	Disease	(69, 83)	tetralogy of Fallot	Disease	(45, 64)	NoRelation	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
associated	Reg	(29, 39)	ROBO1	Gene	(20, 25)	NoRelation	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
septal defects	Disease	(69, 83)	Loss of function	Var	(0, 16)	NoRelation	Loss of function in ROBO1 is associated with tetralogy of Fallot and septal defects.
NFKBIA	Gene	(58, 64)	gain-of-function	PosReg	(22, 38)	NoRelation	Germline heterozygous gain-of-function (GOF) mutations of NFKBIA, encoding IB, cause an autosomal dominant (AD) form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID).
mutations	Var	(45, 54)	anhidrotic ectodermal dysplasia with immunodeficiency	Disease	(122, 175)	NoRelation	Germline heterozygous gain-of-function (GOF) mutations of NFKBIA, encoding IB, cause an autosomal dominant (AD) form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID).
NFKBIA	Gene	(58, 64)	anhidrotic ectodermal dysplasia with immunodeficiency	Disease	(122, 175)	NoRelation	Germline heterozygous gain-of-function (GOF) mutations of NFKBIA, encoding IB, cause an autosomal dominant (AD) form of anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID).
mutations	Var	(4, 13)	inhibitory activity	MPA	(27, 46)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
mutations	Var	(4, 13)	phosphorylation on serine 32 or 36	MPA	(74, 108)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
degradation	MPA	(128, 139)	phosphorylation on serine 32 or 36	MPA	(74, 108)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
phosphorylation on serine 32 or 36	MPA	(74, 108)	inhibitory activity	MPA	(27, 46)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
IB	Protein	(50, 54)	preventing	NegReg	(59, 69)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
degradation	MPA	(128, 139)	inhibitory activity	MPA	(27, 46)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
mutations	Var	(4, 13)	degradation	MPA	(128, 139)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
enhanced	PosReg	(14, 22)	IB	Protein	(50, 54)	NoRelation	All mutations enhanced the inhibitory activity of IB, by preventing its phosphorylation on serine 32 or 36 and its subsequent degradation.
developmental deficit of calbindin-positive cortical GABAergic interneurons	CPA	(102, 177)	ARX	Gene	(0, 3)	NoRelation	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
migration impediment in the rostral cortex coupled	CPA	(44, 94)	ARX	Gene	(0, 3)	NoRelation	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
ARX	Gene	(0, 3)	lead to	Reg	(36, 43)	NoRelation	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
migration impediment in the rostral cortex coupled	CPA	(44, 94)	polyalanine expansion mutations	Var	(4, 35)	NoRelation	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
developmental deficit of calbindin-positive cortical GABAergic interneurons	CPA	(102, 177)	polyalanine expansion mutations	Var	(4, 35)	NoRelation	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
developmental deficit of calbindin-positive cortical GABAergic interneurons	CPA	(102, 177)	migration impediment in the rostral cortex coupled	CPA	(44, 94)	NoRelation	ARX polyalanine expansion mutations lead to migration impediment in the rostral cortex coupled with a developmental deficit of calbindin-positive cortical GABAergic interneurons.
migration	CPA	(85, 94)	polyalanine expansion mutations	Var	(125, 156)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
cortical calbindin interneuron	CPA	(38, 68)	ARX	Gene	(121, 124)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
ARX	Gene	(121, 124)	negatively	NegReg	(98, 108)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
development	CPA	(69, 80)	migration	CPA	(85, 94)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
development	CPA	(69, 80)	polyalanine expansion mutations	Var	(125, 156)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
migration	CPA	(85, 94)	ARX	Gene	(121, 124)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
development	CPA	(69, 80)	ARX	Gene	(121, 124)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
cortical calbindin interneuron	CPA	(38, 68)	polyalanine expansion mutations	Var	(125, 156)	NoRelation	Data from our study demonstrated that cortical calbindin interneuron development and migration is negatively affected by ARX polyalanine expansion mutations.
FGFR2	Gene	(141, 146)	gain-of-function	PosReg	(74, 90)	NoRelation	Apert syndrome is one of the most severe craniosynostoses, resulting from gain-of-function mutations in fibroblast growth factor receptor 2 (FGFR2).
mutations	Var	(91, 100)	Apert syndrome	Disease	(0, 14)	NoRelation	Apert syndrome is one of the most severe craniosynostoses, resulting from gain-of-function mutations in fibroblast growth factor receptor 2 (FGFR2).
FGFR2	Gene	(141, 146)	Apert syndrome	Disease	(0, 14)	NoRelation	Apert syndrome is one of the most severe craniosynostoses, resulting from gain-of-function mutations in fibroblast growth factor receptor 2 (FGFR2).
bone marrow stromal cell	CPA	(150, 174)	Wnt/?-catenin activity	CPA	(265, 287)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	Wnt/?-catenin activity	CPA	(265, 287)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	proliferation	CPA	(191, 204)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	differentiation	CPA	(235, 250)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	proliferation	CPA	(217, 230)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	recruitment	CPA	(175, 186)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(235, 250)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	recruitment	CPA	(175, 186)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
increase	PosReg	(138, 146)	increased	PosReg	(32, 41)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	differentiation	CPA	(235, 250)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(206, 216)	proliferation	CPA	(191, 204)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
increased	PosReg	(32, 41)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(235, 250)	proliferation	CPA	(217, 230)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(175, 186)	osteoblast	CPA	(206, 216)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
increase	PosReg	(138, 146)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(175, 186)	proliferation	CPA	(217, 230)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	differentiation	CPA	(235, 250)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
osteoblast	CPA	(206, 216)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	bone marrow stromal cell	CPA	(150, 174)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(235, 250)	recruitment	CPA	(175, 186)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(191, 204)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
increase	PosReg	(138, 146)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
bone marrow stromal cell	CPA	(150, 174)	osteoblast	CPA	(206, 216)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
increased	PosReg	(32, 41)	enhanced	PosReg	(256, 264)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
enhanced	PosReg	(256, 264)	decreased	NegReg	(72, 81)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(175, 186)	proliferation	CPA	(191, 204)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	proliferation	CPA	(191, 204)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
differentiation	CPA	(235, 250)	proliferation	CPA	(191, 204)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	proliferation	CPA	(217, 230)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(217, 230)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
proliferation	CPA	(217, 230)	proliferation	CPA	(191, 204)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
recruitment	CPA	(175, 186)	bone resorption	CPA	(82, 97)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	proliferation	CPA	(217, 230)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
Wnt/?-catenin activity	CPA	(265, 287)	osteoblast	CPA	(206, 216)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
trabecular bone formation	CPA	(42, 67)	osteoblast	CPA	(206, 216)	NoRelation	We found that MT mice exhibited increased trabecular bone formation and decreased bone resorption after BMX accompanied with a remarkable increase in bone marrow stromal cell recruitment and proliferation, osteoblast proliferation and differentiation, and enhanced Wnt/?-catenin activity.
mutation	Var	(43, 51)	bone formation	CPA	(142, 156)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
FGFR2	Gene	(55, 60)	promoting	PosReg	(132, 141)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone resorption at the adult stage	CPA	(172, 206)	bone formation	CPA	(142, 156)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone formation	CPA	(142, 156)	FGFR2	Gene	(55, 60)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone resorption at the adult stage	CPA	(172, 206)	mutation	Var	(43, 51)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
mutation	Var	(43, 51)	exerts a Wnt/-catenin-dependent anabolic effect	MPA	(61, 109)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone formation	CPA	(142, 156)	exerts a Wnt/-catenin-dependent anabolic effect	MPA	(61, 109)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
inhibiting	NegReg	(161, 171)	FGFR2	Gene	(55, 60)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
exerts a Wnt/-catenin-dependent anabolic effect	MPA	(61, 109)	FGFR2	Gene	(55, 60)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
inhibiting	NegReg	(161, 171)	promoting	PosReg	(132, 141)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
gain-of-function	PosReg	(26, 42)	FGFR2	Gene	(55, 60)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone resorption at the adult stage	CPA	(172, 206)	exerts a Wnt/-catenin-dependent anabolic effect	MPA	(61, 109)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
bone resorption at the adult stage	CPA	(172, 206)	FGFR2	Gene	(55, 60)	NoRelation	Our data demonstrate that gain-of-function mutation in FGFR2 exerts a Wnt/-catenin-dependent anabolic effect on trabecular bone by promoting bone formation and inhibiting bone resorption at the adult stage.
Early-onset autoimmune disease	Disease	(0, 30)	mutation	Var	(70, 78)	NoRelation	Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20).
loss-of-function	NegReg	(53, 69)	TNFAIP3	Gene	(82, 89)	NoRelation	Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20).
Early-onset autoimmune disease	Disease	(0, 30)	TNFAIP3	Gene	(82, 89)	NoRelation	Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20).
TgRON4	Protein	(14, 20)	decreased	NegReg	(32, 41)	NoRelation	Deficiency of TgRON4 moderately decreased invasion ability relative to that of the wild-type parasite.
invasion ability	CPA	(42, 58)	TgRON4	Protein	(14, 20)	NoRelation	Deficiency of TgRON4 moderately decreased invasion ability relative to that of the wild-type parasite.
decreased	NegReg	(70, 79)	RON5	Protein	(65, 69)	NoRelation	In addition, expression of the endogenous N-terminal fragment of RON5 decreased in the mutant.
expression of the endogenous N-terminal fragment	MPA	(13, 61)	mutant	Var	(87, 93)	NoRelation	In addition, expression of the endogenous N-terminal fragment of RON5 decreased in the mutant.
jointless-2 phenotype	CPA	(79, 100)	mutations	Var	(37, 46)	NoRelation	Natural and induced loss of function mutations in SlMBP21 MADS-box gene led to jointless-2 phenotype in tomato.
jointless-2 phenotype	CPA	(79, 100)	SlMBP21	Gene	(50, 57)	NoRelation	Natural and induced loss of function mutations in SlMBP21 MADS-box gene led to jointless-2 phenotype in tomato.
loss of function	NegReg	(20, 36)	SlMBP21	Gene	(50, 57)	NoRelation	Natural and induced loss of function mutations in SlMBP21 MADS-box gene led to jointless-2 phenotype in tomato.
caused by	Reg	(90, 99)	LAMB2	Gene	(105, 110)	NoRelation	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
Nephron development	CPA	(0, 19)	LAMB2	Gene	(105, 110)	NoRelation	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
extrarenal features	CPA	(24, 43)	Nephron development	CPA	(0, 19)	NoRelation	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
Nephron development	CPA	(0, 19)	mutations	Var	(111, 120)	NoRelation	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
extrarenal features	CPA	(24, 43)	mutations	Var	(111, 120)	NoRelation	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
extrarenal features	CPA	(24, 43)	LAMB2	Gene	(105, 110)	NoRelation	Nephron development and extrarenal features in a child with congenital nephrotic syndrome caused by null LAMB2 mutations.
limb girdle muscular dystrophy	Disease	(60, 90)	deletions	Var	(42, 51)	NoRelation	Exome sequencing reveals independent SGCD deletions causing limb girdle muscular dystrophy in Boston terriers.
causing	Reg	(52, 59)	SGCD	Gene	(37, 41)	NoRelation	Exome sequencing reveals independent SGCD deletions causing limb girdle muscular dystrophy in Boston terriers.
limb girdle muscular dystrophy	Disease	(60, 90)	SGCD	Gene	(37, 41)	NoRelation	Exome sequencing reveals independent SGCD deletions causing limb girdle muscular dystrophy in Boston terriers.
SGCD	Gene	(52, 56)	mutations	Var	(5, 14)	NoRelation	Both mutations are predicted to cause an absence of SGCD protein, confirmed by immunohistochemistry.
SGCD	Gene	(52, 56)	absence	NegReg	(41, 48)	NoRelation	Both mutations are predicted to cause an absence of SGCD protein, confirmed by immunohistochemistry.
aca10	Gene	(88, 93)	bon1	Gene	(177, 181)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
LOF	NegReg	(182, 185)	loss of function	NegReg	(94, 110)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
bon1	Gene	(177, 181)	loss of function	NegReg	(94, 110)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
mutants	Var	(117, 124)	bon1	Gene	(177, 181)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
bon1	Gene	(177, 181)	LOF	NegReg	(182, 185)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
aca10	Gene	(88, 93)	mutants	Var	(186, 193)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
aca10	Gene	(88, 93)	LOF	NegReg	(182, 185)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
aca10	Gene	(88, 93)	loss of function	NegReg	(94, 110)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
mutants	Var	(117, 124)	mutants	Var	(186, 193)	NoRelation	We found that BON1 interacts with the autoinhibitory domains of ACA10 and ACA8, and the aca10 loss of function (LOF) mutants have an autoimmune phenotype similar to that of the bon1 LOF mutants.
aca10	Gene	(90, 95)	increased	PosReg	(72, 81)	NoRelation	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
aca10	Gene	(90, 95)	bon1	Gene	(100, 104)	NoRelation	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
steady level of calcium concentration	MPA	(31, 68)	aca10	Gene	(90, 95)	NoRelation	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
increased	PosReg	(72, 81)	bon1	Gene	(100, 104)	NoRelation	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
steady level of calcium concentration	MPA	(31, 68)	mutants	Var	(105, 112)	NoRelation	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
steady level of calcium concentration	MPA	(31, 68)	bon1	Gene	(100, 104)	NoRelation	Consistent with this idea, the steady level of calcium concentration is increased in both aca10 and bon1 mutants.
mutants	Var	(97, 104)	calcium and pathogen induced stomatal closure	CPA	(13, 58)	NoRelation	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
bon1	Gene	(92, 96)	compromised	NegReg	(63, 74)	NoRelation	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
aca10	Gene	(82, 87)	calcium and pathogen induced stomatal closure	CPA	(13, 58)	NoRelation	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
bon1	Gene	(92, 96)	calcium and pathogen induced stomatal closure	CPA	(13, 58)	NoRelation	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
aca10	Gene	(82, 87)	compromised	NegReg	(63, 74)	NoRelation	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
bon1	Gene	(92, 96)	aca10	Gene	(82, 87)	NoRelation	In addition, calcium and pathogen induced stomatal closure was compromised in the aca10 and bon1 mutants.
Wnt pathway	Pathway	(120, 131)	mutation	Var	(22, 30)	NoRelation	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
LoF	NegReg	(18, 21)	activation	PosReg	(102, 112)	NoRelation	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
LoF	NegReg	(18, 21)	Adenomatous polyposis coli	Gene	(51, 77)	NoRelation	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
Wnt pathway	Pathway	(120, 131)	Adenomatous polyposis coli	Gene	(51, 77)	NoRelation	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
activation	PosReg	(102, 112)	Adenomatous polyposis coli	Gene	(51, 77)	NoRelation	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
Wnt pathway	Pathway	(120, 131)	LoF	NegReg	(18, 21)	NoRelation	The most frequent LoF mutation in human cancers is Adenomatous polyposis coli (APC), causing aberrant activation of the Wnt pathway.
APC protein	Protein	(39, 50)	retains partial	NegReg	(75, 90)	NoRelation	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
colon cancer tumors	Disease	(14, 33)	abilities	MPA	(99, 108)	NoRelation	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
APC protein	Protein	(39, 50)	colon cancer tumors	Disease	(14, 33)	NoRelation	In nearly all colon cancer tumors, the APC protein is truncated, but still retains partial binding abilities.
PCSK9	Gene	(62, 67)	loss-of-function	NegReg	(68, 84)	NoRelation	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
steatosis	Disease	(34, 43)	hypocholesterolemia	Disease	(10, 29)	NoRelation	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
hypocholesterolemia	Disease	(10, 29)	mutation	Var	(85, 93)	NoRelation	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
steatosis	Disease	(34, 43)	mutation	Var	(85, 93)	NoRelation	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
hypocholesterolemia	Disease	(10, 29)	PCSK9	Gene	(62, 67)	NoRelation	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
steatosis	Disease	(34, 43)	PCSK9	Gene	(62, 67)	NoRelation	A case of hypocholesterolemia and steatosis in a carrier of a PCSK9 loss-of-function mutation and polymorphisms predisposing to nonalcoholic fatty liver disease.
low-density lipoprotein receptor degradation	MPA	(100, 144)	PCSK9	Gene	(91, 96)	NoRelation	Invitro functional studies demonstrated that this mutation leads to a loss of function of PCSK9 on low-density lipoprotein receptor degradation.
PCSK9	Gene	(91, 96)	loss of function	NegReg	(71, 87)	NoRelation	Invitro functional studies demonstrated that this mutation leads to a loss of function of PCSK9 on low-density lipoprotein receptor degradation.
partial female-to-male sex reversal	CPA	(80, 115)	mutant	Var	(35, 41)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
partial female-to-male sex reversal	CPA	(80, 115)	Ovarian aromatase	Protein	(0, 17)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
Ovarian aromatase	Protein	(0, 17)	loss-of-function	NegReg	(18, 34)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
ovary degeneration	CPA	(57, 75)	partial female-to-male sex reversal	CPA	(80, 115)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
ovary degeneration	CPA	(57, 75)	mutant	Var	(35, 41)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
Ovarian aromatase	Protein	(0, 17)	undergo	Reg	(49, 56)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
ovary degeneration	CPA	(57, 75)	Ovarian aromatase	Protein	(0, 17)	NoRelation	Ovarian aromatase loss-of-function mutant medaka undergo ovary degeneration and partial female-to-male sex reversal after puberty.
loss-of-function	NegReg	(101, 117)	protein	Protein	(57, 64)	NoRelation	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
ALMS1	Gene	(51, 56)	undetectable	NegReg	(69, 81)	NoRelation	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
loss-of-function	NegReg	(101, 117)	undetectable	NegReg	(69, 81)	NoRelation	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
loss-of-function	NegReg	(101, 117)	ALMS1	Gene	(51, 56)	NoRelation	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
mutations	Var	(124, 133)	ALMS1	Gene	(51, 56)	NoRelation	RESULTS: In 16 of the patient cell lines examined, ALMS1 protein was undetectable (14 with biallelic loss-of-function (LoF) mutations), and in two, ALMS1 staining was equivocal (one with biallelic LoF mutations).
up-regulation	PosReg	(92, 105)	Hsp26	Protein	(120, 125)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
eIF2	Protein	(55, 60)	activated	PosReg	(45, 54)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
activated	PosReg	(45, 54)	CG17259	Gene	(37, 44)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
activated	PosReg	(45, 54)	Hsp27	Protein	(130, 135)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
up-regulation	PosReg	(92, 105)	Hsp27	Protein	(130, 135)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
loss-of-function	Var	(14, 30)	autophagy	CPA	(141, 150)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
eIF2	Protein	(55, 60)	autophagy	CPA	(141, 150)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(61, 76)	autophagy	CPA	(141, 150)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(61, 76)	loss-of-function	Var	(14, 30)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp26	Protein	(120, 125)	activated	PosReg	(45, 54)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(61, 76)	Hsp27	Protein	(130, 135)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
CG17259	Gene	(37, 44)	autophagy	CPA	(141, 150)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
eIF2	Protein	(55, 60)	Hsp27	Protein	(130, 135)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
autophagy	CPA	(141, 150)	chaperons	CPA	(109, 118)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(61, 76)	CG17259	Gene	(37, 44)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
eIF2	Protein	(55, 60)	CG17259	Gene	(37, 44)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
CG17259	Gene	(37, 44)	Hsp27	Protein	(130, 135)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
loss-of-function	Var	(14, 30)	chaperons	CPA	(109, 118)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
up-regulation	PosReg	(92, 105)	CG17259	Gene	(37, 44)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
phosphorylation	CPA	(61, 76)	chaperons	CPA	(109, 118)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp26	Protein	(120, 125)	eIF2	Protein	(55, 60)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp26	Protein	(120, 125)	Hsp27	Protein	(130, 135)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
eIF2	Protein	(55, 60)	chaperons	CPA	(109, 118)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
CG17259	Gene	(37, 44)	chaperons	CPA	(109, 118)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp26	Protein	(120, 125)	phosphorylation	CPA	(61, 76)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp26	Protein	(120, 125)	autophagy	CPA	(141, 150)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
Hsp27	Protein	(130, 135)	autophagy	CPA	(141, 150)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
up-regulation	PosReg	(92, 105)	eIF2	Protein	(55, 60)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
up-regulation	PosReg	(92, 105)	activated	PosReg	(45, 54)	NoRelation	We found that loss-of-function (LOF) CG17259 activated eIF2 phosphorylation and subsequent up-regulation of chaperons (Hsp26 and Hsp27) and autophagy.
protective effect	CPA	(92, 109)	phosphorylation	CPA	(38, 53)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(70, 79)	CG17259	Gene	(117, 124)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
phosphorylation	CPA	(38, 53)	Hsp27	Protein	(61, 66)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp27	Protein	(61, 66)	CG17259	Gene	(117, 124)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
CG17259	Gene	(117, 124)	reduced	NegReg	(80, 87)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
protective effect	CPA	(92, 109)	CG17259	Gene	(117, 124)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
eIF2	Protein	(32, 37)	down-regulation	NegReg	(13, 28)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(70, 79)	protective effect	CPA	(92, 109)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	phosphorylation	CPA	(38, 53)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
down-regulation	NegReg	(13, 28)	CG17259	Gene	(117, 124)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	eIF2	Protein	(32, 37)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
eIF2	Protein	(32, 37)	Hsp27	Protein	(61, 66)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(70, 79)	LOF	Var	(113, 116)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	reduced	NegReg	(80, 87)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(70, 79)	eIF2	Protein	(32, 37)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	CG17259	Gene	(117, 124)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(70, 79)	phosphorylation	CPA	(38, 53)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	protective effect	CPA	(92, 109)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
eIF2	Protein	(32, 37)	reduced	NegReg	(80, 87)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	Hsp27	Protein	(61, 66)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
protective effect	CPA	(92, 109)	eIF2	Protein	(32, 37)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
phosphorylation	CPA	(38, 53)	LOF	Var	(113, 116)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
eIF2	Protein	(32, 37)	CG17259	Gene	(117, 124)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp27	Protein	(61, 66)	reduced	NegReg	(80, 87)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
Hsp26	Protein	(55, 60)	autophagy	CPA	(70, 79)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
protective effect	CPA	(92, 109)	Hsp27	Protein	(61, 66)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
phosphorylation	CPA	(38, 53)	CG17259	Gene	(117, 124)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
autophagy	CPA	(70, 79)	Hsp27	Protein	(61, 66)	NoRelation	Genetically, down-regulation of eIF2 phosphorylation, Hsp26/Hsp27 or autophagy reduced the protective effect of LOF CG17259, indicating they function downstream of CG17259.
interferon--mediated effects on antigen presentation	MPA	(133, 186)	PTPN2	Gene	(58, 63)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
enhancing	PosReg	(123, 132)	PTPN2	Gene	(58, 63)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
PTPN2	Gene	(58, 63)	efficacy of immunotherapy	CPA	(94, 119)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
growth suppression	CPA	(191, 209)	efficacy of immunotherapy	CPA	(94, 119)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
interferon--mediated effects on antigen presentation	MPA	(133, 186)	deletion	Var	(13, 21)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
increased	PosReg	(80, 89)	PTPN2	Gene	(58, 63)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
interferon--mediated effects on antigen presentation	MPA	(133, 186)	efficacy of immunotherapy	CPA	(94, 119)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
growth suppression	CPA	(191, 209)	interferon--mediated effects on antigen presentation	MPA	(133, 186)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
growth suppression	CPA	(191, 209)	PTPN2	Gene	(58, 63)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
deletion	Var	(13, 21)	efficacy of immunotherapy	CPA	(94, 119)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
growth suppression	CPA	(191, 209)	deletion	Var	(13, 21)	NoRelation	In addition, deletion of the protein tyrosine phosphatase PTPN2 in tumour cells increased the efficacy of immunotherapy by enhancing interferon--mediated effects on antigen presentation and growth suppression.
myofibromatosis	Disease	(102, 117)	mutations	Var	(41, 50)	NoRelation	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
PDGFRB	Gene	(54, 60)	Kosaki and Penttinen syndromes	Disease	(67, 97)	NoRelation	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
mutations	Var	(41, 50)	Kosaki and Penttinen syndromes	Disease	(67, 97)	NoRelation	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
myofibromatosis	Disease	(102, 117)	PDGFRB	Gene	(54, 60)	NoRelation	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
cause	Reg	(61, 66)	PDGFRB	Gene	(54, 60)	NoRelation	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
myofibromatosis	Disease	(102, 117)	Kosaki and Penttinen syndromes	Disease	(67, 97)	NoRelation	PurposeHeterozygous germ-line activating mutations in PDGFRB cause Kosaki and Penttinen syndromes and myofibromatosis.
responded to the tyrosine kinase inhibitor imatinib	MPA	(77, 128)	p.N666H	Var	(56, 63)	NoRelation	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
PDGFRB	Gene	(146, 152)	responded to the tyrosine kinase inhibitor imatinib	MPA	(77, 128)	NoRelation	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
PDGFRB	Gene	(146, 152)	PDGFRB	Gene	(49, 55)	NoRelation	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
responded to the tyrosine kinase inhibitor imatinib	MPA	(77, 128)	PDGFRB	Gene	(49, 55)	NoRelation	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
inhibition	NegReg	(132, 142)	PDGFRB	Gene	(49, 55)	NoRelation	We describe a 10-year-old child with a germ-line PDGFRB p.N666H mutation who responded to the tyrosine kinase inhibitor imatinib by inhibition of PDGFRB.MethodsThe impact of p.N666H on PDGFRB function and sensitivity to imatinib was studied in cell culture.ResultsCells expressing the p.N666H mutation showed constitutive PDGFRB tyrosine phosphorylation.
